

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 June 2002 (13.06.2002)

(10) International Publication Number
PCT
WO 02/46415 A2

(51) International Patent Classification⁷: **C12N 15/12**,
C12Q 1/68, **C07K 14/705**, **16/28**, **A61K 31/17**, **G01N**
33/50, **33/68**

(21) International Application Number: **PCT/US01/46963**

(22) International Filing Date: 5 December 2001 (05.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/254,303 8 December 2000 (08.12.2000) US
60/256,190 15 December 2000 (15.12.2000) US
60/257,504 21 December 2000 (21.12.2000) US
60/261,546 12 January 2001 (12.01.2001) US
60/262,832 19 January 2001 (19.01.2001) US
60/264,377 26 January 2001 (26.01.2001) US
60/266,019 2 February 2001 (02.02.2001) US

(71) Applicant (for all designated States except US): **INCYTE GENOMICS, INC.** [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors: and

(75) Inventors/Applicants (for US only): **LEE, Ernestine**, A. [US/US]; 624 Kains Street, Albany, CA 94706 (US). **BAUGHN, Maria, R.** [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). **YUE, Henry** [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). **DING, Li** [CN/US]; 3353 Alma Street #146, Palo Alto, CA 94306 (US). **RAUMANN, Brigitte, E.** [US/US]; 5801 South Dorchester Avenue #3B, Chicago, IL 60637 (US). **HAFALIA, April, J., A.** [US/US]; 2227 Calle de Primavera, Santa Clara, CA 95054 (US). **KHAN, Farrah, A.** [IN/US]; 9445 Harrison Street, Des Plaines, IL 60016 (US). **NGUYEN, Dannie, B.** [US/US]; 1403 Ridgewood Drive, San Jose, CA 95118 (US). **ELLIOTT, Vicki, S.** [US/US]; 3770 Polten Place Way, San Jose, CA 95121 (US). **RAMKUMAR, Jayalaxmi** [IN/US]; 34359 Maybird Circle, Fremont, CA 94555 (US). **WALIA, Narinder, K.** [US/US]; 890 Davis Street #205, San Leandro, CA 94577 (US). **ISON, Craig, H.** [US/US]; 1242 Weathersfield Way, San Jose, CA 95118 (US). **LU, Yan** [CN/US]; 3885 Corrina Way, Palo Alto, CA 94303 (US). **GANDHI, Ameena, R.** [US/US]; 705 5th Avenue, San Francisco, CA 94118 (US). **WARREN, Bridget, A.** [US/US]; 10130 Parkwood Drive #2, Cupertino, CA 95014 (US). **DUGGAN, Brendan, M.** [AU/US]; 243

Buena Vista Avenue #306, Sunnyvale, CA 94086 (US). **TRIBOULEY, Catherine, M.** [FR/US]; 1121 Tennessee Street #5, San Francisco, CA 94107 (US). **BURFORD, Neil** [GB/US]; 105 Wildwood Circle, Durham, CT 06422 (US). **LU, Dyung, Aina, M.** [US/US]; 233 Coy Drive, San Jose, CA 95123 (US). **LAL, Preeti, G.** [IN/US]; P.O. Box 5142, Santa Clara, CA 95056 (US). **YAO, Monique, G.** [US/US]; 1189 Woodgate Drive, Carmel, IN 46033 (US). **XU, Yuming** [US/US]; 1739 Walnut Drive, Mountain View, CA 94040 (US). **BRUNS, Christopher, M.** [US/US]; 575 S. Rengstorff Avenue #126, Mountain View, CA 94040 (US). **THANGAVELU, Kavitha** [IN/US]; 1950 Montecito Avenue #23, Mountain View, CA 94043 (US). **SWARNAKAR, Anita** [CA/US]; 8 Locksley Avenue #5D, San Francisco, CA 94122 (US). **TANG, Y, Tom** [US/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). **AZIMZAI, Yalda** [US/US]; 5518 Boulder Canyon Drive, Castro Valley, CA 94552 (US). **THORNTON, Michael** [US/US]; 9 Medway Road, Woodside, CA 94062-2612 (US). **ARVIZU, Chandra** [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). **POLICKY, Jennifer, L.** [US/US]; 1511 Jarvis Court, San Jose, CA 95118 (US).

(74) Agents: **HAMLET-COX, Diana et al.**; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

[Continued on next page]

(54) Title: **TRANSPORTERS AND ION CHANNELS**

(57) Abstract: The invention provides human transporters and ion channels (TRICH) and polynucleotides which identify and encode TRICH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of TRICH.



WO 02/46415 A2



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

TRANSPORTERS AND ION CHANNELS

This invention relates to nucleic acid and amino acid sequences of transporters and ion channels and to the use of these sequences in the diagnosis, treatment, and prevention of transport, neurological, muscle, immunological and cell proliferative disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of transporters and ion channels.

BACKGROUND OF THE INVENTION

Eukaryotic cells are surrounded and subdivided into functionally distinct organelles by hydrophobic lipid bilayer membranes which are highly impermeable to most polar molecules. Cells and organelles require transport proteins to import and export essential nutrients and metal ions including K^+ , NH_4^+ , P_i , SO_4^{2-} , sugars, and vitamins, as well as various metabolic waste products. Transport proteins also play roles in antibiotic resistance, toxin secretion, ion balance, synaptic neurotransmission, kidney function, intestinal absorption, tumor growth, and other diverse cell functions (Griffith, J. and C. Sansom (1998) The Transporter Facts Book, Academic Press, San Diego CA, pp. 3-29). Transport can occur by a passive concentration-dependent mechanism, or can be linked to an energy source such as ATP hydrolysis or an ion gradient. Proteins that function in transport include carrier proteins, which bind to a specific solute and undergo a conformational change that translocates the bound solute across the membrane, and channel proteins, which form hydrophilic pores that allow specific solutes to diffuse through the membrane down an electrochemical solute gradient.

Carrier proteins which transport a single solute from one side of the membrane to the other are called uniporters. In contrast, coupled transporters link the transfer of one solute with simultaneous or sequential transfer of a second solute, either in the same direction (symport) or in the opposite direction (antiport). For example, intestinal and kidney epithelium contains a variety of symporter systems driven by the sodium gradient that exists across the plasma membrane. Sodium moves into the cell down its electrochemical gradient and brings the solute into the cell with it. The sodium gradient that provides the driving force for solute uptake is maintained by the ubiquitous Na^+/K^+ ATPase system. Sodium-coupled transporters include the mammalian glucose transporter (SGLT1), iodide transporter (NIS), and multivitamin transporter (SMVT). All three transporters have twelve putative transmembrane segments, extracellular glycosylation sites, and cytoplasmically-oriented N- and C-termini. NIS plays a crucial role in the evaluation, diagnosis, and treatment of various thyroid pathologies because it is the molecular basis for radioiodide thyroid-imaging techniques and for specific targeting of radioisotopes to the thyroid gland (Levy,

O. et al. (1997) *Proc. Natl. Acad. Sci. USA* 94:5568-5573). SMVT is expressed in the intestinal mucosa, kidney, and placenta, and is implicated in the transport of the water-soluble vitamins, e.g., biotin and pantothenate (Prasad, P.D. et al. (1998) *J. Biol. Chem.* 273:7501-7506).

One of the largest families of transporters is the major facilitator superfamily (MFS), also called the uniporter-symporter-antiporter family. MFS transporters are single polypeptide carriers that transport small solutes in response to ion gradients. Members of the MFS are found in all classes of living organisms, and include transporters for sugars, oligosaccharides, phosphates, nitrates, nucleosides, monocarboxylates, and drugs. MFS transporters found in eukaryotes all have a structure comprising 12 transmembrane segments (Pao, S.S. et al. (1998) *Microbiol. Molec. Biol. Rev.* 62:1-34). The largest family of MFS transporters is the sugar transporter family, which includes the seven glucose transporters (GLUT1-GLUT7) found in humans that are required for the transport of glucose and other hexose sugars. These glucose transport proteins have unique tissue distributions and physiological functions. GLUT1 provides many cell types with their basal glucose requirements and transports glucose across epithelial and endothelial barrier tissues; GLUT2 facilitates glucose uptake or efflux from the liver; GLUT3 regulates glucose supply to neurons; GLUT4 is responsible for insulin-regulated glucose disposal; and GLUT5 regulates fructose uptake into skeletal muscle. Defects in glucose transporters are involved in a recently identified neurological syndrome causing infantile seizures and developmental delay, as well as glycogen storage disease, Fanconi-Bickel syndrome, and non-insulin-dependent diabetes mellitus (Mueckler, M. (1994) *Eur. J. Biochem.* 219:713-725; Longo, N. and L.J. Elsas (1998) *Adv. Pediatr.* 45:293-313).

Monocarboxylate anion transporters are proton-coupled symporters with a broad substrate specificity that includes L-lactate, pyruvate, and the ketone bodies acetate, acetoacetate, and beta-hydroxybutyrate. At least seven isoforms have been identified to date. The isoforms are predicted to have twelve transmembrane (TM) helical domains with a large intracellular loop between TM6 and TM7, and play a critical role in maintaining intracellular pH by removing the protons that are produced stoichiometrically with lactate during glycolysis. The best characterized H⁺-monocarboxylate transporter is that of the erythrocyte membrane, which transports L-lactate and a wide range of other aliphatic monocarboxylates. Other cells possess H⁺-linked monocarboxylate transporters with differing substrate and inhibitor selectivities. In particular, cardiac muscle and tumor cells have transporters that differ in their K_m values for certain substrates, including stereoselectivity for L- over D-lactate, and in their sensitivity to inhibitors. There are Na⁺-monocarboxylate cotransporters on the luminal surface of intestinal and kidney epithelia, which allow the uptake of lactate, pyruvate, and ketone bodies in these tissues. In addition, there are specific and selective transporters for organic cations and organic anions in organs including the

kidney, intestine and liver. Organic anion transporters are selective for hydrophobic, charged molecules with electron-attracting side groups. Organic cation transporters, such as the ammonium transporter, mediate the secretion of a variety of drugs and endogenous metabolites, and contribute to the maintenance of intercellular pH (Poole, R.C. and A.P. Halestrap (1993) *Am. J. Physiol.* 264:C761-C782; Price, N.T. et al. (1998) *Biochem. J.* 329:321-328; and Martinelle, K. and I. Haggstrom (1993) *J. Biotechnol.* 30:339-350).

ATP-binding cassette (ABC) transporters are members of a superfamily of membrane proteins that transport substances ranging from small molecules such as ions, sugars, amino acids, peptides, and phospholipids, to lipopeptides, large proteins, and complex hydrophobic drugs. ABC transporters consist of four modules: two nucleotide-binding domains (NBD), which hydrolyze ATP to supply the energy required for transport, and two membrane-spanning domains (MSD), each containing six putative transmembrane segments. These four modules may be encoded by a single gene, as is the case for the cystic fibrosis transmembrane regulator (CFTR), or by separate genes. When encoded by separate genes, each gene product contains a single NBD and MSD. These "half-molecules" form homo- and heterodimers, such as Tap1 and Tap2, the endoplasmic reticulum-based major histocompatibility (MHC) peptide transport system. Several genetic diseases are attributed to defects in ABC transporters, such as the following diseases and their corresponding proteins: cystic fibrosis (CFTR, an ion channel), adrenoleukodystrophy (adrenoleukodystrophy protein, ALDP), Zellweger syndrome (peroxisomal membrane protein-70, PMP70), and hyperinsulinemic hypoglycemia (sulfonylurea receptor, SUR). Overexpression of the multidrug resistance (MDR) protein, another ABC transporter, in human cancer cells makes the cells resistant to a variety of cytotoxic drugs used in chemotherapy (Taglicht, D. and S. Michaelis (1998) *Meth. Enzymol.* 292:130-162).

A number of metal ions such as iron, zinc, copper, cobalt, manganese, molybdenum, selenium, nickel, and chromium are important as cofactors for a number of enzymes. For example, copper is involved in hemoglobin synthesis, connective tissue metabolism, and bone development, by acting as a cofactor in oxidoreductases such as superoxide dismutase, ferroxidase (ceruloplasmin), and lysyl oxidase. Copper and other metal ions must be provided in the diet, and are absorbed by transporters in the gastrointestinal tract. Plasma proteins transport the metal ions to the liver and other target organs, where specific transporters move the ions into cells and cellular organelles as needed. Imbalances in metal ion metabolism have been associated with a number of disease states (Danks, D.M. (1986) *J. Med. Genet.* 23:99-106).

P-type ATPases comprise a class of cation-transporting transmembrane proteins. They are integral membrane proteins which use an aspartyl phosphate intermediate to move cations across a membrane. Features of P-type ATPases include: (i) a cation channel; (ii) a stalk, formed by

extensions of the transmembrane α -helices into the cytoplasm; (iii) an ATP binding domain; (iv) a phosphorylated aspartic acid; (v) an adjacent transduction domain; (vi) a phosphatase domain, which removes the phosphate from the aspartic acid as part of the reaction cycle; and (vii) six or more transmembrane domains. Included in this class are heavy metal-transporting ATPases as well as aminophospholipid transporters.

The transport of phosphatidylserine and phosphatidylethanolamine by aminophospholipid translocase results in the movement of these molecules from one side of a bilayer to another. This transport is conducted by a newly identified subfamily of P-type ATPases which are proposed to be amphipath transporters. Amphipath transporters move molecules having both a hydrophilic and a hydrophobic region. As many as seventeen different genes belong to this P-type ATPases subfamily, being grouped into several distinct classes and subclasses (Halleck, M.S. et al., (1999) *Physiol. Genomics* 1:139-150; Vulpe, C. et al., (1993) *Nat. Genet.* 3:7-13).

Transport of fatty acids across the plasma membrane can occur by diffusion, a high capacity, low affinity process. However, under normal physiological conditions a significant fraction of fatty acid transport appears to occur via a high affinity, low capacity protein-mediated transport process. Fatty acid transport protein (FATP), an integral membrane protein with four transmembrane segments, is expressed in tissues exhibiting high levels of plasma membrane fatty acid flux, such as muscle, heart, and adipose. Expression of FATP is upregulated in 3T3-L1 cells during adipose conversion, and expression in COS7 fibroblasts elevates uptake of long-chain fatty acids (Hui, T.Y. et al. (1998) *J. Biol. Chem.* 273:27420-27429).

The lipocalin superfamily constitutes a phylogenetically conserved group of more than forty proteins that function as extracellular ligand-binding proteins which bind and transport small hydrophobic molecules. Members of this family function as carriers of retinoids, odorants, chromophores, pheromones, allergens, and sterols, and in a variety of processes including nutrient transport, cell growth regulation, immune response, and prostaglandin synthesis. A subset of these proteins may be multifunctional, serving as either a biosynthetic enzyme or as a specific enzyme inhibitor. (Tanaka, T. et al. (1997) *J. Biol. Chem.* 272:15789-15795; and van't Hof, W. et al. (1997) *J. Biol. Chem.* 272:1837-1841.)

Members of the lipocalin family display unusually low levels of overall sequence conservation. Pairwise sequence identity often falls below 20%. Sequence similarity between family members is limited to conserved cysteines which form disulfide bonds and three motifs which form a juxtaposed cluster that functions as a target cell recognition site. The lipocalins share an eight stranded, anti-parallel beta-sheet which folds back on itself to form a continuously hydrogen-bonded beta-barrel. The pocket formed by the barrel functions as an internal ligand binding site. Seven loops (L1 to L7) form short beta-hairpins, except loop L1 which is a large

omega loop that forms a lid to partially close the internal ligand-binding site (Flower (1996) Biochem. J. 318:1-14).

Lipocalins are important transport molecules. Each lipocalin associates with a particular ligand and delivers that ligand to appropriate target sites within the organism. Retinol-binding protein (RBP), one of the best characterized lipocalins, transports retinol from stores within the liver to target tissues. Apolipoprotein D (apo D), a component of high density lipoproteins (HDLs) and low density lipoproteins (LDLs), functions in the targeted collection and delivery of cholesterol throughout the body. Lipocalins are also involved in cell regulatory processes. Apo D, which is identical to gross-cystic-disease-fluid protein (GCDFP)-24, is a progesterone/pregnenolone-binding protein expressed at high levels in breast cyst fluid. Secretion of apo D in certain human breast cancer cell lines is accompanied by reduced cell proliferation and progression of cells to a more differentiated phenotype. Similarly, apo D and another lipocalin, α_1 -acid glycoprotein (AGP), are involved in nerve cell regeneration. AGP is also involved in anti-inflammatory and immunosuppressive activities. AGP is one of the positive acute-phase proteins (APP); circulating levels of AGP increase in response to stress and inflammatory stimulation. AGP accumulates at sites of inflammation where it inhibits platelet and neutrophil activation and inhibits phagocytosis. The immunomodulatory properties of AGP are due to glycosylation. AGP is 40% carbohydrate, making it unusually acidic and soluble. The glycosylation pattern of AGP changes during acute-phase response, and deglycosylated AGP has no immunosuppressive activity (Flower (1994) FEBS Lett. 354:7-11; Flower (1996) supra).

The lipocalin superfamily also includes several animal allergens, including the mouse major urinary protein (mMUP), the rat α -2-microglobulin (rA2U), the bovine β -lactoglobulin (β lg), the cockroach allergen (Bla g4), bovine dander allergen (Bos d2), and the major horse allergen, designated *Equus caballus* allergen 1 (Equ c1). Equ c1 is a powerful allergen responsible for about 80% of anti-horse IgE antibody response in patients who are chronically exposed to horse allergens. It appears that lipocalins may contain a common structure that is able to induce the IgE response (Gregoire, C. et al., (1996) J. Biol. Chem. 271:32951-32959).

Lipocalins are used as diagnostic and prognostic markers in a variety of disease states. The plasma level of AGP is monitored during pregnancy and in diagnosis and prognosis of conditions including cancer chemotherapy, renal dysfunction, myocardial infarction, arthritis, and multiple sclerosis. RBP is used clinically as a marker of tubular reabsorption in the kidney, and apo D is a marker in gross cystic breast disease (Flower (1996) supra). Additionally, the use of lipocalin animal allergens may help in the diagnosis of allergic reactions to horses (Gregoire supra), pigs, cockroaches, mice and rats.

Mitochondrial carrier proteins are transmembrane-spanning proteins which transport ions

and charged metabolites between the cytosol and the mitochondrial matrix. Examples include the ADP, ATP carrier protein; the 2-oxoglutarate/malate carrier; the phosphate carrier protein; the pyruvate carrier; the dicarboxylate carrier which transports malate, succinate, fumarate, and phosphate; the tricarboxylate carrier which transports citrate and malate; and the Grave's disease carrier protein, a protein recognized by IgG in patients with active Grave's disease, an autoimmune disorder resulting in hyperthyroidism. Proteins in this family consist of three tandem repeats of an approximately 100 amino acid domain, each of which contains two transmembrane regions (Stryer, L. (1995) Biochemistry, W.H. Freeman and Company, New York NY, p. 551; PROSITE PDOC00189 Mitochondrial energy transfer proteins signature; Online Mendelian Inheritance in Man (OMIM) *275000 Graves Disease).

This class of transporters also includes the mitochondrial uncoupling proteins, which create proton leaks across the inner mitochondrial membrane, thus uncoupling oxidative phosphorylation from ATP synthesis. The result is energy dissipation in the form of heat. Mitochondrial uncoupling proteins have been implicated as modulators of thermoregulation and metabolic rate, and have been proposed as potential targets for drugs against metabolic diseases such as obesity (Ricquier, D. et al. (1999) *J. Int. Med.* 245:637-642).

Ion Channels

The electrical potential of a cell is generated and maintained by controlling the movement of ions across the plasma membrane. The movement of ions requires ion channels, which form ion-selective pores within the membrane. There are two basic types of ion channels, ion transporters and gated ion channels. Ion transporters utilize the energy obtained from ATP hydrolysis to actively transport an ion against the ion's concentration gradient. Gated ion channels allow passive flow of an ion down the ion's electrochemical gradient under restricted conditions. Together, these types of ion channels generate, maintain, and utilize an electrochemical gradient that is used in 1) electrical impulse conduction down the axon of a nerve cell, 2) transport of molecules into cells against concentration gradients, 3) initiation of muscle contraction, and 4) endocrine cell secretion.

Ion Transporters

Ion transporters generate and maintain the resting electrical potential of a cell. Utilizing the energy derived from ATP hydrolysis, they transport ions against the ion's concentration gradient. These transmembrane ATPases are divided into three families. The phosphorylated (P) class ion transporters, including $\text{Na}^+\text{-K}^+$ ATPase, Ca^{2+} -ATPase, and H^+ -ATPase, are activated by a phosphorylation event. P-class ion transporters, also known as E1-E2 type ATPases, are responsible for maintaining resting potential distributions such that cytosolic concentrations of Na^+ and Ca^{2+} are low and cytosolic concentration of K^+ is high. The vacuolar (V) class of ion transporters includes H^+ pumps on intracellular organelles, such as lysosomes and Golgi. V-class ion transporters are

responsible for generating the low pH within the lumen of these organelles that is required for function. The coupling factor (F) class consists of H⁺ pumps in the mitochondria. F-class ion transporters utilize a proton gradient to generate ATP from ADP and inorganic phosphate (P_i).

The P-ATPases are hexamers of a 100 kD subunit with ten transmembrane domains and several large cytoplasmic regions that may play a role in ion binding (Scarborough, G.A. (1999) Curr. Opin. Cell Biol. 11:517-522). The V-ATPases are composed of two functional domains: the V₁ domain, a peripheral complex responsible for ATP hydrolysis; and the V₀ domain, an integral complex responsible for proton translocation across the membrane. The F-ATPases are structurally and evolutionarily related to the V-ATPases. The F-ATPase F₀ domain contains 12 copies of the c subunit, a highly hydrophobic protein composed of two transmembrane domains and containing a single buried carboxyl group in TM2 that is essential for proton transport. The V-ATPase V₀ domain contains three types of homologous c subunits with four or five transmembrane domains and the essential carboxyl group in TM4 or TM3. Both types of complex also contain a single a subunit that may be involved in regulating the pH dependence of activity (Forgac, M. (1999) J. Biol. Chem. 274:12951-12954).

The resting potential of the cell is utilized in many processes involving carrier proteins and gated ion channels. Carrier proteins utilize the resting potential to transport molecules into and out of the cell. Amino acid and glucose transport into many cells is linked to sodium ion co-transport (symport) so that the movement of Na⁺ down an electrochemical gradient drives transport of the other molecule up a concentration gradient. Similarly, cardiac muscle links transfer of Ca²⁺ out of the cell with transport of Na⁺ into the cell (antiport).

Gated Ion Channels

Gated ion channels control ion flow by regulating the opening and closing of pores. The ability to control ion flux through various gating mechanisms allows ion channels to mediate such diverse signaling and homeostatic functions as neuronal and endocrine signaling, muscle contraction, fertilization, and regulation of ion and pH balance. Gated ion channels are categorized according to the manner of regulating the gating function. Mechanically-gated channels open their pores in response to mechanical stress; voltage-gated channels (e.g., Na⁺, K⁺, Ca²⁺, and Cl⁻ channels) open their pores in response to changes in membrane potential; and ligand-gated channels (e.g., acetylcholine-, serotonin-, and glutamate-gated cation channels, and GABA- and glycine-gated chloride channels) open their pores in the presence of a specific ion, nucleotide, or neurotransmitter. The gating properties of a particular ion channel (i.e., its threshold for and duration of opening and closing) are sometimes modulated by association with auxiliary channel proteins and/or post translational modifications, such as phosphorylation.

Mechanically-gated or mechanosensitive ion channels act as transducers for the senses of

touch, hearing, and balance, and also play important roles in cell volume regulation, smooth muscle contraction, and cardiac rhythm generation. A stretch-inactivated channel (SIC) was recently cloned from rat kidney. The SIC channel belongs to a group of channels which are activated by pressure or stress on the cell membrane and conduct both Ca^{2+} and Na^+ (Suzuki, M. et al. (1999) J. Biol. Chem. 274:6330-6335).

The pore-forming subunits of the voltage-gated cation channels form a superfamily of ion channel proteins. The characteristic domain of these channel proteins comprises six transmembrane domains (S1-S6), a pore-forming region (P) located between S5 and S6, and intracellular amino and carboxy termini. In the Na^+ and Ca^{2+} subfamilies, this domain is repeated four times, while in the K^+ channel subfamily, each channel is formed from a tetramer of either identical or dissimilar subunits. The P region contains information specifying the ion selectivity for the channel. In the case of K^+ channels, a GYG tripeptide is involved in this selectivity (Ishii, T.M. et al. (1997) Proc. Natl. Acad. Sci. USA 94:11651-11656).

Voltage-gated Na^+ and K^+ channels are necessary for the function of electrically excitable cells, such as nerve and muscle cells. Action potentials, which lead to neurotransmitter release and muscle contraction, arise from large, transient changes in the permeability of the membrane to Na^+ and K^+ ions. Depolarization of the membrane beyond the threshold level opens voltage-gated Na^+ channels. Sodium ions flow into the cell, further depolarizing the membrane and opening more voltage-gated Na^+ channels, which propagates the depolarization down the length of the cell. Depolarization also opens voltage-gated potassium channels. Consequently, potassium ions flow outward, which leads to repolarization of the membrane. Voltage-gated channels utilize charged residues in the fourth transmembrane segment (S4) to sense voltage change. The open state lasts only about 1 millisecond, at which time the channel spontaneously converts into an inactive state that cannot be opened irrespective of the membrane potential. Inactivation is mediated by the channel's N-terminus, which acts as a plug that closes the pore. The transition from an inactive to a closed state requires a return to resting potential.

Voltage-gated Na^+ channels are heterotrimeric complexes composed of a 260 kDa pore-forming α subunit that associates with two smaller auxiliary subunits, $\beta 1$ and $\beta 2$. The $\beta 2$ subunit is an integral membrane glycoprotein that contains an extracellular Ig domain, and its association with α and $\beta 1$ subunits correlates with increased functional expression of the channel, a change in its gating properties, as well as an increase in whole cell capacitance due to an increase in membrane surface area (Isom, L.L. et al. (1995) Cell 83:433-442).

Non voltage-gated Na^+ channels include the members of the amiloride-sensitive Na^+ channel/degenerin (NaC/DEG) family. Channel subunits of this family are thought to consist of two transmembrane domains flanking a long extracellular loop, with the amino and carboxyl termini

located within the cell. The NaC/DEG family includes the epithelial Na⁺ channel (ENaC) involved in Na⁺ reabsorption in epithelia including the airway, distal colon, cortical collecting duct of the kidney, and exocrine duct glands. Mutations in ENaC result in pseudohypoaldosteronism type 1 and Liddle's syndrome (pseudohyperaldosteronism). The NaC/DEG family also includes the recently characterized H⁺-gated cation channels or acid-sensing ion channels (ASIC). ASIC subunits are expressed in the brain and form heteromultimeric Na⁺-permeable channels. These channels require acid pH fluctuations for activation. ASIC subunits show homology to the degenerins, a family of mechanically-gated channels originally isolated from *C. elegans*. Mutations in the degenerins cause neurodegeneration. ASIC subunits may also have a role in neuronal function, or in pain perception, since tissue acidosis causes pain (Waldmann, R. and M. Lazdunski (1998) *Curr. Opin. Neurobiol.* 8:418-424; Eglen, R.M. et al. (1999) *Trends Pharmacol. Sci.* 20:337-342).

K⁺ channels are located in all cell types, and may be regulated by voltage, ATP concentration, or second messengers such as Ca²⁺ and cAMP. In non-excitabile tissue, K⁺ channels are involved in protein synthesis, control of endocrine secretions, and the maintenance of osmotic equilibrium across membranes. In neurons and other excitable cells, in addition to regulating action potentials and repolarizing membranes, K⁺ channels are responsible for setting the resting membrane potential. The cytosol contains non-diffusible anions and, to balance this net negative charge, the cell contains a Na⁺-K⁺ pump and ion channels that provide the redistribution of Na⁺, K⁺, and Cl⁻. The pump actively transports Na⁺ out of the cell and K⁺ into the cell in a 3:2 ratio. Ion channels in the plasma membrane allow K⁺ and Cl⁻ to flow by passive diffusion. Because of the high negative charge within the cytosol, Cl⁻ flows out of the cell. The flow of K⁺ is balanced by an electromotive force pulling K⁺ into the cell, and a K⁺ concentration gradient pushing K⁺ out of the cell. Thus, the resting membrane potential is primarily regulated by K⁺ flow (Salkoff, L. and T. Jegla (1995) *Neuron* 15:489-492).

Potassium channel subunits of the Shaker-like superfamily all have the characteristic six transmembrane/1 pore domain structure. Four subunits combine as homo- or heterotetramers to form functional K channels. These pore-forming subunits also associate with various cytoplasmic β subunits that alter channel inactivation kinetics. The Shaker-like channel family includes the voltage-gated K⁺ channels as well as the delayed rectifier type channels such as the human ether-a-go-go related gene (HERG) associated with long QT, a cardiac dysrhythmia syndrome (Curran, M.E. (1998) *Curr. Opin. Biotechnol.* 9:565-572; Kaczorowski, G.J. and M.L. Garcia (1999) *Curr. Opin. Chem. Biol.* 3:448-458).

A second superfamily of K⁺ channels is composed of the inward rectifying channels (Kir). Kir channels have the property of preferentially conducting K⁺ currents in the inward direction.

These proteins consist of a single potassium selective pore domain and two transmembrane domains, which correspond to the fifth and sixth transmembrane domains of voltage-gated K⁺ channels. Kir subunits also associate as tetramers. The Kir family includes ROMK1, mutations in which lead to Bartter syndrome, a renal tubular disorder. Kir channels are also involved in
5 regulation of cardiac pacemaker activity, seizures and epilepsy, and insulin regulation (Doupnik, C.A. et al. (1995) *Curr. Opin. Neurobiol.* 5:268-277; Curran, *supra*).

The recently recognized TWIK K⁺ channel family includes the mammalian TWIK-1, TREK-1 and TASK proteins. Members of this family possess an overall structure with four transmembrane domains and two P domains. These proteins are probably involved in controlling
10 the resting potential in a large set of cell types (Duprat, F. et al. (1997) *EMBO J* 16:5464-5471).

The voltage-gated Ca²⁺ channels have been classified into several subtypes based upon their electrophysiological and pharmacological characteristics. L-type Ca²⁺ channels are predominantly expressed in heart and skeletal muscle where they play an essential role in excitation-contraction coupling. T-type channels are important for cardiac pacemaker activity, while N-type and P/Q-type
15 channels are involved in the control of neurotransmitter release in the central and peripheral nervous system. The L-type and N-type voltage-gated Ca²⁺ channels have been purified and, though their functions differ dramatically, they have similar subunit compositions. The channels are composed of three subunits. The α_1 subunit forms the membrane pore and voltage sensor, while the $\alpha_2\delta$ and β subunits modulate the voltage-dependence, gating properties, and the current amplitude of the
20 channel. These subunits are encoded by at least six α_1 , one $\alpha_2\delta$, and four β genes. A fourth subunit, γ , has been identified in skeletal muscle (Walker, D. et al. (1998) *J. Biol. Chem.* 273:2361-2367; McCleskey, E.W. (1994) *Curr. Opin. Neurobiol.* 4:304-312).

The high-voltage-activated Ca²⁺ channels that have been characterized biochemically include complexes of a pore-forming α_1 subunit of approximately 190-250 kDa; a
25 transmembrane complex of α_2 and δ subunits; an intracellular β subunit; and in some cases a transmembrane γ subunit. A variety of α_1 subunits, $\alpha_2\delta$ complexes, β subunits, and γ subunits are known. The Cav1 family of α_1 subunits conduct L-type Ca²⁺ currents, which initiate muscle contraction, endocrine secretion, and gene transcription, and are regulated primarily by second messenger-activated protein phosphorylation pathways. The Cav2
30 family of α_1 subunits conduct N-type, P/Q-type, and R-type Ca²⁺ currents, which initiate rapid synaptic transmission and are regulated primarily by direct interaction with G proteins and SNARE proteins and secondarily by protein phosphorylation. The Cav3 family of α_1 subunits conduct T-type Ca²⁺ currents, which are activated and inactivated more rapidly and at more negative membrane potentials than other Ca²⁺ current types. The distinct structures and patterns of
35 regulation of these three families of Ca²⁺ channels provide an array of Ca²⁺ entry pathways in

response to changes in membrane potential and a range of possibilities for regulation of Ca^{2+} entry by second messenger pathways and interacting proteins (Catterall, W.A. (2000) *Annu. Rev. Cell Dev. Biol.* 16:521-555).

The alpha-2 subunit of the voltage-gated Ca^{2+} -channel may include one or more Cache domains. An extracellular Cache domain may be fused to an intracellular catalytic domain, such as the histidine kinase, PP2C phosphatase, GGDEF (a predicted diguanylate cyclase), HD-GYP (a predicted phosphodiesterase) or adenylyl cyclase domain, or to a noncatalytic domain, like the methyl-accepting, DNA-binding winged helix-turn-helix, GAF, PAS or HAMP (a domain found in histidine kinases, denylyl cyclases, ethyl-binding proteins and phosphatases). Small molecules are bound via the Cache domain and this signal is converted into diverse outputs depending on the intracellular domains (Anantharaman, V. and Aravind, L.(2000) *Trends Biochem. Sci.* 25:535-537).

The transient receptor family (Trp) of calcium ion channels are thought to mediate capacitative calcium entry (CCE). CCE is the Ca^{2+} influx into cells to resupply Ca^{2+} stores depleted by the action of inositol triphosphate (IP3) and other agents in response to numerous hormones and growth factors. Trp and Trp-like were first cloned from *Drosophila* and have similarity to voltage gated Ca^{2+} channels in the S3 through S6 regions. This suggests that Trp and/or related proteins may form mammalian CCE channels (Zhu, X. et al. (1996) *Cell* 85:661-671; Boulay, G. et al. (1997) *J. Biol. Chem.* 272:29672-29680). Melastatin is a gene isolated in both the mouse and human, whose expression in melanoma cells is inversely correlated with melanoma aggressiveness in vivo. The human cDNA transcript corresponds to a 1533-amino acid protein having homology to members of the Trp family. It has been proposed that the combined use of malastatin mRNA expression status and tumor thickness might allow for the determination of subgroups of patients at both low and high risk for developing metastatic disease (Duncan, L.M. et al (2001) *J. Clin. Oncol.* 19:568-576).

Chloride channels are necessary in endocrine secretion and in regulation of cytosolic and organelle pH. In secretory epithelial cells, Cl^- enters the cell across a basolateral membrane through an Na^+ , K^+/Cl^- cotransporter, accumulating in the cell above its electrochemical equilibrium concentration. Secretion of Cl^- from the apical surface, in response to hormonal stimulation, leads to flow of Na^+ and water into the secretory lumen. The cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel encoded by the gene for cystic fibrosis, a common fatal genetic disorder in humans. CFTR is a member of the ABC transporter family, and is composed of two domains each consisting of six transmembrane domains followed by a nucleotide-binding site. Loss of CFTR function decreases transepithelial water secretion and, as a result, the layers of mucus that coat the respiratory tree, pancreatic ducts, and intestine are dehydrated and difficult to clear. The resulting blockage of these sites leads to pancreatic insufficiency, "meconium ileus", and

devastating "chronic obstructive pulmonary disease" (Al-Awqati, Q. et al. (1992) J. Exp. Biol. 172:245-266).

The voltage-gated chloride channels (CLC) are characterized by 10-12 transmembrane domains, as well as two small globular domains known as CBS domains. The CLC subunits probably function as homotetramers. CLC proteins are involved in regulation of cell volume, membrane potential stabilization, signal transduction, and transepithelial transport. Mutations in CLC-1, expressed predominantly in skeletal muscle, are responsible for autosomal recessive generalized myotonia and autosomal dominant myotonia congenita, while mutations in the kidney channel CLC-5 lead to kidney stones (Jentsch, T.J. (1996) Curr. Opin. Neurobiol. 6:303-310).

Ligand-gated channels open their pores when an extracellular or intracellular mediator binds to the channel. Neurotransmitter-gated channels are channels that open when a neurotransmitter binds to their extracellular domain. These channels exist in the postsynaptic membrane of nerve or muscle cells. There are two types of neurotransmitter-gated channels. Sodium channels open in response to excitatory neurotransmitters, such as acetylcholine, glutamate, and serotonin. This opening causes an influx of Na^+ and produces the initial localized depolarization that activates the voltage-gated channels and starts the action potential. Chloride channels open in response to inhibitory neurotransmitters, such as γ -aminobutyric acid (GABA) and glycine, leading to hyperpolarization of the membrane and the subsequent generation of an action potential. Neurotransmitter-gated ion channels have four transmembrane domains and probably function as pentamers (Jentsch, supra). Amino acids in the second transmembrane domain appear to be important in determining channel permeation and selectivity (Sather, W.A. et al. (1994) Curr. Opin. Neurobiol. 4:313-323).

Ligand-gated channels can be regulated by intracellular second messengers. For example, calcium-activated K^+ channels are gated by internal calcium ions. In nerve cells, an influx of calcium during depolarization opens K^+ channels to modulate the magnitude of the action potential (Ishi et al., supra). The large conductance (BK) channel has been purified from brain and its subunit composition determined. The α subunit of the BK channel has seven rather than six transmembrane domains in contrast to voltage-gated K^+ channels. The extra transmembrane domain is located at the subunit N-terminus. A 28-amino-acid stretch in the C-terminal region of the subunit (the "calcium bowl" region) contains many negatively charged residues and is thought to be the region responsible for calcium binding. The β subunit consists of two transmembrane domains connected by a glycosylated extracellular loop, with intracellular N- and C-termini (Kaczorowski, supra; Vergara, C. et al. (1998) Curr. Opin. Neurobiol. 8:321-329).

Cyclic nucleotide-gated (CNG) channels are gated by cytosolic cyclic nucleotides. The best examples of these are the cAMP-gated Na^+ channels involved in olfaction and the cGMP-gated

cation channels involved in vision. Both systems involve ligand-mediated activation of a G-protein coupled receptor which then alters the level of cyclic nucleotide within the cell. CNG channels also represent a major pathway for Ca^{2+} entry into neurons, and play roles in neuronal development and plasticity. CNG channels are tetramers containing at least two types of subunits, an α subunit which
5 can form functional homomeric channels, and a β subunit, which modulates the channel properties. All CNG subunits have six transmembrane domains and a pore forming region between the fifth and sixth transmembrane domains, similar to voltage-gated K^+ channels. A large C-terminal domain contains a cyclic nucleotide binding domain, while the N-terminal domain confers variation among channel subtypes (Zufall, F. et al. (1997) *Curr. Opin. Neurobiol.* 7:404-412).

10 The activity of other types of ion channel proteins may also be modulated by a variety of intracellular signalling proteins. Many channels have sites for phosphorylation by one or more protein kinases including protein kinase A, protein kinase C, tyrosine kinase, and casein kinase II, all of which regulate ion channel activity in cells. Kir channels are activated by the binding of the $\text{G}\beta\gamma$ subunits of heterotrimeric G-proteins (Reimann, F. and F.M. Ashcroft (1999) *Curr. Opin. Cell.*
15 *Biol.* 11:503-508). Other proteins are involved in the localization of ion channels to specific sites in the cell membrane. Such proteins include the PDZ domain proteins known as MAGUKs (membrane-associated guanylate kinases) which regulate the clustering of ion channels at neuronal synapses (Craven, S.E. and D.S. Brecht (1998) *Cell* 93:495-498).

Disease Correlation

20 The etiology of numerous human diseases and disorders can be attributed to defects in the transport of molecules across membranes. Defects in the trafficking of membrane-bound transporters and ion channels are associated with several disorders, e.g., cystic fibrosis, glucose-galactose malabsorption syndrome, hypercholesterolemia, von Gierke disease, and certain forms of diabetes mellitus. Single-gene defect diseases resulting in an inability to transport small
25 molecules across membranes include, e.g., cystinuria, iminoglycinuria, Hartup disease, and Fanconi disease (van't Hoff, W.G. (1996) *Exp. Nephrol.* 4:253-262; Talente, G.M. et al. (1994) *Ann. Intern. Med.* 120:218-226; and Chillon, M. et al. (1995) *New Engl. J. Med.* 332:1475-1480).

Human diseases caused by mutations in ion channel genes include disorders of skeletal muscle, cardiac muscle, and the central nervous system. Mutations in the pore-forming subunits of
30 sodium and chloride channels cause myotonia, a muscle disorder in which relaxation after voluntary contraction is delayed. Sodium channel myotonias have been treated with channel blockers. Mutations in muscle sodium and calcium channels cause forms of periodic paralysis, while mutations in the sarcoplasmic calcium release channel, T-tubule calcium channel, and muscle sodium channel cause malignant hyperthermia. Cardiac arrhythmia disorders such as the long QT
35 syndromes and idiopathic ventricular fibrillation are caused by mutations in potassium and sodium

channels (Cooper, E.C. and L.Y. Jan (1998) Proc. Natl. Acad. Sci. USA 96:4759-4766). All four known human idiopathic epilepsy genes code for ion channel proteins (Berkovic, S.F. and I.E. Scheffer (1999) Curr. Opin. Neurology 12:177-182). Other neurological disorders such as ataxias, hemiplegic migraine and hereditary deafness can also result from mutations in ion channel genes

5 (Jen, J. (1999) Curr. Opin. Neurobiol. 9:274-280; Cooper, supra).

Ion channels have been the target for many drug therapies. Neurotransmitter-gated channels have been targeted in therapies for treatment of insomnia, anxiety, depression, and schizophrenia. Voltage-gated channels have been targeted in therapies for arrhythmia, ischemic stroke, head trauma, and neurodegenerative disease (Taylor, C.P. and L.S. Narasimhan (1997) Adv. Pharmacol.

10 39:47-98). Various classes of ion channels also play an important role in the perception of pain, and thus are potential targets for new analgesics. These include the vanilloid-gated ion channels, which are activated by the vanilloid capsaicin, as well as by noxious heat. Local anesthetics such as lidocaine and mexiletine which blockade voltage-gated Na⁺ channels have been useful in the treatment of neuropathic pain (Eglen, supra). Calcium-channel protein expression is altered in

15 metastatic melanomas (Enklaar, T. et al. (2000) Genomics 67:179-187).

Ion channels in the immune system have recently been suggested as targets for immunomodulation. T-cell activation depends upon calcium signaling, and a diverse set of T-cell specific ion channels has been characterized that affect this signaling process. Channel blocking agents can inhibit secretion of lymphokines, cell proliferation, and killing of target cells. A peptide

20 antagonist of the T-cell potassium channel Kv1.3 was found to suppress delayed-type hypersensitivity and allogenic responses in pigs, validating the idea of channel blockers as safe and efficacious immunosuppressants (Cahalan, M.D. and K.G. Chandy (1997) Curr. Opin. Biotechnol. 8:749-756).

The discovery of new transporters and ion channels, and the polynucleotides encoding them, satisfies a need in the art by providing new compositions which are useful in the diagnosis,

25 prevention, and treatment of transport, neurological, muscle, immunological and cell proliferative disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of transporters and ion channels.

30 SUMMARY OF THE INVENTION

The invention features purified polypeptides, transporters and ion channels, referred to collectively as "TRICH" and individually as "TRICH-1," "TRICH-2," "TRICH-3," "TRICH-4," "TRICH-5," "TRICH-6," "TRICH-7," "TRICH-8," "TRICH-9," "TRICH-10," "TRICH-11," "TRICH-12," "TRICH-13," "TRICH-14," "TRICH-15," "TRICH-16," "TRICH-17," "TRICH-18,"

35 "TRICH-19," "TRICH-20," "TRICH-21," "TRICH-22," "TRICH-23," "TRICH-24," "TRICH-25,"

"TRICH-26," "TRICH-27," "TRICH-28," "TRICH-29," "TRICH-30," "TRICH-31," and "TRICH-32." In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-32.

The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-32. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:33-64.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of

SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32.

The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous

nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of
5 SEQ ID NO:33-64, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain
10 reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a
15 naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and a pharmaceutically acceptable excipient. In one embodiment,
20 the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional TRICH, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an
25 agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an
30 immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of
35 treating a disease or condition associated with decreased expression of functional TRICH,

comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide
5 comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. The method comprises a) exposing a sample
10 comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional TRICH, comprising administering to a patient in need of such treatment the composition.

15 The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide
20 having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

25 The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide
30 having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of
35 the polypeptide in the presence of the test compound with the activity of the polypeptide in the

absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

10 The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, ii) 15 a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide 20 in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide 25 complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization 30 complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

35 Table 2 shows the GenBank identification number and annotation of the nearest GenBank

homolog for polypeptides of the invention. The probability scores for the matches between each polypeptide and its homolog(s) are also shown.

Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

Table 5 shows the representative cDNA library for polynucleotides of the invention.

Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"TRICH" refers to the amino acid sequences of substantially purified TRICH obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

5 The term "agonist" refers to a molecule which intensifies or mimics the biological activity of TRICH. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of TRICH either by directly interacting with TRICH or by acting on components of the biological pathway in which TRICH participates.

10 An "allelic variant" is an alternative form of the gene encoding TRICH. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of
15 nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding TRICH include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as TRICH or a polypeptide with at least one functional characteristic of TRICH. Included within this definition
20 are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding TRICH, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding TRICH. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a
25 functionally equivalent TRICH. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of TRICH is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar
30 side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or
35 synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally

occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence.

5 Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of TRICH. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the
10 activity of TRICH either by directly interacting with TRICH or by acting on components of the biological pathway in which TRICH participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind TRICH polypeptides can be prepared using intact polypeptides or
15 using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used
20 to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures
25 on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "aptamer" refers to a nucleic acid or oligonucleotide molecule that binds to a specific molecular target. Aptamers are derived from an in vitro evolutionary process (e.g., SELEX (Systematic Evolution of Ligands by EXponential Enrichment), described in U.S. Patent No.
30 5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries. Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules. The nucleotide components of an aptamer may have modified sugar groups (e.g., the 2'-OH group of a ribonucleotide may be replaced by 2'-F or 2'-NH₂), which may improve a desired property, e.g.,
35 resistance to nucleases or longer lifetime in blood. Aptamers may be conjugated to other molecules,

e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system. Aptamers may be specifically cross-linked to their cognate ligands, e.g., by photo-activation of a cross-linker. (See, e.g., Brody, E.N. and L. Gold (2000) J. Biotechnol. 74:5-13.)

The term "intramer" refers to an aptamer which is expressed in vivo. For example, a
5 vaccinia virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Natl Acad. Sci. USA 96:3606-3610).

The term "spiegelmer" refers to an aptamer which includes L-DNA, L-RNA, or other left-handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed
10 nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on substrates containing right-handed nucleotides.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as
15 phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring
20 nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or
25 "immunogenic" refers to the capability of the natural, recombinant, or synthetic TRICH, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement,
30 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding TRICH or
35 fragments of TRICH may be employed as hybridization probes. The probes may be stored in freeze-

dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

5 "Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, 10 Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows 15 amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
	Ala	Gly, Ser
	Arg	His, Lys
20	Asn	Asp, Gln, His
	Asp	Asn, Glu
	Cys	Ala, Ser
	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
25	Gly	Ala
	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
	Leu	Ile, Val
	Lys	Arg, Gln, Glu
30	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
	Thr	Ser, Val
	Trp	Phe, Tyr
35	Tyr	His, Phe, Trp
	Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical 40 conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the

absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which
5 retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

10 "Differential expression" refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.

"Exon shuffling" refers to the recombination of different coding regions (exons). Since an
15 exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.

A "fragment" is a unique portion of TRICH or the polynucleotide encoding TRICH which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise
20 up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a
25 molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

30 A fragment of SEQ ID NO:33-64 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:33-64, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:33-64 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:33-64 from related polynucleotide sequences. The precise length of a fragment of SEQ
35 ID NO:33-64 and the region of SEQ ID NO:33-64 to which the fragment corresponds are routinely

determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-32 is encoded by a fragment of SEQ ID NO:33-64. A fragment of SEQ ID NO:1-32 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-32. For example, a fragment of SEQ ID NO:1-32 is useful as an
5 immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-32. The precise length of a fragment of SEQ ID NO:1-32 and the region of SEQ ID NO:1-32 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A "full length" polynucleotide sequence is one containing at least a translation initiation
10 codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full length" polynucleotide sequence encodes a "full length" polypeptide sequence.

"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer
15 to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default
20 parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters
25 are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local
30 Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST
35 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2

Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>.

The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool

- 5 Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

Penalty for mismatch: -2

- 10 *Open Gap: 5 and Extension Gap: 2 penalties*

Gap x drop-off: 50

Expect: 10

Word Size: 11

Filter: on

- 15 Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment
- 20 length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

- Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic
- 25 acid sequences that all encode substantially the same protein.

- The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative
- 30 substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

- Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of
- 35 polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap

penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of

complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas

wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

- 5 Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for
10 calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

- High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS,
15 for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under
20 particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

- 25 The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate
30 substrate to which cells or their nucleic acids have been fixed).

 The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

- "Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression
35 of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect

cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of TRICH which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide
5 fragment of TRICH which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other
10 chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of TRICH. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of TRICH.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide,
15 oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a
20 functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which
25 comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an TRICH may involve lipidation, glycosylation,
30 phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of TRICH.

"Probe" refers to nucleic acid sequences encoding TRICH, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are
35 isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule.

Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.

"Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and

5 identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences.

10 Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold
15 Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research,

20 Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer
25 selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for
30 Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human
35 Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple

sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above
5 selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence
10 that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently,
15 a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is
20 expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

25 "Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear
30 sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term "sample" is used in its broadest sense. A sample suspected of containing TRICH, nucleic acids encoding TRICH, or fragments thereof may comprise a bodily fluid; an extract from a
35 cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or

cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" or "expression profile" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed cells" includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention; such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by

infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, or at least 98%, or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, or at least 98%, or greater sequence identity over a certain defined length of one of the polypeptides.

35 THE INVENTION

The invention is based on the discovery of new human transporters and ion channels (TRICH), the polynucleotides encoding TRICH, and the use of these compositions for the diagnosis, treatment, or prevention of transport, neurological, muscle, immunological and cell proliferative disorders.

5 Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide
10 sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the
15 polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (GenBank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability scores for the matches between each polypeptide and its homolog(s). Column 5 shows the annotation of the GenBank homolog(s) along with relevant
20 citations where applicable, all of which are expressly incorporated by reference herein.

Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential
25 phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

30 Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are transporters and ion channels. For example, SEQ ID NO:1 is 83% identical to human sodium-hydrogen exchanger 6 (GenBank ID g2944233) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $5.1e-242$, which indicates the probability of obtaining the observed
35 polypeptide sequence alignment by chance. SEQ ID NO:1 also contains a sodium/hydrogen

exchanger family domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, and other BLAST analyses provide further corroborative evidence that SEQ ID NO:1 is a sodium-hydrogen exchange transporter. In another example, SEQ ID NO:7 is 85% identical to Rattus norvegicus Na⁺/K⁺-ATPase alpha subunit (GenBank ID g619915) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:7 also contains an E1-E2 ATPase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:7 is a cation-transporting ATPase. In yet another example, SEQ ID NO:13 is 77% identical to a human carrier-like protein (GenBank ID g3694661) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 5.5e-209, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:13 also contains a mitochondrial energy transfer protein domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) The presence of this domain is confirmed by BLIMPS, MOTIFS, and PROFILESCAN analyses, providing further corroborative evidence that SEQ ID NO:13 is a transporter. Further, SEQ ID NO:16 is 41% identical to human novel ATPase (GenBank ID g8979801) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 1.1e-165, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:16 also contains an E1-E2 ATPase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:16 is a cation-transporting ATPase. In a further example, SEQ ID NO:19 is 43% identical to Sinorhizobium sp. As4 ArsA, the catalytic subunit of the arsenic oxyanion-translocating ATPase (GenBank ID g5802945) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 7.7e-125, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:19 also contains an anion-transporting ATPase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from additional BLAST and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:19 is an anion-transporting ATPase. In yet a further

example, SEQ ID NO:21 is 54% identical to a murine putative E1-E2 ATPase (GenBank ID g28577) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $5.2e-190$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:21 also contains six transmembrane domains as determined using TMAP, a program which delineates transmembrane segments. (See Table 3.) Data from BLIMPS, and MOTIFS, analyses provide further corroborative evidence that SEQ ID NO:21 is an ATPase. In a further example, SEQ ID NO:24 is 52% identical, from residue A77 to residue L1007, to rat NMDAR-L (GenBank ID g2160125) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $1.5e-262$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:24 also contains a ligand gated ion channel domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS analysis provide further corroborative evidence that SEQ ID NO:24 is a glutamate receptor. SEQ ID NO:2-6, SEQ ID NO:8-12, SEQ ID NO:14-15, SEQ ID NO:17-18, SEQ ID NO:20, SEQ ID NO:22-23, and SEQ ID NO:25-32 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ ID NO:1-32 are described in Table 7.

As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Column 1 lists the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:), the corresponding Incyte polynucleotide consensus sequence number (Incyte ID) for each polynucleotide of the invention, and the length of each polynucleotide sequence in basepairs. Column 2 shows the nucleotide start (5') and stop (3') positions of the cDNA and/or genomic sequences used to assemble the full length polynucleotide sequences of the invention, and of fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:33-64 or that distinguish between SEQ ID NO:33-64 and related polynucleotide sequences.

The polynucleotide fragments described in Column 2 of Table 4 may refer specifically, for example, to Incyte cDNAs derived from tissue-specific cDNA libraries or from pooled cDNA libraries. Alternatively, the polynucleotide fragments described in column 2 may refer to GenBank cDNAs or ESTs which contributed to the assembly of the full length polynucleotide sequences. In addition, the polynucleotide fragments described in column 2 may identify sequences derived from the ENSEMBL (The Sanger Centre, Cambridge, UK) database (*i.e.*, those sequences including the designation "ENST"). Alternatively, the polynucleotide fragments described in column 2 may be derived from the NCBI RefSeq Nucleotide Sequence Records Database (*i.e.*, those sequences

including the designation "NM" or "NT") or the NCBI RefSeq Protein Sequence Records (*i.e.*, those sequences including the designation "NP"). Alternatively, the polynucleotide fragments described in column 2 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. For example, a polynucleotide sequence identified as FL_XXXXXX_N₁_N₂_YYYYY_N₃_N₄ represents a "stitched" sequence in which XXXXXX is the identification number of the cluster of sequences to which the algorithm was applied, and YYYYY is the number of the prediction generated by the algorithm, and N_{1,2,3...}, if present, represent specific exons that may have been manually edited during analysis (See Example V). Alternatively, the polynucleotide fragments in column 2 may refer to assemblages of exons brought together by an "exon-stretching" algorithm. For example, a polynucleotide sequence identified as FLXXXXXX_gAAAAA_gBBBBB_1_N is a "stretched" sequence, with XXXXXX being the Incyte project identification number, gAAAAA being the GenBank identification number of the human genomic sequence to which the "exon-stretching" algorithm was applied, gBBBBB being the GenBank identification number or NCBI RefSeq identification number of the nearest GenBank protein homolog, and N referring to specific exons (See Example V). In instances where a RefSeq sequence was used as a protein homolog for the "exon-stretching" algorithm, a RefSeq identifier (denoted by "NM," "NP," or "NT") may be used in place of the GenBank identifier (*i.e.*, gBBBBB).

Alternatively, a prefix identifies component sequences that were hand-edited, predicted from genomic DNA sequences, or derived from a combination of sequence analysis methods. The following Table lists examples of component sequence prefixes and corresponding sequence analysis methods associated with the prefixes (see Example IV and Example V).

Prefix	Type of analysis and/or examples of programs
GNN, GFG, ENST	Exon prediction from genomic sequences using, for example, GENSCAN (Stanford University, CA, USA) or FGENES (Computer Genomics Group, The Sanger Centre, Cambridge, UK).
GBI	Hand-edited analysis of genomic sequences.
FL	Stitched or stretched genomic sequences (see Example V).
INCY	Full length transcript and exon prediction from mapping of EST sequences to the genome. Genomic location and EST composition data are combined to predict the exons and resulting transcript.

In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in Table 4 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

Table 5 shows the representative cDNA libraries for those full length polynucleotide

sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

5 The invention also encompasses TRICH variants. A preferred TRICH variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the TRICH amino acid sequence, and which contains at least one functional or structural characteristic of TRICH.

10 The invention also encompasses polynucleotides which encode TRICH. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:33-64, which encodes TRICH. The polynucleotide sequences of SEQ ID NO:33-64, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

15 The invention also encompasses a variant of a polynucleotide sequence encoding TRICH. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding TRICH. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID
20 NO:33-64 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:33-64. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of TRICH.

25 In addition, or in the alternative, a polynucleotide variant of the invention is a splice variant of a polynucleotide sequence encoding TRICH. A splice variant may have portions which have significant sequence identity to the polynucleotide sequence encoding TRICH, but will generally have a greater or lesser number of polynucleotides due to additions or deletions of blocks of sequence arising from alternate splicing of exons during mRNA processing. A splice variant may have less than about 70%, or alternatively less than about 60%, or alternatively less than about 50%
30 polynucleotide sequence identity to the polynucleotide sequence encoding TRICH over its entire length; however, portions of the splice variant will have at least about 70%, or alternatively at least about 85%, or alternatively at least about 95%, or alternatively 100% polynucleotide sequence identity to portions of the polynucleotide sequence encoding TRICH. Any one of the splice variants described above can encode an amino acid sequence which contains at least one functional or
35 structural characteristic of TRICH.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding TRICH, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring TRICH, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode TRICH and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring TRICH under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding TRICH or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding TRICH and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode TRICH and TRICH derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding TRICH or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:33-64 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence

preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the MEGABACE 1000 DNA
5 sequencing system (Molecular Dynamics; Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

- 10 The nucleic acid sequences encoding TRICH may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic.
15 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA.
20 (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and
25 PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal
30 to the template at temperatures of about 68°C to 72°C.

When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes; are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of
35 sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode TRICH may be cloned in recombinant DNA molecules that direct expression of TRICH, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express TRICH.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter TRICH-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent No. 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Cramer, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of TRICH, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with

fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding TRICH may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, TRICH itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of TRICH, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

In order to express a biologically active TRICH, the nucleotide sequences encoding TRICH or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding TRICH. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding TRICH. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding TRICH and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ.

20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding TRICH and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, 5 synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express 10 sequences encoding TRICH. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti 15 or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. 20 Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 25 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding TRICH. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding TRICH can be achieved 30 using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding TRICH into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, 35 and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M.

Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of TRICH are needed, e.g. for the production of antibodies, vectors which direct high level expression of TRICH may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

- 5 Yeast expression systems may be used for production of TRICH. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 10 1995, supra; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

- Plant systems may also be used for expression of TRICH. Transcription of sequences encoding TRICH may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO 15 J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology 20 (1992) McGraw Hill, New York NY, pp. 191-196.)

- In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding TRICH may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to 25 obtain infective virus which expresses TRICH in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

- Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of 30 DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

- For long term production of recombinant proteins in mammalian systems, stable expression 35 of TRICH in cell lines is preferred. For example, sequences encoding TRICH can be transformed

into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk*⁻ and *apr*⁻ cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding TRICH is inserted within a marker gene sequence, transformed cells containing sequences encoding TRICH can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding TRICH under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding TRICH and that express TRICH may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of TRICH using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing 5 monoclonal antibodies reactive to two non-interfering epitopes on TRICH is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, 10 Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding TRICH include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled 15 nucleotide. Alternatively, the sequences encoding TRICH, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by 20 Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding TRICH may be cultured under 25 conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode TRICH may be designed to contain signal sequences which direct secretion of TRICH through a prokaryotic or eukaryotic cell membrane.

30 In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. 35 Different host cells which have specific cellular machinery and characteristic mechanisms for

post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding TRICH may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric TRICH protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of TRICH activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the TRICH encoding sequence and the heterologous protein sequence, so that TRICH may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled TRICH may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

TRICH of the present invention or fragments thereof may be used to screen for compounds that specifically bind to TRICH. At least one and up to a plurality of test compounds may be screened for specific binding to TRICH. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of TRICH, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2):_Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which TRICH binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case,

the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express TRICH, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing TRICH or cell membrane fractions which contain TRICH
5 are then contacted with a test compound and binding, stimulation, or inhibition of activity of either TRICH or the compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with TRICH, either in
10 solution or affixed to a solid support, and detecting the binding of TRICH to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

15 TRICH of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of TRICH. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for TRICH activity, wherein TRICH is combined with at least one test compound, and the activity of TRICH in the presence of a test compound is compared with the activity of TRICH in the absence
20 of the test compound. A change in the activity of TRICH in the presence of the test compound is indicative of a compound that modulates the activity of TRICH. Alternatively, a test compound is combined with an in vitro or cell-free system comprising TRICH under conditions suitable for TRICH activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of TRICH may do so indirectly and need not come in direct contact with the
25 test compound. At least one and up to a plurality of test compounds may be screened.

In another embodiment, polynucleotides encoding TRICH or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent No. 5,175,383 and U.S. Patent No.
30 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous
35 recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or

developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

Polynucleotides encoding TRICH may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

Polynucleotides encoding TRICH can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding TRICH is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress TRICH, e.g., by secreting TRICH in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of TRICH and transporters and ion channels. In addition, examples of tissues expressing TRICH can be found in Table 6. Therefore, TRICH appears to play a role in transport, neurological, muscle, immunological and cell proliferative disorders. In the treatment of disorders associated with increased TRICH expression or activity, it is desirable to decrease the expression or activity of TRICH. In the treatment of disorders associated with decreased TRICH expression or activity, it is desirable to increase the expression or activity of TRICH.

Therefore, in one embodiment, TRICH or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TRICH. Examples of such disorders include, but are not limited to, a transport disorder such as akinesia, amyotrophic lateral sclerosis, ataxia telangiectasia, cystic fibrosis, Becker's muscular dystrophy, Bell's palsy, Charcot-Marie Tooth disease, diabetes mellitus, diabetes insipidus, diabetic neuropathy, Duchenne muscular dystrophy, hyperkalemic periodic paralysis, normokalemic periodic paralysis, Parkinson's disease, malignant hyperthermia, multidrug

- resistance, myasthenia gravis, myotonic dystrophy, catatonia, tardive dyskinesia, dystonias, peripheral neuropathy, cerebral neoplasms, prostate cancer, cardiac disorders associated with transport, e.g., angina, bradyarrhythmia, tachyarrhythmia, hypertension, Long QT syndrome, myocarditis, cardiomyopathy, nemaline myopathy, centronuclear myopathy, lipid myopathy,
- 5 mitochondrial myopathy, thyrotoxic myopathy, ethanol myopathy, dermatomyositis, inclusion body myositis, infectious myositis, polymyositis, neurological disorders associated with transport, e.g., Alzheimer's disease, amnesia, bipolar disorder, dementia, depression, epilepsy, Tourette's disorder, paranoid psychoses, and schizophrenia, and other disorders associated with transport, e.g., neurofibromatosis, postherpetic neuralgia, trigeminal neuropathy, sarcoidosis, sickle cell anemia,
- 10 Wilson's disease, cataracts, infertility, pulmonary artery stenosis, sensorineural autosomal deafness, hyperglycemia, hypoglycemia, Grave's disease, goiter, Cushing's disease, Addison's disease, glucose-galactose malabsorption syndrome, glycogen storage disease, hypercholesterolemia, adrenoleukodystrophy, Zellweger syndrome, Menkes disease, occipital horn syndrome, von Gierke disease, pseudohypoaldosteronism type 1, Liddle's syndrome, cystinuria, iminoglycinuria, Hartup
- 15 disease, Fanconi disease, and Bartter syndrome; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating
- 20 diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis,
- 25 encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic
- 30 paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy, hemiplegic migraine, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a muscle disorder such as cardiomyopathy, myocarditis, Duchenne's muscular dystrophy, Becker's muscular
- 35 dystrophy, myotonic dystrophy, central core disease, nemaline myopathy, centronuclear myopathy,

lipid myopathy, mitochondrial myopathy, infectious myositis, polymyositis, dermatomyositis, inclusion body myositis, thyrotoxic myopathy, ethanol myopathy, angina, anaphylactic shock, arrhythmias, asthma, cardiovascular shock, Cushing's syndrome, hypertension, hypoglycemia, myocardial infarction, migraine, pheochromocytoma, and myopathies including encephalopathy, epilepsy, Kearns-Sayre syndrome, lactic acidosis, myoclonic disorder, ophthalmoplegia, acid maltase deficiency (AMD, also known as Pompe's disease), generalized myotonia, and myotonia congenita; an immunological disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus.

In another embodiment, a vector capable of expressing TRICH or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TRICH including, but not limited to, those described above.

In a further embodiment, a composition comprising a substantially purified TRICH in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TRICH including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of TRICH may be

administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TRICH including, but not limited to, those listed above.

In a further embodiment, an antagonist of TRICH may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of TRICH. Examples of such disorders include, but are not limited to, those transport, neurological, muscle, immunological and cell proliferative disorders described above. In one aspect, an antibody which specifically binds TRICH may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express TRICH.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding TRICH may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of TRICH including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of TRICH may be produced using methods which are generally known in the art. In particular, purified TRICH may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind TRICH. Antibodies to TRICH may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with TRICH or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to TRICH have an amino acid sequence consisting of at least about 5 amino acids, and generally will

consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of TRICH amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

5 Monoclonal antibodies to TRICH may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci. USA* 80:2026-2030; and Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and
15 Takeda, S. et al. (1985) *Nature* 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce TRICH-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) *Proc. Natl. Acad. Sci. USA* 88:10134-
20 10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:3833-3837; Winter, G. et al. (1991) *Nature* 349:293-299.)

25 Antibody fragments which contain specific binding sites for TRICH may also be generated. For example, such fragments include, but are not limited to, F(ab')₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D.
30 et al. (1989) *Science* 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between TRICH and its
35 specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies

reactive to two non-interfering TRICH epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for TRICH. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of TRICH-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple TRICH epitopes, represents the average affinity, or avidity, of the antibodies for TRICH. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular TRICH epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the TRICH-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of TRICH, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of TRICH-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding TRICH, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding TRICH. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding TRICH. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence

complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) *J. Allergy Clin. Immunol.* 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) 5 *Blood* 76:271; Ausubel, *supra*; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.* 25(14):2730-2736.)

10 In another embodiment of the invention, polynucleotides encoding TRICH may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) *Science* 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase 15 (ADA) deficiency (Blaese, R.M. et al. (1995) *Science* 270:475-480; Bordignon, C. et al. (1995) *Science* 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) *Cell* 75:207-216; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:643-666; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:667-703), thalassemias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) *Science* 270:404-410; Verma, I.M. and N. Somia (1997) *Nature* 20 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) *Nature* 335:395-396; Poeschla, E. et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida 25 albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in TRICH expression or regulation causes disease, the expression of TRICH from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in 30 TRICH are treated by constructing mammalian expression vectors encoding TRICH and introducing these vectors by mechanical means into TRICH-deficient cells. Mechanical transfer technologies for use with cells *in vivo* or *ex vitro* include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) *Annu. Rev.* 35 *Biochem.* 62:191-217; Ivics, Z. (1997) *Cell* 91:501-510; Boulay, J-L. and H. Récipon (1998) *Curr.*

Opin. Biotechnol. 9:445-450).

Expression vectors that may be effective for the expression of TRICH include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX, PCR2-TOPOTA vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). TRICH may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and H.M. Blau, supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding TRICH from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to TRICH expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding TRICH under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent No. 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant")

discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding TRICH to cells which have one or more genetic abnormalities with respect to the expression of TRICH. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Cséte, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent No. 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I.M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding TRICH to target cells which have one or more genetic abnormalities with respect to the expression of TRICH. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing TRICH to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res. 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent No. 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent No. 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) J. Virol. 73:519-532 and Xu, H. et al. (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to

those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding TRICH to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotechnol. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for TRICH into the alphavirus genome in place of the capsid-coding region results in the production of a large number of TRICH-coding RNAs and the synthesis of high levels of TRICH in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of TRICH into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding TRICH.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by

scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding TRICH. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding TRICH.

Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased TRICH expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding TRICH may be therapeutically useful, and in the treatment of disorders associated with decreased TRICH expression or activity, a compound which specifically promotes expression of the polynucleotide encoding TRICH may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in

altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding TRICH is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an *in vitro* cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding TRICH are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding TRICH. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a *Schizosaccharomyces pombe* gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruce, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruce, T.W. et al. (2000) U.S. Patent No. 6,022,691).

Many methods for introducing vectors into cells or tissues are available and equally suitable for use *in vivo*, *in vitro*, and *ex vivo*. For *ex vivo* therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable

excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of TRICH, antibodies to TRICH, and mimetics, agonists, antagonists, or inhibitors of

5 TRICH.

The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

10 Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar
15 region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active
20 ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising TRICH or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of
25 the macromolecule. Alternatively, TRICH or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell
30 culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example
35 TRICH or fragments thereof, antibodies of TRICH, and agonists, antagonists or inhibitors of

TRICH, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μg to 100,000 μg , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind TRICH may be used for the diagnosis of disorders characterized by expression of TRICH, or in assays to monitor patients being treated with TRICH or agonists, antagonists, or inhibitors of TRICH. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for TRICH include methods which utilize the antibody and a label to detect TRICH in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring TRICH, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of TRICH expression.

Normal or standard values for TRICH expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to TRICH under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of

5 TRICH expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding TRICH may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide
10 sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of TRICH may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of TRICH, and to monitor regulation of TRICH levels during therapeutic intervention.

15 In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding TRICH or closely related molecules may be used to identify nucleic acid sequences which encode TRICH. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine
20 whether the probe identifies only naturally occurring sequences encoding TRICH, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the TRICH encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:33-64 or
25 from genomic sequences including promoters, enhancers, and introns of the TRICH gene.

Means for producing specific hybridization probes for DNAs encoding TRICH include the cloning of polynucleotide sequences encoding TRICH or TRICH derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA
30 polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ³²P or ³⁵S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding TRICH may be used for the diagnosis of disorders associated with expression of TRICH. Examples of such disorders include, but are not limited to, a
35 transport disorder such as akinesia, amyotrophic lateral sclerosis, ataxia telangiectasia, cystic

- fibrosis, Becker's muscular dystrophy, Bell's palsy, Charcot-Marie Tooth disease, diabetes mellitus, diabetes insipidus, diabetic neuropathy, Duchenne muscular dystrophy, hyperkalemic periodic paralysis, normokalemic periodic paralysis, Parkinson's disease, malignant hyperthermia, multidrug resistance, myasthenia gravis, myotonic dystrophy, catatonia, tardive dyskinesia, dystonias,
- 5 peripheral neuropathy, cerebral neoplasms, prostate cancer, cardiac disorders associated with transport, e.g., angina, bradyarrhythmia, tachyarrhythmia, hypertension, Long QT syndrome, myocarditis, cardiomyopathy, nemaline myopathy, centronuclear myopathy, lipid myopathy, mitochondrial myopathy, thyrotoxic myopathy, ethanol myopathy, dermatomyositis, inclusion body myositis, infectious myositis, polymyositis, neurological disorders associated with transport, e.g.,
- 10 Alzheimer's disease, amnesia, bipolar disorder, dementia, depression, epilepsy, Tourette's disorder, paranoid psychoses, and schizophrenia, and other disorders associated with transport, e.g., neurofibromatosis, postherpetic neuralgia, trigeminal neuropathy, sarcoidosis, sickle cell anemia, Wilson's disease, cataracts, infertility, pulmonary artery stenosis, sensorineural autosomal deafness, hyperglycemia, hypoglycemia, Grave's disease, goiter, Cushing's disease, Addison's disease,
- 15 glucose-galactose malabsorption syndrome, glycogen storage disease, hypercholesterolemia, adrenoleukodystrophy, Zellweger syndrome, Menkes disease, occipital horn syndrome, von Gierke disease, pseudohypoadosteronism type 1, Liddle's syndrome, cystinuria, iminoglycinuria, Hartup disease, Fanconi disease, and Bartter syndrome; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease,
- 20 Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system
- 25 disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders, autonomic
- 30 nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy, hemiplegic migraine, tardive
- 35 dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive

supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a muscle disorder such as cardiomyopathy, myocarditis, Duchenne's muscular dystrophy, Becker's muscular dystrophy, myotonic dystrophy, central core disease, nemaline myopathy, centronuclear myopathy, lipid myopathy, mitochondrial myopathy, infectious myositis, polymyositis, dermatomyositis, inclusion body myositis, thyrotoxic myopathy, ethanol myopathy, angina, anaphylactic shock, arrhythmias, asthma, cardiovascular shock, Cushing's syndrome, hypertension, hypoglycemia, myocardial infarction, migraine, pheochromocytoma, and myopathies including encephalopathy, epilepsy, Kearns-Sayre syndrome, lactic acidosis, myoclonic disorder, ophthalmoplegia, acid maltase deficiency (AMD, also known as Pompe's disease), generalized myotonia, and myotonia congenita; an immunological disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus. The polynucleotide sequences encoding TRICH may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered TRICH expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding TRICH may be useful in assays

that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding TRICH may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding TRICH in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

10 In order to provide a basis for the diagnosis of a disorder associated with expression of TRICH, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding TRICH, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from
15 normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated,
20 hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or
25 overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

30 Additional diagnostic uses for oligonucleotides designed from the sequences encoding TRICH may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding TRICH, or a fragment of a polynucleotide complementary to the polynucleotide encoding TRICH, and will be employed under optimized conditions for
35 identification of a specific gene or condition. Oligomers may also be employed under less stringent

conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding TRICH may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding TRICH are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSSCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

Methods which may also be used to quantify the expression of TRICH include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this

information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

5 In another embodiment, TRICH, fragments of TRICH, or antibodies specific for TRICH may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to
10 generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent No. 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be
15 generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

20 Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of
25 pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test
30 compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression
35 of these genes are used to normalize the rest of the expression data. The normalization procedure is

useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National

5 Institute of Environmental Health Sciences, released February 29, 2000, available at <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the
10 treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

15 Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance
20 under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson,
25 supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are
30 compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence
35 data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for TRICH to quantify the levels of TRICH expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal.

5 Biochem. 270:103-111; Mendoz, L.G. et al. (1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and
10 should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Scilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult,
15 due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of
20 each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

25 In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount
30 of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116;
35 Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad.

Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

5 In another embodiment of the invention, nucleic acid sequences encoding TRICH may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during
10 chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J.
15 (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

20 Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding TRICH on a physical map and a specific disorder, or a predisposition to a specific disorder, may
25 help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse,
30 may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for
35 further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide

sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, TRICH, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to
5 a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between TRICH and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT
10 application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with TRICH, or fragments thereof, and washed. Bound TRICH is then detected by methods well known in the art. Purified TRICH can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a
15 solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding TRICH specifically compete with a test compound for binding TRICH. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with TRICH.

20 In additional embodiments, the nucleotide sequences which encode TRICH may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding
25 description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, including U.S. Ser. No. 60/254,303, U.S. Ser. No. 60/256,190, U.S. Ser. No. 60/257,504, U.S. Ser.
30 No. 60/261,546, U.S. Ser. No. 60/262,832, U.S. Ser. No. 60/264,377, and U.S. Ser. No. 60/266,019, are expressly incorporated by reference herein.

EXAMPLES

I. Construction of cDNA Libraries

35 Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD

database (Incyte Genomics, Palo Alto CA). Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPO1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto CA), pRARE (Incyte Genomics), or pINCY (Incyte Genomics), or derivatives thereof. Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids

were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

Incye cDNA recovered in plasmids as described in Example II were sequenced as follows.

Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

The polynucleotide sequences derived from Incye cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incye cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM; PROTEOME databases with sequences from Homo sapiens, Rattus norvegicus, Mus musculus, Caenorhabditis elegans, Saccharomyces cerevisiae, Schizosaccharomyces pombe, and Candida albicans (Incye Genomics, Palo Alto CA); and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incye cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs,

stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, the PROTEOME databases, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:33-64. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 2.

IV. Identification and Editing of Coding Sequences from Genomic DNA

Putative transporters and ion channels were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range

of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode transporters and ion channels, the encoded polypeptides were analyzed by querying against PFAM models for transporters and ion channels. Potential transporters and ion channels were also identified by homology to Incyte cDNA sequences that had been annotated as transporters and ion channels. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpr public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

V. Assembly of Genomic Sequence Data with cDNA Sequence Data

"Stitched" Sequences

Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpr public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from

genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

"Stretched" Sequences

Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

VI. Chromosomal Mapping of TRICH Encoding Polynucleotides

The sequences which were used to assemble SEQ ID NO:33-64 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:33-64 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.

Map locations are represented by ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (<http://www.ncbi.nlm.nih.gov/genemap/>), can be employed to determine if previously

identified disease genes map within or in proximity to the intervals indicated above.

VII. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which
 5 RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel (1995) supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of
 10 the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum} \{ \text{length}(\text{Seq. 1}), \text{length}(\text{Seq. 2}) \}}$$

15

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is
 20 calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100%
 25 identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

Alternatively, polynucleotide sequences encoding TRICH are analyzed with respect to the
 30 tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female;
 35 genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous

system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding TRICH. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

10 VIII. Extension of TRICH Encoding Polynucleotides

Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using
15 OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one
20 extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech),
25 ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step
30 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II
35 (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the

concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:33-64 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ -³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-

based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

X. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, *supra*), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Skena (1999), *supra*). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Skena, M. et al. (1995) *Science* 270:467-470; Shalon, D. et al. (1996) *Genome Res.* 6:639-645; Marshall, A. and J. Hodgson (1998) *Nat. Biotechnol.* 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

Tissue or Cell Sample Preparation

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/ μ l oligo-(dT) primer (21mer), 1X

first strand buffer, 0.03 units/ μ l RNase inhibitor, 500 μ M dATP, 500 μ M dGTP, 500 μ M dTTP, 40 μ M dCTP, 40 μ M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)⁺ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 μ l 5X SSC/0.2% SDS.

Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in U.S. Patent No. 5,807,522, incorporated herein by reference. 1 μ l of the array element DNA, at an average concentration of 100 ng/ μ l, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in 0.2% SDS and distilled water as before.

Hybridization

Hybridization reactions contain 9 μ l of sample mixture consisting of 0.2 μ g each of Cy3 and Cy5-labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μ l of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

10 Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-

compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

XI. Complementary Polynucleotides

Sequences complementary to the TRICH-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring TRICH. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of TRICH. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the TRICH-encoding transcript.

XII. Expression of TRICH

Expression and purification of TRICH is achieved using bacterial or virus-based expression systems. For expression of TRICH in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express TRICH upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of TRICH in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding TRICH by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription.

Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or

washed under conditions that allow the preferential absorbance of TRICH (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/TRICH binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and TRICH is collected.

5 XVI. Identification of Molecules Which Interact with TRICH

Molecules which interact with TRICH may include transporter substrates, agonists or antagonists, modulatory proteins such as G $\beta\gamma$ proteins (Reimann, *supra*) or proteins involved in TRICH localization or clustering such as MAGUKs (Craven, *supra*). TRICH, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled TRICH, washed, and any wells with labeled TRICH complex are assayed. Data obtained using different concentrations of TRICH are used to calculate values for the number, affinity, and association of TRICH with the candidate molecules.

Alternatively, proteins that interact with TRICH are isolated using the yeast 2-hybrid system (Fields, S. and O. Song (1989) *Nature* 340:245-246). TRICH, or fragments thereof, are expressed as fusion proteins with the DNA binding domain of Gal4 or lexA, and potential interacting proteins are expressed as fusion proteins with an activation domain. Interactions between the TRICH fusion protein and the TRICH interacting proteins (fusion proteins with an activation domain) reconstitute a transactivation function that is observed by expression of a reporter gene. Yeast 2-hybrid systems are commercially available, and methods for use of the yeast 2-hybrid system with ion channel proteins are discussed in Niethammer, M. and M. Sheng (1998, *Meth. Enzymol.* 293:104-122).

TRICH may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

Potential TRICH agonists or antagonists may be tested for activation or inhibition of TRICH ion channel activity using the assays described in section XVIII.

XVII. Demonstration of TRICH Activity

Ion channel activity of TRICH is demonstrated using an electrophysiological assay for ion conductance. TRICH can be expressed by transforming a mammalian cell line such as COS7, HeLa or CHO with a eukaryotic expression vector encoding TRICH. Eukaryotic expression vectors are commercially available, and the techniques to introduce them into cells are well known to those skilled in the art. A second plasmid which expresses any one of a number of marker genes, such as β -galactosidase, is co-transformed into the cells to allow rapid identification of those cells which have taken up and expressed the foreign DNA. The cells are incubated for 48-72 hours after

transformation under conditions appropriate for the cell line to allow expression and accumulation of TRICH and β -galactosidase.

Transformed cells expressing β -galactosidase are stained blue when a suitable colorimetric substrate is added to the culture media under conditions that are well known in the art. Stained cells are tested for differences in membrane conductance by electrophysiological techniques that are well known in the art. Untransformed cells, and/or cells transformed with either vector sequences alone or β -galactosidase sequences alone, are used as controls and tested in parallel. Cells expressing TRICH will have higher anion or cation conductance relative to control cells. The contribution of TRICH to conductance can be confirmed by incubating the cells using antibodies specific for TRICH. The antibodies will bind to the extracellular side of TRICH, thereby blocking the pore in the ion channel, and the associated conductance.

Alternatively, ion channel activity of TRICH is measured as current flow across a TRICH-containing *Xenopus laevis* oocyte membrane using the two-electrode voltage-clamp technique (Ishi et al., *supra*; Jegla, T. and L. Salkoff (1997) J. Neurosci. 17:32-44). TRICH is subcloned into an appropriate *Xenopus* oocyte expression vector, such as pBF, and 0.5-5 ng of mRNA is injected into mature stage IV oocytes. Injected oocytes are incubated at 18 °C for 1-5 days. Inside-out macropatches are excised into an intracellular solution containing 116 mM K-gluconate, 4 mM KCl, and 10 mM Hepes (pH 7.2). The intracellular solution is supplemented with varying concentrations of the TRICH mediator, such as cAMP, cGMP, or Ca^{+2} (in the form of CaCl_2), where appropriate. Electrode resistance is set at 2-5 M Ω and electrodes are filled with the intracellular solution lacking mediator. Experiments are performed at room temperature from a holding potential of 0 mV. Voltage ramps (2.5 s) from -100 to 100 mV are acquired at a sampling frequency of 500 Hz. Current measured is proportional to the activity of TRICH in the assay. In particular, the activity of TRICH-1 is measured as Na^+ conductance and the activity of TRICH-3 is measured as Ca^{2+} conductance.

Transport activity of TRICH is assayed by measuring uptake of labeled substrates into *Xenopus laevis* oocytes. Oocytes at stages V and VI are injected with TRICH mRNA (10 ng per oocyte) and incubated for 3 days at 18°C in OR2 medium (82.5mM NaCl, 2.5 mM KCl, 1mM CaCl_2 , 1mM MgCl_2 , 1mM Na_2HPO_4 , 5 mM Hepes, 3.8 mM NaOH, 50 $\mu\text{g/ml}$ gentamycin, pH 7.8) to allow expression of TRICH. Oocytes are then transferred to standard uptake medium (100mM NaCl, 2 mM KCl, 1mM CaCl_2 , 1mM MgCl_2 , 10 mM Hepes/Tris pH 7.5). Uptake of various substrates (e.g., amino acids, sugars, drugs, ions, and neurotransmitters) is initiated by adding labeled substrate (e.g. radiolabeled with ^3H , fluorescently labeled with rhodamine, etc.) to the oocytes. After incubating for 30 minutes, uptake is terminated by washing the oocytes three times in Na^+ -free medium, measuring the incorporated label, and comparing with controls. TRICH

activity is proportional to the level of internalized labeled substrate. Test substrates include ran-
GTP for TRICH-2, glucose for TRICH-5, amino acids for TRICH-6 and TRICH-14, cations for
TRICH-7 and TRICH-16, Na⁺, K⁺ and Cl⁻ ions for TRICH-15, reduced folate or analogues such as
methotrexate for TRICH-17, divalent cations for TRICH-18, anions such as arsenate and antimonite
5 for TRICH-19, and nitrate or oligopeptides for TRICH-20.

ATPase activity associated with TRICH can be measured by hydrolysis of radiolabeled
ATP-[γ -³²P], separation of the hydrolysis products by chromatographic methods, and quantitation of
the recovered ³²P using a scintillation counter. The reaction mixture contains ATP-[γ -³²P] and
varying amounts of TRICH in a suitable buffer incubated at 37°C for a suitable period of time. The
10 reaction is terminated by acid precipitation with trichloroacetic acid and then neutralized with base,
and an aliquot of the reaction mixture is subjected to membrane or filter paper-based
chromatography to separate the reaction products. The amount of ³²P liberated is counted in a
scintillation counter. The amount of radioactivity recovered is proportional to the ATPase activity
of TRICH in the assay.

15 Lipocalin activity of TRICH is measured by ligand fluorescence enhancement
spectrofluorometry (Lin et al. (1997) Molecular Vision 3:17). Examples of ligands include retinol
(Sigma, St. Louis MO) and 16-anthryloxy-palmitic acid (16-AP) (Molecular Probes Inc., Eugene
OR). Ligand is dissolved in 100% ethanol and its concentration is estimated using known
extinction coefficients (retinol: 46,000 A/M/cm at 325 nm; 16-AP: 8,200 A/M/cm at 361 nm). A
20 700 μ l aliquot of 1 μ M TRICH in 10 mM Tris (pH 7.5), 2 mM EDTA, and 500 mM NaCl is placed
in a 1 cm path length quartz cuvette and 1 μ l aliquots of ligand solution are added. Fluorescence is
measured 100 seconds after each addition until readings are stable. Change in fluorescence per unit
change in ligand concentration is proportional to TRICH activity.

XVIII. Identification of TRICH Agonists and Antagonists

25 TRICH is expressed in a eukaryotic cell line such as CHO (Chinese Hamster Ovary) or
HEK (Human Embryonic Kidney) 293. Ion channel activity of the transformed cells is measured in
the presence and absence of candidate agonists or antagonists. Ion channel activity is assayed using
patch clamp methods well known in the art or as described in Example XVII. Alternatively, ion
channel activity is assayed using fluorescent techniques that measure ion flux across the cell
30 membrane (Velicelebi, G. et al. (1999) Meth. Enzymol. 294:20-47; West, M.R. and C.R. Molloy
(1996) Anal. Biochem. 241:51-58). These assays may be adapted for high-throughput screening
using microplates. Changes in internal ion concentration are measured using fluorescent dyes such
as the Ca²⁺ indicator Fluo-4 AM, sodium-sensitive dyes such as SBFI and sodium green, or the Cl⁻
indicator MQAE (all available from Molecular Probes) in combination with the FLIPR fluorimetric
35 plate reading system (Molecular Devices). In a more generic version of this assay, changes in

membrane potential caused by ionic flux across the plasma membrane are measured using oxonyl dyes such as DiBAC₄ (Molecular Probes). DiBAC₄ equilibrates between the extracellular solution and cellular sites according to the cellular membrane potential. The dye's fluorescence intensity is 20-fold greater when bound to hydrophobic intracellular sites, allowing detection of DiBAC₄ entry
5 into the cell (Gonzalez, J.E. and P.A. Negulescu (1998) Curr. Opin. Biotechnol. 9:624-631).
Candidate agonists or antagonists may be selected from known ion channel agonists or antagonists, peptide libraries, or combinatorial chemical libraries.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the
10 invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
7484831	1	7484831CD1	33	7484831CBI
2477266	2	2477266CD1	34	2477266CBI
3552033	3	3552033CD1	35	3552033CBI
4778139	4	4778139CD1	36	4778139CBI
4787433	5	4787433CD1	37	4787433CBI
7483598	6	7483598CD1	38	7483598CBI
7484823	7	7484823CD1	39	7484823CBI
143935	8	143935CD1	40	143935CBI
5923789	9	5923789CD1	41	5923789CBI
6046484	10	6046484CD1	42	6046484CBI
7481427	11	7481427CD1	43	7481427CBI
7483595	12	7483595CD1	44	7483595CBI
3788427	13	3788427CD1	45	3788427CBI
6972455	14	6972455CD1	46	6972455CBI
8077668	15	8077668CD1	47	8077668CBI
55120485	16	55120485CD1	48	55120485CBI
3112883	17	3112883CD1	49	3112883CBI
4253888	18	4253888CD1	50	4253888CBI
7479974	19	7479974CD1	51	7479974CBI
7483850	20	7483850CD1	52	7483850CBI
5508353	21	5508353CD1	53	5508353CBI
8543628	22	8543628CD1	54	8543628CBI
7482754	23	7482754CD1	55	7482754CBI
3794818	24	3794818CD1	56	3794818CBI
4717525	25	4717525CD1	57	4717525CBI
5091793	26	5091793CD1	58	5091793CBI
5945527	27	5945527CD1	59	5945527CBI
6941124	28	6941124CD1	60	6941124CBI
6972530	29	6972530CD1	61	6972530CBI

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
6991750	30	6991750CD1	62	6991750CB1
71726948	31	71726948CD1	63	71726948CB1
7487393	32	7487393CD1	64	7487393CB1

TABLE 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
1	7484831CD1	g2944233	5.1e-242	Sodium-hydrogen exchanger 6 [Homo sapiens] (Numata, M. et al. (1998) J. Biol. Chem. 273:6951-6959)
2	2477266CD1	g2102696	1.0e-37	[Homo sapiens] karyopherin beta 3 Yaseen, N.R. and Blobel, G. (1997) Proc. Natl. Acad. Sci. U.S.A. 94:4451-4456
3	3552033CD1	g3243075	0.0	[Homo sapiens] melastatin 1 Hunter, J.J. et al. (1998) Genomics 1998 54:116-123
4	4778139CD1	g8131903	5.1e-107	[Mus musculus] transient receptor potential-related protein
5	4787433CD1	g2337865	2.3e-251	[Homo sapiens] organic cation transporter
6	7483598CD1	g6978016	1.9e-32	[Rattus norvegicus] neuronal glutamine transporter Varoqui, H. et al. (2000) J. Biol. Chem. 275:4049-4054
7	7484823CD1	g619915	0.0	[Rattus norvegicus] Na,K-ATPase alpha subunit Shamraj, O.I., and Lingrel, J.B. (1994) Proc. Natl. Acad. Sci. USA 91:12952-12956
8	143935CD1	g179304	7.8e-116	B12 protein [Homo sapiens] (Wolf, F.W. et al. (1992) J. Biol. Chem. 267:1317-1326)
9	5923789CD1	g1552526	0.0	sodium-calcium exchanger form 3 [Rattus norvegicus] (Nicoll, D.A. et al. (1996) J. Biol. Chem. 271:24914-24921)
10	6046484CD1	g3243075	0.0	melastatin 1 [Homo sapiens] (Hunter, J.J. (1998) Genomics 54:116-123)
11	7481427CD1	g178661	9.8e-93	adenine nucleotide translocator-2 [Homo sapiens] (Ku, D.H. et al. (1990) J. Biol. Chem. 265: 16060-16063)

Table 2 (cont.)

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
12	7483595CD1	g9453726	3.7e-61	ba48209.2 (Novel sulphate transporter family member) [Homo sapiens]
13	3788427CD1	g3694661	5.5e-209	carrier protein-like; similar to Q01888 (P1D:q266574) [Homo sapiens]
14	6972455CD1	g4155688	1.7e-24	[Helicobacter pylori J99] AMINO ACID ABC TRANSPORTER, BINDING PROTEIN PRECURSOR
15	8077668CD1	g5081312	6.6e-47	[Pantus norvegicus] bumetanide-sensitive Na-K-2Cl cotransporter Anzai, H., et al. (1999) Roles of vasopressin and hypertonicity in basal, arterial Na/K/2Cl cotransporter expression in rat kidney inner medullary collecting duct cells. Jpn. J. Physiol. 49, 201-206
16	55120485CD1	g8979801	1.1e-165	dj37c10.3 (novel ATPase) [Homo sapiens]
17	3112883CD1	g3115983	4.0e-128	dj206d15.1 (Reduced Folate Carrier protein RFC LIKE) [Homo sapiens]
18	4253888CD1	g3925431	1.6e-29	[Caenorhabditis elegans] (Z82084) contains similarity to Pfam domain: PF01769 (Divalent cation transporter), Score=211.5, E-value=4.2e-60, N=2
19	7479974CD1	g5802945	7.7e-125	[Sinorhizobium sp. As4] Arsa (catalytic subunit of arsenic oxyanion-translocating ATPase)
20	7483850CD1	g11933414	6.3e-11	[Glycine max] nitrate transporter NRT1-5
21	5508353CD1	g6457270	5.2e-190	[Mus musculus] putative E1-E2 ATPase Halleck, M.S. et al., (1999) Physiol. Genomics (Online) 1:139-150 MEDLINE : 20473714
22	8543628CD1	g6967939	3.7e-45	[Campylobacter jejuni] amino-acid ABC transporter integral membrane protein Takamori S. et al., (2000) Nature 407:189-94

Table 2 (cont.)

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
23	7482754CD1	g11640743	1.9e-20	[Homo sapiens] amino acid transporter system A1 Wang H. et al., (2000) Biochem. Biophys. Res. Commun. 273:1175-9
24	3794818CD1	g2160125	1.5e-262	NMDAR-L [Rattus norvegicus] Sucher, N.J. et al. (1995) J. Neurosci. 15:6509-6520
25	4717525CD1	g6841066	7.8e-111	calcium-binding transporter [Homo sapiens]
26	5091793CD1	g3880532	1.1e-51	Similarity to multidrug resistance protein (SW:BMRI_BACSU) [Caenorhabditis elegans] The C. elegans Sequencing Consortium (1998) Science 282: 2012-2018
27	5945527CD1	g7543982	1.5e-161	glycerol 3-phosphate permease [Homo sapiens]
28	6941124CD1	g476222	6.8e-66	anion exchanger 3 brain isoform [Homo sapiens] Yannoukakos, D. et al. (1994) Circ. Res. 75:603-614
29	6972530CD1	g10175963	3.5e-16	potassium channel protein [Bacillus halodurans] Takami, H. et al. (1999) Extremophiles 3:21-28
30	6991750CD1	g6273849	5.5e-11	cardiac sodium-calcium exchanger [Oncorhynchus mykiss] Xue, X.H. et al. (1999) Am. J. Physiol. 277:C693-C700
31	71726948CD1	g1628579	1.0e-152	sodium iodide symporter [Homo sapiens] Smanik, P.A. et al. (1996) Biochem. Biophys. Res. Commun. 226:339-345
32	7487393CD1	g7707622	2.2e-118	organic anion transporter 4 [Homo sapiens] Cha, S.H. et al. (2000) J. Biol. Chem. 275:4507-4512

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1	7484831CD1	726	S11 S52 S66 S124 S147 S198 S244 S260 S546 S585 S689 S694 S695 S712 T59 T133 T154 T177 T591 T658 T665 T684	N145 N401 N572 N589 N674	Signal peptide: M1-A37	HMMER
					Transmembrane domains: P18-A39, R68-I88, R95-I115, K175-H203, L208-L236, D245-A269, A282-Q306, A319-L347, L360-L388, Y428-G456, H482-T502, Q508-L536 N-terminus is non-cytosolic	TMAP
					Sodium/hydrogen exchanger family: L74-V540	HMMER-PFAM
					Na+/H+ exchanger isoform signatures PR01088: S44-A63, E64-I88, W89-I107, Y108-Q134, S299-D316, A318-M337, G588-D606, P612-Q640, V641-D668	BLIMPS-PRINTS
					Na+/H+ exchanger signatures PR01084: V182-F193, G196-S210, I211-T219, G256-T266	BLIMPS-PRINTS
					Na+ transport exchanger PD01672: V182-M230, A319-V344, F381-F414, F419-S465, F466-T512	BLIMPS-PRODROM
					Sodium hydrogen exchanger 6, myeloblast PD177855: Y557-N725, G527-E547	BLAST-PRODROM
					Na+/H+ transmembrane transport antiporter, exchanger PD000631: E181-R539, L74-G125	BLAST-PRODROM
					Beta Na exchanger: DM02572 P48764 10-734: D171-R539, R21-L116 DM02572 Q01345 12-703: D179-D563, L22-R117 DM02572 P50482 16-723: E181-F558, G16-S124 DM02572 P26434 14-716: D179-D563, A48-T120, F605-P620	BLAST-DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
2	2477266CD1	1081	S47 S79 S148 S180 S192 S315 S493 S615 S639 S697 S1011 T18 T25 T61 T147 T167 T328 T532 T586 T786 T813 T871 T881 T907 T974	N165 N686	Transmembrane domains: P197-L213 R255-V275 E498-P520 I839-V863 N terminus cytosolic	TMAP
					IMPORTIN SUBUNIT KARYOPHERIN PROTEIN TRANSPORT REPEAT PD014526: F691-D1033 PD014366: A458-S615, Q389-N412 Leucine zipper pattern L177-L198 Phospholipase A2 histidine active site C725-C732	BLAST_PRODROM MOTIFS MOTIFS
3	3552033CD1	1172	S212 S235 S300 S366 S401 S528 S558 S618 S687 S688 S884 S1017 S1059 S1060 S1069 S1076 S1088 S1125 T9 T147 T422 T459 T460 T917 T962 T984 T1031 T1112 T1118 T1132 T1155 Y645 Y857	N144 N233 N298 N420 N576 N579 N789 N915 N960 N1058 N1074	Transient receptor: Y943-M1001, R817-E882, E750-L807, D562-W608	HMME PFAM
					Transmembrane domains: G51-I75 D397-R425 F712-V740 E786-R806 V822-G842 M852-A872 W934-T962 N terminus cytosolic	TMAP
					Transient receptor potential family signature PR01097: A941-T962, F963-F976, V990-M1003 PROTEIN MELASTATIN CHROMOSOME TRANSMEMBRANE PD018035: M1-L333 PD151509: I829-L1117 PD039592: E464-E660 PD022180: W328-R438	BLIMPS_PRINTS BLAST_PRODROM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
3					ANK MOTIF REPEAT DM03196 P34586 38-822: I819-C1009, L583-G619, L702-L807, D114-N144, T9-Q48 Aminoacyl-transfer RNA synthetases class-II signature 2 A1111-L1120	BLAST_DOMO MOTIFS
4	4778139CD1	742	S42 S104 S135 S194 S203 S214 S220 S221 S234 S239 S277 S319 S339 S352 S354 S403 S435 S438 S479 S491 S510 S722 S735 T111 T325 T371 T508 T575 T619 T635 T731	N238 N258 N294 N650 N711	KINASE TRANSFERASE SERINE/THREONINE PROTEIN ATP BINDING ELONGATION FACTOR EEF2 EEF2K CALCIUM/CALMODULINDEPENDENT EUKARYOTIC PD011701: K536-R709	BLAST_PRODUM
5	4787433CD1	577	S70 S119 S176 S319 S337 S544 S550 S560 T135 T356 T521 T534 T535 T569 Y10	N31 N57 N65 N68 N108 N345 N352 N546 N558	Sugar (and other) transporter: K120-E538	HMMER_PPFAM
					Transmembrane domains: G17-G45 R150-R178 L185-Y205 F214-I234 S243-L263 L269-F293 I355-S377 N390-D410 T416-P436 L442-Y462 A488-L516 N terminus cytosolic	TMAP
					Na+/H+ exchanger isoform PR010870 I32-V46 Leucine zipper pattern L146-L167	BLIMPS_PRINTS MOTIFS
6	7483598CD1	462	S24 S56 S90 S242 S243 S393 T282 T391	N100 N331 N436 N441 N457	Transmembrane amino acid transporter protein: S56-G412	HMMER_PPFAM
					Transmembrane domains: C33-L53 G65-K85 T102-A130 N148-L168 A175-V195 W213-Y241 A250-F278 F328-A348 L358-P378 T391-N419 N terminus non-cytosolic	TMAP
					ACID AMINO PROTEIN TRANSPORTER PERMEASE TRANSMEMBRANE INTERGENIC REGION PUTATIVE PROLINE PD001875: F39-T209	BLAST_PRODUM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
7	7484823CD1	1018	S10 S49 S151 S157 S372 S463 S525 S585 S648 S732 S938 T44 T82 T250 T344 T393 T399 T404 T444 T482 T618 T635 T755 T934 Y461 Y889	N212 N480	E1-E2 (cation transport) ATPase: V132-T363	HMMER_PFBM
					Na+/K+ ATPase C-terminus: R829-Y1017, E30-S113	HMMER_PFBM
					Transmembrane domains: H287-L315 E781-T809 I845-F873 V909-I931 A972-R1000 N terminus non-cytosolic	TMAP
					E1-E2 ATPases phosphoryl BL00154: V329- G365, T367-V385, K504-C514, D588-I628, V707-G730, G733-N766, G185-L202	BLIMPS_BLOCKS
					E1-E2 ATPases phosphorylation site atpase_e1_e2.prf: L354-E401	PROFILES CAN
					P-type cation-transporting atpase superfamily signature PR00119: D211-S225, C371-V385, G582-A593, A604-D614, T710-M729, S734-L746	BLIMPS_PRINTS
					H+-transporting ATPase (proton pump) signature PR00120: E682-E698, T710-G726, D742-L767	BLIMPS_PRINTS
					Sodium/potassium-transporting ATPase signature PR00121: L100-I114, L127-Q147, L291-G313, L364-V385, L501-L519, I782-L803, Y849-A869, F911-I931, R945-M969	BLIMPS_PRINTS
					ATPASE TRANSMEMBRANE TRANSPORT PUMP MAGNESIUM PD000132: V132-Y312, W314-N426, D667-E820, K473-D742, F118-S225, V581-I628 CALCIUM PD000121: L643-N749, I587-I629 CALCIUM PD000388: K828-Y1017	BLAST_PRODROM
					PTYPE TRANSPORTING ATPASE 1 PD111120: F750-H842	BLAST_PRODROM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
7					E1-E2 ATPases PHOSPHORYLATION SITE DM00115 P50993 80-807: P79-D806 A34474 80-807: P79-D806 P06686 80-807: P79-D806 P24797 77-804: P79-D806 E1-E2 ATPases phosphorylation site D373-T379	BLAST_DOMO
8	143935CD1	313	S23 S30 S62 S101 S145 S146 S156 S176 S193 T51 T69 T235 T240	N166	K+ channel tetramerisation domain:K32-Q129	HMMER_PFAM
					Na+/H+ exchanger isoform PR01085H: T133-S145	BLIMPS_PRINTS
					EDP1 TNF ALPHA INDUCED ENDOTHELIAL B12 PD037429: L109-Q313	BLAST_PRODOR
					signal_cleavage: M1-T21	MOTIFS
9	5923789CD1	921	S69 S144 S151 S312 S381 S382 S691 S713 S720 S794 T106 T113 T125 T194 T267 T277 T460 T522 T572 T583 T594 T597 T632 T637 T672 Y405 Y608	N45 N130 N135 N817	Sodium/calcium exchanger protein: L757-L905, R110-F257	HMMER_PFAM
					PRECURSOR TRANSPORT SIGNAL GLYCOPROTEIN NA+/CA2+EXCHANGER SYMPORT TRANSMEMBRANE PD004181: W249-E390 PD001766: E385-H528 PD149743: V674-I777 PD149807: A529-G627	BLAST_PRODOR
					SODIUM/CALCIUM EXCHANGER CHAIN DM05297 P48768 1-920: C48-F921 DM05297 P48765 6-969: L6-E625, I628-F921	BLAST_DOMO
					do ANTIPTORTER; MUR2; III; 34.7; DM02122 S20969 450-604: N130-W249	BLAST_DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
9					Transmembrane domains: A2-R29, K73-S101, P167-P190, T194-M219, T237-M261, S720-P741, G748-T776, T776-D797, I815-W841, H849-R877, C891-T911 N-terminus is cytosolic	TMAP
					signal_cleavage: M1-A30	SPSCAN
					Signal Peptide: M1-A32	HMMER
10	6046484CD1	1466	S86 S212 S235 S300 S366 S401 S518 S548 S608 S660 S719 S858 S988 S1011 S1039 S1040 S1049 S1056 S1087 S1114 S1166 S1224 S1234 S1323 S1399 S1410 T9 T422 T449 T450 T629 T637 T742 T941 T963 T1164 T1268 T1297 T1387 T1389 T1449 T1462 Y635	N133 N144 N233 N298 N420 N566 N569 N763 N1054 N1245	Transient receptor: Y922-H979, R791-L851, D552-W598	HMMER_PPFAM
					Transient receptor potential family PR01097: A920-T941, F942-F955	BLIMPS_PRINTS
					MELASTATIN 1 PD183973: L1097-C1466	BLAST_PRODROM
					MELASTATIN CHROMOSOME TRANSMEMBRANE C05C12.3 T01H8.5 I F54D1.5 IV PD018035: M1-L333 PD151509: I803-L1097 PD039592: E454-T652	BLAST_PRODROM
					Transmembrane domains: G51-I75, D397-R425, L602-Y630, F692-V712, W717-I737, N763-N783, Y789-F809, Y818-A846, W913-T941, L970-L987 N-terminus is cytosolic	TMAP
11	7481427CD1	222	S28 S142 S159 T144		Mitochondrial carrier proteins: S7-K105, Y112-T202	HMMER_PPFAM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
11					Mitochondrial energy transfer proteins BL00215: L13-Q37, I158-G170 Mitochondrial energy transfer proteins mitoch_carrier.prf: C110-I158 Mitochondrial energy transfer proteins: P127-A136 Mitochondrial carrier protein signature PR00926: G120-D138, Y168-F186, D11-T24, T24-M38, G73-D93 Adenine nucleotide transfer protein PR00927: F8-A20, C51-R72, T84-K96, R111-V124, R146-L167, S207-S222 PROTEIN TRANSPORT TRANSMEMBRANE REPEAT MITOCHONDRIAL ADP/ATP PD000117: S7-A123, Y112-S222 MITOCHONDRIAL ENERGY TRANSFER PROTEINS DM00026 P02722 I1-96: F12-I98 DM00026 S31935 I4-108: F12-T107 DM00026 P02722 I16-205: L117-N201 DM00026 S31935 I110-208: Q108-N201 Transmembrane domains: I164-R187 N-terminus is cytosolic	BLIMPS_BLOCKS PROFILES SCAN MOTIFS BLIMPS_PRINTS BLIMPS_PRINTS BLAST_PRODOM BLAST_DOMO TMAP
12	7483595CD1	461	S168 S212 S233 S338 S362 S382 S439 T318 T348	N98 N163 N288 N344 N380 N381	SULFATE TRANSPORTER PROTEIN TRANSPORT TRANSMEMBRANE AFFINITY GLYCOPROTEIN SULPHATE HIGH DISEASE PD001755: R216-D272, V414-D459 SULFATE TRANSPORTERS DM01229 P40879 5-462: T23-A140, Q124-L222 DM01229 P45380 10-468: P130-L222, T23-L138 DM01229 P50443 49-505: I136-K247, T23-S144 Transmembrane domains: F6-F26, L31-S51, M62-S82, C91-A111, E128-K156, L161-R186 N-terminus is cytosolic	BLAST_PRODOM BLAST_DOMO TMAP
13	3788427CD1	502	S146 S304 S446 S467 T25 T59 T96 T104 T164 T385 T492 T501		Mitochondrial carrier proteins: S361-Y461, S266-Q359, T172-H264	HMMER_PFAM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
13					Mitochondrial energy transfer proteins mitoch_carrier.prf1: L362-I417 mitoch_carrier.prf2: S270-I315 Mitochondrial energy transfer proteins: P287-I296	PROFILESSCAN MOTIFS
					Mitochondrial carrier protein signature PR00926: G232-R252, V280-Q298, Y325-I343, V369-Q391	BLIMPS_PRINTS
					PROTEIN TRANSPORT TRANSMEMBRANE REPEAT MITOCHONDRION CARRIER MEMBRANE INNER MITOCHONDRIAL ADP/ATP PD00117: Y305-R453	BLAST_PRODROM
					MITOCHONDRIAL ENERGY TRANSFER PROTEINS DM00026 Q01888 126-214: G263-I352 DM00026 P29518 233-310: I271-I352	BLAST_DOMO
					Transmembrane domains: R176-G204, A323-K351, L424-K452 N-terminus is cytosolic	TMAP
14	6972455CD1	261	S6 S26 S135 S198 T2 T36 T64 T84 T92 T165 Y218	N82 N172 N173	signal_cleavage: M1-A23	SPSCAN
					Signal Peptide: M1-P22, M1-A23, M1-A25, M1-G27	HMMER
					Bacterial extracellular solute-binding protein domain: M1-L253	HMMER_PFAM
					Transmembrane domains: T175-A196 N-terminus is non-cytosolic	TMAP
					Bacterial extracellular solute binding protein signature BL01039: G52-L72, R86-Y118, L90-S101	BLIMPS_BLOCKS
					BACTERIAL EXTRACELLULAR SOLUTE-BINDING PROTEINS, FAMILY 3 DM00557 P27676 32-261: S19-K223 DM00557 P30860 5-241: L37-W252 DM00557 P39174 15-260: L8-W252 DM00557 P45678 11-258: A11-W252	BLAST_DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
15	8077668CD1	570	S40 S82 S265 S314 S349 S442 S446 S551 T50 T324 T344	N11 N342 N440	Transmembrane domains: V163-V183 N194-T214 V232-I259 I275-R302 S353-N373 A382-G402 P465-G481 N-terminus is cytosolic Do SENSITIVE; COTRANSPORTER; SODIUM; CHLORIDE; DM01337 P55011 409-906: V278-G402 DM01337 P55013 381-879: V278-G402 DM01337 A53491 381-879: V278-G402 DM01337 P55014 297-795: V278-G402	TMAP
16	55120485CD1	1033	S5 S103 S159 S241 S249 S338 S567 S587 S671 S798 S833 S850 S1008 S1028 T78 T97 T172 T375 T490 T664 T701 T784 T859 T871 Y85	N540 N669 N781 N819 N848 N867 N875 N1005	Transmembrane domains: F24-Y52 K197-L217 Y223-Y243 L394-Y422 D429-N454 T877-F893 T903-L931 L937-E964 N-terminus is non-cytosolic	TMAP
					E1-E2 ATPase domain: V268-P324	HMMER_PFAM
					E1-E2 ATPases phosphorylation site signature BL00154: G284-L301, V442-G478, I480-L498, K624-C634, N695-M735	BLIMPS_BLOCKS
					E1-E2 ATPases phosphorylation site: I466-F515	PROFILESSCAN
					P-type cation-transporting atpase superfamily signature PR00119: N309-T323, C484-L498, A711-D721	BLIMPS_PRINTS
					Sodium/potassium-transporting ATPase signature PR00121: C477-L498, V621-V639	BLIMPS_PRINTS
					ATPASE HYDROLASE TRANSMEMBRANE PHOSPHORYLATION ATP BINDING TRANSPORT PUMP CALCIUM MAGNESIUM MEMBRANE PD000132: I230-D494	BLAST_PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
16					E1-E2 ATPases PHOSPHORYLATION SITE DM00115 P22189 49-801: Q597-P738, W196-K322, P389-P447, S671-L723 DM00115 P37278 58-755: I192-I743, V822-K840 DM00115 P47317 26-695: F600-E749, I230-K559, K815-E853 DM00115 P54707 97-825: I232-I743, L813-E853 E1-E2 ATPases phosphorylation site: D486-T492	BLAST_DOMO
17	3112883CD1	496	S40 S211 S241 S251 S274 S275 S463 S466 S482 S493 T47 T117	N45 N166 N256	Reduced folate carrier domain: S10-V441 Transmembrane domains: L8-M28 N53-Y76 Y79-Q107 F111-R138 L148-S168 V174-K194 K276-D304 N316-Y336 D342-L362 A367-A395 L405-V425 P434-L454 N-terminus is cytosolic FOLATE CARRIER PROTEIN REDUCED TRANSPORTER GLYCOPROTEIN FOLATE BINDING TRANSPORT TRANSMEMBRANE METHOTREXATE PD003967: S11-E230, G327-S493, F262-W303	HMMER_PFAM
18	4253888CD1	573	S8 S35 S77 S88 S106 S137 S229 S304 S321 S340 S379 T10 T27 T148 T194 T401 Y115	N78 N466	Transmembrane domains: G157-Q185 V189-R217 A242-G268 K269-M297 V314-S340 E343-K369 L377-D399 L407-S433 A469-L489 G493-D521 G531-H559 N-terminus is cytosolic Divalent cation transporter domain: L199-S335, Y413-H559	TMAP
19	7479974CD1	573	S69 S138 S198 S221 S261 S355 S473 S478 S509 S543 T24 T159 T176 T401 T406 T474 T499	N80 N174 N294 N491 N529 N558	Anion-transporting ATPase domain: L354-S573	HMMER_PFAM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
19					PLASMID ARSENICAL PUMPDRIVING ATPASE HYDROLASE RESISTANCE ATPBINDING ARSA PD006335: D460-P568	BLAST_PRODROM
					NIFH/FRXC FAMILY DM00105 P08690 7-180: Y20-E191 DM00105 P08690 326-473: L333-K472 DM00105 P30632 17-190: K19-S167	BLAST_DOMO
					ATP/GTP-binding site motif A (P-loop): G25-T32, G337-T344	MOTIFS
20	7483850CD1	248	S42 S85 S121 S198 S215 S227 S233 S239		Transmembrane domains: D8-S36, R44-I72, C96-R123, S133-I158, L171-F194 N-terminus is non-cytosolic	TMAP
					POT family (proton/oligopeptide symporter) domain: G56-N141	HMMER_PFBM
21	5508353CD1	761	S5 S62 S109 S115 S185 S312 S409 S476 S556 S706 S734 T28 T30 T78 T162 T201 T227 T335 T534 T674 T695 T738 Y189	N700 N732	Transmembrane domains: P84-K112, Y459-N487, P528-Y553, G564-K584, L592-C612, I624-Y652 N-terminus is cytosolic	TMAP
					E1-E2 ATPases phosphorylation site proteins: BL00154: D231-L271, T386-S409, K131-L141	BLIMPS_BLOCKS
					P-type cation-transporting atpase superfamily signature PR00119: A247-D257	BLIMPS_PRINTS
					H+-transporting ATPase (proton pump) signature PR00120: T162-A180	BLIMPS_PRINTS
					ATPASE HYDROLASE TRANSMEMBRANE PHOSPHORYLATION ATP-BINDING PROTEIN PROBABLE CALCIUM TRANSPORTING CALCIUM TRANSPORT PD004657: A423-P661	BLAST_PRODROM
					ATPASE HYDROLASE TRANSMEMBRANE PHOSPHORYLATION ATP-BINDING PROBABLE PROTEIN CALCIUM TRANSPORTING CALCIUM TRANSPORT PD149930: C363-F422	BLAST_PRODROM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
21					ATPASE; CALCIUM; TRANSPORTING; DM02405 P32660 318-1225: E45-N487 ATPASE; CALCIUM; TRANSPORTING; DM02405 Q09891 206-1107: L56-N487 ATPASE; CALCIUM; TRANSPORTING; DM02405 S51243 356-1267: E59-F486 ATPASE; CALCIUM; TRANSPORTING; DM02405 P39524 236-1049: Y58-D287, L332-N487 ATP/GTP-binding site motif A (P-loop): G331-T338, A699-S706	BLAST_DOMO BLAST_DOMO BLAST_DOMO BLAST_DOMO MOTIFS
22	8543628CD1	219	S4 T148		Binding-protein-dependent transport system: A112-Y185 Transmembrane domains: A20-N48, V70-S98, T156-R183, Y185-A208 N-terminus is non-cytosolic Binding-protein-dependent transport systems inner membrane component: V105-T161 PROTEIN TRANSPORT TRANSMEMBRANE PERMEASE MEMBRANE AMINO ACID INNER SYSTEM TRANSPORTER ABC PD001196: E7-G111 BINDING-PROTEIN-DEPENDENT TRANSPORT SYSTEMS INNER MEMBRANE DM00388 P10345 3-214: L9-R215 BINDING-PROTEIN-DEPENDENT TRANSPORT SYSTEMS INNER MEMBRANE DM00388 P42399 12-220: S12-R215 BINDING-PROTEIN-DEPENDENT TRANSPORT SYSTEMS INNER MEMBRANE DM00388 P45023 17-232: P14-R215 BINDING-PROTEIN-DEPENDENT TRANSPORT SYSTEMS INNER MEMBRANE DM00388 P42200 15-226: P14-R215 Binding-protein-dependent transport systems inner membrane component signature: L113-P141	HMMER_PFBAM TMAP PROFILESAN BLAST_PRODUM BLAST_DOMO BLAST_DOMO BLAST_DOMO BLAST_DOMO MOTIFS
23	7482754CD1	463	S249 S254 S413 S420 T451 T458		Transmembrane amino acid transporter protein: A48-C433	HMMER_PFBAM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
23					Transmembrane domains: L24-N44, G54-V74, R93-R121, D148-R168, H180-T200, S249-S274, G298-R326, W353-M373, S377-P397 N-terminus is non-cytosolic Transmembrane four family signature PR00259: F59-V82, L73-A99, V302-V328 ACID AMINO PROTEIN TRANSPORTER PERMEASE TRANSMEMBRANE INTERGENIC REGION PUTATIVE PROLINE PD001875: F31-I320	TMAP BLIMPS_PRINTS BLAST_PRODOM
24	3794818CD1	1043	S36 S153 S206 S372 S388 S402 S536 S633 S700 S709 S721 S747 S849 S867 S876 S891 S901 S1014 S1036 T157 T192 T210 T421 T491 T593 T604 T636 T641 T673 T696 T725 T916	N69 N344 N451 N465 N609 N786	Signal Peptide: M1-G21	HMMER
					signal_cleavage: M1-G22	SPSCAN
					Ligand-gated ion channel: H574-E852	HMMER_PFAM
					Transmembrane domains: H574-R598, P640-V667, T823-L847 N terminus is non-cytosolic	TMAP
					NMDA receptor signature PR00177: F493-L521, T577-G602, L644-D671, F831-F855	BLIMPS_PRINTS
					R32184_2 IONOTROPIC GLUTAMATE RECEPTOR PD156309: A77-Y477	BLAST_PRODOM
					RECEPTOR GLUTAMATE SUBUNIT SIGNAL PRECURSOR CHANNEL IONIC TRANSMEMBRANE POSTSYNAPTIC PD000500: M570-E852	BLAST_PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
24					RECEPTOR SIGNAL GLUTAMATE SUBUNIT PROTEIN TRANSMEMBRANE CHANNEL IONIC PD000273: G478-A563, G728-V817 GLUTAMATE RECEPTOR DM00247 Q03391 640-919: T631-S901, C964-P980 DM00247 P35436 615-886: T631-F856 DM00247 Q01098 613-882: T631-E904 DM00393 Q01097 377-614: G387-F628	BLAST_PRODROM BLAST_DOMO
25	4717525CD1	480	S4 S23 S56 S105 S176 S411 S418 T161 T170 T220 T302 T410 T469		Mitochondrial carrier proteins: M184-T276, G319-L413	HMNER_PFAM
					EF hand: Q117-H145, R13-L41, R81-L109	HMNER_PFAM
					Mitochondrial energy transfer proteins BL00215: V190-Q214, I369-G381	BLIMPS_BLOCKS
					Mitochondrial energy transfer proteins signature: I320-S371, K187-L241, V279-S331	PROFILES SCAN
					Mitochondrial carrier protein signature PR00926: Q188-T201, T201-V215, G244-E264, C333-Q351, Y379-Y397, G327-Q349	BLIMPS_PRINTS
					Graves disease carrier protein signature PR00928: Q274-Q294, P205-I225, Y263-S287, I369-V389	BLIMPS_PRINTS
					TRANSPORT TRANSMEMBRANE CARRIER INNER MITOCHONDRIAL ADP/ATP PD000117: K187-S466	BLAST_PRODROM
					MITOCHONDRIAL ENERGY TRANSFER PROTEINS DM00026 S57544 26-107: V190-I270 DM00026 Q01888 38-124: V190-I270	BLAST_DOMO
					EF-hand calcium-binding domain: D22-L34 D90-I102	MOTIFS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
26	5091793CD1	518	S8 S38 S161 S240 S253 S331 S389 S510 T378	N6 N171 N371 N376	Transmembrane domains: G77-W97, K104-L124, N131-V151, A170-T191, Q206-E234, I264-P292, Q304-K332, E336-I364, A406-N434, P481-L509 N terminus is non-cytosolic.	TMAP
27	5945527CD1	501	S39 S66 S263 S267 S329 S421 T338 T418	N53 N62 N68	Transmembrane domains: V9-H37, E85-S105, L114-L134, L197-T225, G290-W317, V342-A362, Y379-G399, T433-L453, N460-L480 N terminus is cytosolic. glpT family of transport BL00942: T29-K41, N82-L124, W171-V190, F211-P247, E281-Y321, L339-D356	TMAP BLIMPS_BLOCKS
					GLPT FAMILY OF TRANSPORTERS DM02439 P37948 1-403: K84-H244, L305-L446 DM02439 P09836 1-401: L87-E234, P295-A426, S16-K41 DM02439 P08194 1-403: L87-D256, Q251-A444, R22-I45	BLAST_DOMO
28	6941124CD1	801	S21 S171 S305 S399 S442 S469 S564 T6 T20 T56 T130 T174 T198 T200 T400 T420 T438 T704 Y791	N52 N388 N455 N463	HCO3- transporter family: A571-L745, H240-F546, R119-L208 Transmembrane domains: V282-G304, L330-I358, T373-M393, I403-I423, H478-Y499, V514-E542, S564-L592, T604-A630, S672-Y700, L748-I776 N terminus is non-cytosolic.	HMMER_PFBM TMAP

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
28					Anion exchangers family BL00219: S448-T483, P243-V282, T289-D312, L342-F380, A382-Y429, Q481-S534, A567-W608, D609-E647, H653-F698, Y700-T743, L748-I787 Anion exchanger signature PR00165: G253-I275, K284-G304, A371-S390, A482-L501, I517-G537 ANION EXCHANGE TRANSMEMBRANE GLYCO-PROTEIN LIPOPROTEIN PALMITATE BICARBONATE COTRANSPORTER PD001455: T483-T743, F752-S457, R158-A237	BLIMPS_BLOCKS BLIMPS_PRINTS
					BAND 3 ANION TRANSPORT PROTEIN DM02294 P48751 601-1229: A190-E798 DM02294 P02730 311-908: T483-E798 DM02294 A42497 403-1027: F252-E798 DM02294 P04920 602-1237: D248-E798	BLAST_DOMO
29	6972530CD1	344	S101 S133 S157 S319 S333 T117 T145 T196 T286 Y330	N223 N299	signal_cleavage: M1-A34	SPSCAN
					Signal Peptide: M9-A34	HMMER
					Transmembrane domains: R8-L36 V39-V63 Q71-T99 N terminus is non-cytosolic.	TMAP

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
30	6991750CD1	2701	S1063 S1231 S1270 S40 S1367 S1526 S551 S1603 S193 S1710 S1793 S223 S1824 S1866 S274 S1879 S230 S1893 S1915 S651 S1922 S307	N56 N218 N319 N330 N364 N396 N452 N480 N539 N607 N667 N691 N772 N828 N875 N885 N921 N949 N964 N988 N1135	Transmembrane domains: I965-S986, E1281-T1300, N1670-S1692, V1836-W1864, V2276-N2292, A2507-F2534 N terminus is non-cytosolic.	TMAP
			S1952 S1978 S461 S2029 S382 S2045 S2090 S2230 S495 S2388 S2438 S792 S2464 S790 S2488 S2496 S2506 S901 S2537 S809 S2545 S2573 S856 S2631	N1153 N1166 N1241 N1259 N1273 N1305 N1323 N1372 N1479 N1525 N1528 N1618 N1624 N1892 N1969 N2134 N2342 N2428 N2510 N2596 N2625	Adenosine and AMP deaminase signature S2386-P2392	MOTIFS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
30			T122 T158 T276 T417 T581 T774 T881 T989 T1004 T1030 T1045 T1051 S941 T1058 T1090 S953 T1307 T1559 T1610 T1658 T1786 T1887 T1945 T2171 T2213 T2266 T2328 T2409 T2415 T2446 T2450 T2459 T2549 T2694 Y130		Sodium/Calcium Exchanger Chain DM05297/P48765/6-969; V263-I492 P=2.8-09	BLAST_DOMO
31	71726948CD1	610	S114 S269 S317 S375 S377 S563 S576 S602 T3 T41 T53 T74 T158 T312 T364 T483 T491 T557 Y554	N260 N481 N485 N606	Signal Peptide: M47-P73	HMMER
					Sodium: solute symporter family: F45-G449	HMMER_PFAM
					Transmembrane domains: P4-Y32, T53-G73, I84-L104, L121-Y148, G159-L179, V190-M210, R239-I256, R273-L301, S385-L405, A412-I432, S439-G459, N515-T543 N terminus is non-cytosolic.	TMAP
					Sodium: solute symporter BL00456: I22-S76, I98-V127, T158-G212	BLIMPS_BLOCKS
					Sodium: solute symporter family signatures: N155-A201	PROFILES SCAN

Table 3 (cont.)

SEQ ID NO:	IncYTE Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
31					TRANSMEMBRANE TRANSPORT PERMEASE SODIUM SYMPORT PROLINE GLYCOPROTEIN PD000991: F45-P234, L129-G449 SYMPORTER SODIUM IODIDE THYROID PD024705: A451-P552 SODIUM: SOLUTE SYMPORTER FAMILY DM00745 JC2382 3-485:Y15-W455 DM00745 P45174 3-495:T9-W455 DM00745 P31448 1-494:F18-G449 DM00745 P44963 1-483:V23-Y463	BLAST_PRODROM BLAST_PRODROM BLAST_DOMO
32	7487393CD1	552	S46 S60 S68 S143 S167 S276 S282 S408 S475 S537 T58 T133 T311 T323 T391 T526	N39 N56 N62 N102 N377	Sugar (and other) transporter: T18-V530	HMMER_PPFAM
					Transmembrane domains: V10-E38, K145-G164, I174-L202, M232-A252, Q262-S282, K345-I368, G375-L397, F412-L440, S475-L496, P497-L514 N terminus is non-cytosolic.	TMAP
					ORGANIC TRANSPORTERLIKE TRANSPORT PROTEIN RENAL ANION TRANSPORTER CATIONIC KIDNEY SPECIFIC SOLUTE PD151320: N102-K145	BLAST_PRODROM

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
33/7484831CB1/2365	1-325, 94-240, 106-240, 106-242, 106-244, 106-245, 106-514, 106-515, 106-582, 106-586, 106-593, 106-597, 106-612, 109-245, 110-245, 128-770, 160-516, 164-267, 176-549, 181-440, 184-581, 234-317, 234-409, 252-770, 275-469, 275-473, 275-570, 275-636, 275-700, 336-1038, 338-1038, 377-543, 413-622, 414-1038, 495-1038, 504-764, 504-1009, 521-952, 521-1034, 521-1038, 523-680, 704-974, 781-1246, 824-1377, 884-1127, 904-1254, 916-1533, 940-1038, 958-1226, 978-1038, 990-1038, 1018-1637, 1031-1722, 1064-1463, 1070-1211, 1086-1149, 1110-1336, 1110-1375, 1110-1386, 1110-1387, 1110-1391, 1110-1462, 1113-1382, 1139-1622, 1144-1622, 1153-1629, 1178-1434, 1178-1749, 1210-1694, 1262-1309, 1445-1969, 1445-2000, 1455-1830, 1463-1630, 1478-1701, 1519-1790, 1526-1952, 1582-1838, 1669-1886, 1676-1846, 1772-2205, 1846-2117, 1847-2060, 1890-2209, 1934-2041, 1938-2315, 1950-2365
34/2477266CB1/3400	1-89, 1-306, 13-348, 13-665, 16-468, 23-270, 23-271, 23-404, 23-512, 27-306, 35-386, 35-589, 37-693, 124-795, 240-510, 317-524, 366-999, 459-996, 473-1144, 492-1041, 493-1060, 505-1019, 761-1360, 798-1025, 798-1268, 872-1360, 875-1143, 988-1278, 996-1252, 996-1612, 1024-1265, 1032-1623, 1054-1507, 1078-1341, 1192-1726, 1213-1608, 1218-1469, 1253-1798, 1332-1567, 1332-1800, 1345-1908, 1387-1693, 1419-1981, 1434-1737, 1436-1726, 1518-2165, 1524-2132, 1562-1836, 1775-2024, 1779-2022, 1797-2084, 1890-2052, 1890-2116, 1890-2334, 1890-2438, 1913-2196, 1942-2197, 1949-2528, 1952-2509, 1954-2029, 1981-2621, 1994-2104, 1994-2174, 1994-2252, 1994-2258, 1994-2259, 2039-2147, 2040-2319, 2062-2315, 2142-2732, 2205-2493, 2238-2536, 2265-2795, 2275-2544, 2277-2528, 2302-2718, 2337-2622, 2380-2920, 2444-2841, 2467-2711, 2472-2728, 2472-2737, 2472-2955, 2484-2753, 2492-2641, 2503-2746, 2512-3142, 2517-3095, 2555-3131, 2568-3246, 2590-2931, 2605-2903, 2643-2973, 2646-2931, 2656-2902, 2673-3284, 2725-3400,
	2766-3312, 2766-3390, 2766-3398, 2795-3082, 2800-3097, 2818-3039, 2818-3355, 2832-3051, 2832-3088, 2851-3007, 2851-3015, 2851-3028, 2854-3120, 2868-3336, 2871-3133, 2871-3195, 2884-3181, 2892-3104
35/3552033CB1/4458	1-1188, 405-1189, 422-1189, 447-1152, 479-1274, 507-1189, 511-1189, 515-1185, 523-1188, 535-1189, 540-1188, 547-1189, 550-1189, 560-1189, 561-1189, 570-1189, 571-1275, 579-1189, 585-1189, 586-1141, 602-1189, 602-1275, 629-1275, 631-1189, 635-1189, 636-1275, 638-1189, 640-1189, 643-1189, 653-1189, 654-1189, 655-1120, 675-1240, 695-1188, 699-1188, 700-1189, 701-1189, 708-1189, 735-1189, 743-1189, 746-1189, 748-1189, 749-1189, 752-1189, 761-1189, 762-1189, 763-1189, 768-1189, 775-1189, 780-1188, 820-1189, 844-1600, 887-1496, 970-1185, 1008-1841, 1023-1188, 1028-1189, 1028-1721, 1055-1574, 1108-1275, 1171-1275, 1491-2041, 1491-2086, 1551-2416, 1874-2534, 1874-2548, 1874-2561, 1874-2568, 1874-2574, 1874-2576, 1874-2580, 1875-2432, 1875-2436, 1875-2539, 1887-2564, 1909-2592, 1917-2507, 1940-2494, 1955-2542, 1959-2477, 1962-2428, 1964-2460, 1978-2424, 1988-2500, 1992-2500, 1994-2673, 1996-2500, 2014-2906, 2017-2437, 2025-2578, 2025-2580, 2033-2525, 2038-2492, 2045-2611, 2053-2644, 2066-2555, 2087-2691, 2104-2699, 2105-2514, 2147-2427.

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
35	2171-2621, 2181-2699, 2196-2743, 2205-3023, 2207-2752, 2215-2959, 2221-3026, 2221-3058, 2222-3020, 2229-2765, 2290-3024, 2291-2959, 2295-2796, 2300-2958, 2320-3022, 2325-2763, 2384-3024, 2391-3024, 2406-3024, 2407-3024, 2414-3023, 2414-3024, 2420-3024, 2433-2718, 2433-2900, 2433-3024, 2433-3025, 2434-3024, 2435-3024, 2438-3024, 2441-3024, 2443-3024, 2446-3024, 2451-3023, 2455-3024, 2470-3024, 2479-3024, 2480-3024, 2482-3024, 2484-3024, 2488-3024, 2489-3024, 2491-3024, 2501-3024, 2508-3024, 2511-3024, 2522-3024, 2582-3024, 2583-3024, 2587-3024, 2590-3024, 2592-2877, 2592-3022, 2592-3024, 2596-3024, 2602-3279, 2612-3024, 2621-3063, 2621-3092, 2626-3279, 2632-3024, 2633-3024, 2652-3024, 2653-3024, 2671-3015, 2671-3020, 2671-3022, 2671-3024, 2686-3024, 2688-3024, 2689-3024, 2718-3024, 2732-3279, 2734-3024, 2736-3279, 2763-3024, 2766-2830, 2770-3021, 2773-3203, 2802-3279, 2812-3004, 2831-3008, 2831-3037, 2831-3117, 2831-3220, 2831-3247, 2831-3275, 2831-3300, 2831-3490, 2842-3330, 2853-3278, 2866-3103, 2902-3270, 2998-3234, 2998-3456, 2998-3524, 2998-3550, 2998-3606, 3003-3715, 3032-3279, 3052-3811, 3078-3810, 3175-3935, 3182-3854,
36/4778139CBI/2722	3219-3792, 3224-3807, 3247-3811, 3267-3885, 3355-3811, 3359-3429, 3359-3811, 3389-4035, 3393-4035, 3402-3915, 3423-3982, 3427-4044, 3444-3811, 3463-4149, 3472-4150, 3485-4080, 3498-3527, 3510-3811, 3521-4030, 3547-3782, 3552-4035, 3552-4039, 3606-4267, 3606-4430, 3629-3871, 3629-3872, 3629-4047, 3631-4047, 3660-4047, 3673-4416, 3676-3848, 3703-3811, 3713-3864, 3714-3972, 3767-4458, 3792-4454, 3817-4084, 3820-4047, 3852-4458, 3857-4035, 3932-4144, 3934-4347, 3939-4152, 4201-4458, 4219-4458, 4295-4458
37/4787433CBI/1924	1-490, 1-545, 1-554, 1-567, 1-574, 1-575, 1-594, 1-606, 1-671, 1-1206, 5-2226, 157-394, 424-874, 433-874, 448-874, 459-874, 461-874, 467-874, 481-874, 498-874, 508-874, 563-874, 580-874, 1464-1728, 1464-1973, 1660-1896, 1660-1919, 1935-2155, 2166-2453, 2166-2722, 2178-2456
38/7483598CBI/1797	1-77, 1-100, 1-480, 154-1023, 513-772, 719-980, 719-1247, 729-984, 805-1016, 843-1529, 848-1456, 849-1459, 902-1530, 902-1552, 940-1543, 951-1593, 952-1426, 962-1646, 990-1548, 1001-1588, 1029-1577, 1047-1657, 1048-1442, 1059-1472, 1059-1569, 1064-1527, 1075-1646, 1076-1628, 1082-1734, 1091-1693, 1095-1701, 1099-1339, 1104-1681, 1104-1707, 1106-1674, 1112-1332, 1119-1583, 1123-1765, 1129-1683, 1169-1608, 1200-1626, 1207-1745, 1218-1832, 1230-1611, 1232-1669, 1244-1741, 1256-1758, 1265-1584, 1273-1758, 1280-1557, 1284-1765, 1303-1924, 1356-1592, 1356-1924, 1359-1585, 1359-1833, 1366-1917, 1382-1911, 1387-1913, 1518-1924, 1575-1909, 1776-1886
38/7483598CBI/1797	1-808, 8-302, 13-417, 14-808, 179-808, 490-808, 491-808, 732-1017, 881-1226, 881-1227, 891-1105, 1157-1429, 1157-1700, 1184-1753, 1184-1760, 1197-1708, 1197-1754, 1197-1755, 1197-1757, 1197-1797, 1198-1757, 1199-1757, 1199-1797, 1200-1754, 1292-1707, 1295-1760, 1324-1759, 1359-1744, 1359-1749, 1359-1760, 1362-1760

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
39/7484823CB1/277	1-174, 64-1458, 1324-1660, 1326-1458, 1327-1458, 1340-1458, 1458-1660, 1459-1659, 1459-1660, 1459-2936, 1484-1651, 1506-1732, 1683-2339, 1700-2334, 1724-2174, 1724-2423, 1792-2400, 1804-2530, 1822-2278, 1834-2323, 1840-2516, 1878-2430, 1891-2244, 1922-2694, 1926-2592, 1931-2472, 1938-2431, 1940-2458, 1941-2472, 1944-2546, 1956-2566, 1962-2561, 1970-2530, 1976-2515, 1977-2497, 1980-2431, 2012-2660, 2020-2596, 2046-2671, 2049-2576, 2083-2578, 2095-2752, 2095-2763, 2098-2659, 2105-2794, 2114-2787, 2129-2908, 2162-2720, 2163-2689, 2225-3024, 2229-2763, 2241-2925, 2358-3057, 2374-3044, 2444-2930, 2455-3277, 2531-3023, 2557-3140, 2586-3078
40/143935CB1/2773	1-217, 1-462, 1-942, 16-601, 34-217, 39-566, 176-217, 206-667, 217-756, 217-769, 274-800, 288-919, 316-814, 316-956, 328-967, 334-597, 374-939, 377-855, 388-785, 388-930, 389-791, 407-678, 409-1068, 435-1053, 464-1123, 468-723, 475-1045, 524-1016, 527-684, 527-1039, 564-964, 564-1004, 564-1098, 565-896, 574-1137, 598-933, 660-1190, 660-1192, 663-1285, 690-967, 704-1368, 713-1134, 748-1007, 760-1016, 760-1032, 760-1210, 769-1455, 771-1097, 782-1415, 808-1391, 867-1133, 870-1407, 873-1460, 885-1501, 899-1078, 899-1158, 961-1613, 976-1240, 994-1459, 1006-1508, 1014-1386, 1017-1416, 1025-1452, 1044-1307, 1059-1249, 1059-1668, 1085-1705, 1098-1506, 1099-1346, 1099-1401, 1099-1545, 1149-1353, 1157-1592, 1157-1661, 1193-1716, 1202-1431, 1212-1753, 1250-1654, 1268-1570, 1285-1748, 1285-1841, 1285-1851, 1285-1919, 1285-1930, 1285-1945, 1285-1952, 1285-1963, 1285-1965, 1285-1979, 1292-1886, 1300-1453, 1305-1577, 1310-1858, 1316-1530, 1317-1569, 1317-1872, 1317-1915, 1353-1865, 1356-1488, 1372-1714, 1416-2049, 1421-1709, 1430-1847, 1437-1742, 1441-1991, 1500-1747, 1505-2163, 1515-1815, 1515-1911, 1538-2068, 1556-1827, 1560-1954, 1572-1793, 1573-1837, 1580-2192, 1585-2093, 1601-1839, 1601-1840, 1618-2132, 1632-1887, 1651-1754, 1686-1934, 1686-1950, 1686-1965, 1686-2298, 1688-1978, 1689-1955, 1734-2319, 1743-2254, 1743-2377, 1749-2032, 1755-1996, 1755-2346, 1762-2492, 1763-2071, 1774-2011, 1784-2152, 1795-2063, 1795-2066, 1797-2299, 1819-2416, 1826-2091, 1827-2517, 1829-2490, 1829-2508, 1839-2076, 1842-2348, 1868-2396, 1868-2421, 1873-2459, 1875-2415, 1877-2145, 1878-2563, 1880-2052, 1880-2415, 1880-2467, 1880-2470, 1897-2131, 1907-2180, 1908-2168, 1917-2209, 1919-2386, 1919-2470, 1922-2470, 1923-2179, 1936-2195, 1937-2180, 1941-2267, 1944-2627, 1945-2556, 1965-2538, 1980-2269, 1982-2504, 1983-2560, 2001-2303, 2005-2567, 2012-2470, 2021-2569, 2027-2289, 2027-2303, 2027-2487, 2039-2531, 2048-2277, 2058-2293, 2089-2569, 2095-2559, 2096-2559, 2104-2561, 2108-2580, 2110-2564, 2113-2559, 2115-2669, 2116-2564, 2117-2561, 2120-2422, 2122-2577, 2128-2439, 2129-2580, 2143-2559, 2145-2670, 2146-2561, 2151-2453, 2152-2559, 2153-2401, 2153-2572, 2154-2562, 2156-2580, 2168-2438, 2168-2550, 2169-2559, 2171-2563, 2188-2405, 2188-2559, 2196-2773, 2204-2472, 2220-2455, 2222-2559, 2230-2538, 2233-2471, 2233-2502, 2233-2773, 2235-2567, 2237-2572, 2243-2536, 2251-2564, 2279-2529, 2279-2543, 2296-2559, 2296-2773, 2299-2561, 2323-2630, 2332-2567, 2333-2621, 2346-2562

Table 4

Polynucleotide SEQ ID NO./ Incye ID/ Sequence Length	Sequence Fragments
41/5923789CB1/2966	1-1985, 1337-1980, 1564-2177, 1960-2223, 1960-2460, 1960-2503, 1960-2510, 1960-2622, 1973-2554, 2029-2390, 2087-2410, 2087-2686, 2087-2838, 2139-2966, 2161-2348, 2193-2420, 2205-2412, 2216-2420, 2227-2838, 2233-2838, 2271-2838, 2306-2833, 2314-2778, 2327-2838, 2337-2838, 2339-2838, 2355-2767, 2355-2838, 2359-2838, 2377-2838, 2378-2838, 2396-2575
42/6046484CB1/4404	1-966, 355-1040, 456-1274, 477-1118, 520-1325, 722-1557, 817-1375, 859-1564, 940-1040, 1025-1441, 1165-1850, 1198-1314, 1314-1850, 1413-1850, 1417-4404, 1444-1850
43/7481427CB1/669	1-669
44/7483595CB1/1823	1-351, 309-664, 348-668, 541-1059, 817-889, 988-1355, 1060-1248, 1060-1663, 1277-1663, 1354-1411, 1354-1577, 1354-1636, 1355-1823
45/3788427CB1/2931	1-1173, 428-1018, 432-983, 463-733, 497-793, 649-1173, 707-1128, 771-1417, 842-1065, 975-1512, 1056-1310, 1056-1604, 1056-1746, 1056-1771, 1099-1681, 1114-1696, 1133-1562, 1197-1817, 1309-1798, 1343-1972, 1344-1884, 1363-1652, 1363-1912, 1364-1978, 1371-1910, 1392-2005, 1396-1803, 1410-1943, 1419-2005, 1498-2167, 1502-1723, 1537-2239, 1547-1822, 1548-1975, 1551-2230, 1558-2210, 1561-2168, 1569-2279, 1570-2232, 1591-2280, 1596-2135, 1602-1879, 1617-2134, 1620-2322, 1670-2289, 1706-2210, 1714-1926, 1755-2450, 1773-2391, 1786-2373, 1805-2270, 1821-2067, 1890-2464, 1968-2608, 1979-2567, 2127-2446, 2161-2439, 2230-2425, 2230-2677, 2230-2722, 2230-2752, 2230-2821, 2245-2512, 2247-2378, 2247-2419, 2247-2838, 2275-2558, 2276-2822, 2314-2585, 2352-2630, 2394-2863, 2446-2930, 2466-2733, 2486-2734, 2490-2743, 2490-2770, 2578-2822, 2599-2834, 2603-2861, 2618-2891, 2628-2931
46/6972455CB1/1492	1-447, 1-576, 1-620, 1-622, 1-649, 255-890, 289-944, 496-1098, 670-1452, 772-1234, 856-1492, 876-1492, 907-1244, 933-1492, 1009-1492, 1061-1492
47/8077668CB1/2406	1-429, 108-429, 331-428, 331-652, 425-934, 430-768, 771-1250, 771-1254, 1212-1343, 1212-1573, 1321-1817, 1374-1664, 1750-2406, 1764-2198
48/55120485CB1/3686	1-63, 9-302, 9-397, 9-484, 9-565, 9-586, 9-628, 9-632, 9-635, 60-301, 60-304, 60-597, 64-238, 186-742, 226-730, 284-784, 335-779, 623-1272, 689-1272, 739-1272, 762-1272, 800-1204, 802-1273, 826-1272, 884-1272, 900-1272, 982-1915, 988-1272, 1024-1272, 1047-1272, 1104-1272, 1107-1272, 1160-1272, 1232-1272, 1262-1675, 1273-1653, 1273-1675, 1322-1675, 1323-1675, 1591-1675, 1634-1918, 1635-1918, 1674-2808, 1675-1918, 1675-2525, 2157-2256, 2526-2764, 2526-2928, 2526-2962, 2557-3036, 2644-2892, 2658-3194, 2664-2790, 2664-2909, 2672-2790, 2874-3078, 2888-3292, 2916-3215, 2916-3530, 2937-3614, 2950-3102, 3000-3665, 3007-3664, 3019-3093, 3090-3349, 3110-3673, 3399-3673, 3419-3681, 3476-3686

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
49/3112883CB1/2807	1-346, 20-455, 23-481, 32-509, 39-710, 83-240, 149-240, 170-281, 170-436, 170-440, 170-661, 170-697, 170-700, 170-725, 170-728, 170-729, 170-737, 170-784, 170-857, 175-705, 216-342, 235-394, 317-704, 408-1134, 428-569, 442-834, 458-1060, 472-912, 547-1270, 575-1134, 583-1254, 586-1204, 595-1258, 652-1234, 656-1231, 662-1226, 676-943, 676-1287, 698-1388, 701-968, 707-992, 707-1098, 762-1077, 762-1309, 765-1335, 788-1403, 798-1366, 805-1032, 816-1391, 825-1415, 843-1421, 857-1367, 866-1448, 930-1331, 936-1539, 946-1551, 947-1206, 949-1476, 1054-1469, 1074-1638, 1089-1638, 1129-1533, 1220-1571, 1232-1810, 1283-1529, 1325-1533, 1445-1674, 1481-2085, 1506-1764, 1515-2092, 1518-2142, 1530-1810, 1531-2141, 1552-2154, 1650-1908, 1650-2149, 1688-1961, 1731-2154, 1749-1984, 1808-2155, 1818-1960, 1838-2155, 2078-2807, 2108-2155, 2198-2426, 2296-2426, 2423-2575, 2423-2578, 2423-2583, 2423-2587, 2423-2625, 2423-2701, 2423-2742, 2423-2769, 2431-2561, 2444-2627, 2444-2769, 2484-2769, 2499-2720, 2499-2769, 2502-2769, 2510-2769, 2516-2571, 2538-2769, 2546-2769, 2552-2769, 2578-2769, 2602-2769, 2611-2769, 2615-2769, 2625-2769
50/4253888CB1/2170	1-629, 105-746, 105-783, 106-600, 676-887, 676-1004, 715-1004, 825-936, 868-1104, 885-1482, 931-1612, 943-1612, 1112-1612, 1125-1348, 1125-1700, 1513-1988, 1532-1596, 1588-2038, 1596-2036, 1661-1893, 1813-2158, 1826-2058, 1826-2146, 1827-2073, 1827-2170, 1904-2162
51/7479974CB1/1722	1-1722, 251-1712
52/7483850CB1/1424	1-283, 1-533, 1-569, 1-578, 1-582, 1-583, 1-584, 5-584, 27-584, 59-285, 61-285, 64-285, 84-285, 139-283, 140-283, 284-334, 284-347, 284-369, 284-403, 284-412, 284-431, 530-659, 594-1248, 594-1320, 594-1321, 594-1335, 594-1424, 599-1042
53/5508353CB1/3598	1-250, 12-553, 12-673, 12-704, 49-248, 49-568, 356-920, 356-929, 482-1038, 767-1173, 767-1201, 771-1247, 789-1080, 810-1477, 958-1217, 958-1486, 1010-1393, 1207-1393, 1348-1891, 1389-1776, 1399-2116, 1431-2008, 1434-2085, 1465-1961, 1682-2144, 1745-2115, 1783-1949, 1783-2318, 1792-1874, 1792-2229, 1833-2070, 1855-2127, 1855-2149, 1855-2185, 1855-2341, 1855-2432, 1958-2588, 1979-2104, 1979-2169, 2033-2712, 2064-2515, 2076-2331, 2177-2441, 2177-2708, 2238-2501, 2243-2883, 2245-2513, 2264-2537, 2301-2555, 2328-2636, 2363-2883, 2367-2906, 2381-2671, 2384-2626, 2384-2849, 2551-2763, 2551-2866, 2551-3054, 2713-2995, 2764-3247, 2799-3041, 2805-3598, 2819-3093, 2832-3264, 2841-3094
54/8543628CB1/1485	1-501, 1-502, 1-525, 1-563, 1-573, 1-580, 1-622, 1-751, 1-782, 1-812, 2-929, 11-37, 30-749, 33-854, 46-929, 65-788, 93-906, 144-883, 231-936, 261-1072, 491-1485, 509-1035
55/7482754CB1/1470	1-817, 73-267, 145-1266, 155-767, 631-734, 631-742, 641-1470, 713-766, 713-767, 793-1055, 908-1055, 908-1143, 1056-1143, 1056-1265, 1144-1265
56/3794818CB1/3132	1-2052, 1021-2199, 2071-3132, 2467-2702, 2555-2792, 2632-2702, 2722-2867

Table 4

Polynucleotide SEQ ID NO./ Incye ID/ Sequence Length	Sequence Fragments
57/4717525CB1/1832	1-447, 69-292, 69-442, 69-460, 69-504, 69-506, 69-534, 69-625, 69-643, 69-675, 69-686, 69-693, 69-703, 69-705, 69-706, 69-732, 69-738, 80-434, 81-606, 83-464, 87-447, 147-1059, 157-413, 157-475, 181-443, 181-570, 187-802, 199-440, 210-537, 210-640, 237-535, 246-841, 255-517, 255-890, 300-830, 301-774, 327-990, 358-889, 377-1018, 379-671, 439-1025, 443-997, 455-1059, 469-1060, 528-1013, 539-1059, 541-1048, 558-1059, 566-1003, 583-1059, 585-1059, 597-882, 599-1014, 619-864, 635-1059, 656-1059, 673-1059, 677-1059, 691-924, 692-1059, 711-1059, 717-1059, 720-1059, 728-1010, 735-1059, 741-1069, 760-1059, 765-1059, 779-1059, 794-1059, 796-1059, 805-1049, 814-1373, 821-941, 850-1059, 858-1069, 862-1059, 876-1059, 881-1059, 889-1059, 905-1049, 915-1059, 916-1059, 918-1059, 931-1059, 935-1059, 949-1046, 959-1059, 967-1059, 975-1059, 981-1049, 987-1059, 1002-1059, 1006-1059, 1008-1059, 1010-1382, 1015-1059, 1019-1059, 1047-1076, 1047-1093, 1047-1114, 1047-1139, 1047-1169, 1047-1173, 1047-1180, 1047-1184, 1047-1191, 1047-1198, 1047-1200, 1047-1206, 1047-1262, 1047-1269, 1047-1290, 1047-1305, 1047-1334, 1047-1335, 1047-1353, 1047-1355, 1047-1381, 1047-1382, 1047-1383, 1049-1382, 1053-1200, 1058-1382, 1063-1315, 1110-1381, 1128-1366, 1317-1832, 1478-1718, 1478-1811, 1482-1567
58/5091793CB1/1902	1-248, 1-544, 1-547, 1-567, 1-598, 1-648, 1-691, 1-720, 1-732, 1-737, 1-752, 1-796, 1-816, 1-833, 13-572, 48-884, 71-486, 71-550, 81-267, 82-549, 113-380, 113-549, 118-514, 127-558, 134-267, 159-986, 176-446, 265-528, 292-578, 375-663, 427-646, 593-879, 645-832, 645-884, 645-1125, 645-1149, 645-1164, 645-1233, 687-808, 769-1108, 806-1047, 806-1271, 806-1353, 807-974, 807-1318, 815-1109, 819-1004, 821-1461, 941-1108, 952-1641, 1041-1108, 1168-1561, 1213-1695, 1213-1742, 1215-1742, 1231-1742, 1233-1742, 1246-1878, 1250-1738, 1257-1614, 1315-1727, 1318-1847, 1349-1742, 1392-1902, 1411-1707, 1422-1742, 1426-1742, 1427-1742, 1438-1742, 1442-1742, 1458-1562, 1458-1628, 1458-1630, 1458-1633, 1458-1666, 1458-1680, 1458-1683, 1458-1693, 1458-1697, 1458-1742, 1476-1742, 1504-1902, 1511-1742, 1565-1742, 1576-1742
59/5945527CB1/2820	1-332, 1-444, 25-450, 31-538, 213-693, 347-617, 451-749, 451-1061, 785-1155, 792-1095, 895-942, 942-1056, 942-1096, 1033-1104, 1033-1199, 1044-1315, 1181-1275, 1181-1423, 1256-1526, 1280-1477, 1280-1905, 1389-1625, 1546-1821, 1546-2082, 1547-1589, 1547-1590, 1547-1611, 1547-1644, 1547-1669, 1547-1680, 1547-1681, 1547-1698, 1547-1717, 1547-1720, 1547-1724, 1547-1734, 1547-1757, 1547-1775, 1547-1776, 1547-1844, 1547-1867, 1547-1912, 1547-1957, 1547-2007, 1547-2042, 1547-2055, 1547-2071, 1547-2269, 1560-1840, 1627-2238, 1648-2068, 1656-1920, 1661-2365, 1667-2189, 1675-2354, 1698-2330, 1761-2039, 1776-2056, 1778-2037, 1778-2238, 1793-2339, 1814-2063, 1822-2494, 1837-2466, 1856-2516, 1868-2572, 1881-2465, 1990-2655, 1995-2567, 2050-2498, 2069-2668, 2134-2660, 2187-2507, 2187-2820, 2220-2820, 2222-2497, 2226-2492, 2240-2668, 2264-2668, 2271-2536, 2316-2668, 2384-2820, 2395-2654, 2395-2676, 2398-2668, 2401-2556, 2410-2558, 2745-2811, 2747-2820

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
60/6941124CB1/3920	1-552, 54-555, 384-722, 455-729, 548-1246, 726-938, 728-1114, 1033-1856, 1203-1438, 1203-1630, 1203-1701, 1260-1857, 1374-1642, 1414-1642, 1502-1642, 1615-2327, 1642-1992, 1642-2002, 1672-2155, 1672-2262, 1673-2328, 1673-2342, 1875-2328, 1932-2328, 1976-2483, 2070-2653, 2086-2328, 2169-2324, 2211-2328, 2296-2323, 2378-2625, 2378-2749, 2378-2816, 2378-2853, 2378-2866, 2378-2879, 2378-2882, 2378-2887, 2378-2908, 2378-2957, 2378-2964, 2378-2970, 2378-2971, 2378-2986, 2378-3019, 2378-3084, 2378-3087, 2378-3095, 2378-3136, 2378-3168, 2379-2852, 2400-3107, 2403-2520, 2403-2647, 2457-3035, 2474-3042, 2494-3206, 2512-3231, 2519-3086, 2521-2983, 2600-3107, 2600-3348, 2612-3344, 2631-3070, 2635-3311, 2663-3259, 2663-3415, 2758-3371, 2786-3425, 2787-2932, 2787-3205, 2793-3341, 2796-3360, 2824-3517, 2833-3458, 2852-3443, 2853-3373, 2856-3465, 2870-3494, 2881-3570, 2888-3404, 2888-3466, 2900-3526, 2907-3255, 2911-3421, 2911-3470, 2911-3479, 2912-3614, 2929-3314, 2938-3443, 2942-3443, 2954-3472, 2967-3537, 2989-3602, 3001-3247, 3004-3717, 3006-3704, 3014-3090, 3049-3536, 3058-3795, 3073-3813, 3078-3670, 3078-3807, 3094-3833, 3096-3785, 3100-3833, 3119-3833, 3168-3417, 3168-3575, 3168-3596, 3168-3838, 3168-3892, 3168-3919, 3169-3443, 3195-3833, 3220-3724, 3229-3856, 3230-3804, 3251-3549, 3254-3506, 3257-3801, 3260-3814, 3288-3832, 3289-3592, 3316-3833, 3333-3832, 3340-3833, 3348-3833, 3363-3840, 3391-3897, 3400-3833, 3402-3653, 3402-3831, 3402-3832, 3409-3839, 3427-3830, 3427-3833, 3449-3720, 3464-3920, 3468-3783, 3477-3761, 3479-3727, 3479-3885, 3479-3920, 3500-3747, 3508-3733, 3521-3760, 3523-3910, 3530-3871, 3550-3690, 3581-3920, 3678-3910, 3701-3918, 3720-3906, 3746-3920, 3747-3894, 3747-3920, 3763-3910, 3786-3920, 3828-3920
61/6972530CB1/1333	1-549, 1-566, 391-966, 421-966, 711-1333
62/6991750CB1/8487	1-724, 32-456, 52-627, 78-723, 105-694, 135-592, 135-637, 143-723, 172-683, 175-420, 175-469, 175-496, 175-500, 175-541, 175-684, 175-764, 175-767, 175-784, 175-918, 187-677, 222-918, 254-723, 258-918, 305-918, 310-720, 358-918, 370-723, 386-918, 432-674, 432-918, 487-918, 847-1242, 847-1290, 895-1285, 896-3353, 917-1415, 917-1416, 917-1417, 920-1414, 1232-1739, 1232-1740, 1233-1739, 1236-1739, 1254-1898, 1266-1739, 1290-1834, 1290-1861, 1290-1868, 1581-2120, 1581-2121, 1584-2121, 1587-2121, 1950-2121, 2085-2762, 2088-2762, 2089-2762, 2090-2744, 2090-2754, 2090-2756, 2090-2758, 2090-2762, 2094-2762, 2152-2938, 2248-2900, 2269-2797, 2269-2949, 2993-3677, 3458-4151, 3585-8102, 3887-4151, 3931-4242, 4024-4540, 4024-4650, 4024-4651, 4027-4643, 4027-4648, 4027-4650, 4027-4651, 4903-5354, 4903-5386, 4903-5433, 4903-5483, 4903-5507, 4903-5517, 4903-5525, 4903-5534, 4903-5548, 4903-5553, 4903-5561, 4903-5565, 4903-5567, 4903-5574, 5176-5434, 5340-6117, 5356-6117, 5364-6113, 5368-6117, 5393-6117, 5404-6117, 5409-6117, 5410-6117, 5417-6117, 5432-6117, 5434-6117, 5439-6117, 5449-6117, 6257-6768, 6398-6543, 6961-7140, 7135-7747, 7140-7955,

Table 4

Polynucleotide SEQ ID NO./ Incye ID/ Sequence Length	Sequence Fragments
62	7508-7900, 7614-8041, 7615-8102, 7843-8102, 7843-8209, 7843-8227, 7843-8236, 7843-8241, 7843-8262, 7843-8280, 7843-8341, 7843-8389, 7843-8430, 7843-8455, 7843-8465, 7843-8485, 7843-8486, 7843-8487
63/71726948CB1/3264	1-486, 4-441, 23-504, 24-504, 253-457, 286-504, 339-860, 355-823, 502-743, 502-1025, 550-856, 574-1259, 784-1237, 1104-1359, 1104-1362, 1104-1639, 1104-1654, 1104-1812, 1116-1681, 1360-1860, 1365-1834, 1366-1834, 1369-1881, 1419-2213, 1424-1890, 1523-2245, 1562-2184, 1724-2515, 1819-2533, 1858-2430, 1888-2228, 1888-2456, 1906-2469, 1931-2199, 1933-2190, 1991-2644, 1993-2507, 2008-2693, 2036-2682, 2046-2496, 2057-2684, 2172-2809, 2173-2809, 2181-2809, 2268-2813, 2271-2813, 2301-2809, 2312-3014, 2328-2953, 2351-2751, 2397-3204, 2397-3261, 2404-2835, 2406-2835, 2444-3013, 2449-2716, 2466-3075, 2492-2960, 2536-3140, 2549-3201, 2574-3173, 2582-2743, 2609-2975, 2762-3237, 2807-3250, 2813-3244, 2852-3060, 3000-3249, 3113-3256, 3113-3264, 3114-3261
64/7487393CB1/1659	1-402, 1-1659, 307-506, 416-506, 547-860, 547-863, 547-867, 1147-1598

Table 5

Polynucleotide SEQ ID NO:	Incyte Project ID:	Representative Library
33	7484831CB1	LIVRNON08
34	2477266CB1	LIVRNON08
35	3552033CB1	BRAHTDK01
36	4778139CB1	PROSTUS19
37	4787433CB1	PGANNOT01
38	7483598CB1	BRAITUT29
39	7484823CB1	TESTNOC01
40	143935CB1	BRACDIK08
41	5923789CB1	BRAIFET02
42	6046484CB1	BRACNOK02
44	7483595CB1	TESTNOC01
45	3788427CB1	BONEUNR01
46	6972455CB1	BMARUNR02
47	8077668CB1	ADRETUE02
48	55120485CB1	BRAITUT29
49	3112883CB1	BRSTNOT03
50	4253888CB1	ADRETUE02
52	7483850CB1	LIVRDIT06
53	5508353CB1	NERDTDN03
54	8543628CB1	BMARUNR02
55	7482754CB1	PTHYTMN05
56	3794818CB1	KIDEUNE02
57	4717525CB1	KIDEUNE02
58	5091793CB1	LUNGTUT08
59	5945527CB1	SINTNOR01
60	6941124CB1	FTUBTUR01
61	6972530CB1	BMARUNR02
62	6991750CB1	BRAIFER06
63	71726948CB1	KIDNNOT32

Table 6

Library	Vector	Library Description
ADRETUE02	PCDNA2.1	This 5' biased random primed library was constructed using RNA isolated from right adrenal tumor tissue removed from a 49-year-old Caucasian male during unilateral adrenalectomy. Pathology indicated adrenal cortical carcinoma comprising nearly the entire specimen. The tumor was attached to the adrenal gland which showed mild cortical atrophy. The tumor was encapsulated, being surrounded by a thin (1-3 mm) rim of connective tissue. The patient presented with adrenal cancer, abdominal pain, pyrexia of unknown origin, and deficiency anemia. Patient history included benign hypertension. Previous surgeries included adrenalectomy. Patient medications included aspirin, calcium, and iron. Family history included atherosclerotic coronary artery disease in the mother; cerebrovascular accident and atherosclerotic coronary artery disease in the father; and benign hypertension in the grandparent(s).
BMARUNR02	PIGEN	This random primed library was constructed using RNA isolated from an untreated SH-SY5Y cell line derived from bone marrow neuroblastoma tumor cells removed from a 4-year-old Caucasian female.
BONEUNR01	PCDNA2.1	This random primed library was constructed using pooled cDNA from two different donors. cDNA was generated using mRNA isolated from an untreated MG-63 cell line derived from an osteosarcoma tumor removed from a 14-year-old Caucasian male (donor A) and using mRNA isolated from sacral bone tumor tissue removed from an 18-year-old Caucasian female (donor B) during an exploratory laparotomy and soft tissue excision. Pathology indicated giant cell tumor of the sacrum in donor B. Donor B's history included pelvic joint pain, constipation, urinary incontinence, unspecified abdominal/pelvic symptoms, and a pelvic soft tissue malignant neoplasm. Family history included prostate cancer in donor B.
BRACDIK08	PSPORT1	This amplified and normalized library was constructed using RNA isolated from diseased corpus callosum tissue removed from the brain of a 57-year-old Caucasian male who died from a cerebrovascular accident. Serologies were negative. Patient history included Huntington's disease, emphysema, and tobacco abuse (3-4 packs per day for 40 years).

Table 6

Library	Vector	Library Description
BRAFNOK02	PSPORT1	This amplified and normalized library was constructed using RNA isolated from posterior cingulate tissue removed from an 85-year-old Caucasian female who died from myocardial infarction and retroperitoneal hemorrhage. Pathology indicated atherosclerosis, moderate to severe, involving the circle of Willis, middle cerebral, basilar and vertebral arteries; infarction, remote, left dentate nucleus; and amyloid plaque deposition consistent with age. There was mild to moderate leptomeningeal fibrosis, especially over the convexity of the frontal lobe. There was mild generalized atrophy involving all lobes. The white matter was mildly thinned. Cortical thickness in the temporal lobes, both maximal and minimal, was slightly reduced. The substantia nigra pars compacta appeared mildly depigmented. Patient history included COPD, hypertension, and recurrent deep venous thrombosis. 6.4 million independent clones from this amplified library were normalized in one round using conditions adapted from Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research 6 (1996):791.
BRAHTDK01	PSPORT1	This amplified and normalized library was constructed using pooled RNA isolated from archaocortex, anterior and posterior hippocampus tissue removed from a 55-year-old Caucasian female who died from cholangiocarcinoma. Pathology indicated mild meningeal fibrosis predominately over the convexities, scattered axonal spheroids in the white matter of the cingulate cortex and the thalamus, and a few scattered neurofibrillary tangles in the entorhinal cortex and the periaqueductal gray region. Pathology for the associated tumor tissue indicated well-differentiated cholangiocarcinoma of the liver with residual or relapsed tumor. Patient history included cholangiocarcinoma, post-operative Budd-Chiari syndrome, biliary ascites, hydrothorax, dehydration, malnutrition, oliguria and acute renal failure. Previous surgeries included cholecystectomy and resection of 85% of the liver. 7.6x10 ⁵ independent clones from this amplified library were normalized in 1 round using conditions adapted Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research (1996) 6:791, except that a significantly longer (48 hours/round) reannealing hybridization was used.
BRAIFER06	PCDNA2.1	This random primed library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus who was stillborn with a hypoplastic left heart at 23 weeks' gestation. Serologies were negative.
BRAIFET02	pINCY	Library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus, who was stillborn with a hypoplastic left heart at 23 weeks' gestation.
BRAITUT29	pINCY	Library was constructed using RNA isolated from brain tumor tissue removed from the parietal lobe of a 43-year-old female during excision of a cerebral meningeal lesion. Pathology indicated high grade glioma. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, benign hypertension, and hyperlipidemia.

Table 6

Library	Vector	Library Description
BRSTNOT03	PSPORT1	Library was constructed using RNA isolated from diseased breast tissue removed from a 54-year-old Caucasian female during a bilateral radical mastectomy. Pathology for the associated tumor tissue indicated residual invasive grade 3 mammary ductal adenocarcinoma. Patient history included kidney infection and condyloma acuminatum. Family history included benign hypertension, hyperlipidemia and a malignant neoplasm of the colon.
FTUBTUR01	PCDNA2.1	This random primed library was constructed using RNA isolated from fallopian tube tumor tissue removed from an 85-year-old Caucasian female during bilateral salpingo-oophorectomy and hysterectomy. Pathology indicated poorly differentiated mixed endometrioid (80%) and serous (20%) adenocarcinoma, which was confined to the mucosa without mural involvement. Endometrioid carcinoma in situ was also present. Pathology for the associated uterus tumor indicated focal endometrioid adenocarcinoma in situ and moderately differentiated invasive adenocarcinoma arising in an endometrial polyp. Metastatic endometrioid and serous adenocarcinoma was present at the cul-de-sac tumor. Patient history included medullary carcinoma of the thyroid and myocardial infarction.
KIDEUNE02	pINCY	This 5' biased random primed library was constructed using RNA isolated from an untreated transformed embryonal cell line (293-EBNA) derived from kidney epithelial tissue (Invitrogen). The cells were transformed with adenovirus 5 DNA.
KIDNNOT32	pINCY	Library was constructed using RNA isolated from kidney tissue removed from a 49-year-old Caucasian male who died from an intracranial hemorrhage and cerebrovascular accident. Patient history included tobacco abuse.
LIVRDIT06	pINCY	This library was constructed using RNA isolated from diseased liver tissue removed from a 35-year-old Caucasian male during needle biopsy of the liver. Patient history included hepatitis C.
LIVRNON08	pINCY	This normalized library was constructed from 5.7 million independent clones from a pooled liver tissue library. Starting RNA was made from pooled liver tissue removed from a 4-year-old Hispanic male who died from anoxia and a 16 week female fetus who died after 16-weeks gestation from anencephaly. Serologies were positive for cytomegalovirus in the 4-year-old. Patient history included asthma in the 4-year-old. Family history included taking daily prenatal vitamins and mitral valve prolapse in the mother of the fetus. The library was normalized in 2 rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228 and Bonaldo et al., Genome Research 6 (1996):791, except that a significantly longer (48 hours/round) reannealing hybridization was used.

Table 6

Library	Vector	Library Description
LUNGTUT08	pINCY	Library was constructed using RNA isolated from lung tumor tissue removed from a 63-year-old Caucasian male during a right upper lobectomy with fiberoptic bronchoscopy. Pathology indicated a grade 3 adenocarcinoma. Patient history included atherosclerotic coronary artery disease, an acute myocardial infarction, rectal cancer, an asymptomatic abdominal aortic aneurysm, tobacco abuse, and cardiac dysrhythmia. Family history included congestive heart failure, stomach cancer, and lung cancer, type II diabetes, atherosclerotic coronary artery disease, and an acute myocardial infarction.
NERDTDN03	pINCY	This normalized dorsal root ganglion tissue library was constructed from 1.05 million independent clones from a dorsal root ganglion tissue library. Starting RNA was made from dorsal root ganglion tissue removed from the cervical spine of a 32-year-old Caucasian male who died from acute pulmonary edema, acute bronchopneumonia, bilateral pleural effusions, pericardial effusion, and malignant lymphoma (natural killer cell type). The patient presented with pyrexia of unknown origin, malaise, fatigue, and gastrointestinal bleeding. Patient history included probable cytomegalovirus infection, liver congestion, and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, respiratory failure, pneumonia of the left lung, natural killer cell lymphoma of the pharynx, Bell's palsy, and tobacco and alcohol abuse. Previous surgeries included colonoscopy, closed colon biopsy, adenotonsillectomy, and nasopharyngeal endoscopy and biopsy. Patient medications included Diflucan (fluconazole), Deltasone (prednisone), hydrocodone, Lortab, Alprazolam, Reazodone, ProMace-Cytabom, Etoposide, Cisplatin, Cytarabine, and dexamethasone. The patient received radiation therapy and multiple blood transfusions. The library was normalized in 2 rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research 6 (1996):791, except that a significantly longer (48 hours/round) reannealing hybridization was used.
PGANNOT01	PSPORT1	Library was constructed using RNA isolated from paraganglionic tumor tissue removed from the intra-abdominal region of a 46-year-old Caucasian male during exploratory laparotomy. Pathology indicated a benign paraganglioma and was associated with a grade 2 renal cell carcinoma, clear cell type, which did not penetrate the capsule. Surgical margins were negative for tumor.

Table 6

Library	Vector	Library Description
PROSTUS19	pINCY	This subtracted prostate tumor tissue library was constructed using 2.36 million clones from the PROSTUT13 library and was subjected to two round sof subtraction hybridization with 2.36 million clones from EPIPNOT01 library. The starting library for subtraction was constructed using RNA isolated from prostate tumor tissue removed from a 59-year-old Caucasian male during a radical prostatectomy with regional lymph node excision. Pathology indicated adenocarcinoma (Gleason grade 3+3) involving the prostate peripherally with invasion of the capsule. Adenofibromatous hyperplasia was present. The patient presented with elevated prostate-specific antigen (PSA). Patient history included diverticulitis of colon, asbestosis, and thrombophlebitis. Family history included benign hypertension, multiple myeloma, hyperlipidemia, and rheumatoid arthritis. Subtractive hybridization conditions were based on the methodologies of Swaroop et al., NAR (1991) 19:1954 and Bonaldo, et al. Genome Research (1996) 6:791.
PTHYTMN05	pINCY	Library was constructed using RNA isolated from parathyroid tissue removed from a 44-year-old Caucasian male during a partial parathyroidectomy. Pathology for the matched tumor tissue indicated parathyroid carcinoma (grade 1 of 4) forming a partially cystic tan mass. Both capsular and vascular invasion were present. The patient presented with unspecified parathyroid disorder and calcium metabolism disorder. Patient history included kidney calculus and obesity. Previous surgeries included vasectomy and parathyroid surgery. Family history included emphysema in the mother; type II diabetes in the father; and type I diabetes and hyperlipidemia in the sibling(s).
SINTNOR01	PCDNA2.1	This random primed library was constructed using RNA isolated from small intestine tissue removed from a 31-year-old Caucasian female during Roux-en-Y gastric bypass. Patient history included clinical obesity.
TESTNOC01	PBLUESCRIPT	This large size fractionated library was constructed using RNA isolated from testicular tissue removed from a pool of eleven, 10 to 61-year-old Caucasian males.

Table 7

Program	Description	Reference	Parameter Threshold
ABIFACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322; Durbin, R. et al. (1998) Our World View, in a Nutshell, Cambridge Univ. Press, pp. 1-350.	PFAM hits: Probability value= 1.0E-3 or less Signal peptide hits: Score= 0 or greater

Table 7 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score \geq GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-499; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielsen, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. Conf. on Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182.	
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:

- 5
- a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32,
 - b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32,
 - 10 c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and
 - d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32.

15 2. An isolated polypeptide of claim 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32.

3. An isolated polynucleotide encoding a polypeptide of claim 1.

20 4. An isolated polynucleotide encoding a polypeptide of claim 2.

5. An isolated polynucleotide of claim 4 comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64.

25 6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

7. A cell transformed with a recombinant polynucleotide of claim 6.

30 8. A transgenic organism comprising a recombinant polynucleotide of claim 6.

9. A method of producing a polypeptide of claim 1, the method comprising:

- 35
- a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and

b) recovering the polypeptide so expressed.

10. A method of claim 9, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-32.

5

11. An isolated antibody which specifically binds to a polypeptide of claim 1.

12. An isolated polynucleotide selected from the group consisting of:

10

a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64,

b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64,

c) a polynucleotide complementary to a polynucleotide of a),

15

d) a polynucleotide complementary to a polynucleotide of b), and

e) an RNA equivalent of a)-d).

13. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 12.

20

14. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:

25

a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and

b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

30

15. A method of claim 14, wherein the probe comprises at least 60 contiguous nucleotides.

16. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:

35

a) amplifying said target polynucleotide or fragment thereof using polymerase chain

reaction amplification, and

- b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

5 17. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

18. A composition of claim 17, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-32.

10

19. A method for treating a disease or condition associated with decreased expression of functional TRICH, comprising administering to a patient in need of such treatment the composition of claim 17.

15

20. A method of screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
b) detecting agonist activity in the sample.

20

a

21. A composition comprising an agonist compound identified by a method of claim 20 and pharmaceutically acceptable excipient.

22. A method for treating a disease or condition associated with decreased expression of functional TRICH, comprising administering to a patient in need of such treatment a composition of claim 21.

25

of

23. A method of screening a compound for effectiveness as an antagonist of a polypeptide claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
b) detecting antagonist activity in the sample.

30

24. A composition comprising an antagonist compound identified by a method of claim 23 and a pharmaceutically acceptable excipient.

35

25. A method for treating a disease or condition associated with overexpression of

functional TRICH, comprising administering to a patient in need of such treatment a
composition of claim 24.

26. A method of screening for a compound that specifically binds to the polypeptide of
5 claim 1, the method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under
suitable conditions, and
- b) detecting binding of the polypeptide of claim 1 to the test compound, thereby
identifying a compound that specifically binds to the polypeptide of claim 1.

10

27. A method of screening for a compound that modulates the activity of the polypeptide of
claim 1, the method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under
conditions permissive for the activity of the polypeptide of claim 1,
- 15 b) assessing the activity of the polypeptide of claim 1 in the presence of the test
compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test
compound with the activity of the polypeptide of claim 1 in the absence of the test
compound, wherein a change in the activity of the polypeptide of claim 1 in the
20 presence of the test compound is indicative of a compound that modulates the
activity of the polypeptide of claim 1.

20

28. A method of screening a compound for effectiveness in altering expression of a target
polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the
25 method comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, under
conditions suitable for the expression of the target polynucleotide,
- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying
30 amounts of the compound and in the absence of the compound.

30

29. A method of assessing toxicity of a test compound, the method comprising:

- a) treating a biological sample containing nucleic acids with the test compound,
- b) hybridizing the nucleic acids of the treated biological sample with a probe
35 comprising at least 20 contiguous nucleotides of a polynucleotide of claim 12 under

35

conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 12 or fragment thereof,

- 5 c) quantifying the amount of hybridization complex, and
d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

10 30. A diagnostic test for a condition or disease associated with the expression of TRICH in biological sample, the method comprising:

- a) combining the biological sample with an antibody of claim 11, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide
15 complex, and
b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

20 31. The antibody of claim 11, wherein the antibody is:

- a) a chimeric antibody,
b) a single chain antibody,
c) a Fab fragment,
d) a F(ab')₂ fragment, or
e) a humanized antibody.

25 32. A composition comprising an antibody of claim 11 and an acceptable excipient.

30 33. A method of diagnosing a condition or disease associated with the expression of TRICH in a subject, comprising administering to said subject an effective amount of the composition of claim 32.

34. A composition of claim 32, wherein the antibody is labeled.

35 35. A method of diagnosing a condition or disease associated with the expression of TRICH in a subject, comprising administering to said subject an effective amount of the

composition of claim 34.

36. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- 5 a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibodies from said animal, and
- 10 c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32.

37. A polyclonal antibody produced by a method of claim 36.

15 38. A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.

39. A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- 20 a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibody producing cells from the animal,
- c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells,
- 25 d) culturing the hybridoma cells, and
- e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32.

30 40. A monoclonal antibody produced by a method of claim 39.

41. A composition comprising the monoclonal antibody of claim 40 and a suitable carrier.

35 42. The antibody of claim 11, wherein the antibody is produced by screening a Fab expression library.

43. The antibody of claim 11, wherein the antibody is produced by screening a recombinant immunoglobulin library.

44. A method of detecting a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32 in a sample, the method comprising:

- a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32 in the sample.

45. A method of purifying a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32 from a sample, the method comprising:

- a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) separating the antibody from the sample and obtaining the purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32.

46. A microarray wherein at least one element of the microarray is a polynucleotide of claim 13.

47. A method of generating an expression profile of a sample which contains polynucleotides, the method comprising:

- a) labeling the polynucleotides of the sample,
- b) contacting the elements of the microarray of claim 46 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and
- c) quantifying the expression of the polynucleotides in the sample.

48. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, and wherein said target polynucleotide is a polynucleotide of claim 12.

49. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.

5 50. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.

10 51. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to said target polynucleotide.

52. An array of claim 48, which is a microarray.

15 53. An array of claim 48, further comprising said target polynucleotide hybridized to a nucleotide molecule comprising said first oligonucleotide or polynucleotide sequence.

54. An array of claim 48, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.

20 55. An array of claim 48, wherein each distinct physical location on the substrate contains multiple nucleotide molecules, and the multiple nucleotide molecules at any single distinct physical location have the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another distinct physical location on the substrate.

25 56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.

30 58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.

59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.

35 60. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.

61. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.

62. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.

5 63. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.

64. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.

10 65. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.

66. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.

67. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.

15 68. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.

69. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.

20 70. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.

71. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:16.

72. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:17.

25 73. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:18.

74. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:19.

30 75. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:20.

76. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:21.

77. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:22.

35 78. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:23.

79. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:24.

80. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:25.

5 81. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:26.

82. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:27.

83. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:28.

10

84. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:29.

85. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:30.

15

86. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:31.

87. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:32.

20

88. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:33.

89. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:34.

25

90. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:35.

91. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:36.

30

92. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:37.

35

93. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:38.

94. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:39.

5 95. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:40.

96. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:41.

10 97. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:42.

98. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:43.

15 99. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:44.

20 100. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:45.

101. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:46.

25 102. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:47.

103. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:48.

30 104. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:49.

35 105. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:50.

106. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:51.

107. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:52.

108. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:53.

109. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:54.

110. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:55.

111. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:56.

112. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:57.

113. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:58.

114. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:59.

115. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:60.

116. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:61.

117. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:62.

118. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:63.

119. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:64.

5

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
13 June 2002 (13.06.2002)

PCT

(10) International Publication Number
WO 02/046415 A2(51) International Patent Classification⁷: C12N 15/12,
C12Q 1/68, C07K 14/705, 16/28, A61K 31/17, G01N
33/50, 33/68

(21) International Application Number: PCT/US01/46963

(22) International Filing Date: 5 December 2001 (05.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/254,303	8 December 2000 (08.12.2000)	US
60/256,190	15 December 2000 (15.12.2000)	US
60/257,504	21 December 2000 (21.12.2000)	US
60/261,546	12 January 2001 (12.01.2001)	US
60/262,832	19 January 2001 (19.01.2001)	US
60/264,377	26 January 2001 (26.01.2001)	US
60/266,019	2 February 2001 (02.02.2001)	US

(71) Applicant (for all designated States except US): INCYTE
GENOMICS, INC. [US/US], 3160 Porter Drive, Palo
Alto, CA 94304 (US)

(72) Inventors; and

(75) Inventors/Applicants (for US only): LEE, Ernestine,
A. [US/US]; 624 Kains Street, Albany, CA 94706 (US).
BAUGHN, Maria, R. [US/US]; 14244 Santiago Road, San
Leandro, CA 94577 (US). YUE, Henry [US/US]; 826 Lois
Avenue, Sunnyvale, CA 94087 (US). DING, Li [CN/US];
3353 Alma Street #146, Palo Alto, CA 94306 (US). RAU-
MANN, Brigitte, E. [US/US]; 5801 South Dorchester
Avenue #3B, Chicago, IL 60637 (US). HAFALIA, April,
J., A. [US/US]; 2227 Calle de Primavera, Santa Clara, CA
95054 (US). KHAN, Farrah, A. [IN/US]; 9445 Harrison
Street, Des Plaines, IL 60016 (US). NGUYEN, Dannie,
B. [US/US]; 1403 Ridgewood Drive, San Jose, CA 95118
(US). ELLIOTT, Vicki, S. [US/US]; 3770 Polten Place
Way, San Jose, CA 95121 (US). RAMKUMAR, Jay-
alaxmi [IN/US]; 34359 Maybird Circle, Fremont, CA
94555 (US). WALIA, Narinder, K. [US/US]; 890 Davis
Street #205, San Leandro, CA 94577 (US). ISON, Craig,
H. [US/US]; 1242 Weathersfield Way, San Jose, CA 95118
(US). LU, Yan [CN/US]; 3885 Corrina Way, Palo Alto,
CA 94303 (US). GANDHI, Ameena, R. [US/US]; 705 5th
Avenue, San Francisco, CA 94118 (US). WARREN, Brid-
get, A. [US/US]; 10130 Parkwood Drive #2, Cupertino,

CA 95014 (US). DUGGAN, Brendan, M. [AU/US]; 243
Buena Vista Avenue #306, Sunnyvale, CA 94086 (US).
TRIBOULEY, Catherine, M. [FR/US]; 1121 Tennessee
Street #5, San Francisco, CA 94107 (US). BURFORD,
Neil [GB/US]; 105 Wildwood Circle, Durham, CT 06422
(US). LU, Dyung, Aina, M. [US/US]; 233 Coy Drive,
San Jose, CA 95123 (US). LAL, Preeti, G. [IN/US]; P.O.
Box 5142, Santa Clara, CA 95056 (US). YAO, Monique,
G. [US/US]; 1189 Woodgate Drive, Carmel, IN 46033
(US). XU, Yuming [US/US]; 1739 Walnut Drive, Moun-
tain View, CA 94040 (US). BRUNS, Christopher, M.
[US/US]; 575 S. Rengstorff Avenue #126, Mountain View,
CA 94040 (US). THANGAVELU, Kavitha [IN/US];
1950 Montecito Avenue #23, Mountain View, CA 94043
(US). SWARNAKAR, Anita [CA/US]; 8 Locksley Av-
enue #5D, San Francisco, CA 94122 (US). TANG, Y, Tom
[US/US]; 4230 Ranwick Court, San Jose, CA 95118 (US).
AZIMZAI, Yalda [US/US]; 5518 Boulder Canyon Drive,
Castro Valley, CA 94552 (US). THORNTON, Michael
[US/US]; 9 Medway Road, Woodside, CA 94062-2612
(US). ARVIZU, Chandra [US/US]; 490 Sherwood Way
#1, Menlo Park, CA 94025 (US). POLICKY, Jennifer, L.
[US/US]; 1511 Jarvis Court, San Jose, CA 95118 (US).

(74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics,
Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

[Continued on next page]

WO 02/046415 A2

(54) Title: TRANSPORTERS AND ION CHANNELS

(57) Abstract: The invention provides human transporters and ion channels (TRICH) and polynucleotides which identify and en-
code TRICH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also
provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of TRICH.



(48) Date of publication of this corrected version:

6 September 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(15) Information about Correction:

see PCT Gazette No. 36/2002 of 6 September 2002, Section II

TRANSPORTERS AND ION CHANNELS

This invention relates to nucleic acid and amino acid sequences of transporters and ion channels and to the use of these sequences in the diagnosis, treatment, and prevention of transport, neurological, muscle, immunological and cell proliferative disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of transporters and ion channels.

BACKGROUND OF THE INVENTION

Eukaryotic cells are surrounded and subdivided into functionally distinct organelles by hydrophobic lipid bilayer membranes which are highly impermeable to most polar molecules. Cells and organelles require transport proteins to import and export essential nutrients and metal ions including K^+ , NH_4^+ , P_i , SO_4^{2-} , sugars, and vitamins, as well as various metabolic waste products. Transport proteins also play roles in antibiotic resistance, toxin secretion, ion balance, synaptic neurotransmission, kidney function, intestinal absorption, tumor growth, and other diverse cell functions (Griffith, J. and C. Sansom (1998) The Transporter Facts Book, Academic Press, San Diego CA, pp. 3-29). Transport can occur by a passive concentration-dependent mechanism, or can be linked to an energy source such as ATP hydrolysis or an ion gradient. Proteins that function in transport include carrier proteins, which bind to a specific solute and undergo a conformational change that translocates the bound solute across the membrane, and channel proteins, which form hydrophilic pores that allow specific solutes to diffuse through the membrane down an electrochemical solute gradient.

Carrier proteins which transport a single solute from one side of the membrane to the other are called uniporters. In contrast, coupled transporters link the transfer of one solute with simultaneous or sequential transfer of a second solute, either in the same direction (symport) or in the opposite direction (antiport). For example, intestinal and kidney epithelium contains a variety of symporter systems driven by the sodium gradient that exists across the plasma membrane. Sodium moves into the cell down its electrochemical gradient and brings the solute into the cell with it. The sodium gradient that provides the driving force for solute uptake is maintained by the ubiquitous Na^+/K^+ ATPase system. Sodium-coupled transporters include the mammalian glucose transporter (SGLT1), iodide transporter (NIS), and multivitamin transporter (SMVT). All three transporters have twelve putative transmembrane segments, extracellular glycosylation sites, and cytoplasmically-oriented N- and C-termini. NIS plays a crucial role in the evaluation, diagnosis, and treatment of various thyroid pathologies because it is the molecular basis for radioiodide thyroid-imaging techniques and for specific targeting of radioisotopes to the thyroid gland (Levy,

O. et al. (1997) *Proc. Natl. Acad. Sci. USA* 94:5568-5573). SMVT is expressed in the intestinal mucosa, kidney, and placenta, and is implicated in the transport of the water-soluble vitamins, e.g., biotin and pantothenate (Prasad, P.D. et al. (1998) *J. Biol. Chem.* 273:7501-7506).

One of the largest families of transporters is the major facilitator superfamily (MFS), also called the uniporter-symporter-antiporter family. MFS transporters are single polypeptide carriers that transport small solutes in response to ion gradients. Members of the MFS are found in all classes of living organisms, and include transporters for sugars, oligosaccharides, phosphates, nitrates, nucleosides, monocarboxylates, and drugs. MFS transporters found in eukaryotes all have a structure comprising 12 transmembrane segments (Pao, S.S. et al. (1998) *Microbiol. Molec. Biol. Rev.* 62:1-34). The largest family of MFS transporters is the sugar transporter family, which includes the seven glucose transporters (GLUT1-GLUT7) found in humans that are required for the transport of glucose and other hexose sugars. These glucose transport proteins have unique tissue distributions and physiological functions. GLUT1 provides many cell types with their basal glucose requirements and transports glucose across epithelial and endothelial barrier tissues; GLUT2 facilitates glucose uptake or efflux from the liver; GLUT3 regulates glucose supply to neurons; GLUT4 is responsible for insulin-regulated glucose disposal; and GLUT5 regulates fructose uptake into skeletal muscle. Defects in glucose transporters are involved in a recently identified neurological syndrome causing infantile seizures and developmental delay, as well as glycogen storage disease, Fanconi-Bickel syndrome, and non-insulin-dependent diabetes mellitus (Mueckler, M. (1994) *Eur. J. Biochem.* 219:713-725; Longo, N. and L.J. Elsas (1998) *Adv. Pediatr.* 45:293-313).

Monocarboxylate anion transporters are proton-coupled symporters with a broad substrate specificity that includes L-lactate, pyruvate, and the ketone bodies acetate, acetoacetate, and beta-hydroxybutyrate. At least seven isoforms have been identified to date. The isoforms are predicted to have twelve transmembrane (TM) helical domains with a large intracellular loop between TM6 and TM7, and play a critical role in maintaining intracellular pH by removing the protons that are produced stoichiometrically with lactate during glycolysis. The best characterized H⁺-monocarboxylate transporter is that of the erythrocyte membrane, which transports L-lactate and a wide range of other aliphatic monocarboxylates. Other cells possess H⁺-linked monocarboxylate transporters with differing substrate and inhibitor selectivities. In particular, cardiac muscle and tumor cells have transporters that differ in their K_m values for certain substrates, including stereoselectivity for L- over D-lactate, and in their sensitivity to inhibitors. There are Na⁺-monocarboxylate cotransporters on the luminal surface of intestinal and kidney epithelia, which allow the uptake of lactate, pyruvate, and ketone bodies in these tissues. In addition, there are specific and selective transporters for organic cations and organic anions in organs including the

kidney, intestine and liver. Organic anion transporters are selective for hydrophobic, charged molecules with electron-attracting side groups. Organic cation transporters, such as the ammonium transporter, mediate the secretion of a variety of drugs and endogenous metabolites, and contribute to the maintenance of intercellular pH (Poole, R.C. and A.P. Halestrap (1993) *Am. J. Physiol.* 264:C761-C782; Price, N.T. et al. (1998) *Biochem. J.* 329:321-328; and Martinelle, K. and I. Haggstrom (1993) *J. Biotechnol.* 30:339-350).

ATP-binding cassette (ABC) transporters are members of a superfamily of membrane proteins that transport substances ranging from small molecules such as ions, sugars, amino acids, peptides, and phospholipids, to lipopeptides, large proteins, and complex hydrophobic drugs. ABC transporters consist of four modules: two nucleotide-binding domains (NBD), which hydrolyze ATP to supply the energy required for transport, and two membrane-spanning domains (MSD), each containing six putative transmembrane segments. These four modules may be encoded by a single gene, as is the case for the cystic fibrosis transmembrane regulator (CFTR), or by separate genes. When encoded by separate genes, each gene product contains a single NBD and MSD. These "half-molecules" form homo- and heterodimers, such as Tap1 and Tap2, the endoplasmic reticulum-based major histocompatibility (MHC) peptide transport system. Several genetic diseases are attributed to defects in ABC transporters, such as the following diseases and their corresponding proteins: cystic fibrosis (CFTR, an ion channel), adrenoleukodystrophy (adrenoleukodystrophy protein, ALDP), Zellweger syndrome (peroxisomal membrane protein-70, PMP70), and hyperinsulinemic hypoglycemia (sulfonylurea receptor, SUR). Overexpression of the multidrug resistance (MDR) protein, another ABC transporter, in human cancer cells makes the cells resistant to a variety of cytotoxic drugs used in chemotherapy (Taglicht, D. and S. Michaelis (1998) *Meth. Enzymol.* 292:130-162).

A number of metal ions such as iron, zinc, copper, cobalt, manganese, molybdenum, selenium, nickel, and chromium are important as cofactors for a number of enzymes. For example, copper is involved in hemoglobin synthesis, connective tissue metabolism, and bone development, by acting as a cofactor in oxidoreductases such as superoxide dismutase, ferroxidase (ceruloplasmin), and lysyl oxidase. Copper and other metal ions must be provided in the diet, and are absorbed by transporters in the gastrointestinal tract. Plasma proteins transport the metal ions to the liver and other target organs, where specific transporters move the ions into cells and cellular organelles as needed. Imbalances in metal ion metabolism have been associated with a number of disease states (Danks, D.M. (1986) *J. Med. Genet.* 23:99-106).

P-type ATPases comprise a class of cation-transporting transmembrane proteins. They are integral membrane proteins which use an aspartyl phosphate intermediate to move cations across a membrane. Features of P-type ATPases include: (i) a cation channel; (ii) a stalk, formed by

extensions of the transmembrane α -helices into the cytoplasm; (iii) an ATP binding domain; (iv) a phosphorylated aspartic acid; (v) an adjacent transduction domain; (vi) a phosphatase domain, which removes the phosphate from the aspartic acid as part of the reaction cycle; and (vii) six or more transmembrane domains. Included in this class are heavy metal-transporting ATPases as well
5 as aminophospholipid transporters.

The transport of phosphatidylserine and phosphatidylethanolamine by aminophospholipid translocase results in the movement of these molecules from one side of a bilayer to another. This transport is conducted by a newly identified subfamily of P-type ATPases which are proposed to be amphipath transporters. Amphipath transporters move molecules having both a hydrophilic and a
10 hydrophobic region. As many as seventeen different genes belong to this P-type ATPases subfamily, being grouped into several distinct classes and subclasses (Halleck, M.S. et al., (1999) *Physiol. Genomics* 1:139-150; Vulpe, C. Et al., (1993) *Nat. Genet.* 3:7-13).

Transport of fatty acids across the plasma membrane can occur by diffusion, a high capacity, low affinity process. However, under normal physiological conditions a significant
15 fraction of fatty acid transport appears to occur via a high affinity, low capacity protein-mediated transport process. Fatty acid transport protein (FATP), an integral membrane protein with four transmembrane segments, is expressed in tissues exhibiting high levels of plasma membrane fatty acid flux, such as muscle, heart, and adipose. Expression of FATP is upregulated in 3T3-L1 cells during adipose conversion, and expression in COS7 fibroblasts elevates uptake of long-chain fatty
20 acids (Hui, T.Y. et al. (1998) *J. Biol. Chem.* 273:27420-27429).

The lipocalin superfamily constitutes a phylogenetically conserved group of more than forty proteins that function as extracellular ligand-binding proteins which bind and transport small hydrophobic molecules. Members of this family function as carriers of retinoids, odorants, chromophores, pheromones, allergens, and sterols, and in a variety of processes including nutrient
25 transport, cell growth regulation, immune response, and prostaglandin synthesis. A subset of these proteins may be multifunctional, serving as either a biosynthetic enzyme or as a specific enzyme inhibitor. (Tanaka, T. et al. (1997) *J. Biol. Chem.* 272:15789-15795; and van't Hof, W. et al. (1997) *J. Biol. Chem.* 272:1837-1841.)

Members of the lipocalin family display unusually low levels of overall sequence
30 conservation. Pairwise sequence identity often falls below 20%. Sequence similarity between family members is limited to conserved cysteines which form disulfide bonds and three motifs which form a juxtaposed cluster that functions as a target cell recognition site. The lipocalins share an eight stranded, anti-parallel beta-sheet which folds back on itself to form a continuously hydrogen-bonded beta-barrel. The pocket formed by the barrel functions as an internal ligand
35 binding site. Seven loops (L1 to L7) form short beta-hairpins, except loop L1 which is a large

omega loop that forms a lid to partially close the internal ligand-binding site (Flower (1996) Biochem. J. 318:1-14).

Lipocalins are important transport molecules. Each lipocalin associates with a particular ligand and delivers that ligand to appropriate target sites within the organism. Retinol-binding protein (RBP), one of the best characterized lipocalins, transports retinol from stores within the liver to target tissues. Apolipoprotein D (apo D), a component of high density lipoproteins (HDLs) and low density lipoproteins (LDLs), functions in the targeted collection and delivery of cholesterol throughout the body. Lipocalins are also involved in cell regulatory processes. Apo D, which is identical to gross-cystic-disease-fluid protein (GCDFP)-24, is a progesterone/pregnenolone-binding protein expressed at high levels in breast cyst fluid. Secretion of apo D in certain human breast cancer cell lines is accompanied by reduced cell proliferation and progression of cells to a more differentiated phenotype. Similarly, apo D and another lipocalin, α_1 -acid glycoprotein (AGP), are involved in nerve cell regeneration. AGP is also involved in anti-inflammatory and immunosuppressive activities. AGP is one of the positive acute-phase proteins (APP); circulating levels of AGP increase in response to stress and inflammatory stimulation. AGP accumulates at sites of inflammation where it inhibits platelet and neutrophil activation and inhibits phagocytosis. The immunomodulatory properties of AGP are due to glycosylation. AGP is 40% carbohydrate, making it unusually acidic and soluble. The glycosylation pattern of AGP changes during acute-phase response, and deglycosylated AGP has no immunosuppressive activity (Flower (1994) FEBS Lett. 354:7-11; Flower (1996) supra).

The lipocalin superfamily also includes several animal allergens, including the mouse major urinary protein (mMUP), the rat α -2-microglobulin (rA2U), the bovine β -lactoglobulin (β lg), the cockroach allergen (Blâ g4), bovine dander allergen (Bos d2), and the major horse allergen, designated *Equus caballus* allergen 1 (Equ c1). Equ c1 is a powerful allergen responsible for about 80% of anti-horse IgE antibody response in patients who are chronically exposed to horse allergens. It appears that lipocalins may contain a common structure that is able to induce the IgE response (Gregoire, C. et al., (1996) J. Biol. Chem. 271:32951-32959).

Lipocalins are used as diagnostic and prognostic markers in a variety of disease states. The plasma level of AGP is monitored during pregnancy and in diagnosis and prognosis of conditions including cancer chemotherapy, renal dysfunction, myocardial infarction, arthritis, and multiple sclerosis. RBP is used clinically as a marker of tubular reabsorption in the kidney, and apo D is a marker in gross cystic breast disease (Flower (1996) supra). Additionally, the use of lipocalin animal allergens may help in the diagnosis of allergic reactions to horses (Gregoire supra), pigs, cockroaches, mice and rats.

Mitochondrial carrier proteins are transmembrane-spanning proteins which transport ions

and charged metabolites between the cytosol and the mitochondrial matrix. Examples include the ADP, ATP carrier protein; the 2-oxoglutarate/malate carrier; the phosphate carrier protein; the pyruvate carrier; the dicarboxylate carrier which transports malate, succinate, fumarate, and phosphate; the tricarboxylate carrier which transports citrate and malate; and the Grave's disease carrier protein, a protein recognized by IgG in patients with active Grave's disease, an autoimmune disorder resulting in hyperthyroidism. Proteins in this family consist of three tandem repeats of an approximately 100 amino acid domain, each of which contains two transmembrane regions (Stryer, L. (1995) Biochemistry, W.H. Freeman and Company, New York NY, p. 551; PROSITE PDOC00189 Mitochondrial energy transfer proteins signature; Online Mendelian Inheritance in Man (OMIM) *275000 Graves Disease).

This class of transporters also includes the mitochondrial uncoupling proteins, which create proton leaks across the inner mitochondrial membrane, thus uncoupling oxidative phosphorylation from ATP synthesis. The result is energy dissipation in the form of heat. Mitochondrial uncoupling proteins have been implicated as modulators of thermoregulation and metabolic rate, and have been proposed as potential targets for drugs against metabolic diseases such as obesity (Ricquier, D. et al. (1999) J. Int. Med. 245:637-642).

Ion Channels

The electrical potential of a cell is generated and maintained by controlling the movement of ions across the plasma membrane. The movement of ions requires ion channels, which form ion-selective pores within the membrane. There are two basic types of ion channels, ion transporters and gated ion channels. Ion transporters utilize the energy obtained from ATP hydrolysis to actively transport an ion against the ion's concentration gradient. Gated ion channels allow passive flow of an ion down the ion's electrochemical gradient under restricted conditions. Together, these types of ion channels generate, maintain, and utilize an electrochemical gradient that is used in 1) electrical impulse conduction down the axon of a nerve cell, 2) transport of molecules into cells against concentration gradients, 3) initiation of muscle contraction, and 4) endocrine cell secretion.

Ion Transporters

Ion transporters generate and maintain the resting electrical potential of a cell. Utilizing the energy derived from ATP hydrolysis, they transport ions against the ion's concentration gradient. These transmembrane ATPases are divided into three families. The phosphorylated (P) class ion transporters, including Na⁺-K⁺ ATPase, Ca²⁺-ATPase, and H⁺-ATPase, are activated by a phosphorylation event. P-class ion transporters, also known as E1-E2 type ATPases, are responsible for maintaining resting potential distributions such that cytosolic concentrations of Na⁺ and Ca²⁺ are low and cytosolic concentration of K⁺ is high. The vacuolar (V) class of ion transporters includes H⁺ pumps on intracellular organelles, such as lysosomes and Golgi. V-class ion transporters are

responsible for generating the low pH within the lumen of these organelles that is required for function. The coupling factor (F) class consists of H⁺ pumps in the mitochondria. F-class ion transporters utilize a proton gradient to generate ATP from ADP and inorganic phosphate (P_i).

The P-ATPases are hexamers of a 100 kD subunit with ten transmembrane domains and several large cytoplasmic regions that may play a role in ion binding (Scarborough, G.A. (1999) Curr. Opin. Cell Biol. 11:517-522). The V-ATPases are composed of two functional domains: the V₁ domain, a peripheral complex responsible for ATP hydrolysis; and the V₀ domain, an integral complex responsible for proton translocation across the membrane. The F-ATPases are structurally and evolutionarily related to the V-ATPases. The F-ATPase F₀ domain contains 12 copies of the c subunit, a highly hydrophobic protein composed of two transmembrane domains and containing a single buried carboxyl group in TM2 that is essential for proton transport. The V-ATPase V₀ domain contains three types of homologous c subunits with four or five transmembrane domains and the essential carboxyl group in TM4 or TM3. Both types of complex also contain a single a subunit that may be involved in regulating the pH dependence of activity (Forgac, M. (1999) J. Biol. Chem. 274:12951-12954).

The resting potential of the cell is utilized in many processes involving carrier proteins and gated ion channels. Carrier proteins utilize the resting potential to transport molecules into and out of the cell. Amino acid and glucose transport into many cells is linked to sodium ion co-transport (symport) so that the movement of Na⁺ down an electrochemical gradient drives transport of the other molecule up a concentration gradient. Similarly, cardiac muscle links transfer of Ca²⁺ out of the cell with transport of Na⁺ into the cell (antiport).

Gated Ion Channels

Gated ion channels control ion flow by regulating the opening and closing of pores. The ability to control ion flux through various gating mechanisms allows ion channels to mediate such diverse signaling and homeostatic functions as neuronal and endocrine signaling, muscle contraction, fertilization, and regulation of ion and pH balance. Gated ion channels are categorized according to the manner of regulating the gating function. Mechanically-gated channels open their pores in response to mechanical stress; voltage-gated channels (e.g., Na⁺, K⁺, Ca²⁺, and Cl⁻ channels) open their pores in response to changes in membrane potential; and ligand-gated channels (e.g., acetylcholine-, serotonin-, and glutamate-gated cation channels, and GABA- and glycine-gated chloride channels) open their pores in the presence of a specific ion, nucleotide, or neurotransmitter. The gating properties of a particular ion channel (i.e., its threshold for and duration of opening and closing) are sometimes modulated by association with auxiliary channel proteins and/or post translational modifications, such as phosphorylation.

Mechanically-gated or mechanosensitive ion channels act as transducers for the senses of

touch, hearing, and balance, and also play important roles in cell volume regulation, smooth muscle contraction, and cardiac rhythm generation. A stretch-inactivated channel (SIC) was recently cloned from rat kidney. The SIC channel belongs to a group of channels which are activated by pressure or stress on the cell membrane and conduct both Ca^{2+} and Na^{+} (Suzuki, M. et al. (1999) J. Biol. Chem. 274:6330-6335).

The pore-forming subunits of the voltage-gated cation channels form a superfamily of ion channel proteins. The characteristic domain of these channel proteins comprises six transmembrane domains (S1-S6), a pore-forming region (P) located between S5 and S6, and intracellular amino and carboxy termini. In the Na^{+} and Ca^{2+} subfamilies, this domain is repeated four times, while in the K^{+} channel subfamily, each channel is formed from a tetramer of either identical or dissimilar subunits. The P region contains information specifying the ion selectivity for the channel. In the case of K^{+} channels, a GYG tripeptide is involved in this selectivity (Ishii, T.M. et al. (1997) Proc. Natl. Acad. Sci. USA 94:11651-11656).

Voltage-gated Na^{+} and K^{+} channels are necessary for the function of electrically excitable cells, such as nerve and muscle cells. Action potentials, which lead to neurotransmitter release and muscle contraction, arise from large, transient changes in the permeability of the membrane to Na^{+} and K^{+} ions. Depolarization of the membrane beyond the threshold level opens voltage-gated Na^{+} channels. Sodium ions flow into the cell, further depolarizing the membrane and opening more voltage-gated Na^{+} channels, which propagates the depolarization down the length of the cell. Depolarization also opens voltage-gated potassium channels. Consequently, potassium ions flow outward, which leads to repolarization of the membrane. Voltage-gated channels utilize charged residues in the fourth transmembrane segment (S4) to sense voltage change. The open state lasts only about 1 millisecond, at which time the channel spontaneously converts into an inactive state that cannot be opened irrespective of the membrane potential. Inactivation is mediated by the channel's N-terminus, which acts as a plug that closes the pore. The transition from an inactive to a closed state requires a return to resting potential.

Voltage-gated Na^{+} channels are heterotrimeric complexes composed of a 260 kDa pore-forming α subunit that associates with two smaller auxiliary subunits, $\beta 1$ and $\beta 2$. The $\beta 2$ subunit is an integral membrane glycoprotein that contains an extracellular Ig domain, and its association with α and $\beta 1$ subunits correlates with increased functional expression of the channel, a change in its gating properties, as well as an increase in whole cell capacitance due to an increase in membrane surface area (Isom, L.L. et al. (1995) Cell 83:433-442).

Non voltage-gated Na^{+} channels include the members of the amiloride-sensitive Na^{+} channel/degenerin (NaC/DEG) family. Channel subunits of this family are thought to consist of two transmembrane domains flanking a long extracellular loop, with the amino and carboxyl termini

located within the cell. The NaC/DEG family includes the epithelial Na⁺ channel (ENaC) involved in Na⁺ reabsorption in epithelia including the airway, distal colon, cortical collecting duct of the kidney, and exocrine duct glands. Mutations in ENaC result in pseudohypoaldosteronism type 1 and Liddle's syndrome (pseudohyperaldosteronism). The NaC/DEG family also includes the recently characterized H⁺-gated cation channels or acid-sensing ion channels (ASIC). ASIC subunits are expressed in the brain and form heteromultimeric Na⁺-permeable channels. These channels require acid pH fluctuations for activation. ASIC subunits show homology to the degenerins, a family of mechanically-gated channels originally isolated from *C. elegans*. Mutations in the degenerins cause neurodegeneration. ASIC subunits may also have a role in neuronal function, or in pain perception, since tissue acidosis causes pain (Waldmann, R. and M. Lazdunski (1998) *Curr. Opin. Neurobiol.* 8:418-424; Eglén, R.M. et al. (1999) *Trends Pharmacol. Sci.* 20:337-342).

K⁺ channels are located in all cell types, and may be regulated by voltage, ATP concentration, or second messengers such as Ca²⁺ and cAMP. In non-excitable tissue, K⁺ channels are involved in protein synthesis, control of endocrine secretions, and the maintenance of osmotic equilibrium across membranes. In neurons and other excitable cells, in addition to regulating action potentials and repolarizing membranes, K⁺ channels are responsible for setting the resting membrane potential. The cytosol contains non-diffusible anions and, to balance this net negative charge, the cell contains a Na⁺-K⁺ pump and ion channels that provide the redistribution of Na⁺, K⁺, and Cl⁻. The pump actively transports Na⁺ out of the cell and K⁺ into the cell in a 3:2 ratio. Ion channels in the plasma membrane allow K⁺ and Cl⁻ to flow by passive diffusion. Because of the high negative charge within the cytosol, Cl⁻ flows out of the cell. The flow of K⁺ is balanced by an electromotive force pulling K⁺ into the cell, and a K⁺ concentration gradient pushing K⁺ out of the cell. Thus, the resting membrane potential is primarily regulated by K⁺ flow (Salkoff, L. and T. Jegla (1995) *Neuron* 15:489-492).

Potassium channel subunits of the Shaker-like superfamily all have the characteristic six transmembrane/1 pore domain structure. Four subunits combine as homo- or heterotetramers to form functional K channels. These pore-forming subunits also associate with various cytoplasmic β subunits that alter channel inactivation kinetics. The Shaker-like channel family includes the voltage-gated K⁺ channels as well as the delayed rectifier type channels such as the human ether-a-go-go related gene (HERG) associated with long QT, a cardiac dysrhythmia syndrome (Curran, M.E. (1998) *Curr. Opin. Biotechnol.* 9:565-572; Kaczorowski, G.J. and M.L. Garcia (1999) *Curr. Opin. Chem. Biol.* 3:448-458).

A second superfamily of K⁺ channels is composed of the inward rectifying channels (Kir). Kir channels have the property of preferentially conducting K⁺ currents in the inward direction.

These proteins consist of a single potassium selective pore domain and two transmembrane domains, which correspond to the fifth and sixth transmembrane domains of voltage-gated K⁺ channels. Kir subunits also associate as tetramers. The Kir family includes ROMK1, mutations in which lead to Bartter syndrome, a renal tubular disorder. Kir channels are also involved in
5 regulation of cardiac pacemaker activity, seizures and epilepsy, and insulin regulation (Doupnik, C.A. et al. (1995) *Curr. Opin. Neurobiol.* 5:268-277; Curran, *supra*).

The recently recognized TWIK K⁺ channel family includes the mammalian TWIK-1, TREK-1 and TASK proteins. Members of this family possess an overall structure with four transmembrane domains and two P domains. These proteins are probably involved in controlling
10 the resting potential in a large set of cell types (Duprat, F. et al. (1997) *EMBO J* 16:5464-5471).

The voltage-gated Ca²⁺ channels have been classified into several subtypes based upon their electrophysiological and pharmacological characteristics. L-type Ca²⁺ channels are predominantly expressed in heart and skeletal muscle where they play an essential role in excitation-contraction coupling. T-type channels are important for cardiac pacemaker activity, while N-type and P/Q-type
15 channels are involved in the control of neurotransmitter release in the central and peripheral nervous system. The L-type and N-type voltage-gated Ca²⁺ channels have been purified and, though their functions differ dramatically, they have similar subunit compositions. The channels are composed of three subunits. The α_1 subunit forms the membrane pore and voltage sensor, while the $\alpha_2\delta$ and β subunits modulate the voltage-dependence, gating properties, and the current amplitude of the
20 channel. These subunits are encoded by at least six α_1 , one $\alpha_2\delta$, and four β genes. A fourth subunit, γ , has been identified in skeletal muscle (Walker, D. et al. (1998) *J. Biol. Chem.* 273:2361-2367; McCleskey, E.W. (1994) *Curr. Opin. Neurobiol.* 4:304-312).

The high-voltage-activated Ca²⁺ channels that have been characterized biochemically include complexes of a pore-forming α_1 subunit of approximately 190-250 kDa; a
25 transmembrane complex of α_2 and δ subunits; an intracellular β subunit; and in some cases a transmembrane γ subunit. A variety of α_1 subunits, $\alpha_2\delta$ complexes, β subunits, and γ subunits are known. The Cav1 family of α_1 subunits conduct L-type Ca²⁺ currents, which initiate muscle contraction, endocrine secretion, and gene transcription, and are regulated primarily by second messenger-activated protein phosphorylation pathways. The Cav2
30 family of α_1 subunits conduct N-type, P/Q-type, and R-type Ca²⁺ currents, which initiate rapid synaptic transmission and are regulated primarily by direct interaction with G proteins and SNARE proteins and secondarily by protein phosphorylation. The Cav3 family of α_1 subunits conduct T-type Ca²⁺ currents, which are activated and inactivated more rapidly and at more negative membrane potentials than other Ca²⁺ current types. The distinct structures and patterns of
35 regulation of these three families of Ca²⁺ channels provide an array of Ca²⁺ entry pathways in

response to changes in membrane potential and a range of possibilities for regulation of Ca^{2+} entry by second messenger pathways and interacting proteins (Catterall, W.A. (2000) *Annu. Rev. Cell Dev. Biol.* 16:521-555).

The alpha-2 subunit of the voltage-gated Ca^{2+} -channel may include one or more Cache domains. An extracellular Cache domain may be fused to an intracellular catalytic domain, such as the histidine kinase, PP2C phosphatase, GGDEF (a predicted diguanylate cyclase), HD-GYP (a predicted phosphodiesterase) or adenylyl cyclase domain, or to a noncatalytic domain, like the methyl-accepting, DNA-binding winged helix-turn-helix, GAF, PAS or HAMP (a domain found in histidine kinases, denylyl cyclases, ethyl-binding proteins and phosphatases). Small molecules are bound via the Cache domain and this signal is converted into diverse outputs depending on the intracellular domains (Anantharaman, V. and Aravind, L.(2000) *Trends Biochem. Sci.* 25:535-537).

The transient receptor family (Trp) of calcium ion channels are thought to mediate capacitative calcium entry (CCE). CCE is the Ca^{2+} influx into cells to resupply Ca^{2+} stores depleted by the action of inositol triphosphate (IP_3) and other agents in response to numerous hormones and growth factors. Trp and Trp-like were first cloned from *Drosophila* and have similarity to voltage gated Ca^{2+} channels in the S3 through S6 regions. This suggests that Trp and/or related proteins may form mammalian CCE channels (Zhu, X. et al. (1996) *Cell* 85:661-671; Boulay, G. et al. (1997) *J. Biol. Chem.* 272:29672-29680). Melastatin is a gene isolated in both the mouse and human, whose expression in melanoma cells is inversely correlated with melanoma aggressiveness in vivo. The human cDNA transcript corresponds to a 1533-amino acid protein having homology to members of the Trp family. It has been proposed that the combined use of malastatin mRNA expression status and tumor thickness might allow for the determination of subgroups of patients at both low and high risk for developing metastatic disease (Duncan, L.M. et al (2001) *J. Clin. Oncol.* 19:568-576).

Chloride channels are necessary in endocrine secretion and in regulation of cytosolic and organelle pH. In secretory epithelial cells, Cl^- enters the cell across a basolateral membrane through an Na^+ , K^+/Cl^- cotransporter, accumulating in the cell above its electrochemical equilibrium concentration. Secretion of Cl^- from the apical surface, in response to hormonal stimulation, leads to flow of Na^+ and water into the secretory lumen. The cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel encoded by the gene for cystic fibrosis, a common fatal genetic disorder in humans. CFTR is a member of the ABC transporter family, and is composed of two domains each consisting of six transmembrane domains followed by a nucleotide-binding site. Loss of CFTR function decreases transepithelial water secretion and, as a result, the layers of mucus that coat the respiratory tree, pancreatic ducts, and intestine are dehydrated and difficult to clear. The resulting blockage of these sites leads to pancreatic insufficiency, "meconium ileus", and

devastating "chronic obstructive pulmonary disease" (Al-Awqati, Q. et al. (1992) J. Exp. Biol. 172:245-266).

The voltage-gated chloride channels (CLC) are characterized by 10-12 transmembrane domains, as well as two small globular domains known as CBS domains. The CLC subunits probably function as homotetramers. CLC proteins are involved in regulation of cell volume, membrane potential stabilization, signal transduction, and transepithelial transport. Mutations in CLC-1, expressed predominantly in skeletal muscle, are responsible for autosomal recessive generalized myotonia and autosomal dominant myotonia congenita, while mutations in the kidney channel CLC-5 lead to kidney stones (Jentsch, T.J. (1996) Curr. Opin. Neurobiol. 6:303-310).

Ligand-gated channels open their pores when an extracellular or intracellular mediator binds to the channel. Neurotransmitter-gated channels are channels that open when a neurotransmitter binds to their extracellular domain. These channels exist in the postsynaptic membrane of nerve or muscle cells. There are two types of neurotransmitter-gated channels. Sodium channels open in response to excitatory neurotransmitters, such as acetylcholine, glutamate, and serotonin. This opening causes an influx of Na^+ and produces the initial localized depolarization that activates the voltage-gated channels and starts the action potential. Chloride channels open in response to inhibitory neurotransmitters, such as γ -aminobutyric acid (GABA) and glycine, leading to hyperpolarization of the membrane and the subsequent generation of an action potential. Neurotransmitter-gated ion channels have four transmembrane domains and probably function as pentamers (Jentsch, supra). Amino acids in the second transmembrane domain appear to be important in determining channel permeation and selectivity (Sather, W.A. et al. (1994) Curr. Opin. Neurobiol. 4:313-323).

Ligand-gated channels can be regulated by intracellular second messengers. For example, calcium-activated K^+ channels are gated by internal calcium ions. In nerve cells, an influx of calcium during depolarization opens K^+ channels to modulate the magnitude of the action potential (Ishi et al., supra). The large conductance (BK) channel has been purified from brain and its subunit composition determined. The α subunit of the BK channel has seven rather than six transmembrane domains in contrast to voltage-gated K^+ channels. The extra transmembrane domain is located at the subunit N-terminus. A 28-amino-acid stretch in the C-terminal region of the subunit (the "calcium bowl" region) contains many negatively charged residues and is thought to be the region responsible for calcium binding. The β subunit consists of two transmembrane domains connected by a glycosylated extracellular loop, with intracellular N- and C-termini (Kaczorowski, supra; Vergara, C. et al. (1998) Curr. Opin. Neurobiol. 8:321-329).

Cyclic nucleotide-gated (CNG) channels are gated by cytosolic cyclic nucleotides. The best examples of these are the cAMP-gated Na^+ channels involved in olfaction and the cGMP-gated

cation channels involved in vision. Both systems involve ligand-mediated activation of a G-protein coupled receptor which then alters the level of cyclic nucleotide within the cell. CNG channels also represent a major pathway for Ca^{2+} entry into neurons, and play roles in neuronal development and plasticity. CNG channels are tetramers containing at least two types of subunits, an α subunit which
5 can form functional homomeric channels, and a β subunit, which modulates the channel properties. All CNG subunits have six transmembrane domains and a pore forming region between the fifth and sixth transmembrane domains, similar to voltage-gated K^+ channels. A large C-terminal domain contains a cyclic nucleotide binding domain, while the N-terminal domain confers variation among channel subtypes (Zufall, F. et al. (1997) *Curr. Opin. Neurobiol.* 7:404-412).

10 The activity of other types of ion channel proteins may also be modulated by a variety of intracellular signalling proteins. Many channels have sites for phosphorylation by one or more protein kinases including protein kinase A, protein kinase C, tyrosine kinase, and casein kinase II, all of which regulate ion channel activity in cells. Kir channels are activated by the binding of the $\text{G}\beta\gamma$ subunits of heterotrimeric G-proteins (Reimann, F. and F.M. Ashcroft (1999) *Curr. Opin. Cell.*
15 *Biol.* 11:503-508). Other proteins are involved in the localization of ion channels to specific sites in the cell membrane. Such proteins include the PDZ domain proteins known as MAGUKs (membrane-associated guanylate kinases) which regulate the clustering of ion channels at neuronal synapses (Craven, S.E. and D.S. Brecht (1998) *Cell* 93:495-498).

Disease Correlation

20 The etiology of numerous human diseases and disorders can be attributed to defects in the transport of molecules across membranes. Defects in the trafficking of membrane-bound transporters and ion channels are associated with several disorders, e.g., cystic fibrosis, glucose-galactose malabsorption syndrome, hypercholesterolemia, von Gierke disease, and certain forms of diabetes mellitus. Single-gene defect diseases resulting in an inability to transport small
25 molecules across membranes include, e.g., cystinuria, iminoglycinuria, Hartup disease, and Fanconi disease (van't Hoff, W.G. (1996) *Exp. Nephrol.* 4:253-262; Talente, G.M. et al. (1994) *Ann. Intern. Med.* 120:218-226; and Chillon, M. et al. (1995) *New Engl. J. Med.* 332:1475-1480).

Human diseases caused by mutations in ion channel genes include disorders of skeletal muscle, cardiac muscle, and the central nervous system. Mutations in the pore-forming subunits of
30 sodium and chloride channels cause myotonia, a muscle disorder in which relaxation after voluntary contraction is delayed. Sodium channel myotonias have been treated with channel blockers. Mutations in muscle sodium and calcium channels cause forms of periodic paralysis, while mutations in the sarcoplasmic calcium release channel, T-tubule calcium channel, and muscle sodium channel cause malignant hyperthermia. Cardiac arrhythmia disorders such as the long QT
35 syndromes and idiopathic ventricular fibrillation are caused by mutations in potassium and sodium

channels (Cooper, E.C. and L.Y. Jan (1998) Proc. Natl. Acad. Sci. USA 96:4759-4766). All four known human idiopathic epilepsy genes code for ion channel proteins (Berkovic, S.F. and I.E. Scheffer (1999) Curr. Opin. Neurology 12:177-182). Other neurological disorders such as ataxias, hemiplegic migraine and hereditary deafness can also result from mutations in ion channel genes
5 (Jen, J. (1999) Curr. Opin. Neurobiol. 9:274-280; Cooper, supra).

Ion channels have been the target for many drug therapies. Neurotransmitter-gated channels have been targeted in therapies for treatment of insomnia, anxiety, depression, and schizophrenia. Voltage-gated channels have been targeted in therapies for arrhythmia, ischemic stroke, head trauma, and neurodegenerative disease (Taylor, C.P. and L.S. Narasimhan (1997) Adv. Pharmacol.
10 39:47-98). Various classes of ion channels also play an important role in the perception of pain, and thus are potential targets for new analgesics. These include the vanilloid-gated ion channels, which are activated by the vanilloid capsaicin, as well as by noxious heat. Local anesthetics such as lidocaine and mexiletine which blockade voltage-gated Na⁺ channels have been useful in the treatment of neuropathic pain (Eglen, supra). Calcium-channel protein expression is altered in
15 metastatic melanomas (Enkelaar, T. et al. (2000) Genomics 67:179-187).

Ion channels in the immune system have recently been suggested as targets for immunomodulation. T-cell activation depends upon calcium signaling, and a diverse set of T-cell specific ion channels has been characterized that affect this signaling process. Channel blocking agents can inhibit secretion of lymphokines, cell proliferation, and killing of target cells. A peptide
20 antagonist of the T-cell potassium channel Kv1.3 was found to suppress delayed-type hypersensitivity and allogenic responses in pigs, validating the idea of channel blockers as safe and efficacious immunosuppressants (Cahalan, M.D. and K.G. Chandy (1997) Curr. Opin. Biotechnol. 8:749-756).

The discovery of new transporters and ion channels, and the polynucleotides encoding
25 them, satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of transport, neurological, muscle, immunological and cell proliferative disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of transporters and ion channels.

30 SUMMARY OF THE INVENTION

The invention features purified polypeptides, transporters and ion channels, referred to collectively as "TRICH" and individually as "TRICH-1," "TRICH-2," "TRICH-3," "TRICH-4," "TRICH-5," "TRICH-6," "TRICH-7," "TRICH-8," "TRICH-9," "TRICH-10," "TRICH-11," "TRICH-12," "TRICH-13," "TRICH-14," "TRICH-15," "TRICH-16," "TRICH-17," "TRICH-18,"
35 "TRICH-19," "TRICH-20," "TRICH-21," "TRICH-22," "TRICH-23," "TRICH-24," "TRICH-25,"

"TRICH-26," "TRICH-27," "TRICH-28," "TRICH-29," "TRICH-30," "TRICH-31," and "TRICH-32." In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-32.

The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-32. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:33-64.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of

SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32.

The method comprises a) culturing a cell under conditions suitable for expression of the

- 5 polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid

- 10 sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group
15 consisting of SEQ ID NO:1-32.

The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, b) a polynucleotide comprising a naturally occurring

- 20 polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group

- 25 consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-
30 d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if
35 present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous

nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of
5 SEQ ID NO:33-64, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain
10 reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a
15 naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and a pharmaceutically acceptable excipient. In one embodiment,
20 the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional TRICH, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an
25 agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an
30 immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of
35 treating a disease or condition associated with decreased expression of functional TRICH,

comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide
5 comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. The method comprises a) exposing a sample
10 comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional TRICH, comprising administering to a patient in need of such treatment the composition.

15 The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide
20 having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

25 The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, c) a biologically active fragment of a polypeptide
30 having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of
35 the polypeptide in the presence of the test compound with the activity of the polypeptide in the

absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

10 The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, ii) 15 a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide 20 in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide 25 complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization 30 complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

35 Table 2 shows the GenBank identification number and annotation of the nearest GenBank

homolog for polypeptides of the invention. The probability scores for the matches between each polypeptide and its homolog(s) are also shown.

Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used
5 for analysis of the polypeptides.

Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

Table 5 shows the representative cDNA library for polynucleotides of the invention.

10 Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

15

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the
20 purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an
25 antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described
30 herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of
35 prior invention.

DEFINITIONS

"TRICH" refers to the amino acid sequences of substantially purified TRICH obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

5 The term "agonist" refers to a molecule which intensifies or mimics the biological activity of TRICH. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of TRICH either by directly interacting with TRICH or by acting on components of the biological pathway in which TRICH participates.

10 An "allelic variant" is an alternative form of the gene encoding TRICH. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of
15 nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

 "Altered" nucleic acid sequences encoding TRICH include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as TRICH or a polypeptide with at least one functional characteristic of TRICH. Included within this definition
20 are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding TRICH, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding TRICH. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a
25 functionally equivalent TRICH. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of TRICH is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar
30 side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

 The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or
35 synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally

occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence.

- 5 Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of TRICH. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the
10 activity of TRICH either by directly interacting with TRICH or by acting on components of the biological pathway in which TRICH participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind TRICH polypeptides can be prepared using intact polypeptides or
15 using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used
20 to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures
25 on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "aptamer" refers to a nucleic acid or oligonucleotide molecule that binds to a specific molecular target. Aptamers are derived from an in vitro evolutionary process (e.g., SELEX (Systematic Evolution of Ligands by EXponential Enrichment), described in U.S. Patent No.
30 5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries. Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules. The nucleotide components of an aptamer may have modified sugar groups (e.g., the 2'-OH group of a ribonucleotide may be replaced by 2'-F or 2'-NH₂), which may improve a desired property, e.g.,
35 resistance to nucleases or longer lifetime in blood. Aptamers may be conjugated to other molecules,

e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system. Aptamers may be specifically cross-linked to their cognate ligands, e.g., by photo-activation of a cross-linker. (See, e.g., Brody, E.N. and L. Gold (2000) J. Biotechnol. 74:5-13.)

The term "intramer" refers to an aptamer which is expressed in vivo. For example, a
5 vaccinia virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Natl Acad. Sci. USA 96:3606-3610).

The term "spiegelmer" refers to an aptamer which includes L-DNA, L-RNA, or other left-handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed
10 nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on substrates containing right-handed nucleotides.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as
15 phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring
20 nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or
25 "immunogenic" refers to the capability of the natural, recombinant, or synthetic TRICH, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement,
30 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding TRICH or
35 fragments of TRICH may be employed as hybridization probes. The probes may be stored in freeze-

dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

5 "Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG,
10 Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows
15 amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
	Ala	Gly, Ser
	Arg	His, Lys
20	Asn	Asp, Gln, His
	Asp	Asn, Glu
	Cys	Ala, Ser
	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
25	Gly	Ala
	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
	Leu	Ile, Val
	Lys	Arg, Gln, Glu
30	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
	Thr	Ser, Val
	Trp	Phe, Tyr
35	Tyr	His, Phe, Trp
	Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical
40 conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the

absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to a chemically modified polynucleotide or polypeptide.

Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which
5 retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

10 "Differential expression" refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.

"Exon shuffling" refers to the recombination of different coding regions (exons). Since an
15 exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.

A "fragment" is a unique portion of TRICH or the polynucleotide encoding TRICH which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise
20 up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a
25 molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

30 A fragment of SEQ ID NO:33-64 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:33-64, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:33-64 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:33-64 from related polynucleotide sequences. The precise length of a fragment of SEQ
35 ID NO:33-64 and the region of SEQ ID NO:33-64 to which the fragment corresponds are routinely

determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-32 is encoded by a fragment of SEQ ID NO:33-64. A fragment of SEQ ID NO:1-32 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-32. For example, a fragment of SEQ ID NO:1-32 is useful as an

5 immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-32. The precise length of a fragment of SEQ ID NO:1-32 and the region of SEQ ID NO:1-32 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A "full length" polynucleotide sequence is one containing at least a translation initiation
10 codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full length" polynucleotide sequence encodes a "full length" polypeptide sequence.

"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer
15 to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default
20 parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters
25 are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local
30 Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST
35 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2

Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>.

The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool

- 5 Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

Penalty for mismatch: -2

- 10 *Open Gap: 5 and Extension Gap: 2 penalties*

Gap x drop-off: 50

Expect: 10

Word Size: 11

Filter: on

- 15 Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment
- 20 length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

- Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic
- 25 acid sequences that all encode substantially the same protein.

- The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative
- 30 substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

- Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of
- 35 polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap

penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas

wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

- 5 Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for
10 calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS,
15 for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under
20 particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

- 25 The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate
30 substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

- "Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression
35 of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect

cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of TRICH which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide
5 fragment of TRICH which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other
10 chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of TRICH. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of TRICH.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide,
15 oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a
20 functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which
25 comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an TRICH may involve lipidation, glycosylation,
30 phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of TRICH.

"Probe" refers to nucleic acid sequences encoding TRICH, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are
35 isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule.

Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.

"Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and
5 identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences.
10 Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold
15 Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research,
20 Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer
25 selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for
30 Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human
35 Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple

sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above
5 selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence
10 that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently,
15 a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is
20 expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

25 "Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear
30 sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term "sample" is used in its broadest sense. A sample suspected of containing TRICH, nucleic acids encoding TRICH, or fragments thereof may comprise a bodily fluid; an extract from a
35 cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or

cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" or "expression profile" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed cells" includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by

infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or *in vitro* fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), *supra*.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, or at least 98%, or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, or at least 98%, or greater sequence identity over a certain defined length of one of the polypeptides.

35 THE INVENTION

The invention is based on the discovery of new human transporters and ion channels (TRICH), the polynucleotides encoding TRICH, and the use of these compositions for the diagnosis, treatment, or prevention of transport, neurological, muscle, immunological and cell proliferative disorders.

5 Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide
10 sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the
15 polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (GenBank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability scores for the matches between each polypeptide and its homolog(s). Column 5 shows the annotation of the GenBank homolog(s) along with relevant
20 citations where applicable, all of which are expressly incorporated by reference herein.

Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential
25 phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

30 Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are transporters and ion channels. For example, SEQ ID NO:1 is 83% identical to human sodium-hydrogen exchanger 6 (GenBank ID g2944233) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $5.1e-242$, which indicates the probability of obtaining the observed
35 polypeptide sequence alignment by chance. SEQ ID NO:1 also contains a sodium/hydrogen

exchanger family domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, and other BLAST analyses provide further corroborative evidence that SEQ ID NO:1 is a sodium-hydrogen exchange transporter. In another example, SEQ ID NO:7 is 85% identical to Rattus norvegicus Na⁺/K⁺-ATPase alpha subunit (GenBank ID g619915) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:7 also contains an E1-E2 ATPase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:7 is a cation-transporting ATPase. In yet another example, SEQ ID NO:13 is 77% identical to a human carrier-like protein (GenBank ID g3694661) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 5.5e-209, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:13 also contains a mitochondrial energy transfer protein domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) The presence of this domain is confirmed by BLIMPS, MOTIFS, and PROFILESCAN analyses, providing further corroborative evidence that SEQ ID NO:13 is a transporter. Further, SEQ ID NO:16 is 41% identical to human novel ATPase (GenBank ID g8979801) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 1.1e-165, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:16 also contains an E1-E2 ATPase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:16 is a cation-transporting ATPase. In a further example, SEQ ID NO:19 is 43% identical to Sinorhizobium sp. As4 ArsA, the catalytic subunit of the arsenic oxyanion-translocating ATPase (GenBank ID g5802945) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 7.7e-125, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:19 also contains an anion-transporting ATPase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from additional BLAST and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:19 is an anion-transporting ATPase. In yet a further

example, SEQ ID NO:21 is 54% identical to a murine putative E1-E2 ATPase (GenBank ID g28577) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $5.2e-190$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:21 also contains six transmembrane domains as determined using TMAP, a program which delineates transmembrane segments. (See Table 3.) Data from BLIMPS, and MOTIFS, analyses provide further corroborative evidence that SEQ ID NO:21 is an ATPase. In a further example, SEQ ID NO:24 is 52% identical, from residue A77 to residue L1007, to rat NMDAR-L (GenBank ID g2160125) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $1.5e-262$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:24 also contains a ligand gated ion channel domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS analysis provide further corroborative evidence that SEQ ID NO:24 is a glutamate receptor. SEQ ID NO:2-6, SEQ ID NO:8-12, SEQ ID NO:14-15, SEQ ID NO:17-18, SEQ ID NO:20, SEQ ID NO:22-23, and SEQ ID NO:25-32 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ ID NO:1-32 are described in Table 7.

As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Column 1 lists the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:), the corresponding Incyte polynucleotide consensus sequence number (Incyte ID) for each polynucleotide of the invention, and the length of each polynucleotide sequence in basepairs. Column 2 shows the nucleotide start (5') and stop (3') positions of the cDNA and/or genomic sequences used to assemble the full length polynucleotide sequences of the invention, and of fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:33-64 or that distinguish between SEQ ID NO:33-64 and related polynucleotide sequences.

The polynucleotide fragments described in Column 2 of Table 4 may refer specifically, for example, to Incyte cDNAs derived from tissue-specific cDNA libraries or from pooled cDNA libraries. Alternatively, the polynucleotide fragments described in column 2 may refer to GenBank cDNAs or ESTs which contributed to the assembly of the full length polynucleotide sequences. In addition, the polynucleotide fragments described in column 2 may identify sequences derived from the ENSEMBL (The Sanger Centre, Cambridge, UK) database (*i.e.*, those sequences including the designation "ENST"). Alternatively, the polynucleotide fragments described in column 2 may be derived from the NCBI RefSeq Nucleotide Sequence Records Database (*i.e.*, those sequences

including the designation "NM" or "NT") or the NCBI RefSeq Protein Sequence Records (*i.e.*, those sequences including the designation "NP"). Alternatively, the polynucleotide fragments described in column 2 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. For example, a polynucleotide sequence identified as FL_XXXXXX_N₁_N₂_YYYYY_N₃_N₄ represents a "stitched" sequence in which XXXXXX is the identification number of the cluster of sequences to which the algorithm was applied, and YYYYY is the number of the prediction generated by the algorithm, and N_{1,2,3,...}, if present, represent specific exons that may have been manually edited during analysis (See Example V). Alternatively, the polynucleotide fragments in column 2 may refer to assemblages of exons brought together by an "exon-stretching" algorithm. For example, a polynucleotide sequence identified as FL_XXXXXX_gAAAAA_gBBBBB_1_N is a "stretched" sequence, with XXXXXX being the Incyte project identification number, gAAAAA being the GenBank identification number of the human genomic sequence to which the "exon-stretching" algorithm was applied, gBBBBB being the GenBank identification number or NCBI RefSeq identification number of the nearest GenBank protein homolog, and N referring to specific exons (See Example V). In instances where a RefSeq sequence was used as a protein homolog for the "exon-stretching" algorithm, a RefSeq identifier (denoted by "NM," "NP," or "NT") may be used in place of the GenBank identifier (*i.e.*, gBBBBB).

Alternatively, a prefix identifies component sequences that were hand-edited, predicted from genomic DNA sequences, or derived from a combination of sequence analysis methods. The following Table lists examples of component sequence prefixes and corresponding sequence analysis methods associated with the prefixes (see Example IV and Example V).

Prefix	Type of analysis and/or examples of programs
GNN, GFG, ENST	Exon prediction from genomic sequences using, for example, GENSCAN (Stanford University, CA, USA) or FGENES (Computer Genomics Group, The Sanger Centre, Cambridge, UK).
GBI	Hand-edited analysis of genomic sequences.
FL	Stitched or stretched genomic sequences (see Example V).
INCY	Full length transcript and exon prediction from mapping of EST sequences to the genome. Genomic location and EST composition data are combined to predict the exons and resulting transcript.

In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in Table 4 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

Table 5 shows the representative cDNA libraries for those full length polynucleotide

sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

5 The invention also encompasses TRICH variants. A preferred TRICH variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the TRICH amino acid sequence, and which contains at least one functional or structural characteristic of TRICH.

 The invention also encompasses polynucleotides which encode TRICH. In a particular
10 embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:33-64, which encodes TRICH. The polynucleotide sequences of SEQ ID NO:33-64, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

15 The invention also encompasses a variant of a polynucleotide sequence encoding TRICH. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding TRICH. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID
20 NO:33-64 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:33-64. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of TRICH.

 In addition, or in the alternative, a polynucleotide variant of the invention is a splice variant
25 of a polynucleotide sequence encoding TRICH. A splice variant may have portions which have significant sequence identity to the polynucleotide sequence encoding TRICH, but will generally have a greater or lesser number of polynucleotides due to additions or deletions of blocks of sequence arising from alternate splicing of exons during mRNA processing. A splice variant may have less than about 70%, or alternatively less than about 60%, or alternatively less than about 50%
30 polynucleotide sequence identity to the polynucleotide sequence encoding TRICH over its entire length; however, portions of the splice variant will have at least about 70%, or alternatively at least about 85%, or alternatively at least about 95%, or alternatively 100% polynucleotide sequence identity to portions of the polynucleotide sequence encoding TRICH. Any one of the splice variants described above can encode an amino acid sequence which contains at least one functional or
35 structural characteristic of TRICH.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding TRICH, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide
5 sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring TRICH, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode TRICH and its variants are generally capable
10 of hybridizing to the nucleotide sequence of the naturally occurring TRICH under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding TRICH or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with
15 which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding TRICH and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode TRICH and
20 TRICH derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding TRICH or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of
25 hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:33-64 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

30 Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the

35 ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence

preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

- 10 The nucleic acid sequences encoding TRICH may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and
- 25 PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal
- 30 to the template at temperatures of about 68°C to 72°C.

- When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of
- 35 sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode TRICH may be cloned in recombinant DNA molecules that direct expression of TRICH, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express TRICH.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter TRICH-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent No. 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of TRICH, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with

fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding TRICH may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, TRICH itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of TRICH, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

In order to express a biologically active TRICH, the nucleotide sequences encoding TRICH or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding TRICH. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding TRICH. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding TRICH and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ.

20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding TRICH and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding TRICH. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding TRICH. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding TRICH can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding TRICH into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M.

Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of TRICH are needed, e.g. for the production of antibodies, vectors which direct high level expression of TRICH may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

5 Yeast expression systems may be used for production of TRICH. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 10 1995, supra; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of TRICH. Transcription of sequences encoding TRICH may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO 15 J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology 20 (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding TRICH may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to 25 obtain infective virus which expresses TRICH in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of 30 DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression 35 of TRICH in cell lines is preferred. For example, sequences encoding TRICH can be transformed

into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk⁻* and *ap^r* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding TRICH is inserted within a marker gene sequence, transformed cells containing sequences encoding TRICH can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding TRICH under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding TRICH and that express TRICH may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of TRICH using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing 5 monoclonal antibodies reactive to two non-interfering epitopes on TRICH is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, 10 Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding TRICH include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled 15 nucleotide. Alternatively, the sequences encoding TRICH, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by 20 Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding TRICH may be cultured under 25 conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode TRICH may be designed to contain signal sequences which direct secretion of TRICH through a prokaryotic or eukaryotic cell membrane.

30 In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. 35 Different host cells which have specific cellular machinery and characteristic mechanisms for

post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding TRICH may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric TRICH protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of TRICH activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the TRICH encoding sequence and the heterologous protein sequence, so that TRICH may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled TRICH may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

TRICH of the present invention or fragments thereof may be used to screen for compounds that specifically bind to TRICH. At least one and up to a plurality of test compounds may be screened for specific binding to TRICH. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of TRICH, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which TRICH binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case,

the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express TRICH, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing TRICH or cell membrane fractions which contain TRICH
5 are then contacted with a test compound and binding, stimulation, or inhibition of activity of either TRICH or the compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with TRICH, either in
10 solution or affixed to a solid support, and detecting the binding of TRICH to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

15 TRICH of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of TRICH. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for TRICH activity, wherein TRICH is combined with at least one test compound, and the activity of TRICH in the presence of a test compound is compared with the activity of TRICH in the absence
20 of the test compound. A change in the activity of TRICH in the presence of the test compound is indicative of a compound that modulates the activity of TRICH. Alternatively, a test compound is combined with an in vitro or cell-free system comprising TRICH under conditions suitable for TRICH activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of TRICH may do so indirectly and need not come in direct contact with the
25 test compound. At least one and up to a plurality of test compounds may be screened.

In another embodiment, polynucleotides encoding TRICH or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent No. 5,175,383 and U.S. Patent No.
30 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous
35 recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or

developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

Polynucleotides encoding TRICH may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

Polynucleotides encoding TRICH can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding TRICH is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress TRICH, e.g., by secreting TRICH in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of TRICH and transporters and ion channels. In addition, examples of tissues expressing TRICH can be found in Table 6. Therefore, TRICH appears to play a role in transport, neurological, muscle, immunological and cell proliferative disorders. In the treatment of disorders associated with increased TRICH expression or activity, it is desirable to decrease the expression or activity of TRICH. In the treatment of disorders associated with decreased TRICH expression or activity, it is desirable to increase the expression or activity of TRICH.

Therefore, in one embodiment, TRICH or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TRICH. Examples of such disorders include, but are not limited to, a transport disorder such as akinesia, amyotrophic lateral sclerosis, ataxia telangiectasia, cystic fibrosis, Becker's muscular dystrophy, Bell's palsy, Charcot-Marie Tooth disease, diabetes mellitus, diabetes insipidus, diabetic neuropathy, Duchenne muscular dystrophy, hyperkalemic periodic paralysis, normokalemic periodic paralysis, Parkinson's disease, malignant hyperthermia, multidrug

resistance, myasthenia gravis, myotonic dystrophy, catatonia, tardive dyskinesia, dystonias, peripheral neuropathy, cerebral neoplasms, prostate cancer, cardiac disorders associated with transport, e.g., angina, bradyarrhythmia, tachyarrhythmia, hypertension, Long QT syndrome, myocarditis, cardiomyopathy, nemaline myopathy, centronuclear myopathy, lipid myopathy,

5 mitochondrial myopathy, thyrotoxic myopathy, ethanol myopathy, dermatomyositis, inclusion body myositis, infectious myositis, polymyositis, neurological disorders associated with transport, e.g., Alzheimer's disease, amnesia, bipolar disorder, dementia, depression, epilepsy, Tourette's disorder, paranoid psychoses, and schizophrenia, and other disorders associated with transport, e.g., neurofibromatosis, postherpetic neuralgia, trigeminal neuropathy, sarcoidosis, sickle cell anemia,

10 Wilson's disease, cataracts, infertility, pulmonary artery stenosis, sensorineural autosomal deafness, hyperglycemia, hypoglycemia, Grave's disease, goiter, Cushing's disease, Addison's disease, glucose-galactose malabsorption syndrome, glycogen storage disease, hypercholesterolemia, adrenoleukodystrophy, Zellweger syndrome, Menkes disease, occipital horn syndrome, von Gierke disease, pseudohypoaldosteronism type 1, Liddle's syndrome, cystinuria, iminoglycinuria, Hartup

15 disease, Fanconi disease, and Bartter syndrome; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating

20 diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis,

25 encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic

30 paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy, hemiplegic migraine, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a muscle disorder such as cardiomyopathy, myocarditis, Duchenne's muscular dystrophy, Becker's muscular

35 dystrophy, myotonic dystrophy, central core disease, nemaline myopathy, centronuclear myopathy,

lipid myopathy, mitochondrial myopathy, infectious myositis, polymyositis, dermatomyositis, inclusion body myositis, thyrotoxic myopathy, ethanol myopathy, angina, anaphylactic shock, arrhythmias, asthma, cardiovascular shock, Cushing's syndrome, hypertension, hypoglycemia, myocardial infarction, migraine, pheochromocytoma, and myopathies including encephalopathy,

5 epilepsy, Kearns-Sayre syndrome, lactic acidosis, myoclonic disorder, ophthalmoplegia, acid maltase deficiency (AMD, also known as Pompe's disease), generalized myotonia, and myotonia congenita; an immunological disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune

10 thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple

15 sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and

20 helminthic infections, and trauma; and a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone,

25 bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus.

In another embodiment, a vector capable of expressing TRICH or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased

30 expression or activity of TRICH including, but not limited to, those described above.

In a further embodiment, a composition comprising a substantially purified TRICH in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TRICH including, but not limited to, those provided above.

35 In still another embodiment, an agonist which modulates the activity of TRICH may be

administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TRICH including, but not limited to, those listed above.

In a further embodiment, an antagonist of TRICH may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of TRICH. Examples of such disorders include, but are not limited to, those transport, neurological, muscle, immunological and cell proliferative disorders described above. In one aspect, an antibody which specifically binds TRICH may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express TRICH.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding TRICH may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of TRICH including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of TRICH may be produced using methods which are generally known in the art. In particular, purified TRICH may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind TRICH. Antibodies to TRICH may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with TRICH or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide; and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to TRICH have an amino acid sequence consisting of at least about 5 amino acids, and generally will

consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of TRICH amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

- 5 Monoclonal antibodies to TRICH may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci. USA* 80:2026-2030; and Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

- In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda, S. et al. (1985) *Nature* 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce TRICH-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) *Proc. Natl. Acad. Sci. USA* 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:3833-3837; Winter, G. et al. (1991) *Nature* 349:293-299.)

- 25 Antibody fragments which contain specific binding sites for TRICH may also be generated. For example, such fragments include, but are not limited to, F(ab')₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) *Science* 246:1275-1281.)

- Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between TRICH and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies

reactive to two non-interfering TRICH epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for TRICH. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of TRICH-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple TRICH epitopes, represents the average affinity, or avidity, of the antibodies for TRICH. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular TRICH epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the TRICH-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of TRICH, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of TRICH-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding TRICH, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding TRICH. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding TRICH. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence

complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) *J. Allergy Clin. Immunol.* 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) *Blood* 76:271; Ausubel, *supra*; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.* 25(14):2730-2736.)

10 In another embodiment of the invention, polynucleotides encoding TRICH may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) *Science* 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase
15 (ADA) deficiency (Blaese, R.M. et al. (1995) *Science* 270:475-480; Bordignon, C. et al. (1995) *Science* 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) *Cell* 75:207-216; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:643-666; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:667-703), thalassemias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) *Science* 270:404-410; Verma, I.M. and N. Somia (1997) *Nature*
20 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) *Nature* 335:395-396; Poeschla, E. et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida
25 albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in TRICH expression or regulation causes disease, the expression of TRICH from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in
30 TRICH are treated by constructing mammalian expression vectors encoding TRICH and introducing these vectors by mechanical means into TRICH-deficient cells. Mechanical transfer technologies for use with cells *in vivo* or *ex vitro* include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) *Annu. Rev.*
35 *Biochem.* 62:191-217; Ivics, Z. (1997) *Cell* 91:501-510; Boulay, J-L. and H. Récipon (1998) *Curr.*

Opin. Biotechnol. 9:445-450).

Expression vectors that may be effective for the expression of TRICH include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX, PCR2-TOPOTA vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). TRICH may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and H.M. Blau, *supra*), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding TRICH from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to TRICH expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding TRICH under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent No. 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant")

discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding TRICH to cells which have one or more genetic abnormalities with respect to the expression of TRICH. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent No. 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I.M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding TRICH to target cells which have one or more genetic abnormalities with respect to the expression of TRICH. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing TRICH to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res. 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent No. 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent No. 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) J. Virol. 73:519-532 and Xu, H. et al. (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to

those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding TRICH to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotechnol. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for TRICH into the alphavirus genome in place of the capsid-coding region results in the production of a large number of TRICH-coding RNAs and the synthesis of high levels of TRICH in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of TRICH into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding TRICH.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by

scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding TRICH. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding TRICH. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased TRICH expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding TRICH may be therapeutically useful, and in the treatment of disorders associated with decreased TRICH expression or activity, a compound which specifically promotes expression of the polynucleotide encoding TRICH may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in

altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding TRICH is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an *in vitro* cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding TRICH are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding TRICH. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a *Schizosaccharomyces pombe* gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruce, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruce, T.W. et al. (2000) U.S. Patent No. 6,022,691).

Many methods for introducing vectors into cells or tissues are available and equally suitable for use *in vivo*, *in vitro*, and *ex vivo*. For *ex vivo* therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable

excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of TRICH, antibodies to TRICH, and mimetics, agonists, antagonists, or inhibitors of

5 TRICH.

The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

10 Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar
15 region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active
20 ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising TRICH or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of
25 the macromolecule. Alternatively, TRICH or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell
30 culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example
35 TRICH or fragments thereof, antibodies of TRICH, and agonists, antagonists or inhibitors of

TRICH, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about $0.1 \mu\text{g}$ to $100,000 \mu\text{g}$, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind TRICH may be used for the diagnosis of disorders characterized by expression of TRICH, or in assays to monitor patients being treated with TRICH or agonists, antagonists, or inhibitors of TRICH. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for TRICH include methods which utilize the antibody and a label to detect TRICH in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring TRICH, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of TRICH expression.

Normal or standard values for TRICH expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to TRICH under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of

5 TRICH expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding TRICH may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide

10 sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of TRICH may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of TRICH, and to monitor regulation of TRICH levels during therapeutic intervention.

15 In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding TRICH or closely related molecules may be used to identify nucleic acid sequences which encode TRICH. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine

20 whether the probe identifies only naturally occurring sequences encoding TRICH, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the TRICH encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:33-64 or

25 from genomic sequences including promoters, enhancers, and introns of the TRICH gene.

Means for producing specific hybridization probes for DNAs encoding TRICH include the cloning of polynucleotide sequences encoding TRICH or TRICH derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA

30 polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding TRICH may be used for the diagnosis of disorders associated with expression of TRICH. Examples of such disorders include, but are not limited to, a

35 transport disorder such as akinesia, amyotrophic lateral sclerosis, ataxia telangiectasia, cystic

- fibrosis, Becker's muscular dystrophy, Bell's palsy, Charcot-Marie Tooth disease, diabetes mellitus, diabetes insipidus, diabetic neuropathy, Duchenne muscular dystrophy, hyperkalemic periodic paralysis, normokalemic periodic paralysis, Parkinson's disease, malignant hyperthermia, multidrug resistance, myasthenia gravis, myotonic dystrophy, catatonia, tardive dyskinesia, dystonias,
- 5 peripheral neuropathy, cerebral neoplasms, prostate cancer, cardiac disorders associated with transport, e.g., angina, bradyarrhythmia, tachyarrhythmia, hypertension, Long QT syndrome, myocarditis, cardiomyopathy, nemaline myopathy, centronuclear myopathy, lipid myopathy, mitochondrial myopathy, thyrotoxic myopathy, ethanol myopathy, dermatomyositis, inclusion body myositis, infectious myositis, polymyositis, neurological disorders associated with transport, e.g.,
- 10 Alzheimer's disease, amnesia, bipolar disorder, dementia, depression, epilepsy, Tourette's disorder, paranoid psychoses, and schizophrenia, and other disorders associated with transport, e.g., , neurofibromatosis, postherpetic neuralgia, trigeminal neuropathy, sarcoidosis, sickle cell anemia, Wilson's disease, cataracts, infertility, pulmonary artery stenosis, sensorineural autosomal deafness, hyperglycemia, hypoglycemia, Grave's disease, goiter, Cushing's disease, Addison's disease,
- 15 glucose-galactose malabsorption syndrome, glycogen storage disease, hypercholesterolemia, adrenoleukodystrophy, Zellweger syndrome, Menkes disease, occipital horn syndrome, von Gierke disease, pseudohypoaldosteronism type 1, Liddle's syndrome, cystinuria, iminoglycinuria, Hartup disease, Fanconi disease, and Bartter syndrome; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease,
- 20 Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system
- 25 disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders, autonomic
- 30 nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy, hemiplegic migraine, tardive
- 35 dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive

supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a muscle disorder such as cardiomyopathy, myocarditis, Duchenne's muscular dystrophy, Becker's muscular dystrophy, myotonic dystrophy, central core disease, nemaline myopathy, centronuclear myopathy, lipid myopathy, mitochondrial myopathy, infectious myositis, polymyositis, dermatomyositis,

5 inclusion body myositis, thyrotoxic myopathy, ethanol myopathy, angina, anaphylactic shock, arrhythmias, asthma, cardiovascular shock, Cushing's syndrome, hypertension, hypoglycemia, myocardial infarction, migraine, pheochromocytoma, and myopathies including encephalopathy, epilepsy, Kearns-Sayre syndrome, lactic acidosis, myoclonic disorder, ophthalmoplegia, acid maltase deficiency (AMD, also known as Pompe's disease), generalized myotonia, and myotonia

10 congenita; an immunological disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis,

15 diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma,

20 Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease

25 (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis,

30 thymus, thyroid, and uterus. The polynucleotide sequences encoding TRICH may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered TRICH expression. Such qualitative or quantitative methods are well known in the art.

35 In a particular aspect, the nucleotide sequences encoding TRICH may be useful in assays

that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding TRICH may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding TRICH in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

10 In order to provide a basis for the diagnosis of a disorder associated with expression of TRICH, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding TRICH, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from 15 normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, 20 hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or 25 overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

30 Additional diagnostic uses for oligonucleotides designed from the sequences encoding TRICH may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding TRICH, or a fragment of a polynucleotide complementary to the polynucleotide encoding TRICH, and will be employed under optimized conditions for 35 identification of a specific gene or condition. Oligomers may also be employed under less stringent

conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding TRICH may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding TRICH are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSSCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed *in silico* SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

Methods which may also be used to quantify the expression of TRICH include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this

information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

5 In another embodiment, TRICH, fragments of TRICH, or antibodies specific for TRICH may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to
10 generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent No. 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be
15 generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

20 Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of
25 pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test
30 compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression
35 of these genes are used to normalize the rest of the expression data. The normalization procedure is

useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National

5 Institute of Environmental Health Sciences, released February 29, 2000, available at <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the
10 treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

15 Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance
20 under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson,
25 supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are
30 compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence
35 data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for TRICH to quantify the levels of TRICH expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal.

5 Biochem. 270:103-111; Mendozé, L.G. et al. (1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and
10 should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult,
15 due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of
20 each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

25 In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount
30 of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116;
35 Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad.

Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

5 In another embodiment of the invention, nucleic acid sequences encoding TRICH may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during
10 chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J.
15 (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

20 Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding TRICH on a physical map and a specific disorder, or a predisposition to a specific disorder, may
25 help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse,
30 may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for
35 further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide

sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, TRICH, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between TRICH and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with TRICH, or fragments thereof, and washed. Bound TRICH is then detected by methods well known in the art. Purified TRICH can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding TRICH specifically compete with a test compound for binding TRICH. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with TRICH.

In additional embodiments, the nucleotide sequences which encode TRICH may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, including U.S. Ser. No. 60/254,303, U.S. Ser. No. 60/256,190, U.S. Ser. No. 60/257,504, U.S. Ser. No. 60/261,546, U.S. Ser. No. 60/262,832, U.S. Ser. No. 60/264,377, and U.S. Ser. No. 60/266,019, are expressly incorporated by reference herein.

EXAMPLES

I. Construction of cDNA Libraries

Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD

database (Incyte Genomics, Palo Alto CA). Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto CA), pRARE (Incyte Genomics), or pINCY (Incyte Genomics), or derivatives thereof. Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids

were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows.

Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM; PROTEOME databases with sequences from Homo sapiens, Rattus norvegicus, Mus musculus, Caenorhabditis elegans, Saccharomyces cerevisiae, Schizosaccharomyces pombe, and Candida albicans (Incyte Genomics, Palo Alto CA); and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs,

stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length
5 polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, the PROTEOME databases, BLOCKS, PRINTS, DOMO, PRODOM, Prosite,
10 and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program
15 (DNASTAR), which also calculates the percent identity between aligned sequences.

Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used; the second column provides brief descriptions thereof, the third column presents appropriate
20 references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

The programs described above for the assembly and analysis of full length polynucleotide
25 and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:33-64. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 2.

IV. Identification and Editing of Coding Sequences from Genomic DNA

Putative transporters and ion channels were initially identified by running the Genscan gene
30 identification program against public genomic sequence databases (e.g., gbpr1 and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of
35 Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range

of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode transporters and ion channels, the encoded polypeptides were analyzed by querying against PFAM models for transporters and ion channels. Potential transporters and ion channels were also identified by homology to Incyte cDNA sequences that had
5 been annotated as transporters and ion channels. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpi public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted
10 sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited
15 or unedited Genscan-predicted coding sequences.

V. Assembly of Genomic Sequence Data with cDNA Sequence Data

"Stitched" Sequences

Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example
20 III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the
25 interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm
30 in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpi public databases.
35 Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from

genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

"Stretched" Sequences

Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

VI. Chromosomal Mapping of TRICH Encoding Polynucleotides

The sequences which were used to assemble SEQ ID NO:33-64 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:33-64 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.

Map locations are represented by ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (<http://www.ncbi.nlm.nih.gov/genemap/>), can be employed to determine if previously

identified disease genes map within or in proximity to the intervals indicated above.

VII. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which
 5 RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel (1995) supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of
 10 the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum \{length(Seq. 1), length(Seq. 2)\}}}$$

15

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is
 20 calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100%
 25 identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

Alternatively, polynucleotide sequences encoding TRICH are analyzed with respect to the
 30 tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female;
 35 genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous

system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding TRICH. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

10 VIII. Extension of TRICH Encoding Polynucleotides

Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the

concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, 5 digested with CviII cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector 10 (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase 15 (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were 20 diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides 25 designed for such extension, and an appropriate genomic library.

IX. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:33-64 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide 30 fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ -³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). 35 An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-

based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16
5 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

X. Microarrays

10 The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon
15 wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645;
20 Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides
25 in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element
30 on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

Tissue or Cell Sample Preparation

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is
35 reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/μl oligo-(dT) primer (21mer), 1X

first strand buffer, 0.03 units/ μ l RNase inhibitor, 500 μ M dATP, 500 μ M dGTP, 500 μ M dTTP, 40 μ M dCTP, 40 μ M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)⁺ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 μ l 5X SSC/0.2% SDS.

Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in U.S. Patent No. 5,807,522, incorporated herein by reference. 1 μ l of the array element DNA, at an average concentration of 100 ng/ μ l, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in 0.2% SDS and distilled water as before.

Hybridization

Hybridization reactions contain 9 μ l of sample mixture consisting of 0.2 μ g each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μ l of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

10 Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-

compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

XI. Complementary Polynucleotides

Sequences complementary to the TRICH-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring TRICH. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of TRICH. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the TRICH-encoding transcript.

XII. Expression of TRICH

Expression and purification of TRICH is achieved using bacterial or virus-based expression systems. For expression of TRICH in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express TRICH upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of TRICH in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding TRICH by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or

human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, TRICH is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from TRICH at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified TRICH obtained by these methods can be used directly in the assays shown in Examples XVI, XVII, and XVIII where applicable.

XIII. Functional Assays

TRICH function is assessed by expressing the sequences encoding TRICH at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane

composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of TRICH on gene expression can be assessed using highly purified
5 populations of cells transfected with sequences encoding TRICH and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by
10 those of skill in the art. Expression of mRNA encoding TRICH and other genes of interest can be analyzed by northern analysis or microarray techniques.

XIV. Production of TRICH Specific Antibodies

TRICH substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used
15 to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the TRICH amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are
20 well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using Fmoc chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the
25 oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-TRICH activity by, for example, binding the peptide or TRICH to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XV. Purification of Naturally Occurring TRICH Using Specific Antibodies

30 Naturally occurring or recombinant TRICH is substantially purified by immunoaffinity chromatography using antibodies specific for TRICH. An immunoaffinity column is constructed by covalently coupling anti-TRICH antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

35 Media containing TRICH are passed over the immunoaffinity column, and the column is

washed under conditions that allow the preferential absorbance of TRICH (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/TRICH binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and TRICH is collected.

5 XVI. Identification of Molecules Which Interact with TRICH

Molecules which interact with TRICH may include transporter substrates, agonists or antagonists, modulatory proteins such as G β y proteins (Reimann, *supra*) or proteins involved in TRICH localization or clustering such as MAGUKs (Craven, *supra*). TRICH, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M.

10 Hunter (1973) *Biochem. J.* 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled TRICH, washed, and any wells with labeled TRICH complex are assayed. Data obtained using different concentrations of TRICH are used to calculate values for the number, affinity, and association of TRICH with the candidate molecules.

Alternatively, proteins that interact with TRICH are isolated using the yeast 2-hybrid system
15 (Fields, S. and O. Song (1989) *Nature* 340:245-246). TRICH, or fragments thereof, are expressed as fusion proteins with the DNA binding domain of Gal4 or *lexA*, and potential interacting proteins are expressed as fusion proteins with an activation domain. Interactions between the TRICH fusion protein and the TRICH interacting proteins (fusion proteins with an activation domain) reconstitute a transactivation function that is observed by expression of a reporter gene. Yeast 2-hybrid systems
20 are commercially available, and methods for use of the yeast 2-hybrid system with ion channel proteins are discussed in Niethammer, M. and M. Sheng (1998, *Meth. Enzymol.* 293:104-122).

TRICH may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al.
25 (2000) U.S. Patent No. 6,057,101).

Potential TRICH agonists or antagonists may be tested for activation or inhibition of TRICH ion channel activity using the assays described in section XVIII.

XVII. Demonstration of TRICH Activity

Ion channel activity of TRICH is demonstrated using an electrophysiological assay for ion
30 conductance. TRICH can be expressed by transforming a mammalian cell line such as COS7, HeLa or CHO with a eukaryotic expression vector encoding TRICH. Eukaryotic expression vectors are commercially available, and the techniques to introduce them into cells are well known to those skilled in the art. A second plasmid which expresses any one of a number of marker genes, such as β -galactosidase, is co-transformed into the cells to allow rapid identification of those cells which
35 have taken up and expressed the foreign DNA. The cells are incubated for 48-72 hours after

transformation under conditions appropriate for the cell line to allow expression and accumulation of TRICH and β -galactosidase.

Transformed cells expressing β -galactosidase are stained blue when a suitable colorimetric substrate is added to the culture media under conditions that are well known in the art. Stained cells
5 are tested for differences in membrane conductance by electrophysiological techniques that are well known in the art. Untransformed cells, and/or cells transformed with either vector sequences alone or β -galactosidase sequences alone, are used as controls and tested in parallel. Cells expressing TRICH will have higher anion or cation conductance relative to control cells. The contribution of TRICH to conductance can be confirmed by incubating the cells using antibodies specific for
10 TRICH. The antibodies will bind to the extracellular side of TRICH, thereby blocking the pore in the ion channel, and the associated conductance.

Alternatively, ion channel activity of TRICH is measured as current flow across a TRICH-
containing Xenopus laevis oocyte membrane using the two-electrode voltage-clamp technique (Ishi
et al., supra; Jegla, T. and L. Salkoff (1997) J. Neurosci. 17:32-44). TRICH is subcloned into an
15 appropriate Xenopus oocyte expression vector, such as pBF, and 0.5-5 ng of mRNA is injected into mature stage IV oocytes. Injected oocytes are incubated at 18 °C for 1-5 days. Inside-out macropatches are excised into an intracellular solution containing 116 mM K-gluconate, 4 mM KCl, and 10 mM Hepes (pH 7.2). The intracellular solution is supplemented with varying concentrations of the TRICH mediator, such as cAMP, cGMP, or Ca^{+2} (in the form of CaCl_2), where appropriate.
20 Electrode resistance is set at 2-5 M Ω and electrodes are filled with the intracellular solution lacking mediator. Experiments are performed at room temperature from a holding potential of 0 mV. Voltage ramps (2.5 s) from -100 to 100 mV are acquired at a sampling frequency of 500 Hz. Current measured is proportional to the activity of TRICH in the assay. In particular, the activity of TRICH-1 is measured as Na^+ conductance and the activity of TRICH-3 is measured as Ca^{2+}
25 conductance.

Transport activity of TRICH is assayed by measuring uptake of labeled substrates into Xenopus laevis oocytes. Oocytes at stages V and VI are injected with TRICH mRNA (10 ng per oocyte) and incubated for 3 days at 18°C in OR2 medium (82.5mM NaCl, 2.5 mM KCl, 1mM CaCl_2 , 1mM MgCl_2 , 1mM Na_2HPO_4 , 5 mM Hepes, 3.8 mM NaOH, 50 $\mu\text{g/ml}$ gentamycin, pH 7.8) to
30 allow expression of TRICH. Oocytes are then transferred to standard uptake medium (100mM NaCl, 2 mM KCl, 1mM CaCl_2 , 1mM MgCl_2 , 10 mM Hepes/Tris pH 7.5). Uptake of various substrates (e.g., amino acids, sugars, drugs, ions, and neurotransmitters) is initiated by adding labeled substrate (e.g. radiolabeled with ^3H , fluorescently labeled with rhodamine, etc.) to the oocytes. After incubating for 30 minutes, uptake is terminated by washing the oocytes three times
35 in Na^+ -free medium, measuring the incorporated label, and comparing with controls. TRICH

activity is proportional to the level of internalized labeled substrate. Test substrates include ran-GTP for TRICH- 2, glucose for TRICH-5, amino acids for TRICH-6 and TRICH-14, cations for TRICH-7 and TRICH-16, Na⁺, K⁺ and Cl⁻ ions for TRICH-15, reduced folate or analogues such as methotrexate for TRICH-17, divalent cations for TRICH-18, anions such as arsenate and antimonite
5 for TRICH-19, and nitrate or oligopeptides for TRICH-20.

ATPase activity associated with TRICH can be measured by hydrolysis of radiolabeled ATP-[γ -³²P], separation of the hydrolysis products by chromatographic methods, and quantitation of the recovered ³²P using a scintillation counter. The reaction mixture contains ATP-[γ -³²P] and varying amounts of TRICH in a suitable buffer incubated at 37°C for a suitable period of time. The
10 reaction is terminated by acid precipitation with trichloroacetic acid and then neutralized with base, and an aliquot of the reaction mixture is subjected to membrane or filter paper-based chromatography to separate the reaction products. The amount of ³²P liberated is counted in a scintillation counter. The amount of radioactivity recovered is proportional to the ATPase activity of TRICH in the assay.

15 Lipocalin activity of TRICH is measured by ligand fluorescence enhancement spectrofluorometry (Lin et al. (1997) Molecular Vision 3:17). Examples of ligands include retinol (Sigma, St. Louis MO) and 16-anthryloxy-palmitic acid (16-AP) (Molecular Probes Inc., Eugene OR). Ligand is dissolved in 100% ethanol and its concentration is estimated using known extinction coefficients (retinol: 46,000 A/M/cm at 325 nm; 16-AP: 8,200 A/M/cm at 361 nm). A
20 700 μ l aliquot of 1 μ M TRICH in 10 mM Tris (pH 7.5), 2 mM EDTA, and 500 mM NaCl is placed in a 1 cm path length quartz cuvette and 1 μ l aliquots of ligand solution are added. Fluorescence is measured 100 seconds after each addition until readings are stable. Change in fluorescence per unit change in ligand concentration is proportional to TRICH activity.

XVIII. Identification of TRICH Agonists and Antagonists

25 TRICH is expressed in a eukaryotic cell line such as CHO (Chinese Hamster Ovary) or HEK (Human Embryonic Kidney) 293. Ion channel activity of the transformed cells is measured in the presence and absence of candidate agonists or antagonists. Ion channel activity is assayed using patch clamp methods well known in the art or as described in Example XVII. Alternatively, ion channel activity is assayed using fluorescent techniques that measure ion flux across the cell
30 membrane (Velicelebi, G. et al. (1999) Meth. Enzymol. 294:20-47; West, M.R. and C.R. Molloy (1996) Anal. Biochem. 241:51-58). These assays may be adapted for high-throughput screening using microplates. Changes in internal ion concentration are measured using fluorescent dyes such as the Ca²⁺ indicator Fluo-4 AM, sodium-sensitive dyes such as SBFI and sodium green, or the Cl⁻ indicator MQAE (all available from Molecular Probes) in combination with the FLIPR fluorimetric
35 plate reading system (Molecular Devices). In a more generic version of this assay, changes in

membrane potential caused by ionic flux across the plasma membrane are measured using oxonyl dyes such as DiBAC₄ (Molecular Probes). DiBAC₄ equilibrates between the extracellular solution and cellular sites according to the cellular membrane potential. The dye's fluorescence intensity is 20-fold greater when bound to hydrophobic intracellular sites, allowing detection of DiBAC₄ entry
5 into the cell (Gonzalez, J.E. and P.A. Negulescu (1998) Curr. Opin. Biotechnol. 9:624-631).
Candidate agonists or antagonists may be selected from known ion channel agonists or antagonists, peptide libraries, or combinatorial chemical libraries.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the
10 invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
7484831	1	7484831CD1	33	7484831CB1
2477266	2	2477266CD1	34	2477266CB1
3552033	3	3552033CD1	35	3552033CB1
4778139	4	4778139CD1	36	4778139CB1
4787433	5	4787433CD1	37	4787433CB1
7483598	6	7483598CD1	38	7483598CB1
7484823	7	7484823CD1	39	7484823CB1
143935	8	143935CD1	40	143935CB1
5923789	9	5923789CD1	41	5923789CB1
6046484	10	6046484CD1	42	6046484CB1
7481427	11	7481427CD1	43	7481427CB1
7483595	12	7483595CD1	44	7483595CB1
3788427	13	3788427CD1	45	3788427CB1
6972455	14	6972455CD1	46	6972455CB1
8077668	15	8077668CD1	47	8077668CB1
55120485	16	55120485CD1	48	55120485CB1
3112883	17	3112883CD1	49	3112883CB1
4253888	18	4253888CD1	50	4253888CB1
7479974	19	7479974CD1	51	7479974CB1
7483850	20	7483850CD1	52	7483850CB1
5508353	21	5508353CD1	53	5508353CB1
8543628	22	8543628CD1	54	8543628CB1
7482754	23	7482754CD1	55	7482754CB1
3794818	24	3794818CD1	56	3794818CB1
4717525	25	4717525CD1	57	4717525CB1
5091793	26	5091793CD1	58	5091793CB1
5945527	27	5945527CD1	59	5945527CB1
6941124	28	6941124CD1	60	6941124CB1
6972530	29	6972530CD1	61	6972530CB1

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
6991750	30	6991750CD1	62	6991750CB1
71726948	31	71726948CD1	63	71726948CB1
7487393	32	7487393CD1	64	7487393CB1

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
1	7484831CD1	g2944233	5.1e-242	Sodium-hydrogen exchanger 6 [Homo sapiens] (Numata, M. et al. (1998) J. Biol. Chem. 273:6951-6959)
2	2477266CD1	g2102696	1.0e-37	[Homo sapiens] karyopherin beta 3 Yaseen, N.R. and Blobel, G. (1997) Proc. Natl. Acad. Sci. U.S.A. 94:4451-4456
3	3552033CD1	g3243075	0.0	[Homo sapiens] melastatin 1 Hunter, J.J. et al. (1998) Genomics 1998 54:116-123
4	4778139CD1	g8131903	5.1e-107	[Mus musculus] transient receptor potential-related protein
5	4787433CD1	g2337865	2.3e-251	[Homo sapiens] organic cation transporter
6	7483598CD1	g6978016	1.9e-32	[Rattus norvegicus] neuronal glutamine transporter Varoqui, H. et al. (2000) J. Biol. Chem. 275:4049-4054
7	7484823CD1	g619915	0.0	[Rattus norvegicus] Na,K-ATPase alpha subunit Shamraj, O.I., and Lingrel, J.B. (1994) Proc. Natl. Acad. Sci. USA 91:12952-12956
8	143935CD1	g179304	7.8e-116	B12 protein [Homo sapiens] (Wolf, F.W. et al. (1992) J. Biol. Chem. 267:1317-1326)
9	5923789CD1	g1552526	0.0	sodium-calcium exchanger form 3 [Rattus norvegicus] (Nicoll, D.A. et al. (1996) J. Biol. Chem. 271:24914-24921)
10	6046484CD1	g3243075	0.0	melastatin 1 [Homo sapiens] (Hunter, J.J. (1998) Genomics 54:116-123)
11	7481427CD1	g178661	9.8e-93	adenine nucleotide translocator-2 [Homo sapiens] (Ku, D.H. et al. (1990) J. Biol. Chem. 265: 16060-16063)

Table 2 (cont.)

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
12	7483595CD1	g9453726	3.7e-61	bA48209.2 (Novel sulphate transporter family member) [Homo sapiens]
13	3788427CD1	g3694661	5.5e-209	carrier protein-like; similar to Q01888 (PID:g266574) [Homo sapiens]
14	6972455CD1	g4155688	1.7e-24	[Helicobacter pylori J99] AMINO ACID ABC TRANSPORTER, BINDING PROTEIN PRECURSOR
15	8077668CD1	g5081312	6.6e-47	[Rattus norvegicus] bumetanide-sensitive Na-K-2Cl cotransporter Anzai, N., et al. (1999) Roles of vasopressin and hypertonicity in basolateral Na/K/2Cl cotransporter expression in rat kidney inner medullary collecting duct cells. Jpn. J. Physiol. 49, 201-206
16	55120485CD1	g8979801	1.1e-165	dJ37C10.3 (novel ATPase) [Homo sapiens]
17	3112883CD1	g3115983	4.0e-128	dJ206D15.1 (Reduced Folate Carrier protein RFC LIKE) [Homo sapiens]
18	4253888CD1	g3925431	1.6e-29	[Caenorhabditis elegans] (Z82084) contains similarity to Pfam domain: PF01769 (Divalent cation transporter), Score=211.5, E-value=4.2e-60, N=2
19	7479974CD1	g5802945	7.7e-125	[Sinorhizobium sp. As4] Arsa (catalytic subunit of arsenic oxyanion-translocating ATPase)
20	7483850CD1	g11933414	6.3e-11	[Glycine max] nitrate transporter NRT1-5
21	5508353CD1	g6457270	5.2e-190	[Mus musculus] putative E1-E2 ATPase Halleck, M.S. et al., (1999) Physiol. Genomics (Online) 1:139-150 MEDLINE : 20473714
22	8543628CD1	g6967939	3.7e-45	[Campylobacter jejuni] amino-acid ABC transporter integral membrane protein Takamori S. et al., (2000) Nature 407:189-94

Table 2 (cont.)

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
23	7482754CD1	g11640743	1.9e-20	[Homo sapiens] amino acid transporter system A1 Wang H. et al., (2000) Biochem. Biophys. Res. Commun. 273:1175-9
24	3794818CD1	g2160125	1.5e-262	NMDAR-L [Rattus norvegicus] Sucher, N.J. et al. (1995) J. Neurosci. 15:6509-6520
25	4717525CD1	g6841066	7.8e-111	calcium-binding transporter [Homo sapiens]
26	5091793CD1	g3880532	1.1e-51	Similarity to multidrug resistance protein (SW:BMRI_BACSU) [Caenorhabditis elegans] The C. elegans Sequencing Consortium (1998) Science 282: 2012-2018
27	5945527CD1	g7543982	1.5e-161	glycerol 3-phosphate permease [Homo sapiens]
28	6941124CD1	g476222	6.8e-66	anion exchanger 3 brain isoform [Homo sapiens] Yannoukakos, D. et al. (1994) Circ. Res. 75:603-614
29	6972530CD1	g10175963	3.5e-16	potassium channel protein [Bacillus halodurans] Takami, H. et al. (1999) Extremophiles 3:21-28
30	6991750CD1	g6273849	5.5e-11	cardiac sodium-calcium exchanger [Oncorhynchus mykiss] Xue, X.H. et al. (1999) Am. J. Physiol. 277:C693-C700
31	71726948CD1	g1628579	1.0e-152	sodium iodide symporter [Homo sapiens] Smanik, P.A. et al. (1996) Biochem. Biophys. Res. Commun. 226:339-345
32	7487393CD1	g7707622	2.2e-118	organic anion transporter 4 [Homo sapiens] Cha, S.H. et al. (2000) J. Biol. Chem. 275:4507-4512

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1	7484831CD1	726	S11 S52 S66 S124 S147 S198 S244 S260 S546 S585 S689 S694 S695 S712 T59 T133 T154 T177 T591 T658 T665 T684	N145 N401 N572 N589 N674	Signal peptide: M1-A37	HMMER
					Transmembrane domains: P18-A39, R68-I88, R95-I115, K175-H203, I208-L236, D245-A269, A282-Q306, A319-L347, L360-L388, Y428-G456, H482-T502, Q508-L536 N-terminus is non-cytosolic Sodium/hydrogen exchanger family: L74-V540	TMAP
					Na ⁺ /H ⁺ exchanger isoform signatures PR01088: S44-A63, E64-I88, W89-I107, Y108-Q134, S299-D316, A318-M337, G588-D606, P612-Q640, V641-D668	HMMER-PFAM
					Na ⁺ /H ⁺ exchanger signatures PR01084: V182-F193, G196-S210, I211-T219, G256-T266	BLIMPS-PRINTS
					Na ⁺ transport exchanger PD01672: V182-M230, A319-V344, F381-F414, F419-S465, F466-T512	BLIMPS-PRINTS
					Sodium hydrogen exchanger 6, myeloblast PD177855: Y557-N725, G527-E547	BLIMPS-PRODROM
					Na ⁺ /H ⁺ transmembrane transport antiporter, exchanger PD000631: E181-R539, L74-G125	BLAST-PRODROM
					Beta Na exchanger: DM02572 P48764 10-734: D171-R539, R21-L116, DM02572 Q01345 12-703: D179-D563, L22-R117 DM02572 P50482 16-723: E181-F558, G16-S124 DM02572 P26434 14-716: D179-D563, A48-T120, F605-P620	BLAST-DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
2	2477266CD1	1081	S47 S79 S148 S180 S192 S315 S493 S615 S639 S697 S1011 T18 T25 T61 T147 T167 T328 T532 T586 T786 T813 T871 T881 T907 T974	N165 N686	Transmembrane domains: P197-L213 R255-V275 E498-P520 I839-V863 N terminus cytosolic	TMAP
					IMPORTIN SUBUNIT KARYOPHERIN PROTEIN TRANSPORT REPEAT PD014526: F691-D1033 PD014366: A458-S615, Q389-N412 Leucine zipper pattern L177-L198 Phospholipase A2 histidine active site C725-C732	BLAST_PRODOR MOTIFS MOTIFS
3	3552033CD1	1172	S212 S235 S300 S366 S401 S528 S558 S618 S687 S688 S884 S1017 S1059 S1060 S1069 S1076 S1088 S1125 T9 T147 T422 T459 T460 T917 T962 T984 T1031 T1112 T1118 T1132 T1155 Y645 Y857	N144 N233 N298 N420 N576 N579 N789 N915 N960 N1058 N1074	Transient receptor: Y943-M1001, R817-E882, E750-L807, D562-W608	HMMER_PPFAM
					Transmembrane domains: G51-I75 D397-R425 F712-V740 E786-R806 V822-G842 M852-A872 W934-T962 N terminus cytosolic	TMAP
					Transient receptor potential family signature PR01097: A941-T962, F963-F976, V990-M1003	BLIMPS_PRINTS
					PROTEIN MELASTATIN CHROMOSOME TRANSMEMBRANE PD018035: M1-L333 PD151509: I829-L1117 PD039592: E464-E660 PD022180: W328-R438	BLAST_PRODOR

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
3					ANK MOTIF REPEAT DM031196 P34586 38-822: I819-C1009, L583-G619, L702-L807, D114-N144, T9-Q48 Aminoacyl-transfer RNA synthetases class-II signature 2 A1111-L1120	BLAST_DOMO MOTIFS
4	4778139CD1	742	S42 S104 S135 S194 S203 S214 S220 S221 S234 S239 S277 S319 S339 S352 S354 S403 S435 S438 S479 S491 S510 S722 S735 T111 T325 T371 T508 T575 T619 T635 T731	N238 N258 N294 N650 N711	KINASE TRANSFERASE SERINE/THREONINE PROTEIN ATP BINDING ELONGATION FACTOR EEF2 EEF2K CALCIUM/CALMODULINDEPENDENT EUKARYOTIC PD011701: K536-R709	BLAST_PRODOM
5	4787433CD1	577	S70 S119 S176 S319 S337 S544 S550 S560 T135 T356 T521 T534 T535 T569 Y10	N31 N57 N65 N68 N108 N345 N352 N546 N558	Sugar (and other) transporter: K120-E538	HMMER_PFAM
					Transmembrane domains: G17-G45 R150-R178 L185-Y205 F214-I234 S243-L263 L269-F293 I355-S377 N390-D410 T416-P436 L442-Y462 A488-L516 N terminus cytosolic	TMAP
					Na+/H+ exchanger isoform PR010870 I32-V46 Leucine zipper pattern L146-L167	BLIMPS_PRINTS MOTIFS
6	7483598CD1	462	S24 S56 S90 S242 S243 S393 T282 T391	N100 N331 N436 N441 N457	Transmembrane amino acid transporter protein: S56-G412	HMMER_PFAM
					Transmembrane domains: C33-L53 G65-K85 T102-A130 N148-L168 A175-V195 W213-Y241 A250-F278 F328-A348 L358-P378 T391-N419 N terminus non-cytosolic	TMAP
					ACID AMINO PROTEIN TRANSPORTER PERMEASE TRANSMEMBRANE INTERGENIC REGION PUTATIVE PROLINE PD001875: F39-T209	BLAST_PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
7	7484823CD1	1018	S10 S49 S151 S157 S372 S463 S525 S585 S648 S732 S938 T44 T82 T250 T344 T393 T399 T404 T444 T482 T618 T635 T755 T934 Y461 Y889	N212 N480	E1-E2 (cation transport) ATPase: V132-T363	HMMER_Pfam
					Na ⁺ /K ⁺ ATPase C-terminus: R829-Y1017, E30-S113	HMMER_Pfam
					Transmembrane domains: H287-L315 E781-T809 I845-F873 V909-I931 A972-R1000 N terminus non-cytosolic	TMAP
					E1-E2 ATPases phosphoryl BL00154: V329-G365, T367-V385, K504-C514, D588-I628, V707-G730, G733-N766, G185-L202	BLIMPS_BLOCKS
					E1-E2 ATPases phosphorylation site atpase_e1_e2.prf: L354-E401	PROFILES SCAN
					P-type cation-transporting atpase superfamily signature PR00119: D211-S225, C371-V385, G582-A593, A604-D614, T710-M729, S734-L746	BLIMPS_PRINTS
					H ⁺ -transporting ATPase (proton pump) signature PR00120: E682-E698, T710-G726, D742-L767	BLIMPS_PRINTS
					Sodium/potassium-transporting ATPase signature PR00121: L100-I114, L127-Q147, L291-G313, L364-V385, L501-L519, I782-L803, Y849-A869, F911-I931, R945-M969	BLIMPS_PRINTS
					ATPASE TRANSMEMBRANE TRANSPORT PUMP MAGNESIUM PD000132: V132-Y312, W314-N426, D667-E820, K473-D742, F118-S225, V581-I628 CALCIUM PD000121: L643-N749, I587-I629 CALCIUM PD000388: K828-Y1017	BLAST_PRODUM
					PTYPE TRANSPORTING ATPASE 1 PD111120: F750-H842	BLAST_PRODUM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
7					E1-E2 ATPases PHOSPHORYLATION SITE DM00115 P50993 80-807: P79-D806 A34474 80-807: P79-D806 P06686 80-807: P79-D806 P24797 77-804: P79-D806 E1-E2 ATPases phosphorylation site D373-T379	BLAST_DOMO
8	143935CD1	313	S23 S30 S62 S101 S145 S146 S156 S176 S193 T51 T69 T235 T240	N166	K+ channel tetramerisation domain:K32-Q129	HMMER_PFAM
					Na+/H+ exchanger isoform PR01085H: T133-S145	BLIMPS_PRINTS
					EDP1 TNF ALPHA INDUCED ENDOTHELIAL B12 PD037429: L109-Q313	BLAST_PRODUM
9	5923789CD1	921	S69 S144 S151 S312 S381 S382 S691 S713 S720 S794 T106 T113 T125 T194 T267 T277 T460 T522 T572 T583 T594 T597 T632 T637 T672 Y405 Y608	N45 N130 N135 N817	signal cleavage: M1-T21 Sodium/calcium exchanger protein: L757-L905, R110-F257	MOTIFS HMMER_PFAM
					PRECURSOR TRANSPORT SIGNAL GLYCOPROTEIN NA+/CA2+EXCHANGER SYMPORT TRANSMEMBRANE PD004181: W249-E390 PD001766: E385-H528 PD149743: V674-I777 PD149807: A529-G627 SODIUM/CALCIUM EXCHANGER CHAIN DM05297 P48768 1-920: C48-F921 DM05297 P48765 6-969: I6-E625, I628-F921 GO ANTIPOPTER; MURZ; III; 34.7; DM02122 S20969 450-604: N130-W249	BLAST_PRODUM BLAST_DOMO BLAST_DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
9					Transmembrane domains: A2-R29, K73-S101, P167-P190, T194-M219, T237-M261, S720-P741, G748-T776, T776-D797, I815-W841, H849-R877, C891-T911 N-terminus is cytosolic signal_cleavage: M1-A30 Signal Peptide: M1-A32	TMAP
10	6046484CD1	1466	S86 S212 S235 S300 S366 S401 S518 S548 S608 S660 S719 S858 S988 S1011 S1039 S1040 S1049 S1056 S1087 S1114 S1166 S1224 S1234 S1323 S1399 S1410 T9 T422 T449 T450 T629 T637 T742 T941 T963 T1164 T1268 T1297 T1387 T1389 T1449 T1462 Y635	N133 N144 N233 N298 N420 N566 N569 N763 N1054 N1245	Transient receptor: Y922-H979, R791-L851, D552-W598	SPSCAN HMMER HMMER_PFAM
11	7481427CD1	222	S28 S142 S159 T144		Transient receptor potential family PR01097: A920-T941, F942-F955 MELASTATIN 1 PD183973: L1097-C1466 MELASTATIN CHROMOSOME TRANSMEMBRANE C05C12.3 T01H8.5 I F54D1.5 IV PD018035: M1-L333 PD151509: I803-L1097 PD039592: E454-T652 Transmembrane domains: G51-I75, D397-R425, L602-Y630, F692-V712, W717-I737, N763-N783, Y789-F809, Y818-A846, W913-T941, L970-L987 N-terminus is cytosolic Mitochondrial carrier proteins: S7-K105, Y112-T202	BLIMPS_PRINTS BLAST_PRODROM BLAST_PRODROM TMAP HMMER_PFAM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
11					Mitochondrial energy transfer proteins BL00215: L13-Q37, I158-G170 Mitochondrial energy transfer proteins mitoch_carrier.prf: C110-I158 Mitochondrial energy transfer proteins: P127-A136	BLIMPS_BLOCKS PROFILES SCAN MOTIFS
					Mitochondrial carrier protein signature PR00926: G120-D138, Y168-F186, D11-T24, T24-M38, G73-D93	BLIMPS_PRINTS
					Adenine nucleotide transfer protein PR00927: F8-A20, C51-R72, T84-K96, R111-V124, R146-L167, S207-S222	BLIMPS_PRINTS
					PROTEIN TRANSPORT TRANSMEMBRANE REPEAT MITOCHONDRIAL CARRIER MEMBRANE INNER MITOCHONDRIAL ADP/ATP PD000117: S7-A123, Y112-S222	BLAST_PRODROM
					MITOCHONDRIAL ENERGY TRANSFER PROTEINS DM00026 P02722 11-96: F12-I98 DM00026 S31935 14-108: F12-T107 DM00026 P02722 116-205: L117-N201 DM00026 S31935 110-208: Q108-N201	BLAST_DOMO
					Transmembrane domains: I164-R187 N-terminus is cytosolic	TMAP
12	7483595CD1	461	S168 S212 S233 S338 S362 S382 S439 T318 T348	N98 N163 N288 N344 N380 N381	SULFATE TRANSPORTER PROTEIN TRANSPORT TRANSMEMBRANE AFFINITY GLYCOPROTEIN SULPHATE HIGH DISEASE PD001755: R216-D272, V414-D459 SULFATE TRANSPORTERS DM01229 P40879 5-462: T23-A140, Q124-L222 DM01229 P45380 10-468: P130-L222, T23-L138 DM01229 P50443 49-505: I136-K247, T23-S144	BLAST_PRODROM BLAST_DOMO
					Transmembrane domains: F6-F26, L31-S51, M62-S82, C91-A111, E128-K156, L161-R186 N-terminus is cytosolic	TMAP
13	3788427CD1	502	S146 S304 S446 S467 T25 T59 T96 T104 T164 T385 T492 T501		Mitochondrial carrier proteins: S361-Y461, S266-Q359, T172-H264	HMMER_PPFAM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
13					Mitochondrial energy transfer proteins mitoch_carrier.prf1: L362-I417 mitoch_carrier.prf2: S270-I315 Mitochondrial energy transfer proteins: P287-I296 Mitochondrial carrier protein signature PR00926: G232-R252, V280-Q298, Y325-L343, V369-Q391 PROTEIN TRANSPORT TRANSMEMBRANE REPEAT MITOCHONDRION CARRIER MEMBRANE INNER MITOCHONDRIAL ADP/ATP PD000117: Y305-R453 MITOCHONDRIAL ENERGY TRANSFER PROTEINS DM00026 Q01888 126-214: G263-I352 DM00026 P29518 233-310: I271-I352 Transmembrane domains: R176-G204, A323-K351, L424-K452 N-terminus is cytosolic	PROFILESSCAN MOTIFS BLIMPS_PRINTS BLAST_PRODROM BLAST_DOMO TMAP
14	6972455CD1	261	S6 S26 S135 S198 T2 T36 T64 T84 T92 T165 Y218	N82 N172 N173	signal_cleavage: M1-A23 Signal Peptide: M1-P22, M1-A23, M1-A25, M1-G27 Bacterial extracellular solute-binding protein domain: M1-L253 Transmembrane domains: T175-A196 N-terminus is non-cytosolic Bacterial extracellular solute binding protein signature BL01039: G52-L72, R86-Y118, L90-S101 BACTERIAL EXTRACELLULAR SOLUTE-BINDING PROTEINS, FAMILY 3 DM00557 P27676 32-261: S19-K223 DM00557 P30860 5-241: L37-W252 DM00557 P39174 15-260: L8-W252 DM00557 P45678 11-258: A11-W252	SPSCAN HMMER HMMER_PFAM TMAP BLIMPS_BLOCKS BLAST_DOMO

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residue	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
115	8077668CD1	570	S40 S82 S265 S314 S349 S442 S446 S551 T50 T324 T344	N11 N342 N440	Transmembrane domains: V163-V183 N194-T214 V232-I259 I275-R302 S353-N373 A382-G402 P465-G481 N-terminus is cytosolic do SENSITIVE; COTRANSPORTER; SODIUM; CHLORIDE; DM01337 P55011 409-906: V278-G402 DM01337 P55013 381-879: V278-G402 DM01337 A53491 381-879: V278-G402 DM01337 P55014 297-795: V278-G402	TMAP
116	55120485CD1	1033	S5 S103 S159 S241 S249 S338 S567 S587 S671 S798 S833 S850 S1008 S1028 T78 T97 T172 T375 T490 T664 T701 T784 T859 T871 Y85	N540 N669 N781 N819 N848 N867 N875 N1005	Transmembrane domains: F24-Y52 K197-L217 Y223-Y243 L394-Y422 D429-N454 T877-F893 T903-L931 L937-E964 N-terminus is non-cytosolic	TMAP
					E1-E2 ATPase domain: V268-P324 E1-E2 ATPases phosphorylation site signature BL00154: G284-L301, V442-G478, I480-L498, K624-C634, N695-M735 E1-E2 ATPases phosphorylation site: I466-F515	HMMER_PFBAM BLIMPS_BLOCKS
					P-type cation-transporting atpase superfamily signature PR00119: N309-T323, C484-L498, A711-D721 Sodium/potassium-transporting ATPase signature PR00121: C477-L498, V621-V639	BLIMPS_PRINTS BLIMPS_PRINTS
					ATPASE HYDROLASE TRANSMEMBRANE PHOSPHORYLATION ATP BINDING TRANSPORT PUMP CALCIUM MAGNESIUM MEMBRANE PD000132: I230-T494	BLAST_PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
16					E1-E2 ATPASES PHOSPHORYLATION SITE DM00115 P22189 49-801: Q597-P738, W196-K322, P389-P447, S671-L723 DM00115 P37278 58-755: I192-I743, V822-K840 DM00115 P47317 26-695: F600-E749, I230-K559, K815-E853 DM00115 P54707 97-825: I232-I743, L813-E853 E1-E2 ATPases phosphorylation site: D486-T492	BLAST_DOMO
17	3112883CD1	496	S40 S211 S241 S251 S274 S275 S463 S466 S482 S493 T47 T117	N45 N166 N256	Reduced folate carrier domain: S10-V441 Transmembrane domains: L8-M28 N53-Y76 Y79-Q107 F111-R138 L148-S168 V174-K194 K276-D304 N316-Y336 D342-L362 A367-A395 L405-V425 P434-L454 N-terminus is cytosolic FOLATE CARRIER PROTEIN REDUCED TRANSPORTER GLYCOPROTEIN FOLATE BINDING TRANSPORT TRANSMEMBRANE METHOTREXATE PD003967: S11-E230, G327-S493, F262-W303	HMME PFAM
18	4253888CD1	573	S8 S35 S77 S88 S106 S137 S229 S304 S321 S340 S379 T10 T27 T148 T194 T401 Y115	N78 N466	Transmembrane domains: G157-Q185 V189-R217 A242-G268 K269-M297 V314-S340 E343-K369 L377-D399 L407-S433 A469-L489 G493-D521 G531-H559 N-terminus is cytosolic	TMAP
19	7479974CD1	573	S69 S138 S198 S221 S261 S355 S473 S478 S509 S543 T24 T159 T176 T401 T406 T474 T499	N80 N174 N294 N491 N529 N558	Divalent cation transporter domain: L199-S335, Y413-H559 Anion-transporting ATPase domain: L354-S573	HMME PFAM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
19					PLASMID ARSENICAL PUMPDRIVING ATPASE HYDROLASE RESISTANCE ATPBINDING ARSA PD006335: D460-P568 NIFH/FRXC FAMILY DM00105 P08690 7-180: Y20-E191 DM00105 P08690 326-473: L333-K472 DM00105 P30632 17-190: K19-S167 ATP/GTP-binding site motif A (P-loop): G25-T32, G337-T344	BLAST_PRODUM BLAST_DOMO
20	7483850CD1	248	S42 S85 S121 S198 S215 S227 S233 S239		Transmembrane domains: D8-S36, R44-I72, C96-R123, S133-I158, L171-F194 N-terminus is non-cytosolic POT family (proton/oligopeptide symporter) domain: G56-N141	TMAP HMME PFAM
21	5508353CD1	761	S5 S62 S109 S115 S185 S312 S409 S476 S556 S706 S734 T28 T30 T78 T162 T201 T227 T335 T534 T674 T695 T738 Y189	N700 N732	Transmembrane domains: P84-K112, Y459-N487, P528-Y553, G564-K584, L592-C612, I624-Y652 N-terminus is cytosolic E1-E2 ATPases phosphorylation site proteins: BL00154: D231-L271, T386-S409, K131-L141 P-type cation-transporting atpase superfamily signature PR00119: A247-D257 H+-transporting ATPase (proton pump) signature PR00120: T162-A180 ATPASE HYDROLASE TRANSMEMBRANE PHOSPHORYLATION ATP-BINDING PROTEIN PROBABLE CALCIUM TRANSPORTING CALCIUM TRANSPORT PD004657: A423-P661 ATPASE HYDROLASE TRANSMEMBRANE PHOSPHORYLATION ATP-BINDING PROBABLE PROTEIN CALCIUM TRANSPORTING CALCIUM TRANSPORT PD149930: C363-F422	BLIMPS_BLOCKS BLIMPS_PRINTS BLAST_PRODUM BLAST_PRODUM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
21					ATPASE; CALCIUM; TRANSPORTING; DM02405 P32660 318-1225: E45-N487 ATPASE; CALCIUM; TRANSPORTING; DM02405 Q09891 206-1107: L56-N487 ATPASE; CALCIUM; TRANSPORTING; DM02405 S51243 356-1267: E59-F486 ATPASE; CALCIUM; TRANSPORTING; DM02405 P39524 236-1049: Y58-D287, L332-N487 ATP/GTP-binding site motif A (P-loop): G331-T338, A699-S706	BLAST_DOMO BLAST_DOMO BLAST_DOMO BLAST_DOMO MOTIFS
22	8543628CD1	219	S4 T148		Binding-protein-dependent transport system: A112-Y185 Transmembrane domains: A20-N48, V70-S98, T156-R183, Y185-A208 N-terminus is non-cytosolic Binding-protein-dependent transport systems inner membrane component: V105-T161 PROTEIN TRANSPORT TRANSMEMBRANE PERMEASE MEMBRANE AMINO ACID INNER SYSTEM TRANSPORTER ABC PD001196: E7-G111 BINDING-PROTEIN-DEPENDENT TRANSPORT SYSTEMS INNER MEMBRANE DM00388 P10345 3-214: L9-R215 BINDING-PROTEIN-DEPENDENT TRANSPORT SYSTEMS INNER MEMBRANE DM00388 P42399 12-220: S12-R215 BINDING-PROTEIN-DEPENDENT TRANSPORT SYSTEMS INNER MEMBRANE DM00388 P45023 17-232: P14-R215 BINDING-PROTEIN-DEPENDENT TRANSPORT SYSTEMS INNER MEMBRANE DM00388 P42200 15-226: P14-R215 Binding-protein-dependent transport systems inner membrane component signature: L113-P141	HMMER_PFAM TMAP PROFILES CAN BLAST_PROD OM BLAST_DOMO BLAST_DOMO BLAST_DOMO MOTIFS HMMER_PFAM
23	7482754CD1	463	S249 S254 S413 S420 T451 T458		Transmembrane amino acid transporter protein: A48-C433	HMMER_PFAM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
23					Transmembrane domains: L24-N44, G54-V74, R93-R121, D148-R168, H180-T200, S249-S274, G298-R326, W353-M373, S377-P397 N-terminus is non-cytosolic Transmembrane four family signature PR00259: F59-V82, L73-A99, V302-V328 ACID AMINO PROTEIN TRANSPORTER PERMEASE TRANSMEMBRANE INTERGENIC REGION PUTATIVE PROLINE PD001875: F31-I320	TMAP BLIMPS_PRINTS BLAST_PRODROM
24	3794818CD1	1043	S36 S153 S206 S372 S388 S402 S536 S633 S700 S709 S721 S747 S849 S867 S876 S891 S901 S1014 S1036 T157 T192 T210 T421 T491 T593 T604 T636 T641 T673 T696 T725 T916	N69 N344 N451 N465 N609 N786	signal_cleavage: M1-G22 Ligand-gated ion channel: H574-E852 Transmembrane domains: H574-R598, P640-V667, T823-L847 N terminus is non-cytosolic NMDA receptor signature PR00177: F493-L521, T577-G602, L644-D671, F831-F855 R32184_2 IONOTROPIC GLUTAMATE RECEPTOR PD156309: A77-Y477 RECEPTOR GLUTAMATE SUBUNIT SIGNAL PRECURSOR CHANNEL IONIC TRANSMEMBRANE POSTSYNAPTIC PD000500: M570-E852	SPSCAN HMMER_PPFAM TMAP BLIMPS_PRINTS BLAST_PRODROM BLAST_PRODROM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
24					RECEPTOR SIGNAL GLUTAMATE SUBUNIT PROTEIN TRANSMEMBRANE CHANNEL IONIC PD000273: G478-A563, G728-V817	BLAST_PRODOM
					GLUTAMATE RECEPTOR DM00247 Q03391 640-919: T631-S901, C964-P980 DM00247 P35436 615-886: T631-F856 DM00247 Q01098 613-882: T631-E904 DM00393 Q01097 377-614: G387-F628	BLAST_DOMO
25	4717525CD1	480	S4 S23 S56 S105 S176 S411 S418 T161 T170 T220 T302 T410 T469		Mitochondrial carrier proteins: M184-T276, G319-L413	HMMER_PFAM
					EF hand: Q117-H145, R13-L41, R81-L109	HMMER_PFAM
					Mitochondrial energy transfer proteins BL00215: V190-Q214, I369-G381	BLIMPS_BLOCKS
					Mitochondrial energy transfer proteins signature: I320-S371, K187-L241, V279-S331	PROFILES SCAN
					Mitochondrial carrier protein signature PR00926: Q188-T201, T201-V215, G244-E264, C333-Q351, Y379-Y397, G327-Q349	BLIMPS_PRINTS
					Graves disease carrier protein signature PR00928: Q274-Q294, P205-I225, Y263-S287, I369-V389	BLIMPS_PRINTS
					TRANSPORT TRANSMEMBRANE CARRIER INNER MITOCHONDRIAL ADP/ATP PD000117: K187-S466	BLAST_PRODOM
					MITOCHONDRIAL ENERGY TRANSFER PROTEINS DM00026 S57544 26-107: V190-I270 DM00026 Q01888 38-124: V190-I270	BLAST_DOMO
					EF-hand calcium-binding domain: D22-L34 D90-I102	MOTIFS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
26	5091793CD1	518	S8 S38 S161 S240 S253 S331 S389 S510 T378	N6 N171 N371 N376	Transmembrane domains: G77-W97, K104-L124, N131-V151, A170-T191, Q206-E234, I264-P292, Q304-K332, E336-I364, A406-N434, P481-L509 N terminus is non-cytosolic.	TMAP
27	5945527CD1	501	S39 S66 S263 S267 S329 S421 T338 T418	N53 N62 N68	Transmembrane domains: V9-H37, E85-S105, L114-L134, L197-T225, G290-W317, V342-A362, Y379-G399, T433-L453, N460-L480 N terminus is cytosolic. glPT family of transport BL00942: T29-K41, N82-L124, W171-V190, F211-P247, E281-Y321, L339-D356	TMAP BLIMPS_BLOCKS
					GLPT FAMILY OF TRANSPORTERS DM02439 P37948 1-403: K84-H244, L305-L446 DM02439 P09836 1-401: L87-E234, P295-A426, S16-K41 DM02439 P08194 1-403: L87-D256, Q251-A444, R22-I45	BLAST_DOMO
28	6941124CD1	801	S21 S171 S305 S399 S442 S469 S564 T6 T20 T56 T130 T174 T198 T200 T400 T420 T438 T704 Y791	N52 N388 N455 N463	HCO3- transporter family: A571-L745, H240-F546, R119-L208	HMMER_PFAM
					Transmembrane domains: V282-G304, L330-I358, T373-M393, I403-I423, H478-Y499, V514-E542, S564-L592, T604-A630, S672-Y700, L748-I776 N terminus is non-cytosolic.	TMAP

Table 3 (cont.)

SEQ ID NO:	Incyste Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
28					Anion exchangers family BL00219: S448-T483, P243-V282, T289-D312, L342-F380, A382-Y429, Q481-S534, A567-W608, D609-E647, H653-F698, Y700-T743, L748-I787 Anion exchanger signature PR00165: G253-I275, K284-G304, A371-S390, A482-L501, I517-G537 ANION EXCHANGE TRANSMEMBRANE GLYCO-PROTEIN LIPOPROTEIN PALMITATE BICARBONATE COTRANSPORTER PD001455: T483-T743, F752-S457, R158-A237 BAND 3 ANION TRANSPORT PROTEIN DM02294 P48751 601-1229: A190-E798 DM02294 P02730 311-908: T483-E798 DM02294 A42497 403-1027: F252-E798 DM02294 P04920 602-1237: D248-E798	BLIMPS_BLOCKS
29	6972530CD1	344	S101 S133 S157 S319 S333 T117 T145 T196 T286 Y330	N223 N299	signal_cleavage: M1-A34	SPSCAN
					Signal Peptide: M9-A34	HMMER
					Transmembrane domains: R8-L36 V39-V63 Q71-T99 N terminus is non-cytosolic.	TMAP

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
30	6991750CD1	2701	S1063 S1231 S1270 S40 S1367 S1526 S551 S1603 S193 S1710 S1793 S223 S1824 S1866 S274 S1879 S230 S1893 S1915 S651 S1922 S307	N56 N218 N319 N330 N364 N396 N452 N480 N539 N607 N667 N691 N772 N828 N875 N885 N921 N949 N964 N988 N1135	Transmembrane domains: I965-S986, E1281-T1300, N1670-S1692, V1836-W1864, V2276-N2292, A2507-F2534 N terminus is non-cytosolic.	TMAP
			S1952 S1978 S461 S2029 S382 S2045 S2090 S2230 S495 S2388 S2438 S792 S2464 S790 S2488 S2496 S2506 S901 S2537 S809 S2545 S2573 S856 S2631	N1153 N1166 N1241 N1259 N1273 N1305 N1323 N1372 N1479 N1525 N1528 N1618 N1624 N1892 N1969 N2134 N2342 N2428 N2510 N2596 N2625	Adenosine and AMP deaminase signature S2386-P2392	MOTIFS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
30			T122 T158 T276 T417 T581 T774 T881 T989 T1004 T1030 T1045 T1051 S941 T1058 T1090 S953 T1307 T1559 T1610 T1658 T1786 T1887 T1945 T2171 T2213 T2266 T2328 T2409 T2415 T2446 T2450 T2459 T2549 T2694 Y130		Sodium/Calcium Exchanger Chain DM05297 P48765 6-969: V263-I492 P=2.8-09	BLAST_DOMO
31	71726948CD1	610	S114 S269 S317 S375 S377 S563 S576 S602 T3 T41 T53 T74 T158 T312 T364 T483 T491 T557 Y554	N260 N481 N485 N606	Signal Peptide: M47-P73	HMME
					Sodium: solute symporter family: F45-G449	HMME_PPFAM
					Transmembrane domains: P4-Y32, T53-G73, I84-L104, L121-Y148, G159-L179, V190-M210, R239-I256, R273-L301, S385-L405, A412-I432, S439-G459, N515-T543 N terminus is non-cytosolic.	TMAP
					Sodium: solute symporter BL00456: L22-S76, I98-V127, T158-G212	BLIMPS_BLOCKS
					Sodium: solute symporter family signatures: N155-A201	PROFILES SCAN

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
31					TRANSMEMBRANE TRANSPORT PERMEASE SODIUM SYMPORT PROLINE GLYCOPROTEIN PD000991: F45-P234, L129-G449 SYMPORTER SODIUM IODIDE THYROID PD024705: A451-P552 SODIUM: SOLUTE SYMPORTER FAMILY DM00745 JC2382 3-485:Y15-W455 DM00745 P45174 3-495:T9-W455 DM00745 P31448 1-494:F18-G449 DM00745 P44963 1-483:V23-Y463	BLAST_PRODOM BLAST_PRODOM BLAST_DOMO
32	7487393CD1	552	S46 S60 S68 S143 S167 S276 S282 S408 S475 S537 T58 T133 T311 T323 T391 T526	N39 N56 N62 N102 N377	Sugar (and other) transporter: I18-V530 Transmembrane domains: V10-E38, K145-G164, I174-L202, M232-A252, Q262-S282, K345-I368, G375-L397, F412-L440, S475-L496, P497-L514 N terminus is non-cytosolic.	HMMER_PFAM TMAP
					ORGANIC TRANSPORTERLIKE TRANSPORT PROTEIN RENAL ANION TRANSPORTER CATIONIC KIDNEY SPECIFIC SOLUTE PD151320: N102-K145	BLAST_PRODOM

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
33/7484831CBI/2365	1-325, 94-240, 106-240, 106-242, 106-244, 106-514, 106-515, 106-582, 106-586, 106-593, 106-597, 106-612, 109-245, 110-245, 128-770, 160-516, 164-267, 176-549, 181-440, 184-581, 234-317, 234-409, 252-770, 275-469, 275-473, 275-570, 275-636, 275-700, 336-1038, 338-1038, 377-543, 413-622, 414-1038, 495-1038, 504-764, 504-1009, 521-952, 521-1034, 521-1038, 523-680, 704-974, 781-1246, 824-1377, 884-1127, 904-1254, 916-1533, 940-1038, 958-1226, 978-1038, 990-1038, 1018-1637, 1031-1722, 1064-1463, 1070-1211, 1086-1149, 1110-1336, 1110-1375, 1110-1386, 1110-1387, 1110-1391, 1110-1462, 1113-1382, 1139-1622, 1144-1622, 1153-1629, 1178-1434, 1178-1749, 1210-1694, 1262-1309, 1445-1969, 1445-2000, 1455-1830, 1463-1630, 1478-1701, 1519-1790, 1526-1952, 1582-1838, 1669-1886, 1676-1846, 1772-2205, 1846-2117, 1847-2060, 1890-2209, 1934-2041, 1938-2315, 1950-2365
34/2477266CBI/3400	1-89, 1-306, 13-348, 13-665, 16-468, 23-270, 23-271, 23-404, 23-512, 27-306, 35-386, 35-589, 37-693, 124-795, 240-510, 317-524, 366-999, 459-996, 473-1144, 492-1041, 493-1060, 505-1019, 761-1360, 798-1025, 798-1268, 872-1360, 875-1143, 988-1278, 996-1252, 996-1612, 1024-1265, 1032-1623, 1054-1507, 1078-1341, 1192-1726, 1213-1608, 1218-1469, 1253-1798, 1332-1567, 1332-1800, 1345-1908, 1387-1693, 1419-1981, 1434-1737, 1436-1726, 1518-2165, 1524-2132, 1562-1836, 1775-2024, 1779-2022, 1797-2084, 1890-2052, 1890-2116, 1890-2334, 1890-2438, 1913-2196, 1942-2197, 1949-2528, 1952-2509, 1954-2029, 1981-2621, 1994-2104, 1994-2174, 1994-2252, 1994-2258, 1994-2259, 2039-2147, 2040-2319, 2062-2315, 2142-2732, 2205-2493, 2238-2536, 2265-2795, 2275-2544, 2277-2528, 2302-2718, 2337-2622, 2380-2920, 2444-2841, 2467-2711, 2472-2728, 2472-2737, 2472-2955, 2484-2753, 2492-2641, 2503-2746, 2512-3142, 2517-3095, 2555-3131, 2568-3246, 2590-2931, 2605-2903, 2643-2973, 2646-2931, 2656-2902, 2673-3284, 2725-3400,
35/3552033CBI/4458	2766-3312, 2766-3390, 2766-3398, 2795-3082, 2800-3097, 2818-3039, 2818-3355, 2832-3051, 2832-3088, 2851-3007, 2851-3015, 2851-3028, 2854-3120, 2868-3336, 2871-3133, 2871-3195, 2884-3181, 2892-3104 1-1188, 405-1189, 422-1189, 447-1152, 479-1274, 507-1189, 511-1189, 515-1185, 523-1188, 535-1189, 540-1188, 547-1189, 550-1189, 560-1189, 561-1189, 570-1189, 571-1275, 579-1189, 585-1189, 586-1141, 602-1189, 602-1275, 629-1275, 631-1189, 635-1189, 636-1275, 638-1189, 640-1189, 643-1189, 653-1189, 654-1189, 655-1120, 675-1240, 695-1188, 699-1188, 700-1189, 701-1189, 708-1189, 735-1189, 743-1189, 746-1189, 748-1189, 749-1189, 752-1189, 761-1189, 762-1189, 763-1189, 768-1189, 775-1189, 780-1188, 820-1189, 844-1600, 887-1496, 970-1185, 1008-1841, 1023-1188, 1028-1189, 1028-1721, 1055-1574, 1108-1275, 1171-1275, 1491-2041, 1491-2086, 1551-2416, 1874-2534, 1874-2548, 1874-2561, 1874-2576, 1874-2580, 1875-2432, 1875-2436, 1875-2539, 1887-2564, 1909-2592, 1917-2507, 1940-2494, 1955-2542, 1959-2477, 1962-2428, 1964-2460, 1978-2424, 1988-2500, 1992-2500, 1994-2673, 1996-2500, 2014-2906, 2017-2437, 2025-2578, 2025-2580, 2033-2525, 2038-2492, 2045-2611, 2053-2644, 2066-2555, 2087-2691, 2104-2699, 2105-2514, 2147-2427,

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
35	2171-2621, 2181-2699, 2196-2743, 2205-3023, 2207-2752, 2215-2959, 2221-3026, 2221-3058, 2222-3020, 2249-2765, 2290-3024, 2291-2959, 2295-2796, 2300-2958, 2320-3022, 2325-2763, 2384-3024, 2391-3024, 2406-3024, 2407-3024, 2414-3023, 2414-3024, 2420-3024, 2433-2718, 2433-2900, 2433-3024, 2433-3025, 2434-3024, 2435-3024, 2438-3024, 2441-3024, 2443-3024, 2446-3024, 2451-3023, 2455-3024, 2470-3024, 2479-3024, 2480-3024, 2482-3024, 2484-3024, 2488-3024, 2489-3024, 2491-3024, 2501-3024, 2508-3024, 2511-3024, 2522-3024, 2582-3024, 2583-3024, 2587-3024, 2590-3024, 2592-2877, 2592-3022, 2592-3024, 2596-3024, 2602-3279, 2612-3024, 2621-3063, 2621-3092, 2626-3279, 2632-3024, 2633-3024, 2652-3024, 2653-3024, 2671-3015, 2671-3020, 2671-3022, 2671-3024, 2686-3024, 2688-3024, 2689-3024, 2718-3024, 2732-3279, 2734-3024, 2736-3279, 2763-3024, 2766-2830, 2770-3021, 2773-3203, 2802-3279, 2812-3004, 2831-3008, 2831-3037, 2831-3117, 2831-3220, 2831-3247, 2831-3275, 2831-3300, 2831-3490, 2842-3330, 2853-3278, 2866-3103, 2902-3270, 2998-3234, 2998-3524, 2998-3550, 2998-3606, 3003-3715, 3032-3279, 3052-3811, 3078-3810, 3175-3935, 3182-3854, 3219-3792, 3224-3807, 3247-3811, 3267-3885, 3355-3811, 3359-3429, 3359-3811, 3389-4035, 3393-4035, 3402-3915, 3423-3982, 3427-4044, 3444-3811, 3463-4149, 3472-4150, 3485-4080, 3498-3527, 3510-3811, 3521-4030, 3547-3782, 3552-4035, 3552-4039, 3606-4267, 3606-4430, 3629-3871, 3629-3872, 3629-4047, 3631-4047, 3660-4047, 3673-4416, 3676-3848, 3703-3811, 3713-3864, 3714-3972, 3767-4458, 3792-4454, 3817-4084, 3820-4047, 3852-4458, 3857-4035, 3932-4144, 3934-4347, 3939-4152, 4201-4458, 4219-4458, 4295-4458
36/4778139CB1/2722	1-490, 1-545, 1-554, 1-567, 1-574, 1-575, 1-594, 1-606, 1-671, 1-1206, 5-2226, 157-394, 424-874, 433-874, 448-874, 459-874, 461-874, 467-874, 481-874, 498-874, 508-874, 563-874, 580-874, 1464-1728, 1464-1773, 1660-1896, 1660-1919, 1935-2155, 2166-2453, 2166-2722, 2178-2456
37/4787433CB1/1924	1-77, 1-100, 1-480, 154-1023, 513-772, 719-980, 719-1247, 729-984, 805-1016, 843-1529, 848-1456, 849-1459, 902-1530, 902-1552, 940-1543, 951-1593, 952-1426, 962-1646, 990-1548, 1001-1588, 1029-1577, 1047-1657, 1048-1442, 1059-1472, 1059-1569, 1064-1527, 1075-1646, 1076-1628, 1082-1734, 1091-1693, 1095-1701, 1099-1339, 1104-1681, 1104-1707, 1106-1674, 1112-1332, 1119-1583, 1123-1765, 1129-1683, 1169-1608, 1200-1626, 1207-1745, 1218-1832, 1230-1611, 1232-1669, 1244-1741, 1256-1758, 1265-1584, 1273-1758, 1280-1557, 1284-1765, 1303-1924, 1356-1592, 1356-1924, 1359-1585, 1359-1833, 1366-1917, 1382-1911, 1387-1913, 1518-1924, 1575-1909, 1776-1886
38/7483598CB1/1797	1-808, 8-302, 13-417, 14-808, 179-808, 490-808, 491-808, 732-1017, 881-1226, 881-1227, 891-1105, 1157-1429, 1157-1700, 1184-1753, 1184-1760, 1197-1708, 1197-1754, 1197-1755, 1197-1757, 1197-1797, 1198-1757, 1199-1757, 1199-1797, 1200-1754, 1292-1707, 1295-1760, 1324-1759, 1359-1744, 1359-1749, 1359-1760, 1362-1760

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
39/7484823CB1/3277	1-174, 64-1458, 1324-1660, 1326-1458, 1327-1458, 1340-1458, 1458-1660, 1459-1659, 1459-1660, 1459-2936, 1484-1651, 1506-1732, 1683-2339, 1700-2334, 1724-2174, 1724-2423, 1792-2400, 1804-2530, 1822-2278, 1834-2323, 1840-2516, 1878-2430, 1891-2244, 1922-2694, 1926-2592, 1931-2472, 1938-2431, 1940-2458, 1941-2472, 1944-2546, 1956-2566, 1962-2561, 1970-2530, 1976-2515, 1977-2497, 1980-2431, 2012-2660, 2020-2596, 2046-2671, 2049-2576, 2083-2578, 2095-2752, 2095-2763, 2098-2659, 2105-2794, 2114-2787, 2129-2908, 2162-2720, 2163-2689, 2225-3024, 2229-2763, 2241-2925, 2358-3057, 2374-3044, 2444-2930, 2455-3277, 2531-3023, 2557-3140, 2586-3078
40/143935CB1/2773	1-217, 1-462, 1-942, 16-601, 34-217, 39-566, 176-217, 206-667, 217-756, 217-769, 274-800, 288-919, 316-814, 316-956, 328-967, 334-597, 374-939, 377-855, 388-785, 388-930, 389-791, 407-678, 409-1068, 435-1053, 464-1123, 468-723, 475-1045, 524-1016, 527-684, 527-1039, 564-964, 564-1004, 564-1098, 565-896, 574-1137, 598-933, 660-1190, 660-1192, 663-1285, 690-967, 704-1368, 713-1134, 748-1007, 760-1016, 760-1032, 760-1210, 769-1455, 771-1097, 782-1415, 808-1391, 867-1133, 870-1407, 873-1460, 885-1501, 899-1078, 899-1158, 961-1613, 976-1240, 994-1459, 1006-1508, 1014-1386, 1017-1416, 1025-1452, 1044-1307, 1059-1249, 1059-1668, 1085-1705, 1098-1506, 1099-1346, 1099-1401, 1099-1545, 1149-1353, 1157-1592, 1157-1661, 1193-1716, 1202-1431, 1212-1753, 1250-1654, 1268-1570, 1285-1748, 1285-1841, 1285-1851, 1285-1919, 1285-1930, 1285-1945, 1285-1952, 1285-1963, 1285-1965, 1285-1979, 1292-1886, 1300-1453, 1305-1577, 1310-1858, 1316-1530, 1317-1569, 1317-1872, 1317-1915, 1353-1865, 1356-1488, 1372-1714, 1416-2049, 1421-1709, 1430-1847, 1437-1742, 1441-1991, 1500-1747, 1505-2163, 1515-1815, 1515-1911, 1538-2068, 1556-1827, 1560-1954, 1572-1793, 1573-1837, 1580-2192, 1585-2093, 1601-1839, 1601-1840, 1618-2132, 1632-1887, 1651-1754, 1686-1934, 1686-1950, 1686-1965, 1686-2298, 1688-1978, 1689-1955, 1734-2319, 1743-2254, 1743-2377, 1749-2032, 1755-1996, 1755-2346, 1762-2492, 1763-2071, 1774-2011, 1784-2152, 1795-2063, 1795-2066, 1797-2299, 1819-2416, 1826-2091, 1827-2517, 1829-2490, 1829-2508, 1839-2076, 1842-2348, 1868-2396, 1868-2421, 1873-2459, 1875-2415, 1877-2145, 1878-2563, 1880-2052, 1880-2415, 1880-2467, 1880-2470, 1897-2131, 1907-2180, 1908-2168, 1917-2209, 1919-2386, 1919-2470, 1922-2470, 1923-2179, 1936-2195, 1937-2180, 1941-2267, 1944-2627, 1945-2556, 1965-2538, 1980-2269, 1982-2504, 1983-2560, 2001-2303, 2005-2567, 2012-2470, 2021-2569, 2027-2289, 2027-2303, 2027-2487, 2039-2531, 2048-2277, 2058-2293, 2089-2569, 2095-2559, 2096-2559, 2104-2561, 2108-2580, 2110-2564, 2113-2559, 2115-2669, 2116-2564, 2117-2561, 2120-2422, 2122-2577, 2128-2439, 2129-2580, 2143-2559, 2145-2670, 2146-2561, 2151-2453, 2152-2559, 2153-2401, 2153-2572, 2154-2562, 2156-2580, 2168-2438, 2168-2550, 2169-2559, 2171-2563, 2188-2405, 2188-2559, 2196-2773, 2204-2472, 2220-2455, 2222-2559, 2230-2538, 2233-2471, 2233-2502, 2233-2773, 2235-2567, 2237-2572, 2243-2536, 2251-2564, 2279-2529, 2279-2543, 2296-2559, 2296-2773, 2299-2561, 2323-2630, 2332-2567, 2333-2621, 2346-2562

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
41/5923789CB1/2966	1-1985, 1337-1980, 1564-2177, 1960-2223, 1960-2460, 1960-2503, 1960-2510, 1960-2622, 1973-2554, 2029-2390, 2087-2410, 2087-2686, 2087-2838, 2139-2966, 2161-2348, 2193-2420, 2205-2412, 2216-2420, 2227-2838, 2233-2838, 2271-2838, 2306-2833, 2314-2778, 2327-2838, 2337-2838, 2339-2838, 2355-2767, 2355-2838, 2377-2838, 2378-2838, 2396-2575
42/6046484CB1/4404	1-966, 355-1040, 456-1274, 477-1118, 520-1325, 722-1557, 817-1375, 859-1564, 940-1040, 1025-1441, 1165-1850, 1198-1314, 1314-1850, 1413-1850, 1417-4404, 1444-1850
43/7481427CB1/669	1-669
44/7483595CB1/1823	1-351, 309-664, 348-668, 541-1059, 817-889, 988-1355, 1060-1248, 1060-1663, 1277-1663, 1354-1411, 1354-1577, 1354-1636, 1355-1823
45/3788427CB1/2931	1-1173, 428-1018, 432-983, 463-733, 497-793, 649-1173, 707-1128, 771-1417, 842-1065, 975-1512, 1056-1310, 1056-1604, 1056-1746, 1056-1771, 1099-1681, 1114-1696, 1133-1562, 1197-1817, 1309-1798, 1343-1972, 1344-1884, 1363-1652, 1363-1912, 1364-1978, 1371-1910, 1392-2005, 1396-1803, 1410-1943, 1419-2005, 1498-2167, 1502-1723, 1537-2239, 1547-1822, 1548-1975, 1551-2230, 1558-2210, 1561-2168, 1569-2279, 1570-2232, 1591-2280, 1596-2135, 1602-1879, 1617-2134, 1620-2322, 1670-2289, 1706-2210, 1714-1926, 1755-2450, 1773-2391, 1786-2373, 1805-2270, 1821-2067, 1890-2464, 1968-2608, 1979-2567, 2127-2446, 2161-2439, 2230-2425, 2230-2677, 2230-2722, 2230-2752, 2230-2821, 2245-2512, 2247-2378, 2247-2419, 2247-2838, 2275-2558, 2276-2822, 2314-2585, 2352-2630, 2394-2863, 2446-2930, 2466-2733, 2486-2734, 2490-2770, 2578-2822, 2599-2834, 2603-2861, 2618-2891, 2628-2931
46/6972455CB1/1492	1-447, 1-576, 1-620, 1-622, 1-649, 255-890, 289-944, 496-1098, 670-1452, 772-1234, 856-1492, 876-1492, 907-1244, 933-1492, 1009-1492, 1061-1492
47/8077668CB1/2406	1-429, 108-429, 331-428, 331-652, 425-934, 430-768, 771-1250, 771-1254, 1212-1343, 1212-1573, 1321-1817, 1374-1664, 1750-2406, 1764-2198
48/55120485CB1/3686	1-63, 9-302, 9-397, 9-484, 9-565, 9-586, 9-628, 9-632, 9-635, 60-301, 60-304, 60-597, 64-238, 186-742, 226-730, 284-784, 335-779, 623-1272, 689-1272, 739-1272, 762-1272, 800-1204, 802-1273, 826-1272, 884-1272, 900-1272, 982-1915, 988-1272, 1024-1272, 1047-1272, 1104-1272, 1107-1272, 1160-1272, 1232-1272, 1262-1675, 1273-1653, 1273-1675, 1322-1675, 1323-1675, 1591-1675, 1634-1918, 1635-1918, 1674-2808, 1675-1918, 1675-2525, 2157-2256, 2526-2764, 2526-2928, 2526-2962, 2557-3036, 2644-2892, 2658-3194, 2664-2790, 2664-2909, 2672-2790, 2874-3078, 2888-3292, 2916-3215, 2916-3530, 2937-3614, 2950-3102, 3000-3665, 3007-3664, 3019-3093, 3090-3349, 3110-3673, 3399-3673, 3419-3681, 3476-3686

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
49/3112883CB1/2807	1-346, 20-455, 23-481, 32-509, 39-710, 83-240, 149-240, 170-281, 170-436, 170-440, 170-661, 170-697, 170-700, 170-725, 170-728, 170-729, 170-737, 170-784, 170-857, 175-705, 216-342, 235-394, 317-704, 408-1134, 428-569, 442-834, 458-1060, 472-912, 547-1270, 575-1134, 583-1254, 586-1204, 595-1258, 652-1234, 656-1231, 662-1226, 676-943, 676-1287, 698-1388, 701-968, 707-992, 707-1098, 762-1077, 762-1309, 765-1335, 788-1403, 798-1366, 805-1032, 816-1391, 825-1415, 843-1421, 857-1367, 866-1448, 930-1331, 936-1539, 946-1551, 947-1206, 949-1476, 1054-1469, 1074-1638, 1089-1638, 1129-1533, 1220-1571, 1232-1810, 1283-1529, 1325-1533, 1445-1674, 1481-2085, 1506-1764, 1515-2092, 1518-2142, 1530-1810, 1531-2141, 1552-2154, 1650-1908, 1650-2149, 1688-1961, 1731-2154, 1749-1984, 1808-2155, 1818-1960, 1838-2155, 2078-2807, 2108-2155, 2198-2426, 2296-2426, 2423-2575, 2423-2578, 2423-2583, 2423-2587, 2423-2625, 2423-2701, 2423-2742, 2423-2769, 2431-2561, 2444-2627, 2444-2769, 2484-2769, 2499-2720, 2499-2769, 2502-2769, 2510-2769, 2516-2571, 2538-2769, 2546-2769, 2552-2769, 2578-2769, 2602-2769, 2611-2769, 2615-2769, 2625-2769
50/4253888CB1/2170	1-629, 105-746, 105-783, 106-600, 676-887, 676-1004, 715-1004, 825-936, 868-1104, 885-1482, 931-1612, 943-1612, 1112-1612, 1125-1348, 1125-1700, 1513-1988, 1532-1596, 1588-2038, 1596-2036, 1661-1893, 1813-2158, 1826-2058, 1826-2146, 1827-2073, 1827-2170, 1904-2162
51/7479974CB1/1722	1-1722, 251-1712
52/7483850CB1/1424	1-283, 1-533, 1-569, 1-578, 1-582, 1-583, 1-584, 5-584, 27-584, 59-285, 61-285, 64-285, 84-285, 139-283, 140-283, 284-334, 284-347, 284-369, 284-403, 284-412, 284-431, 530-659, 594-1248, 594-1320, 594-1321, 594-1335, 594-1424, 599-1042
53/5508353CB1/3598	1-250, 12-553, 12-673, 12-704, 49-248, 49-568, 356-920, 356-929, 482-1038, 767-1173, 767-1201, 771-1247, 789-1080, 810-1477, 958-1217, 958-1486, 1010-1393, 1207-1393, 1348-1891, 1389-1776, 1399-2116, 1431-2008, 1434-2085, 1465-1961, 1682-2144, 1745-2115, 1783-1949, 1783-2318, 1792-1874, 1792-2229, 1833-2070, 1855-2127, 1855-2149, 1855-2185, 1855-2341, 1855-2432, 1958-2588, 1979-2104, 1979-2169, 2033-2712, 2064-2515, 2076-2331, 2177-2441, 2177-2708, 2238-2501, 2243-2883, 2245-2513, 2264-2537, 2301-2555, 2328-2636, 2363-2883, 2367-2906, 2381-2671, 2384-2626, 2384-2849, 2551-2763, 2551-2866, 2551-3054, 2713-2995, 2764-3247, 2799-3041, 2805-3598, 2819-3093, 2832-3264, 2841-3094
54/8543628CB1/1485	1-501, 1-502, 1-525, 1-563, 1-573, 1-580, 1-622, 1-751, 1-782, 1-812, 2-929, 11-37, 30-749, 33-854, 46-929, 65-788, 93-906, 144-883, 231-936, 261-1072, 491-1485, 509-1035
55/7482754CB1/1470	1-817, 73-267, 145-1266, 155-767, 631-734, 631-742, 641-1470, 713-766, 713-767, 793-1055, 908-1055, 908-1143, 1056-1143, 1056-1265, 1144-1265
56/3794818CB1/3132	1-2052, 1021-2199, 2071-3132, 2467-2702, 2555-2792, 2632-2702, 2722-2867

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
57/4717525CB1/1832	1-447, 69-292, 69-442, 69-460, 69-504, 69-506, 69-534, 69-625, 69-643, 69-675, 69-686, 69-693, 69-703, 69-705, 69-706, 69-732, 69-738, 80-434, 81-606, 83-464, 87-447, 147-1059, 157-413, 157-475, 181-443, 181-570, 187-802, 199-440, 210-537, 210-640, 237-535, 246-841, 255-517, 255-890, 300-830, 301-774, 327-990, 358-889, 377-1018, 379-671, 439-1025, 443-781, 445-997, 455-1059, 469-1060, 528-1013, 539-1059, 541-1048, 558-1059, 566-1003, 583-1059, 585-1059, 597-882, 599-1014, 619-864, 635-1059, 656-1059, 673-1059, 677-1059, 691-924, 692-1059, 711-1059, 717-1059, 720-1059, 728-1010, 735-1059, 741-1069, 760-1059, 765-1059, 779-1059, 794-1059, 796-1059, 805-1049, 814-1373, 821-941, 850-1059, 858-1069, 862-1059, 876-1059, 881-1059, 889-1059, 905-1049, 915-1059, 916-1059, 918-1059, 931-1059, 935-1059, 949-1046, 959-1059, 967-1059, 975-1059, 981-1049, 987-1059, 1002-1059, 1006-1059, 1008-1059, 1010-1382, 1015-1059, 1019-1059, 1047-1076, 1047-1093, 1047-1114, 1047-1139, 1047-1169, 1047-1173, 1047-1180, 1047-1184, 1047-1191, 1047-1198, 1047-1200, 1047-1206, 1047-1262, 1047-1269, 1047-1290, 1047-1305, 1047-1334, 1047-1335, 1047-1353, 1047-1381, 1047-1382, 1047-1383, 1049-1382, 1053-1200, 1058-1382, 1063-1315, 1110-1381, 1128-1366, 1317-1832, 1478-1718, 1478-1811, 1482-1567
58/5091793CB1/1902	1-248, 1-544, 1-547, 1-567, 1-598, 1-648, 1-691, 1-720, 1-732, 1-737, 1-752, 1-796, 1-816, 1-833, 13-572, 48-884, 71-486, 71-550, 81-267, 82-549, 113-380, 113-549, 118-514, 127-558, 134-267, 159-986, 176-446, 265-528, 292-578, 375-663, 427-646, 593-879, 645-832, 645-884, 645-1125, 645-1149, 645-1164, 645-1233, 687-808, 769-1108, 806-1047, 806-1271, 806-1353, 807-974, 807-1318, 815-1109, 819-1004, 821-1461, 941-1108, 952-1641, 1041-1108, 1168-1561, 1213-1695, 1213-1742, 1215-1742, 1231-1742, 1233-1742, 1246-1878, 1250-1738, 1257-1614, 1315-1727, 1318-1847, 1349-1742, 1392-1902, 1411-1707, 1422-1742, 1426-1742, 1427-1742, 1438-1742, 1442-1742, 1458-1562, 1458-1628, 1458-1630, 1458-1633, 1458-1666, 1458-1680, 1458-1683, 1458-1693, 1458-1697, 1458-1742, 1476-1742, 1504-1902, 1511-1742, 1565-1742, 1576-1742
59/5945527CB1/2820	1-332, 1-444, 25-450, 31-538, 213-693, 347-617, 451-749, 451-1061, 785-1155, 792-1095, 895-942, 942-1056, 942-1096, 1033-1104, 1033-1199, 1044-1315, 1181-1275, 1181-1423, 1256-1526, 1280-1477, 1280-1905, 1389-1625, 1546-1821, 1546-2082, 1547-1589, 1547-1590, 1547-1611, 1547-1644, 1547-1669, 1547-1680, 1547-1681, 1547-1698, 1547-1717, 1547-1720, 1547-1724, 1547-1734, 1547-1757, 1547-1775, 1547-1776, 1547-1844, 1547-1867, 1547-1912, 1547-1957, 1547-2007, 1547-2042, 1547-2055, 1547-2071, 1547-2269, 1560-1840, 1627-2238, 1648-2068, 1656-1920, 1661-2365, 1667-2189, 1675-2354, 1698-2330, 1761-2039, 1776-2056, 1778-2037, 1778-2238, 1793-2339, 1814-2063, 1822-2494, 1837-2466, 1856-2516, 1868-2572, 1881-2465, 1990-2655, 1995-2567, 2050-2498, 2069-2668, 2134-2660, 2187-2507, 2187-2820, 2220-2820, 2222-2497, 2226-2492, 2240-2668, 2264-2668, 2271-2536, 2316-2668, 2384-2820, 2395-2654, 2395-2676, 2398-2668, 2401-2556, 2410-2558, 2745-2811, 2747-2820

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
60/6941124CB1/3920	1-552, 54-555, 384-722, 455-729, 548-1246, 726-938, 728-1114, 1033-1856, 1203-1438, 1203-1630, 1203-1701, 1260-1857, 1374-1642, 1414-1642, 1502-1642, 1615-2327, 1642-1992, 1642-2002, 1672-2155, 1672-2262, 1673-2328, 1673-2342, 1875-2328, 1932-2328, 1976-2483, 2070-2653, 2086-2328, 2169-2324, 2211-2328, 2296-2323, 2378-2625, 2378-2749, 2378-2816, 2378-2853, 2378-2866, 2378-2879, 2378-2882, 2378-2887, 2378-2908, 2378-2957, 2378-2964, 2378-2970, 2378-2971, 2378-2986, 2378-3019, 2378-3084, 2378-3087, 2378-3095, 2378-3136, 2378-3168, 2379-2852, 2400-3107, 2403-2520, 2403-2647, 2457-3035, 2474-3042, 2494-3206, 2512-3231, 2519-3086, 2521-2983, 2600-3107, 2600-3348, 2612-3344, 2631-3070, 2635-3311, 2663-3259, 2663-3415, 2758-3371, 2786-3425, 2787-2932, 2787-3205, 2793-3341, 2796-3360, 2824-3517, 2833-3458, 2852-3443, 2853-3373, 2856-3465, 2870-3494, 2881-3570, 2888-3404, 2888-3466, 2900-3526, 2907-3255, 2911-3421, 2911-3470, 2911-3479, 2912-3614, 2929-3314, 2938-3443, 2942-3443, 2954-3472, 2967-3537, 2989-3602, 3001-3247, 3004-3717, 3006-3704, 3014-3090, 3049-3536, 3058-3795, 3073-3813, 3078-3670, 3078-3807, 3094-3833, 3096-3785, 3100-3833, 3119-3833, 3168-3417, 3168-3575, 3168-3596, 3168-3838, 3168-3892, 3168-3919, 3169-3443, 3195-3833, 3220-3724, 3229-3856, 3230-3804, 3251-3549, 3254-3506, 3257-3801, 3260-3814, 3288-3832, 3289-3592, 3316-3833, 3333-3832, 3340-3833, 3348-3833, 3363-3840, 3391-3897, 3400-3833, 3402-3653, 3402-3831, 3402-3832, 3409-3839, 3427-3830, 3427-3833, 3449-3720, 3464-3920, 3468-3783, 3477-3761, 3479-3727, 3479-3885, 3479-3920, 3500-3747, 3508-3733, 3521-3760, 3523-3910, 3530-3871, 3550-3690, 3581-3920, 3678-3910, 3701-3918, 3720-3906, 3746-3920, 3747-3894, 3747-3920, 3763-3910, 3786-3920, 3828-3920
61/6972530CB1/1333	1-549, 1-566, 391-966, 421-966, 711-1333
62/6991750CB1/8487	1-724, 32-456, 52-627, 78-723, 105-694, 135-592, 135-637, 143-723, 172-683, 175-420, 175-469, 175-496, 175-500, 175-541, 175-684, 175-764, 175-767, 175-784, 175-918, 187-677, 222-918, 254-723, 258-918, 305-918, 310-720, 358-918, 370-723, 386-918, 432-674, 432-918, 487-918, 847-1242, 847-1290, 895-1285, 896-3353, 917-1415, 917-1416, 917-1417, 920-1414, 1232-1739, 1232-1740, 1233-1739, 1236-1739, 1254-1898, 1266-1739, 1290-1834, 1290-1861, 1290-1868, 1581-2120, 1581-2121, 1584-2121, 1587-2121, 1950-2121, 2085-2762, 2088-2762, 2089-2762, 2090-2744, 2090-2754, 2090-2756, 2090-2758, 2090-2762, 2094-2762, 2152-2938, 2248-2900, 2269-2797, 2269-2949, 2993-3677, 3458-4151, 3585-8102, 3887-4151, 3931-4242, 4024-4540, 4024-4650, 4024-4651, 4027-4643, 4027-4648, 4027-4650, 4027-4651, 4903-5354, 4903-5386, 4903-5433, 4903-5483, 4903-5507, 4903-5517, 4903-5525, 4903-5534, 4903-5548, 4903-5553, 4903-5561, 4903-5567, 4903-5574, 5176-5434, 5340-6117, 5356-6117, 5364-6113, 5368-6117, 5393-6117, 5404-6117, 5409-6117, 5410-6117, 5417-6117, 5432-6117, 5434-6117, 5439-6117, 5449-6117, 6257-6768, 6398-6543, 6961-7140, 7135-7747, 7140-7955,

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
62	7508-7900, 7614-8041, 7615-8102, 7843-8102, 7843-8209, 7843-8227, 7843-8236, 7843-8241, 7843-8262, 7843-8280, 7843-8341, 7843-8389, 7843-8430, 7843-8455, 7843-8465, 7843-8485, 7843-8486, 7843-8487
63/71726948CBI/3264	1-486, 4-441, 23-504, 24-504, 253-457, 286-504, 339-860, 355-823, 502-743, 502-1025, 550-856, 574-1259, 784-1237, 1104-1359, 1104-1362, 1104-1639, 1104-1654, 1104-1812, 1116-1681, 1360-1860, 1365-1834, 1366-1834, 1369-1881, 1419-2213, 1424-1890, 1523-2245, 1562-2184, 1724-2515, 1819-2533, 1858-2430, 1888-2228, 1888-2456, 1906-2469, 1931-2199, 1933-2190, 1991-2644, 1993-2507, 2008-2693, 2036-2682, 2046-2496, 2057-2684, 2172-2809, 2173-2809, 2181-2809, 2268-2813, 2271-2813, 2301-2809, 2312-3014, 2328-2953, 2351-2751, 2397-3204, 2397-3261, 2404-2835, 2406-2835, 2444-3013, 2449-2716, 2466-3075, 2492-2960, 2536-3140, 2549-3201, 2574-3173, 2582-2743, 2609-2975, 2762-3237, 2807-3250, 2813-3244, 2852-3060, 3000-3249, 3113-3256, 3113-3264, 3114-3261
64/7487393CBI/1659	1-402, 1-1659, 307-506, 416-506, 547-860, 547-863, 547-867, 1147-1598

Table 5

Polynucleotide SEQ ID NO:	Incyte Project ID:	Representative Library
33	7484831CB1	LIVRNON08
34	2477266CB1	LIVRNON08
35	3552033CB1	BRAHTDK01
36	4778139CB1	PROSTUS19
37	4787433CB1	PGANNOT01
38	7483598CB1	BRAITUT29
39	7484823CB1	TESTNOC01
40	143935CB1	BRACDIK08
41	5923789CB1	BRAIFET02
42	6046484CB1	BRACNOK02
44	7483595CB1	TESTNOC01
45	3788427CB1	BONEUNR01
46	6972455CB1	BMARUNR02
47	8077668CB1	ADRETUE02
48	55120485CB1	BRAITUT29
49	3112883CB1	BRSTNOT03
50	4253888CB1	ADRETUE02
52	7483850CB1	LIVRDIT06
53	5508353CB1	NERDITDN03
54	8543628CB1	BMARUNR02
55	7482754CB1	PTHYTMN05
56	3794818CB1	KIDEUNE02
57	4717525CB1	KIDEUNE02
58	5091793CB1	LUNGTUT08
59	5945527CB1	SINTNOR01
60	6941124CB1	FTUBTUR01
61	6972530CB1	BMARUNR02
62	6991750CB1	BRAIFER06
63	71726948CB1	KIDNNOT32

Table 6

Library	Vector	Library Description
ADRETUE02	PCDNA2.1	This 5' biased random primed library was constructed using RNA isolated from right adrenal tumor tissue removed from a 49-year-old Caucasian male during unilateral adrenalectomy. Pathology indicated adrenal cortical carcinoma comprising nearly the entire specimen. The tumor was attached to the adrenal gland which showed mild cortical atrophy. The tumor was encapsulated, being surrounded by a thin (1-3 mm) rim of connective tissue. The patient presented with adrenal cancer, abdominal pain, pyrexia of unknown origin, and deficiency anemia. Patient history included benign hypertension. Previous surgeries included adenotonsillectomy. Patient medications included aspirin, calcium, and iron. Family history included atherosclerotic coronary artery disease in the mother; cerebrovascular accident and atherosclerotic coronary artery disease in the father; and benign hypertension in the grandparent(s).
BMARUNR02	P1GEN	This random primed library was constructed using RNA isolated from an untreated SH-SY5Y cell line derived from bone marrow neuroblastoma tumor cells removed from a 4-year-old Caucasian female.
BONEUNR01	PCDNA2.1	This random primed library was constructed using pooled cDNA from two different donors. cDNA was generated using mRNA isolated from an untreated MG-63 cell line derived from an osteosarcoma tumor removed from a 14-year-old Caucasian male (donor A) and using mRNA isolated from sacral bone tumor tissue removed from an 18-year-old Caucasian female (donor B) during an exploratory laparotomy and soft tissue excision. Pathology indicated giant cell tumor of the sacrum in donor B. Donor B's history included pelvic joint pain, constipation, urinary incontinence, unspecified abdominal/pelvic symptoms, and a pelvic soft tissue malignant neoplasm. Family history included prostate cancer in donor B.
BRACDIK08	PSPORT1	This amplified and normalized library was constructed using RNA isolated from diseased corpus callosum tissue removed from the brain of a 57-year-old Caucasian male who died from a cerebrovascular accident. Serologies were negative. Patient history included Huntington's disease, emphysema, and tobacco abuse (3-4 packs per day for 40 years).

Table 6

Library	Vector	Library Description
BRAFNOK02	PSPORT1	This amplified and normalized library was constructed using RNA isolated from posterior cingulate tissue removed from an 85-year-old Caucasian female who died from myocardial infarction and retroperitoneal hemorrhage. Pathology indicated atherosclerosis, moderate to severe, involving the circle of Willis, middle cerebral, basilar and vertebral arteries; infarction, remote, left dentate nucleus; and amyloid plaque deposition consistent with age. There was mild to moderate leptomeningeal fibrosis, especially over the convexity of the frontal lobe. There was mild generalized atrophy involving all lobes. The white matter was mildly thinned. Cortical thickness in the temporal lobes, both maximal and minimal, was slightly reduced. The substantia nigra pars compacta appeared mildly depigmented. Patient history included COPD, hypertension, and recurrent deep venous thrombosis. 6.4 million independent clones from this amplified library were normalized in one round using conditions adapted from Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research 6 (1996):791.
BRAHTDK01	PSPORT1	This amplified and normalized library was constructed using pooled RNA isolated from archaocortex, anterior and posterior hippocampus tissue removed from a 55-year-old Caucasian female who died from cholangiocarcinoma. Pathology indicated mild meningeal fibrosis predominately over the convexities, scattered axonal spheroids in the white matter of the cingulate cortex and the thalamus, and a few scattered neurofibrillary tangles in the entorhinal cortex and the periaqueductal gray region. Pathology for the associated tumor tissue indicated well-differentiated cholangiocarcinoma of the liver with residual or relapsed tumor. Patient history included cholangiocarcinoma, post-operative Budd-Chiari syndrome, biliary ascites, hydrothorax, dehydration, malnutrition, oliguria and acute renal failure. Previous surgeries included cholecystectomy and resection of 85% of the liver. 7.6x10 ⁵ independent clones from this amplified library were normalized in 1 round using conditions adapted Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research (1996) 6:791, except that a significantly longer (48 hours/round) reannealing hybridization was used.
BRAIFER06	PCDNA2.1	This random primed library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus who was stillborn with a hypoplastic left heart at 23 weeks' gestation. Serologies were negative.
BRAIFET02	pINCY	Library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus, who was stillborn with a hypoplastic left heart at 23 weeks' gestation.
BRAITUT29	pINCY	Library was constructed using RNA isolated from brain tumor tissue removed from the parietal lobe of a 43-year-old female during excision of a cerebral meningeal lesion. Pathology indicated high grade glioma. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, benign hypertension, and hyperlipidemia.

Table 6

Library	Vector	Library Description
BRSTNOT03	PSPORT1	Library was constructed using RNA isolated from diseased breast tissue removed from a 54-year-old Caucasian female during a bilateral radical mastectomy. Pathology for the associated tumor tissue indicated residual invasive grade 3 mammary ductal adenocarcinoma. Patient history included kidney infection and condyloma acuminatum. Family history included benign hypertension, hyperlipidemia and a malignant neoplasm of the colon.
FTUBTUR01	PCDNA2.1	This random primed library was constructed using RNA isolated from fallopian tube tumor tissue removed from an 85-year-old Caucasian female during bilateral salpingo-oophorectomy and hysterectomy. Pathology indicated poorly differentiated mixed endometrioid (80%) and serous (20%) adenocarcinoma, which was confined to the mucosa without mural involvement. Endometrioid carcinoma in situ was also present. Pathology for the associated uterus tumor indicated focal endometrioid adenocarcinoma in situ and moderately differentiated invasive adenocarcinoma arising in an endometrial polyp. Metastatic endometrioid and serous adenocarcinoma was present at the cul-de-sac tumor. Patient history included medullary carcinoma of the thyroid and myocardial infarction.
KIDUNE02	pINCY	This 5' biased random primed library was constructed using RNA isolated from an untreated transformed embryonal cell line (293-EBNA) derived from kidney epithelial tissue (Invitrogen). The cells were transformed with adenovirus 5 DNA.
KIDNNOT32	pINCY	Library was constructed using RNA isolated from kidney tissue removed from a 49-year-old Caucasian male who died from an intracranial hemorrhage and cerebrovascular accident. Patient history included tobacco abuse.
LIVRDI06	pINCY	This library was constructed using RNA isolated from diseased liver tissue removed from a 35-year-old Caucasian male during needle biopsy of the liver. Patient history included hepatitis C.
LIVRNON08	pINCY	This normalized library was constructed from 5.7 million independent clones from a pooled liver tissue library. Starting RNA was made from pooled liver tissue removed from a 4-year-old Hispanic male who died from anoxia and a 16 week female fetus who died after 16-weeks gestation from anencephaly. Serologies were positive for cytomegalovirus in the 4-year-old. Patient history included asthma in the 4-year-old. Family history included taking daily prenatal vitamins and mitral valve prolapse in the mother of the fetus. The library was normalized in 2 rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228 and Bonaldo et al., Genome Research 6 (1996):791, except that a significantly longer (48 hours/round) reannealing hybridization was used.

Table 6

Library	Vector	Library Description
LUNGTUT08	pINCY	Library was constructed using RNA isolated from lung tumor tissue removed from a 63-year-old Caucasian male during a right upper lobectomy with fiberoptic bronchoscopy. Pathology indicated a grade 3 adenocarcinoma. Patient history included atherosclerotic coronary artery disease, an acute myocardial infarction, rectal cancer, an asymptomatic abdominal aortic aneurysm, tobacco abuse, and cardiac dysrhythmia. Family history included congestive heart failure, stomach cancer, and lung cancer, type II diabetes, atherosclerotic coronary artery disease, and an acute myocardial infarction.
NERDND03	pINCY	This normalized dorsal root ganglion tissue library was constructed from 1.05 million independent clones from a dorsal root ganglion tissue library. Starting RNA was made from dorsal root ganglion tissue removed from the cervical spine of a 32-year-old Caucasian male who died from acute pulmonary edema, acute bronchopneumonia, bilateral pleural effusions, pericardial effusion, and malignant lymphoma (natural killer cell type). The patient presented with pyrexia of unknown origin, malaise, fatigue, and gastrointestinal bleeding. Patient history included probable cytomegalovirus infection, liver congestion, and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, respiratory failure, pneumonia of the left lung, natural killer cell lymphoma of the pharynx, Bell's palsy, and tobacco and alcohol abuse. Previous surgeries included colonoscopy, closed colon biopsy, adenotomylectomy, and nasopharyngeal endoscopy and biopsy. Patient medications included Diflucan (fluconazole), Deltasone (prednisone), hydrocodone, Lortab, Alprazolam,
PGANNOT01	PSPORT1	Reazodone, ProMace-Cytobom, Etoposide, Cisplatin, Cytarabine, and dexamethasone. The patient received radiation therapy and multiple blood transfusions. The library was normalized in 2 rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research 6 (1996):791, except that a significantly longer (48 hours/round) reannealing hybridization was used. Library was constructed using RNA isolated from paraganglionic tumor tissue removed from the intra-abdominal region of a 46-year-old Caucasian male during exploratory laparotomy. Pathology indicated a benign paraganglioma and was associated with a grade 2 renal cell carcinoma, clear cell type, which did not penetrate the capsule. Surgical margins were negative for tumor.

Table 6

Library	Vector	Library Description
PROSTUS19	pINCY	This subtracted prostate tumor tissue library was constructed using 2.36 million clones from the PROSTUT13 library and was subjected to two round soft subtraction hybridization with 2.36 million clones from EPIPNOT01 library. The starting library for subtraction was constructed using RNA isolated from prostate tumor tissue removed from a 59-year-old Caucasian male during a radical prostatectomy with regional lymph node excision. Pathology indicated adenocarcinoma (Gleason grade 3+3) involving the prostate peripherally with invasion of the capsule. Adenofibromatous hyperplasia was present. The patient presented with elevated prostate-specific antigen (PSA). Patient history included diverticulitis of colon, asbestosis, and thrombophlebitis. Family history included benign hypertension, multiple myeloma, hyperlipidemia, and rheumatoid arthritis. Subtractive hybridization conditions were based on the methodologies of Swaroop et al., NAR (1991) 19:1954 and Bonaldo, et al. Genome Research (1996) 6:791.
PTHYTMN05	pINCY	Library was constructed using RNA isolated from parathyroid tissue removed from a 44-year-old Caucasian male during a partial parathyroidectomy. Pathology for the matched tumor tissue indicated parathyroid carcinoma (grade 1 of 4) forming a partially cystic tan mass. Both capsular and vascular invasion were present. The patient presented with unspecified parathyroid disorder and calcium metabolism disorder. Patient history included kidney calculus and obesity. Previous surgeries included vasectomy and parathyroid surgery. Family history included emphysema in the mother; type II diabetes in the father; and type I diabetes and hyperlipidemia in the sibling(s).
SINTNOR01	PCDNA2.1	This random primed library was constructed using RNA isolated from small intestine tissue removed from a 31-year-old Caucasian female during Roux-en-Y gastric bypass. Patient history included clinical obesity.
TESTNOC01	PBLUESCRIPT	This large size fractionated library was constructed using RNA isolated from testicular tissue removed from a pool of eleven, 10 to 61-year-old Caucasian males.

Table 7

Program	Description	Reference	Parameter Threshold
ABI/FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI/AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLOCKS IMPROVED Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1998) Nucleic Acids Res. 26:320-322; Durbin, R. et al. (1998) Our World View, in a Nutsell, Cambridge Univ. Press, pp. 1-350.	PFAM hits: Probability value= 1.0E-3 or less Signal peptide hits: Score= 0 or greater

Table 7 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribkov, M. et al. (1988) CABIOS 4:61-66; Gribkov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score \geq GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater, Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. Conf. on Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182.	
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:

- 5
- a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32,
 - b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-32,
 - 10 c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, and
 - d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-32.

15 2. An isolated polypeptide of claim 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32.

3. An isolated polynucleotide encoding a polypeptide of claim 1.

20 4. An isolated polynucleotide encoding a polypeptide of claim 2.

5. An isolated polynucleotide of claim 4 comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64.

25 6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

7. A cell transformed with a recombinant polynucleotide of claim 6.

30 8. A transgenic organism comprising a recombinant polynucleotide of claim 6.

9. A method of producing a polypeptide of claim 1, the method comprising:

- 35
- a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and

b) recovering the polypeptide so expressed.

10. A method of claim 9, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-32.

5

11. An isolated antibody which specifically binds to a polypeptide of claim 1.

12. An isolated polynucleotide selected from the group consisting of:

10

a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64,

b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:33-64,

15

c) a polynucleotide complementary to a polynucleotide of a),

d) a polynucleotide complementary to a polynucleotide of b), and

e) an RNA equivalent of a)-d).

13. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 12.

20

14. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:

25

a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and

b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

30

15. A method of claim 14, wherein the probe comprises at least 60 contiguous nucleotides.

16. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:

35

a) amplifying said target polynucleotide or fragment thereof using polymerase chain

reaction amplification, and

- b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

5 17. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

18. A composition of claim 17, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-32.

10

19. A method for treating a disease or condition associated with decreased expression of functional TRICH, comprising administering to a patient in need of such treatment the composition of claim 17.

15 20. A method of screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
b) detecting agonist activity in the sample.

20 21. A composition comprising an agonist compound identified by a method of claim 20 and
a pharmaceutically acceptable excipient.

22. A method for treating a disease or condition associated with decreased expression of functional TRICH, comprising administering to a patient in need of such treatment a
25 composition of claim 21.

23. A method of screening a compound for effectiveness as an antagonist of a polypeptide
of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
30 b) detecting antagonist activity in the sample.

24. A composition comprising an antagonist compound identified by a method of claim 23 and a pharmaceutically acceptable excipient.

35 25. A method for treating a disease or condition associated with overexpression of

functional TRICH, comprising administering to a patient in need of such treatment a
composition of claim 24.

26. A method of screening for a compound that specifically binds to the polypeptide of
5 claim 1, the method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under
suitable conditions, and
- b) detecting binding of the polypeptide of claim 1 to the test compound, thereby
identifying a compound that specifically binds to the polypeptide of claim 1.

10

27. A method of screening for a compound that modulates the activity of the polypeptide of
claim 1, the method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under
conditions permissive for the activity of the polypeptide of claim 1,
- 15 b) assessing the activity of the polypeptide of claim 1 in the presence of the test
compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test
compound with the activity of the polypeptide of claim 1 in the absence of the test
compound, wherein a change in the activity of the polypeptide of claim 1 in the
20 presence of the test compound is indicative of a compound that modulates the
activity of the polypeptide of claim 1.

20

28. A method of screening a compound for effectiveness in altering expression of a target
polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the
25 method comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, under
conditions suitable for the expression of the target polynucleotide,
- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying
30 amounts of the compound and in the absence of the compound.

30

29. A method of assessing toxicity of a test compound, the method comprising:

- a) treating a biological sample containing nucleic acids with the test compound,
- b) hybridizing the nucleic acids of the treated biological sample with a probe
35 comprising at least 20 contiguous nucleotides of a polynucleotide of claim 12 under

35

conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 12 or fragment thereof,

- c) quantifying the amount of hybridization complex, and
- d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

30. A diagnostic test for a condition or disease associated with the expression of TRICH in biological sample, the method comprising:

- a) combining the biological sample with an antibody of claim 11, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex, and
- b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

31. The antibody of claim 11, wherein the antibody is:

- a) a chimeric antibody,
- b) a single chain antibody,
- c) a Fab fragment,
- d) a F(ab')₂ fragment, or
- e) a humanized antibody.

32. A composition comprising an antibody of claim 11 and an acceptable excipient.

33. A method of diagnosing a condition or disease associated with the expression of TRICH in a subject, comprising administering to said subject an effective amount of the composition of claim 32.

34. A composition of claim 32, wherein the antibody is labeled.

35. A method of diagnosing a condition or disease associated with the expression of TRICH in a subject, comprising administering to said subject an effective amount of the

composition of claim 34.

36. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- 5 a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibodies from said animal, and
- 10 c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32.

37. A polyclonal antibody produced by a method of claim 36.

15 38. A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.

39. A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- 20 a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-32, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibody producing cells from the animal,
- c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells,
- 25 d) culturing the hybridoma cells, and
- e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32.

30 40. A monoclonal antibody produced by a method of claim 39.

41. A composition comprising the monoclonal antibody of claim 40 and a suitable carrier.

35 42. The antibody of claim 11, wherein the antibody is produced by screening a Fab expression library.

43. The antibody of claim 11, wherein the antibody is produced by screening a recombinant immunoglobulin library.

44. A method of detecting a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32 in a sample, the method comprising:

- a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32 in the sample.

45. A method of purifying a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32 from a sample, the method comprising:

- a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) separating the antibody from the sample and obtaining the purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-32.

46. A microarray wherein at least one element of the microarray is a polynucleotide of claim 13.

47. A method of generating an expression profile of a sample which contains polynucleotides, the method comprising:

- a) labeling the polynucleotides of the sample,
- b) contacting the elements of the microarray of claim 46 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and
- c) quantifying the expression of the polynucleotides in the sample.

48. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, and wherein said target polynucleotide is a polynucleotide of claim 12.

49. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.
- 5 50. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.
- 10 51. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to said target polynucleotide.
52. An array of claim 48, which is a microarray.
- 15 53. An array of claim 48, further comprising said target polynucleotide hybridized to a nucleotide molecule comprising said first oligonucleotide or polynucleotide sequence.
54. An array of claim 48, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.
- 20 55. An array of claim 48, wherein each distinct physical location on the substrate contains multiple nucleotide molecules, and the multiple nucleotide molecules at any single distinct physical location have the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another distinct physical location on the substrate.
- 25 56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.
57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.
- 30 58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.
59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.
- 35 60. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.

61. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.

62. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.

5 63. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.

64. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.

10 65. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.

66. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.

67. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.

15 68. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.

69. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.

20 70. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.

71. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:16.

72. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:17.

25 73. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:18.

74. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:19.

30 75. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:20.

76. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:21.

77. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:22.

35 78. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:23.

79. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:24.
80. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:25.
- 5 81. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:26.
82. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:27.
83. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:28.
- 10 84. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:29.
85. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:30.
- 15 86. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:31.
87. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:32.
88. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
20 NO:33.
89. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:34.
- 25 90. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:35.
91. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:36.
- 30 92. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:37.
93. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
35 NO:38.

94. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:39.

5 95. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:40.

96. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:41.

10 97. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:42.

98. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:43.

15 99. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:44.

20 100. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:45.

101. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:46.

25 102. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:47.

103. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:48.

30 104. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:49.

35 105. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:50.

106. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:51.

5

107. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:52.

108. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:53.

10

109. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:54.

110. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:55.

15

111. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:56.

20

112. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:57.

113. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:58.

25

114. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:59.

115. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:60.

30

116. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:61.

35

117. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:62.

118. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:63.

119. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:64.

5

<110> INCYTE GENOMICS, INC.
 LEE, Ernestine A.
 BAUGHN, Mariah R.
 YUE, Henry
 DING, Li
 RAUMANN, Brigitte E.
 HAFALIA, April J.A.
 KHAN, Farrah A.
 NGUYEN, Danniel B.
 ELLIOTT, Vicki S.
 RAMKUMAR, Jayalaxmi
 WALIA, Narinder K.
 ISON, Craig H.
 LU, Yan
 GANDHI, Ameena R.
 WARREN, Bridget A.
 DUGGAN, Brendan M.
 TRIBOULEY, Catherine M.
 BURFORD, Neil
 LU, Dyung Aina M.
 LAL, Preeti
 YAO, Monique G.
 XU, Yuming
 BRUNS, Christopher M.
 THANGAVELU, Kavitha
 SWARNAKAR, Anita
 TANG, Y. Tom
 AZIMZAI, Yalda
 THORNTON, Michael
 ARVIZU, Chandra
 POLICKY, Jennifer L.

<120> TRANSPORTERS AND ION CHANNELS

<130> PI-0314 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/254,303; 60/256,190; 60/257,504; 60/261,546; 60/262,832;
 60/264,377; 60/266,019

<151> 2000-12-08; 2000-12-15; 2000-12-21; 2001-01-12; 2001-01-19;
 2001-01-26; 2000-02-02

<160> 64

<170> PERL Program

<210> 1

<211> 726

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7484831CD1

<400> 1

Met	Glu	Pro	Gly	Asp	Ala	Ala	Arg	Pro	Gly	Ser	Gly	Arg	Ala	Thr
1				5					10					15
Gly	Ala	Pro	Pro	Pro	Arg	Leu	Leu	Leu	Leu	Pro	Leu	Leu	Leu	Gly
				20					25					30
Trp	Gly	Leu	Arg	Val	Ala	Ala	Ala	Ala	Ser	Ala	Ser	Ser	Ser	Gly

Ala	Ala	Ala	Glu	Asp	Ser	Ser	Ala	Met	Glu	Glu	Leu	Ala	Thr	Glu	35	40	45
Lys	Glu	Ala	Glu	Glu	Ser	His	Arg	Gln	Asp	Ser	Val	Ser	Leu	Leu	50	55	60
Thr	Phe	Ile	Leu	Leu	Leu	Thr	Leu	Thr	Ile	Leu	Thr	Ile	Trp	Leu	65	70	75
Phe	Lys	His	Arg	Arg	Val	Arg	Phe	Leu	His	Glu	Thr	Gly	Leu	Ala	80	85	90
Met	Ile	Tyr	Gly	Leu	Ile	Val	Gly	Val	Ile	Leu	Arg	Tyr	Gly	Thr	95	100	105
Pro	Ala	Thr	Ser	Gly	Arg	Asp	Lys	Ser	Leu	Ser	Cys	Thr	Gln	Glu	110	115	120
Asp	Arg	Ala	Phe	Ser	Thr	Leu	Leu	Val	Asn	Val	Ser	Gly	Lys	Phe	125	130	135
Phe	Glu	Tyr	Thr	Leu	Lys	Gly	Glu	Ile	Ser	Pro	Gly	Lys	Ile	Asn	140	145	150
Ser	Val	Glu	Gln	Asn	Asp	Met	Leu	Arg	Lys	Val	Thr	Phe	Asp	Pro	155	160	165
Glu	Val	Phe	Phe	Asn	Ile	Leu	Leu	Pro	Pro	Ile	Ile	Phe	His	Ala	170	175	180
Gly	Tyr	Ser	Leu	Lys	Lys	Arg	His	Phe	Phe	Arg	Asn	Leu	Gly	Ser	185	190	195
Ile	Leu	Ala	Tyr	Ala	Phe	Leu	Gly	Thr	Ala	Val	Ser	Cys	Phe	Ile	200	205	210
Ile	Gly	Asn	Leu	Met	Tyr	Gly	Val	Val	Lys	Leu	Met	Lys	Ile	Met	215	220	225
Gly	Gln	Leu	Ser	Asp	Lys	Phe	Tyr	Tyr	Thr	Asp	Cys	Leu	Phe	Phe	230	235	240
Gly	Ala	Ile	Ile	Ser	Ala	Thr	Asp	Pro	Val	Thr	Val	Leu	Ala	Ile	245	250	255
Phe	Asn	Glu	Leu	His	Ala	Asp	Val	Asp	Leu	Tyr	Ala	Leu	Leu	Phe	260	265	270
Gly	Glu	Ser	Val	Leu	Asn	Asp	Ala	Val	Ala	Ile	Val	Leu	Ser	Ser	275	280	285
Ser	Ile	Val	Ala	Tyr	Gln	Pro	Ala	Gly	Leu	Asn	Thr	His	Ala	Phe	290	295	300
Asp	Ala	Ala	Ala	Phe	Phe	Lys	Ser	Val	Gly	Ile	Phe	Leu	Gly	Ile	305	310	315
Phe	Ser	Gly	Ser	Phe	Thr	Met	Gly	Ala	Val	Thr	Gly	Val	Val	Thr	320	325	330
Ala	Leu	Val	Thr	Lys	Phe	Thr	Lys	Leu	His	Cys	Phe	Pro	Leu	Leu	335	340	345
Glu	Thr	Ala	Leu	Phe	Phe	Leu	Met	Ser	Trp	Ser	Thr	Phe	Leu	Leu	350	355	360
Ala	Glu	Ala	Cys	Gly	Phe	Thr	Gly	Val	Val	Ala	Val	Leu	Phe	Cys	365	370	375
Gly	Ile	Thr	Gln	Ala	His	Tyr	Thr	Tyr	Asn	Asn	Leu	Ser	Val	Glu	380	385	390
Ser	Arg	Ser	Arg	Thr	Lys	Gln	Leu	Phe	Glu	Val	Leu	His	Phe	Leu	395	400	405
Ala	Glu	Asn	Phe	Ile	Phe	Ser	Tyr	Met	Gly	Leu	Ala	Leu	Phe	Thr	410	415	420
Phe	Gln	Lys	His	Val	Phe	Ser	Pro	Ile	Phe	Ile	Ile	Gly	Ala	Phe	425	430	435
Val	Ala	Ile	Phe	Leu	Gly	Arg	Ala	Ala	His	Ile	Tyr	Pro	Leu	Ser	440	445	450
Phe	Phe	Leu	Asn	Leu	Gly	Arg	Arg	His	Lys	Ile	Gly	Trp	Asn	Phe	455	460	465
Gln	His	Met	Met	Met	Phe	Ser	Gly	Leu	Arg	Gly	Ala	Met	Ala	Phe	470	475	480
Ala	Leu	Ala	Ile	Arg	Asp	Thr	Ala	Ser	Tyr	Ala	Arg	Gln	Met	Met	485	490	495
															500	505	510

Phe Thr Thr Thr	Leu	Leu Ile Val	Phe	Phe Thr Val Trp Ile Ile	
	515			520	525
Gly Gly Gly Thr	Thr	Pro Met Leu Ser	Trp	Leu Asn Ile Arg Val	
	530			535	540
Gly Val Glu Glu	Pro	Ser Glu Glu Asp	Gln	Asn Glu His His Trp	
	545			550	555
Gln Tyr Phe Arg	Val	Gly Val Asp Pro	Asp	Gln Asp Pro Pro Pro	
	560			565	570
Asn Asn Asp Ser	Phe	Gln Val Leu Gln	Gly	Asp Gly Pro Asp Ser	
	575			580	585
Ala Arg Gly Asn	Arg	Thr Lys Gln Glu	Ser	Thr Trp Ile Phe Arg	
	590			595	600
Leu Trp Tyr Ser	Phe	Asp His Asn Tyr	Leu	Lys Pro Ile Leu Thr	
	605			610	615
His Ser Gly Pro	Pro	Leu Thr Thr Thr	Leu	Pro Ala Trp Cys Gly	
	620			625	630
Leu Leu Ala Arg	Cys	Leu Thr Ser Pro	Gln	Val Tyr Asp Asn Gln	
	635			640	645
Glu Pro Leu Arg	Glu	Glu Asp Ser Asp	Phe	Ile Leu Thr Glu Gly	
	650			655	660
Asp Leu Thr Leu	Thr	Tyr Gly Asp Ser	Thr	Val Thr Ala Asn Gly	
	665			670	675
Ser Ser Ser Ser	His	Thr Ala Ser Thr	Ser	Leu Glu Gly Ser Arg	
	680			685	690
Arg Thr Lys Ser	Ser	Ser Glu Glu Val	Leu	Glu Arg Asp Leu Gly	
	695			700	705
Met Gly Asp Gln	Lys	Val Ser Ser Arg	Gly	Thr Arg Leu Val Phe	
	710			715	720
Pro Leu Glu Asp	Asn	Ala			
	725				

<210> 2

<211> 1081

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2477266CD1

<400> 2

Met Glu Ser Ala Gly	Leu	Glu Gln Leu Leu	Arg Glu Leu Leu Leu	
1	5		10	15
Pro Asp Thr Glu Arg	Ile Arg Arg Ala Thr	Glu Gln Leu Gln Ile		
	20		25	30
Val Leu Arg Ala Pro	Ala Ala Leu Pro Ala	Leu Cys Asp Leu Leu		
	35		40	45
Ala Ser Ala Ala Asp	Pro Gln Ile Arg Gln	Phe Ala Ala Val Leu		
	50		55	60
Thr Arg Arg Arg Leu	Asn Thr Arg Trp Arg	Arg Leu Ala Ala Glu		
	65		70	75
Gln Arg Glu Ser Leu	Lys Ser Leu Ile Leu	Thr Ala Leu Gln Arg		
	80		85	90
Glu Thr Glu His Cys	Val Ser Leu Ser Leu	Ala Gln Leu Ser Ala		
	95		100	105
Thr Ile Phe Arg Lys	Glu Gly Leu Glu Ala	Trp Pro Gln Leu Leu		
	110		115	120
Gln Leu Leu Gln His	Ser Thr His Ser Pro	His Ser Pro Glu Arg		
	125		130	135
Glu Met Gly Leu Leu	Leu Leu Ser Val Val	Val Thr Ser Arg Pro		
	140		145	150
Glu Ala Phe Gln Pro	His His Arg Glu Leu	Leu Arg Leu Leu Asn		
	155		160	165

Glu Thr Leu Gly	Glu Val Gly Ser Pro	Gly Leu Leu Phe Tyr	Ser
170	175	180	
Leu Arg Thr Leu	Thr Thr Met Ala Pro	Tyr Leu Ser Thr Glu	Asp
185	190	195	
Val Pro Leu Ala	Arg Met Leu Val Pro	Lys Leu Ile Met Ala	Met
200	205	210	
Gln Thr Leu Ile	Pro Ile Asp Glu Ala	Lys Ala Cys Glu Ala	Leu
215	220	225	
Glu Ala Leu Asp	Glu Leu Leu Glu Ser	Glu Val Pro Val Ile	Thr
230	235	240	
Pro Tyr Leu Ser	Glu Val Leu Thr Phe	Cys Leu Glu Val Ala	Arg
245	250	255	
Asn Val Ala Leu	Gly Asn Ala Ile Arg	Ile Arg Ile Leu Cys	Cys
260	265	270	
Leu Thr Phe Leu	Val Lys Val Lys Ser	Lys Ala Leu Leu Lys	Asn
275	280	285	
Arg Leu Leu Pro	Pro Leu Leu His Thr	Leu Phe Pro Ile Val	Ala
290	295	300	
Ala Glu Pro Pro	Pro Gly Gln Leu Asp	Pro Glu Asp Gln Asp	Ser
305	310	315	
Glu Glu Glu Glu	Leu Glu Ile Glu Leu	Met Gly Glu Thr Pro	Lys
320	325	330	
His Phe Ala Val	Gln Val Val Asp Met	Leu Ala Leu His Leu	Pro
335	340	345	
Pro Glu Lys Leu	Cys Pro Gln Leu Met	Pro Met Leu Glu Glu	Ala
350	355	360	
Leu Arg Ser Glu	Ser Pro Tyr Gln Arg	Lys Ala Gly Leu Leu	Val
365	370	375	
Leu Ala Val Leu	Ser Asp Gly Ala Gly	Asp His Ile Arg Gln	Arg
380	385	390	
Leu Leu Pro Pro	Leu Leu Gln Ile Val	Cys Lys Gly Leu Glu	Asp
395	400	405	
Pro Ser Gln Val	Val Arg Asn Ala Ala	Leu Phe Ala Leu Gly	Gln
410	415	420	
Phe Ser Glu Asn	Leu Gln Pro His Ile	Ser Ser Tyr Ser Arg	Glu
425	430	435	
Val Met Pro Leu	Leu Leu Ala Tyr Leu	Lys Ser Val Pro Leu	Gly
440	445	450	
His Thr His His	Leu Ala Lys Ala Cys	Tyr Ala Leu Glu Asn	Phe
455	460	465	
Val Glu Asn Leu	Gly Pro Lys Val Gln	Pro Tyr Leu Pro Glu	Leu
470	475	480	
Met Glu Cys Met	Leu Gln Leu Leu Arg	Asn Pro Ser Ser Pro	Arg
485	490	495	
Ala Lys Glu Leu	Ala Val Ser Ala Leu	Gly Ala Ile Ala Thr	Ala
500	505	510	
Ala Gln Ala Ser	Leu Leu Pro Tyr Phe	Pro Ala Ile Met Glu	His
515	520	525	
Leu Arg Glu Phe	Leu Leu Thr Gly Arg	Glu Asp Leu Gln Pro	Val
530	535	540	
Gln Ile Gln Ser	Leu Glu Thr Leu Gly	Val Leu Ala Arg Ala	Val
545	550	555	
Gly Glu Pro Met	Arg Pro Leu Ala Glu	Glu Cys Cys Gln Leu	Gly
560	565	570	
Leu Gly Leu Cys	Asp Gln Val Asp Asp	Ala Asp Leu Arg Arg	Cys
575	580	585	
Thr Tyr Ser Leu	Phe Ala Ala Leu Ser	Gly Leu Met Gly Glu	Gly
590	595	600	
Leu Ala Pro His	Leu Glu Gln Ile Thr	Thr Leu Met Leu Leu	Ser
605	610	615	
Leu Arg Ser Thr	Glu Gly Ile Val Pro	Gln Tyr Asp Gly Ser	Ser
620	625	630	
Ser Phe Leu Leu	Phe Asp Asp Glu Ser	Asp Gly Glu Glu Glu	Glu

	635		640		645
Glu Leu Met Asp	Glu Asp Val Glu Glu	Glu Asp Asp Ser Glu Ile			
	650		655		660
Ser Gly Tyr Ser	Val Glu Asn Ala Phe	Phe Asp Glu Lys Glu Asp			
	665		670		675
Thr Cys Ala Ala	Val Gly Glu Ile Ser	Val Asn Thr Ser Val Ala			
	680		685		690
Phe Leu Pro Tyr	Met Glu Ser Val Phe	Glu Glu Val Phe Lys Leu			
	695		700		705
Leu Glu Cys Pro	His Leu Asn Val Arg	Lys Ala Ala His Glu Ala			
	710		715		720
Leu Gly Gln Phe	Cys Cys Ala Leu His	Lys Ala Cys Gln Ser Cys			
	725		730		735
Pro Ser Glu Pro	Asn Thr Ala Ala Leu	Gln Ala Ala Leu Ala Arg			
	740		745		750
Val Val Pro Ser	Tyr Met Gln Ala Val	Asn Arg Glu Arg Glu Arg			
	755		760		765
Gln Val Val Met	Ala Val Leu Glu Ala	Leu Thr Gly Val Leu Arg			
	770		775		780
Ser Cys Gly Thr	Leu Thr Leu Lys Pro	Pro Gly Arg Leu Ala Glu			
	785		790		795
Leu Cys Gly Val	Leu Lys Ala Val Leu	Gln Arg Lys Thr Ala Cys			
	800		805		810
Gln Asp Thr Asp	Glu Glu Glu Glu Glu	Glu Asp Asp Asp Gln Ala			
	815		820		825
Glu Tyr Asp Ala	Met Leu Leu Glu His	Ala Gly Glu Ala Ile Pro			
	830		835		840
Ala Leu Ala Ala	Ala Ala Gly Gly Asp	Ser Phe Ala Pro Phe Phe			
	845		850		855
Ala Gly Phe Leu	Pro Leu Leu Val Cys	Lys Thr Lys Gln Gly Cys			
	860		865		870
Thr Val Ala Glu	Lys Ser Phe Ala Val	Gly Thr Leu Ala Glu Thr			
	875		880		885
Ile Gln Gly Leu	Gly Ala Ala Ser Ala	Gln Phe Val Ser Arg Leu			
	890		895		900
Leu Pro Val Leu	Leu Ser Thr Ala Gln	Glu Ala Asp Pro Glu Val			
	905		910		915
Arg Ser Asn Ala	Ile Phe Gly Met Gly	Val Leu Ala Glu His Gly			
	920		925		930
Gly His Pro Ala	Gln Glu His Phe Pro	Lys Leu Leu Gly Leu Leu			
	935		940		945
Phe Pro Leu Leu	Ala Arg Glu Arg His	Asp Arg Val Arg Asp Asn			
	950		955		960
Ile Cys Gly Ala	Leu Ala Arg Leu Leu	Met Ala Ser Pro Thr Arg			
	965		970		975
Lys Pro Glu Pro	Gln Val Leu Ala Ala	Leu Leu His Ala Leu Pro			
	980		985		990
Leu Lys Glu Asp	Leu Glu Glu Trp Val	Thr Ile Gly Arg Leu Phe			
	995		1000		1005
Ser Phe Leu Tyr	Gln Ser Ser Pro Asp	Gln Val Ile Asp Val Ala			
	1010		1015		1020
Pro Glu Leu Leu	Arg Ile Cys Ser Leu	Ile Leu Ala Asp Asn Lys			
	1025		1030		1035
Ile Pro Pro Asp	Thr Lys Ala Ala Leu	Leu Leu Leu Thr Phe			
	1040		1045		1050
Leu Ala Lys Gln	His Thr Asp Ser Phe	Gln Ala Ala Leu Gly Ser			
	1055		1060		1065
Leu Pro Val Asp	Lys Ala Gln Glu Leu	Gln Ala Val Leu Gly Leu			
	1070		1075		1080
Ser					

<210> 3

<211> 1172
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3552033CD1

<400> 3
 Met Tyr Val Arg Val Ser Phe Asp Thr Lys Pro Asp Leu Leu Leu
 1 5 10 15
 His Leu Met Thr Lys Glu Trp Gln Leu Glu Leu Pro Lys Leu Leu
 20 25 30
 Ile Ser Val His Gly Gly Leu Gln Asn Phe Glu Leu Gln Pro Lys
 35 40 45
 Leu Lys Gln Val Phe Gly Lys Gly Leu Ile Lys Ala Ala Met Thr
 50 55 60
 Thr Gly Ala Trp Ile Phe Thr Gly Gly Val Asn Thr Gly Val Ile
 65 70 75
 Arg His Val Gly Asp Ala Leu Lys Asp His Ala Ser Lys Ser Arg
 80 85 90
 Gly Lys Ile Cys Thr Ile Gly Ile Ala Pro Trp Gly Ile Val Glu
 95 100 105
 Asn Gln Glu Asp Leu Ile Gly Arg Asp Val Val Arg Pro Tyr Gln
 110 115 120
 Thr Met Ser Asn Pro Met Ser Lys Leu Thr Val Leu Asn Ser Met
 125 130 135
 His Ser His Phe Ile Leu Ala Asp Asn Gly Thr Thr Gly Lys Tyr
 140 145 150
 Gly Ala Glu Val Lys Leu Arg Arg Gln Leu Glu Lys His Ile Ser
 155 160 165
 Leu Gln Lys Ile Asn Thr Arg Ile Gly Gln Gly Val Pro Val Val
 170 175 180
 Ala Leu Ile Val Glu Gly Gly Pro Asn Val Ile Ser Ile Val Leu
 185 190 195
 Glu Tyr Leu Arg Asp Thr Pro Pro Val Pro Val Val Val Cys Asp
 200 205 210
 Gly Ser Gly Arg Ala Ser Asp Ile Leu Ala Phe Gly His Lys Tyr
 215 220 225
 Ser Glu Glu Gly Gly Leu Ile Asn Glu Ser Leu Arg Asp Gln Leu
 230 235 240
 Leu Val Thr Ile Gln Lys Thr Phe Thr Tyr Thr Arg Thr Gln Ala
 245 250 255
 Gln His Leu Phe Ile Ile Leu Met Glu Cys Met Lys Lys Lys Glu
 260 265 270
 Leu Ile Thr Val Phe Arg Met Gly Ser Glu Gly His Gln Asp Ile
 275 280 285
 Asp Leu Ala Ile Leu Thr Ala Leu Leu Lys Gly Ala Asn Ala Ser
 290 295 300
 Ala Pro Asp Gln Leu Ser Leu Ala Leu Ala Trp Asn Arg Val Asp
 305 310 315
 Ile Ala Arg Ser Gln Ile Phe Ile Tyr Gly Gln Gln Trp Pro Val
 320 325 330
 Gly Ser Leu Glu Gln Ala Met Leu Asp Ala Leu Val Leu Asp Arg
 335 340 345
 Val Asp Phe Val Lys Leu Leu Ile Glu Asn Gly Val Ser Met His
 350 355 360
 Arg Phe Leu Thr Ile Ser Arg Leu Glu Glu Leu Tyr Asn Thr Arg
 365 370 375
 His Gly Pro Ser Asn Thr Leu Tyr His Leu Val Arg Asp Val Lys
 380 385 390
 Lys Gly Asn Leu Pro Pro Asp Tyr Arg Ile Ser Leu Ile Asp Ile
 395 400 405

Gly	Leu	Val	Ile	Glu	Tyr	Leu	Met	Gly	Gly	Ala	Tyr	Arg	Cys	Asn
				410					415					420
Tyr	Thr	Arg	Lys	Arg	Phe	Arg	Thr	Leu	Tyr	His	Asn	Leu	Phe	Gly
				425					430					435
Pro	Lys	Arg	Pro	Lys	Ala	Leu	Lys	Leu	Leu	Gly	Met	Glu	Asp	Asp
				440					445					450
Ile	Pro	Leu	Arg	Arg	Gly	Arg	Lys	Thr	Thr	Lys	Lys	Arg	Glu	Glu
				455					460					465
Glu	Val	Asp	Ile	Asp	Leu	Asp	Asp	Pro	Glu	Ile	Asn	His	Phe	Pro
				470					475					480
Phe	Pro	Phe	His	Glu	Leu	Met	Val	Trp	Ala	Val	Leu	Met	Lys	Arg
				485					490					495
Gln	Lys	Met	Ala	Leu	Phe	Phe	Trp	Gln	His	Gly	Glu	Glu	Ala	Met
				500					505					510
Ala	Lys	Ala	Leu	Val	Ala	Cys	Lys	Leu	Cys	Lys	Ala	Met	Ala	His
				515					520					525
Glu	Ala	Ser	Glu	Asn	Asp	Met	Val	Asp	Asp	Ile	Ser	Gln	Glu	Leu
				530					535					540
Asn	His	Asn	Ser	Arg	Asp	Phe	Gly	Gln	Leu	Ala	Val	Glu	Leu	Leu
				545					550					555
Asp	Gln	Ser	Tyr	Lys	Gln	Asp	Glu	Gln	Leu	Ala	Met	Lys	Leu	Leu
				560					565					570
Thr	Tyr	Glu	Leu	Lys	Asn	Trp	Ser	Asn	Ala	Thr	Cys	Leu	Gln	Leu
				575					580					585
Ala	Val	Ala	Ala	Lys	His	Arg	Asp	Phe	Ile	Ala	His	Thr	Cys	Ser
				590					595					600
Gln	Met	Leu	Leu	Thr	Asp	Met	Trp	Met	Gly	Arg	Leu	Arg	Met	Arg
				605					610					615
Lys	Asn	Ser	Gly	Leu	Lys	Val	Ile	Leu	Gly	Ile	Leu	Leu	Pro	Pro
				620					625					630
Ser	Ile	Leu	Ser	Leu	Glu	Phe	Lys	Asn	Lys	Asp	Asp	Met	Pro	Tyr
				635					640					645
Met	Ser	Gln	Ala	Gln	Glu	Ile	His	Leu	Gln	Glu	Lys	Glu	Ala	Glu
				650					655					660
Glu	Pro	Glu	Lys	Pro	Thr	Lys	Glu	Lys	Glu	Glu	Glu	Asp	Met	Glu
				665					670					675
Leu	Ile	Ala	Met	Leu	Gly	Arg	Asn	Asn	Gly	Glu	Ser	Ser	Arg	Lys
				680					685					690
Lys	Asp	Glu	Glu	Glu	Val	Gln	Ser	Glu	His	Arg	Leu	Ile	Pro	Leu
				695					700					705
Gly	Arg	Lys	Ile	Tyr	Glu	Phe	Tyr	Asn	Ala	Pro	Ile	Val	Lys	Phe
				710					715					720
Trp	Phe	Tyr	Thr	Leu	Ala	Tyr	Ile	Gly	Tyr	Leu	Met	Leu	Phe	Asn
				725					730					735
Tyr	Ile	Val	Leu	Val	Lys	Met	Glu	Arg	Trp	Pro	Pro	Thr	Gln	Glu
				740					745					750
Trp	Ile	Val	Ile	Ser	Tyr	Ile	Phe	Thr	Leu	Gly	Ile	Glu	Lys	Met
				755					760					765
Arg	Glu	Ile	Leu	Met	Ser	Glu	Pro	Gly	Lys	Leu	Leu	Gln	Lys	Val
				770					775					780
Lys	Val	Trp	Leu	Gln	Glu	His	Trp	Asn	Val	Thr	Asp	Leu	Ile	Ala
				785					790					795
Ile	Leu	Leu	Phe	Ser	Val	Gly	Met	Ile	Leu	Arg	Leu	Gln	Asp	Gln
				800					805					810
Pro	Phe	Arg	Ser	Asp	Gly	Arg	Val	Ile	Tyr	Cys	Val	Asn	Ile	Ile
				815					820					825
Tyr	Trp	Tyr	Ile	Arg	Leu	Leu	Asp	Ile	Phe	Gly	Val	Asn	Lys	Tyr
				830					835					840
Leu	Gly	Pro	Tyr	Val	Met	Met	Ile	Gly	Lys	Met	Met	Ile	Asp	Met
				845					850					855
Met	Tyr	Phe	Val	Ile	Ile	Met	Leu	Val	Val	Leu	Met	Ser	Phe	Gly
				860					865					870
Val	Ala	Arg	Gln	Ala	Ile	Leu	Phe	Pro	Asn	Glu	Glu	Pro	Ser	Trp

	875		880		885
Lys Leu Ala Lys	Asn Ile Phe Tyr Met	Pro Tyr Trp Met Ile Tyr			
	890		895		900
Gly Glu Val Phe	Ala Asp Gln Ile Asp	Pro Pro Cys Gly Gln Asn			
	905		910		915
Glu Thr Arg Glu	Asp Gly Lys Ile Ile	Gln Leu Pro Pro Cys Lys			
	920		925		930
Thr Gly Ala Trp	Ile Val Pro Ala Ile	Met Ala Cys Tyr Leu Leu			
	935		940		945
Val Ala Asn Ile	Leu Leu Val Asn Leu	Leu Ile Ala Val Phe Asn			
	950		955		960
Asn Thr Phe Phe	Glu Val Lys Ser Ile	Ser Asn Gln Val Trp Lys			
	965		970		975
Phe Gln Arg Tyr	Gln Leu Ile Met Thr	Phe His Glu Arg Pro Val			
	980		985		990
Leu Pro Pro Pro	Leu Ile Ile Phe Ser	His Met Thr Met Ile Phe			
	995		1000		1005
Gln His Leu Cys	Cys Arg Trp Arg Lys	His Glu Ser Asp Pro Asp			
	1010		1015		1020
Glu Arg Asp Tyr	Gly Leu Lys Leu Phe	Ile Thr Asp Asp Glu Leu			
	1025		1030		1035
Lys Lys Val His	Asp Phe Glu Glu Gln	Cys Ile Glu Glu Tyr Phe			
	1040		1045		1050
Arg Glu Lys Asp	Asp Arg Phe Asn Ser	Ser Asn Asp Glu Arg Ile			
	1055		1060		1065
Arg Val Thr Ser	Glu Arg Val Glu Asn	Met Ser Met Arg Leu Glu			
	1070		1075		1080
Glu Val Asn Glu	Arg Glu His Ser Met	Lys Ala Ser Leu Gln Thr			
	1085		1090		1095
Val Asp Ile Arg	Leu Ala Gln Leu Glu	Asp Leu Ile Gly Arg Met			
	1100		1105		1110
Ala Thr Ala Leu	Glu Arg Leu Thr Gly	Leu Glu Arg Ala Glu Ser			
	1115		1120		1125
Asn Lys Ile Arg	Ser Arg Thr Ser Ser	Asp Cys Thr Asp Ala Ala			
	1130		1135		1140
Tyr Ile Val Arg	Gln Ser Ser Phe Asn	Ser Gln Glu Gly Asn Thr			
	1145		1150		1155
Phe Lys Leu Gln	Glu Ser Ile Asp Pro	Ala Glu His Pro Leu Tyr			
	1160		1165		1170
Ser Val					

<210> 4
 <211> 742
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 4778139CD1

<400> 4
 Met Glu Ile Ala Gly Glu Lys Lys Tyr Gln Tyr Tyr Ser Met Pro
 1 5 10 15
 Ser Ser Leu Leu Arg Ser Leu Ala Gly Gly Arg His Pro Pro Arg
 20 25 30
 Val Gln Arg Gly Ala Leu Leu Glu Ile Thr Asn Ser Lys Arg Glu
 35 40 45
 Ala Thr Asn Val Arg Asn Asp Gln Glu Arg Gln Glu Thr Gln Ser
 50 55 60
 Ser Ile Val Val Ser Gly Val Ser Pro Asn Arg Gln Ala His Ser
 65 70 75
 Lys Tyr Gly Gln Phe Leu Leu Val Pro Ser Asn Leu Lys Arg Val

	80		85		90
Pro Phe Ser Ala	Glu Thr Val Leu Pro	Leu Ser Arg Pro Ser	Val		
	95		100		105
Pro Asp Val Leu	Ala Thr Glu Gln Asp	Ile Gln Thr Glu Val	Leu		
	110		115		120
Val His Leu Thr	Gly Gln Thr Pro Val	Val Ser Asp Trp Ala	Ser		
	125		130		135
Val Asp Glu Pro	Lys Glu Lys His Glu	Pro Ile Ala His Leu	Leu		
	140		145		150
Asp Gly Gln Asp	Lys Ala Glu Gln Val	Leu Pro Thr Leu Ser	Cys		
	155		160		165
Thr Pro Glu Pro	Met Thr Met Ser Ser	Pro Leu Ser Gln Ala	Lys		
	170		175		180
Ile Met Gln Thr	Gly Gly Gly Tyr Val	Asn Trp Ala Phe Ser	Glu		
	185		190		195
Gly Asp Glu Thr	Gly Val Phe Ser Ile	Lys Lys Lys Trp Gln	Thr		
	200		205		210
Cys Leu Pro Ser	Thr Cys Asp Ser Asp	Ser Ser Arg Ser Glu	Gln		
	215		220		225
His Gln Lys Gln	Ala Gln Asp Ser Ser	Leu Ser Asp Asn Ser	Thr		
	230		235		240
Arg Ser Ala Gln	Ser Ser Glu Cys Ser	Glu Val Gly Pro Trp	Leu		
	245		250		255
Gln Pro Asn Thr	Ser Phe Trp Ile Asn	Pro Leu Arg Arg Tyr	Arg		
	260		265		270
Pro Phe Ala Arg	Ser His Ser Phe Arg	Phe His Lys Glu Glu	Lys		
	275		280		285
Leu Met Lys Ile	Cys Lys Ile Lys Asn	Leu Ser Gly Ser Ser	Glu		
	290		295		300
Ile Gly Gln Gly	Ala Trp Val Lys Ala	Lys Met Leu Thr Lys	Asp		
	305		310		315
Arg Arg Leu Ser	Lys Lys Lys Lys Asn	Thr Gln Gly Leu Gln	Val		
	320		325		330
Pro Ile Ile Thr	Val Asn Ala Cys Ser	Gln Ser Asp Gln Leu	Asn		
	335		340		345
Pro Glu Pro Gly	Glu Asn Ser Ile Ser	Glu Glu Glu Tyr Ser	Lys		
	350		355		360
Asn Trp Phe Thr	Val Ser Lys Phe Ser	His Thr Gly Val Glu	Pro		
	365		370		375
Tyr Ile His Gln	Lys Met Lys Thr Lys	Glu Ile Gly Gln Cys	Ala		
	380		385		390
Ile Gln Ile Ser	Asp Tyr Leu Lys Gln	Ser Gln Glu Ser Ala	Gln		
	395		400		405
Asp Leu Ser Lys	Asn Ser Leu Trp Asn	Ser Arg Ser Thr Asn	Leu		
	410		415		420
Asn Arg Asn Ser	Leu Ser Ser Leu Ile	Ser Glu Ile Ser Ala	Ser		
	425		430		435
Leu Lys Ser Pro	Gln Glu Pro His His	Tyr Ser Pro Ser	Leu		
	440		445		450
Leu Phe Ala Ala	Gly Glu Glu Ile Thr	Val Tyr Arg Leu Glu	Glu		
	455		460		465
Ser Ser Pro Leu	Asn Leu Asp Lys Ser	Met Ser Ser Trp Ser	Gln		
	470		475		480
Arg Gly Arg Ala	Ala Met Ile Gln Val	Leu Ser Arg Glu Glu	Met		
	485		490		495
Asp Gly Gly Leu	Arg Lys Ala Met Arg	Val Val Ser Thr Trp	Ser		
	500		505		510
Glu Asp Asp Ile	Leu Lys Pro Gly Gln	Val Phe Ile Val Lys	Ser		
	515		520		525
Phe Leu Pro Glu	Val Val Arg Thr Trp	His Lys Ile Phe Gln	Glu		
	530		535		540
Ser Thr Val Leu	His Leu Cys Leu Arg	Glu Ile Gln Gln Gln	Arg		
	545		550		555

Ala	Ala	Gln	Lys	Leu	Ile	Tyr	Thr	Phe	Asn	Gln	Val	Lys	Pro	Gln	
				560					565					570	
Thr	Ile	Pro	Tyr	Thr	Pro	Arg	Phe	Leu	Glu	Val	Phe	Leu	Ile	Tyr	
				575					580					585	
Cys	His	Ser	Ala	Asn	Gln	Trp	Leu	Thr	Ile	Glu	Lys	Tyr	Met	Thr	
				590					595					600	
Gly	Glu	Phe	Arg	Lys	Tyr	Asn	Asn	Asn	Asn	Gly	Asp	Glu	Ile	Thr	
				605					610					615	
Pro	Thr	Asn	Thr	Leu	Glu	Glu	Leu	Met	Leu	Ala	Phe	Ser	His	Trp	
				620					625					630	
Thr	Tyr	Glu	Tyr	Thr	Arg	Gly	Glu	Leu	Leu	Val	Leu	Asp	Leu	Gln	
				635					640					645	
Gly	Val	Gly	Glu	Asn	Leu	Thr	Asp	Pro	Ser	Val	Ile	Lys	Pro	Glu	
				650					655					660	
Val	Lys	Gln	Ser	Arg	Gly	Met	Val	Phe	Gly	Pro	Ala	Asn	Leu	Gly	
				665					670					675	
Glu	Asp	Ala	Ile	Arg	Asn	Phe	Ile	Ala	Lys	His	His	Trp	Asn	Ser	
				680					685					690	
Cys	Cys	Arg	Lys	Leu	Lys	Leu	Pro	Asp	Leu	Lys	Arg	Asn	Asp	Tyr	
				695					700					705	
Ser	Pro	Glu	Arg	Ile	Asn	Ser	Thr	Phe	Gly	Leu	Glu	Ile	Lys	Ile	
				710					715					720	
Glu	Ser	Ala	Glu	Glu	Pro	Pro	Ala	Arg	Glu	Thr	Gly	Arg	Asn	Ser	
				725					730					735	
Pro	Glu	Asp	Asp	Met	Gln	Leu									
				740											

<210> 5

<211> 577

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4787433CD1

<400> 5

Met	Gly	Ser	Arg	His	Phe	Glu	Gly	Ile	Tyr	Asp	His	Val	Gly	His	
1				5					10					15	
Phe	Gly	Arg	Phe	Gln	Arg	Val	Leu	Tyr	Phe	Ile	Cys	Ala	Phe	Gln	
				20					25					30	
Asn	Ile	Ser	Cys	Gly	Ile	His	Tyr	Leu	Ala	Ser	Val	Phe	Met	Gly	
				35					40					45	
Val	Thr	Pro	His	His	Val	Cys	Arg	Pro	Pro	Gly	Asn	Val	Ser	Gln	
				50					55					60	
Val	Val	Phe	His	Asn	His	Ser	Asn	Trp	Ser	Leu	Glu	Asp	Thr	Gly	
				65					70					75	
Ala	Leu	Leu	Ser	Ser	Gly	Gln	Lys	Asp	Tyr	Val	Thr	Val	Gln	Leu	
				80					85					90	
Gln	Asn	Gly	Glu	Ile	Trp	Glu	Leu	Ser	Arg	Cys	Ser	Arg	Asn	Lys	
				95					100					105	
Arg	Glu	Asn	Thr	Ser	Ser	Leu	Gly	Tyr	Glu	Tyr	Thr	Gly	Ser	Lys	
				110					115					120	
Lys	Glu	Phe	Pro	Cys	Val	Asp	Gly	Tyr	Ile	Tyr	Asp	Gln	Asn	Thr	
				125					130					135	
Trp	Lys	Ser	Thr	Ala	Val	Thr	Gln	Trp	Asn	Leu	Val	Cys	Asp	Arg	
				140					145					150	
Lys	Trp	Leu	Ala	Met	Leu	Ile	Gln	Pro	Leu	Phe	Met	Phe	Gly	Val	
				155					160					165	
Leu	Leu	Gly	Ser	Val	Thr	Phe	Gly	Tyr	Phe	Ser	Asp	Arg	Leu	Gly	
				170					175					180	
Arg	Arg	Val	Val	Leu	Trp	Ala	Thr	Ser	Ser	Ser	Met	Phe	Leu	Phe	
				185					190					195	

Gly	Ile	Ala	Ala	Ala	Phe	Ala	Val	Asp	Tyr	Tyr	Thr	Phe	Met	Ala
				200					205					210
Ala	Arg	Phe	Phe	Leu	Ala	Met	Val	Ala	Ser	Gly	Tyr	Leu	Val	Val
				215					220					225
Gly	Phe	Val	Tyr	Val	Met	Glu	Phe	Ile	Gly	Met	Lys	Ser	Arg	Thr
				230					235					240
Trp	Ala	Ser	Val	His	Leu	His	Ser	Phe	Phe	Ala	Val	Gly	Thr	Leu
				245					250					255
Leu	Val	Ala	Leu	Thr	Gly	Tyr	Leu	Val	Arg	Thr	Trp	Trp	Leu	Tyr
				260					265					270
Gln	Met	Ile	Leu	Ser	Thr	Val	Thr	Val	Pro	Phe	Ile	Leu	Cys	Cys
				275					280					285
Trp	Val	Leu	Pro	Glu	Thr	Pro	Phe	Trp	Leu	Leu	Ser	Glu	Gly	Arg
				290					295					300
Tyr	Glu	Glu	Ala	Gln	Lys	Ile	Val	Asp	Ile	Met	Ala	Lys	Trp	Asn
				305					310					315
Arg	Ala	Ser	Ser	Cys	Lys	Leu	Ser	Glu	Leu	Leu	Ser	Leu	Asp	Leu
				320					325					330
Gln	Gly	Pro	Val	Ser	Asn	Ser	Pro	Thr	Glu	Val	Gln	Lys	His	Asn
				335					340					345
Leu	Ser	Tyr	Leu	Phe	Tyr	Asn	Trp	Ser	Ile	Thr	Lys	Arg	Thr	Leu
				350					355					360
Thr	Val	Trp	Leu	Ile	Trp	Phe	Thr	Gly	Ser	Leu	Gly	Phe	Tyr	Ser
				365					370					375
Phe	Ser	Leu	Asn	Ser	Val	Asn	Leu	Gly	Gly	Asn	Glu	Tyr	Leu	Asn
				380					385					390
Leu	Phe	Leu	Leu	Gly	Val	Val	Glu	Ile	Pro	Ala	Tyr	Thr	Phe	Val
				395					400					405
Cys	Ile	Ala	Met	Asp	Lys	Val	Gly	Arg	Arg	Thr	Val	Leu	Ala	Tyr
				410					415					420
Ser	Leu	Phe	Cys	Ser	Ala	Leu	Ala	Cys	Gly	Val	Val	Met	Val	Ile
				425					430					435
Pro	Gln	Lys	His	Tyr	Ile	Leu	Gly	Val	Val	Thr	Ala	Met	Val	Gly
				440					445					450
Lys	Phe	Ala	Ile	Gly	Ala	Ala	Phe	Gly	Leu	Ile	Tyr	Leu	Tyr	Thr
				455					460					465
Ala	Glu	Leu	Tyr	Pro	Thr	Ile	Val	Arg	Ser	Leu	Ala	Val	Gly	Ser
				470					475					480
Gly	Ser	Met	Val	Cys	Arg	Leu	Ala	Ser	Ile	Leu	Ala	Pro	Phe	Ser
				485					490					495
Val	Asp	Leu	Ser	Ser	Ile	Trp	Ile	Phe	Ile	Pro	Gln	Leu	Phe	Val
				500					505					510
Gly	Thr	Met	Ala	Leu	Leu	Ser	Gly	Val	Leu	Thr	Leu	Lys	Leu	Pro
				515					520					525
Glu	Thr	Leu	Gly	Lys	Arg	Leu	Ala	Thr	Thr	Trp	Glu	Glu	Ala	Ala
				530					535					540
Lys	Leu	Glu	Ser	Glu	Asn	Glu	Ser	Lys	Ser	Ser	Lys	Leu	Leu	Leu
				545					550					555
Thr	Thr	Asn	Asn	Ser	Gly	Leu	Glu	Lys	Thr	Glu	Ala	Ile	Thr	Pro
				560					565					570
Arg	Asp	Ser	Gly	Leu	Gly	Glu								
				575										

<210> 6
 <211> 462
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7483598CD1

<400> 6

Met	Gly	Tyr	Gln	Arg	Gln	Glu	Pro	Val	Ile	Pro	Pro	Gln	Arg	Asp
1				5					10					15
Leu	Asp	Asp	Arg	Glu	Thr	Leu	Val	Ser	Glu	His	Glu	Tyr	Lys	Glu
				20					25					30
Lys	Thr	Cys	Gln	Ser	Ala	Ala	Leu	Phe	Asn	Val	Val	Asn	Ser	Ile
				35					40					45
Ile	Gly	Ser	Gly	Ile	Ile	Gly	Leu	Pro	Tyr	Ser	Met	Lys	Gln	Ala
				50					55					60
Gly	Phe	Pro	Leu	Gly	Ile	Leu	Leu	Leu	Phe	Trp	Val	Ser	Tyr	Val
				65					70					75
Thr	Asp	Phe	Ser	Leu	Val	Leu	Leu	Ile	Lys	Gly	Gly	Ala	Leu	Ser
				80					85					90
Gly	Thr	Asp	Thr	Tyr	Gln	Ser	Leu	Val	Asn	Lys	Thr	Phe	Gly	Phe
				95					100					105
Pro	Gly	Tyr	Leu	Leu	Leu	Ser	Val	Leu	Gln	Phe	Leu	Tyr	Pro	Phe
				110					115					120
Ile	Ala	Met	Ile	Ser	Tyr	Asn	Ile	Ile	Ala	Gly	Asp	Thr	Leu	Ser
				125					130					135
Lys	Val	Phe	Gln	Arg	Ile	Pro	Gly	Val	Asp	Pro	Glu	Asn	Val	Phe
				140					145					150
Ile	Gly	Arg	His	Phe	Ile	Ile	Gly	Leu	Ser	Thr	Val	Thr	Phe	Thr
				155					160					165
Leu	Pro	Leu	Ser	Leu	Tyr	Arg	Asn	Ile	Ala	Lys	Leu	Gly	Lys	Val
				170					175					180
Ser	Leu	Ile	Ser	Thr	Gly	Leu	Thr	Thr	Leu	Ile	Leu	Gly	Ile	Val
				185					190					195
Met	Ala	Arg	Ala	Ile	Ser	Leu	Gly	Pro	His	Ile	Pro	Lys	Thr	Glu
				200					205					210
Asp	Ala	Trp	Val	Phe	Ala	Lys	Pro	Asn	Ala	Ile	Gln	Ala	Val	Gly
				215					220					225
Val	Met	Ser	Phe	Ala	Phe	Ile	Cys	His	His	Asn	Ser	Phe	Leu	Val
				230					235					240
Tyr	Ser	Ser	Leu	Glu	Glu	Pro	Thr	Val	Ala	Lys	Trp	Ser	Arg	Leu
				245					250					255
Ile	His	Met	Ser	Ile	Val	Ile	Ser	Val	Phe	Ile	Cys	Ile	Phe	Phe
				260					265					270
Ala	Thr	Cys	Gly	Tyr	Leu	Thr	Phe	Thr	Gly	Phe	Thr	Gln	Gly	Asp
				275					280					285
Leu	Phe	Glu	Asn	Tyr	Cys	Arg	Asn	Asp	Asp	Leu	Val	Thr	Phe	Gly
				290					295					300
Arg	Phe	Cys	Tyr	Gly	Val	Thr	Val	Ile	Leu	Thr	Tyr	Pro	Met	Glu
				305					310					315
Cys	Phe	Val	Thr	Arg	Glu	Val	Ile	Ala	Asn	Val	Phe	Phe	Gly	Gly
				320					325					330
Asn	Leu	Ser	Ser	Val	Phe	His	Ile	Val	Val	Thr	Val	Met	Val	Ile
				335					340					345
Thr	Val	Ala	Thr	Leu	Val	Ser	Leu	Leu	Ile	Asp	Cys	Leu	Gly	Ile
				350					355					360
Val	Leu	Glu	Leu	Asn	Gly	Val	Leu	Cys	Ala	Thr	Pro	Leu	Ile	Phe
				365					370					375
Ile	Ile	Pro	Ser	Ala	Cys	Tyr	Leu	Lys	Leu	Ser	Glu	Glu	Pro	Arg
				380					385					390
Thr	His	Ser	Asp	Lys	Ile	Met	Ser	Cys	Val	Met	Leu	Pro	Ile	Gly
				395					400					405
Ala	Val	Val	Met	Val	Phe	Gly	Phe	Val	Met	Ala	Ile	Thr	Asn	Thr
				410					415					420
Gln	Asp	Cys	Thr	His	Gly	Gln	Glu	Met	Phe	Tyr	Cys	Phe	Pro	Asp
				425					430					435
Asn	Phe	Ser	Leu	Thr	Asn	Thr	Ser	Glu	Ser	His	Val	Gln	Gln	Thr
				440					445					450
Thr	Gln	Leu	Ser	Thr	Leu	Asn	Ile	Ser	Ile	Phe	Gln			
				455					460					

<210> 7
 <211> 1018
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7484823CD1

<400> 7
 Met Gly Glu Gly Asp Ser Gly Leu Arg Ser Pro Arg Gly Pro Gln
 1 5 10 15
 Glu Gly Gly Lys Cys Ser Arg Glu Lys Gln Lys Arg Asn Met Glu
 20 25 30
 Glu Leu Lys Lys Glu Val Val Met Asp Asp His Lys Leu Thr Leu
 35 40 45
 Glu Glu Leu Ser Thr Lys Tyr Ser Val Asp Leu Thr Lys Gly His
 50 55 60
 Ser His Gln Arg Ala Lys Glu Ile Leu Thr Arg Gly Gly Pro Asn
 65 70 75
 Thr Val Thr Pro Pro Pro Thr Thr Pro Glu Trp Val Lys Phe Cys
 80 85 90
 Lys Gln Leu Phe Gly Gly Phe Ser Leu Leu Leu Trp Thr Gly Ala
 95 100 105
 Ile Leu Cys Phe Val Ala Tyr Ser Ile Gln Ile Tyr Phe Asn Glu
 110 115 120
 Glu Pro Thr Lys Asp Asn Leu Tyr Leu Ser Ile Val Leu Ser Val
 125 130 135
 Val Val Ile Val Thr Gly Cys Phe Ser Tyr Tyr Gln Glu Ala Lys
 140 145 150
 Ser Ser Lys Ile Met Glu Ser Phe Lys Asn Met Val Pro Gln Gln
 155 160 165
 Ala Leu Val Ile Arg Gly Gly Glu Lys Met Gln Ile Asn Val Gln
 170 175 180
 Glu Val Val Leu Gly Asp Leu Val Glu Ile Lys Gly Gly Asp Arg
 185 190 195
 Val Pro Ala Asp Leu Arg Leu Ile Ser Ala Gln Gly Cys Lys Val
 200 205 210
 Asp Asn Ser Ser Leu Thr Gly Glu Ser Glu Pro Gln Ser Arg Ser
 215 220 225
 Pro Asp Phe Thr His Glu Asn Pro Leu Glu Thr Arg Asn Ile Cys
 230 235 240
 Phe Phe Ser Thr Asn Cys Val Glu Gly Thr Ala Arg Gly Ile Val
 245 250 255
 Ile Ala Thr Gly Asp Ser Thr Val Met Gly Arg Ile Ala Ser Leu
 260 265 270
 Thr Ser Gly Leu Ala Val Gly Gln Thr Pro Ile Ala Ala Glu Ile
 275 280 285
 Glu His Phe Ile His Leu Ile Thr Val Val Ala Val Phe Leu Gly
 290 295 300
 Val Thr Phe Phe Ala Leu Ser Leu Leu Leu Gly Tyr Gly Trp Leu
 305 310 315
 Glu Ala Ile Ile Phe Leu Ile Gly Ile Ile Val Ala Asn Val Pro
 320 325 330
 Glu Gly Leu Leu Ala Thr Val Thr Val Cys Leu Thr Leu Thr Ala
 335 340 345
 Lys Arg Met Ala Arg Lys Asn Cys Leu Val Lys Asn Leu Glu Ala
 350 355 360
 Val Glu Thr Leu Gly Ser Thr Ser Thr Ile Cys Ser Asp Lys Thr
 365 370 375
 Gly Thr Leu Thr Gln Asn Arg Met Thr Val Ala His Met Trp Phe
 380 385 390
 Asp Met Thr Val Tyr Glu Ala Asp Thr Thr Glu Glu Gln Thr Gly

Lys Thr Phe Thr	395	Lys Ser Ser Asp Thr	400	Trp Phe Met Leu Ala Arg	405
Ile Ala Gly Leu	410	Cys Asn Arg Ala Asp	415	Phe Lys Ala Asn Gln Glu	420
Ile Leu Pro Ile	425	Ala Lys Arg Ala Thr	430	Thr Gly Asp Ala Ser Glu	435
Ser Ala Leu Leu	440	Lys Phe Ile Glu Gln	445	Ser Tyr Ser Ser Val Ala	450
Glu Met Arg Glu	455	Lys Asn Pro Lys Val	460	Ala Glu Val Pro Phe Asn	465
Ser Thr Asn Lys	470	Tyr Gln Met Ser Ile	475	His Leu Arg Glu Asp Ser	480
Ser Gln Thr His	485	Val Leu Met Met Lys	490	Gly Ala Pro Glu Arg Ile	495
Leu Glu Phe Cys	500	Ser Thr Phe Leu Leu	505	Asn Gly Gln Glu Tyr Ser	510
Met Asn Asp Glu	515	Met Lys Glu Ala Phe	520	Gln Asn Ala Tyr Leu Glu	525
Leu Gly Gly Leu	530	Gly Glu Arg Val Leu	535	Gly Phe Cys Phe Leu Asn	540
Leu Pro Ser Ser	545	Phe Ser Lys Gly Phe	550	Pro Phe Asn Thr Asp Glu	555
Ile Asn Phe Pro	560	Met Asp Asn Leu Cys	565	Phe Val Gly Leu Ile Ser	570
Met Ile Asp Pro	575	Pro Arg Ala Ala Val	580	Pro Asp Ala Val Ser Lys	585
Cys Arg Ser Ala	590	Gly Ile Lys Val Ile	595	Met Val Thr Gly Asp His	600
Pro Ile Thr Ala	605	Lys Ala Ile Ala Lys	610	Gly Val Gly Ile Ile Ser	615
Glu Gly Thr Glu	620	Thr Ala Glu Glu Val	625	Ala Ala Arg Leu Lys Ile	630
Pro Ile Ser Lys	635	Val Asp Ala Ser Ala	640	Ala Lys Ala Ile Val Val	645
His Gly Ala Glu	650	Leu Lys Asp Ile Gln	655	Ser Lys Gln Leu Asp Gln	660
Ile Leu Gln Asn	665	His Pro Glu Ile Val	670	Phe Ala Arg Thr Ser Pro	675
Gln Gln Lys Leu	680	Ile Ile Val Glu Gly	685	Cys Gln Arg Leu Gly Ala	690
Val Val Ala Val	695	Thr Gly Asp Gly Val	700	Asn Asp Ser Pro Ala Leu	705
Lys Lys Ala Asp	710	Ile Gly Ile Ala Met	715	Gly Ile Ser Gly Ser Asp	720
Val Ser Lys Gln	725	Ala Ala Asp Met Ile	730	Leu Leu Asp Asp Asn Phe	735
Ala Ser Ile Val	740	Thr Gly Val Glu Glu	745	Gly Arg Leu Ile Phe Asp	750
Asn Leu Lys Lys	755	Ser Ile Met Tyr Thr	760	Leu Thr Ser Asn Ile Pro	765
Glu Ile Thr Pro	770	Phe Leu Met Phe Ile	775	Ile Leu Gly Ile Pro Leu	780
Pro Leu Gly Thr	785	Ile Thr Ile Leu Cys	790	Ile Asp Leu Gly Thr Asp	795
Met Val Pro Ala	800	Ile Ser Leu Ala Tyr	805	Glu Ser Ala Glu Ser Asp	810
Ile Met Lys Arg	815	Leu Pro Arg Asn Pro	820	Lys Thr Asp Asn Leu Val	825
Asn His Arg Leu	830	Ile Gly Met Ala Tyr	835	Gly Gln Ile Gly Met Ile	840
Gln Ala Leu Ala	845	Gly Phe Phe Thr Tyr	850	Phe Val Ile Leu Ala Glu	855
	860		865		870

Asn	Gly	Phe	Arg	Pro	Val	Asp	Leu	Leu	Gly	Ile	Arg	Leu	His	Trp	
				875					880					885	
Glu	Asp	Lys	Tyr	Leu	Asn	Asp	Leu	Glu	Asp	Ser	Tyr	Gly	Gln	Gln	
				890					895					900	
Trp	Thr	Tyr	Glu	Gln	Arg	Lys	Val	Val	Glu	Phe	Thr	Cys	Gln	Thr	
				905					910					915	
Ala	Phe	Phe	Val	Thr	Ile	Val	Val	Val	Gln	Trp	Ala	Asp	Leu	Ile	
				920					925					930	
Ile	Ser	Lys	Thr	Arg	Arg	Asn	Ser	Leu	Phe	Gln	Gln	Gly	Met	Arg	
				935					940					945	
Asn	Lys	Val	Leu	Ile	Phe	Gly	Ile	Leu	Glu	Glu	Thr	Leu	Leu	Ala	
				950					955					960	
Ala	Phe	Leu	Ser	Tyr	Thr	Pro	Gly	Met	Asp	Val	Ala	Leu	Arg	Met	
				965					970					975	
Tyr	Pro	Leu	Lys	Ile	Thr	Trp	Trp	Leu	Cys	Ala	Ile	Pro	Tyr	Ser	
				980					985					990	
Ile	Leu	Ile	Phe	Val	Tyr	Asp	Glu	Ile	Arg	Lys	Leu	Leu	Ile	Arg	
				995					1000					1005	
Gln	His	Pro	Asp	Gly	Trp	Val	Glu	Arg	Glu	Thr	Tyr	Tyr			
				1010					1015						

<210> 8

<211> 313

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 143935CD1

<400> 8

Met	Glu	Glu	Met	Ser	Gly	Glu	Ser	Val	Val	Ser	Ser	Ala	Val	Pro	
1				5					10					15	
Ala	Ala	Ala	Thr	Arg	Thr	Thr	Ser	Phe	Lys	Gly	Thr	Ser	Pro	Ser	
				20					25					30	
Ser	Lys	Tyr	Val	Lys	Leu	Asn	Val	Gly	Gly	Ala	Leu	Tyr	Tyr	Thr	
				35					40					45	
Thr	Met	Gln	Thr	Leu	Thr	Lys	Gln	Asp	Thr	Met	Leu	Lys	Ala	Met	
				50					55					60	
Phe	Ser	Gly	Arg	Met	Glu	Val	Leu	Thr	Asp	Ser	Glu	Gly	Trp	Ile	
				65					70					75	
Leu	Ile	Asp	Arg	Cys	Gly	Lys	His	Phe	Gly	Thr	Ile	Leu	Asn	Tyr	
				80					85					90	
Leu	Arg	Asp	Gly	Ala	Val	Pro	Leu	Pro	Glu	Ser	Arg	Arg	Glu	Ile	
				95					100					105	
Glu	Glu	Leu	Leu	Ala	Glu	Ala	Lys	Tyr	Tyr	Leu	Val	Gln	Gly	Leu	
				110					115					120	
Val	Glu	Glu	Cys	Gln	Ala	Ala	Leu	Gln	Asn	Lys	Asp	Thr	Tyr	Glu	
				125					130					135	
Pro	Phe	Cys	Lys	Val	Pro	Val	Ile	Thr	Ser	Ser	Lys	Glu	Glu	Gln	
				140					145					150	
Lys	Leu	Ile	Ala	Thr	Ser	Asn	Lys	Pro	Ala	Val	Lys	Leu	Leu	Tyr	
				155					160					165	
Asn	Arg	Ser	Asn	Asn	Lys	Tyr	Ser	Tyr	Thr	Ser	Asn	Ser	Asp	Asp	
				170					175					180	
Asn	Met	Leu	Lys	Asn	Ile	Glu	Leu	Phe	Asp	Lys	Leu	Ser	Leu	Arg	
				185					190					195	
Phe	Asn	Gly	Arg	Val	Leu	Phe	Ile	Lys	Asp	Val	Ile	Gly	Asp	Glu	
				200					205					210	
Ile	Cys	Cys	Trp	Ser	Phe	Tyr	Gly	Gln	Gly	Arg	Lys	Ile	Ala	Glu	
				215					220					225	
Val	Cys	Cys	Thr	Ser	Ile	Val	Tyr	Ala	Thr	Glu	Lys	Lys	Gln	Thr	
				230					235					240	

Lys	Val	Glu	Phe	Pro	Glu	Ala	Arg	Ile	Tyr	Glu	Glu	Thr	Leu	Asn	
				245					250					255	
Ile	Leu	Leu	Tyr	Glu	Ala	Gln	Asp	Gly	Arg	Gly	Pro	Asp	Asn	Ala	
				260					265					270	
Leu	Leu	Glu	Ala	Thr	Gly	Gly	Ala	Ala	Gly	Arg	Ser	His	His	Leu	
				275					280					285	
Asp	Glu	Asp	Glu	Glu	Arg	Glu	Arg	Ile	Glu	Arg	Val	Arg	Arg	Ile	
				290					295					300	
His	Ile	Lys	Arg	Pro	Asp	Asp	Arg	Ala	His	Leu	His	Gln			
				305					310						

<210> 9

<211> 921

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5923789CD1

<400> 9

Met	Ala	Trp	Leu	Arg	Leu	Gln	Pro	Leu	Thr	Ser	Ala	Phe	Leu	His	
1				5					10					15	
Phe	Gly	Leu	Val	Thr	Phe	Val	Leu	Phe	Leu	Asn	Gly	Leu	Arg	Ala	
				20					25					30	
Glu	Ala	Gly	Gly	Ser	Gly	Asp	Val	Pro	Ser	Thr	Gly	Gln	Asn	Asn	
				35					40					45	
Glu	Ser	Cys	Ser	Gly	Ser	Ser	Asp	Cys	Lys	Glu	Gly	Val	Ile	Leu	
				50					55					60	
Pro	Ile	Trp	Tyr	Pro	Glu	Asn	Pro	Ser	Leu	Gly	Asp	Lys	Ile	Ala	
				65					70					75	
Arg	Val	Ile	Val	Tyr	Phe	Val	Ala	Leu	Ile	Tyr	Met	Phe	Leu	Gly	
				80					85					90	
Val	Ser	Ile	Ile	Ala	Asp	Arg	Phe	Met	Ala	Ser	Ile	Glu	Val	Ile	
				95					100					105	
Thr	Ser	Gln	Glu	Arg	Glu	Val	Thr	Ile	Lys	Lys	Pro	Asn	Gly	Glu	
				110					115					120	
Thr	Ser	Thr	Thr	Thr	Ile	Arg	Val	Trp	Asn	Glu	Thr	Val	Ser	Asn	
				125					130					135	
Leu	Thr	Leu	Met	Ala	Leu	Gly	Ser	Ser	Ala	Pro	Glu	Ile	Leu	Leu	
				140					145					150	
Ser	Leu	Ile	Glu	Val	Cys	Gly	His	Gly	Phe	Ile	Ala	Gly	Asp	Leu	
				155					160					165	
Gly	Pro	Ser	Thr	Ile	Val	Gly	Ser	Ala	Ala	Phe	Asn	Met	Phe	Ile	
				170					175					180	
Ile	Ile	Gly	Ile	Cys	Val	Tyr	Val	Ile	Pro	Asp	Gly	Glu	Thr	Arg	
				185					190					195	
Lys	Ile	Lys	His	Leu	Arg	Val	Phe	Phe	Ile	Thr	Ala	Ala	Trp	Ser	
				200					205					210	
Ile	Phe	Ala	Tyr	Ile	Trp	Leu	Tyr	Met	Ile	Leu	Ala	Val	Phe	Ser	
				215					220					225	
Pro	Gly	Val	Val	Gln	Val	Trp	Glu	Gly	Leu	Leu	Thr	Leu	Phe	Phe	
				230					235					240	
Phe	Pro	Val	Cys	Val	Leu	Leu	Ala	Trp	Val	Ala	Asp	Lys	Arg	Leu	
				245					250					255	
Leu	Phe	Tyr	Lys	Tyr	Met	His	Lys	Lys	Tyr	Arg	Thr	Asp	Lys	His	
				260					265					270	
Arg	Gly	Ile	Ile	Ile	Glu	Thr	Glu	Gly	Asp	His	Pro	Lys	Gly	Ile	
				275					280					285	
Glu	Met	Asp	Gly	Lys	Met	Met	Asn	Ser	His	Phe	Leu	Asp	Gly	Asn	
				290					295					300	
Leu	Val	Pro	Leu	Glu	Gly	Lys	Glu	Val	Asp	Glu	Ser	Arg	Arg	Glu	
				305					310					315	

Met	Ile	Arg	Ile	Leu	Lys	Asp	Leu	Lys	Gln	Lys	His	Pro	Glu	Lys
				320					325					330
Asp	Leu	Asp	Gln	Leu	Val	Glu	Met	Ala	Asn	Tyr	Tyr	Ala	Leu	Ser
				335					340					345
His	Gln	Gln	Lys	Ser	Arg	Ala	Phe	Tyr	Arg	Ile	Gln	Ala	Thr	Arg
				350					355					360
Met	Met	Thr	Gly	Ala	Gly	Asn	Ile	Leu	Lys	Lys	His	Ala	Ala	Glu
				365					370					375
Gln	Ala	Lys	Lys	Ala	Ser	Ser	Met	Ser	Glu	Val	His	Thr	Asp	Glu
				380					385					390
Pro	Glu	Asp	Phe	Ile	Ser	Lys	Val	Phe	Phe	Asp	Pro	Cys	Ser	Tyr
				395					400					405
Gln	Cys	Leu	Glu	Asn	Cys	Gly	Ala	Val	Leu	Leu	Thr	Val	Val	Arg
				410					415					420
Lys	Gly	Gly	Asp	Met	Ser	Lys	Thr	Met	Tyr	Val	Asp	Tyr	Lys	Thr
				425					430					435
Glu	Asp	Gly	Ser	Ala	Asn	Ala	Gly	Ala	Asp	Tyr	Glu	Phe	Thr	Glu
				440					445					450
Gly	Thr	Val	Val	Leu	Lys	Pro	Gly	Glu	Thr	Gln	Lys	Glu	Phe	Ser
				455					460					465
Val	Gly	Ile	Ile	Asp	Asp	Asp	Ile	Phe	Glu	Glu	Asp	Glu	His	Phe
				470					475					480
Phe	Val	Arg	Leu	Ser	Asn	Val	Arg	Ile	Glu	Glu	Glu	Gln	Pro	Glu
				485					490					495
Glu	Gly	Met	Pro	Pro	Ala	Ile	Phe	Asn	Ser	Leu	Pro	Leu	Pro	Arg
				500					505					510
Ala	Val	Leu	Ala	Ser	Pro	Cys	Val	Ala	Thr	Val	Thr	Ile	Leu	Asp
				515					520					525
Asp	Asp	His	Ala	Gly	Ile	Phe	Thr	Phe	Glu	Cys	Asp	Thr	Ile	His
				530					535					540
Val	Ser	Glu	Ser	Ile	Gly	Val	Met	Glu	Val	Lys	Val	Leu	Arg	Thr
				545					550					555
Ser	Gly	Ala	Arg	Gly	Thr	Val	Ile	Val	Pro	Phe	Arg	Thr	Val	Glu
				560					565					570
Gly	Thr	Ala	Lys	Gly	Gly	Gly	Glu	Asp	Phe	Glu	Asp	Thr	Tyr	Gly
				575					580					585
Glu	Leu	Glu	Phe	Lys	Asn	Asp	Glu	Thr	Val	Lys	Thr	Ile	Arg	Val
				590					595					600
Lys	Ile	Val	Asp	Glu	Glu	Glu	Tyr	Glu	Arg	Gln	Glu	Asn	Phe	Phe
				605					610					615
Ile	Ala	Leu	Gly	Glu	Pro	Lys	Trp	Met	Glu	Arg	Gly	Ile	Ser	Asp
				620					625					630
Val	Thr	Asp	Arg	Lys	Leu	Thr	Met	Glu	Glu	Glu	Ala	Lys	Arg	
				635					640					645
Ile	Ala	Glu	Met	Gly	Lys	Pro	Val	Leu	Gly	Glu	His	Pro	Lys	Leu
				650					655					660
Glu	Val	Ile	Ile	Glu	Glu	Ser	Tyr	Glu	Phe	Lys	Thr	Thr	Val	Asp
				665					670					675
Lys	Leu	Ile	Lys	Lys	Thr	Asn	Leu	Ala	Leu	Val	Val	Gly	Thr	His
				680					685					690
Ser	Trp	Arg	Asp	Gln	Phe	Met	Glu	Ala	Ile	Thr	Val	Ser	Ala	Ala
				695					700					705
Gly	Asp	Glu	Asp	Glu	Asp	Glu	Ser	Gly	Glu	Glu	Arg	Leu	Pro	Ser
				710					715					720
Cys	Phe	Asp	Tyr	Val	Met	His	Phe	Leu	Thr	Val	Phe	Trp	Lys	Val
				725					730					735
Leu	Phe	Ala	Cys	Val	Pro	Pro	Thr	Glu	Tyr	Cys	His	Gly	Trp	Ala
				740					745					750
Cys	Phe	Ala	Val	Ser	Ile	Leu	Ile	Ile	Gly	Met	Leu	Thr	Ala	Ile
				755					760					765
Ile	Gly	Asp	Leu	Ala	Ser	His	Phe	Gly	Cys	Thr	Ile	Gly	Leu	Lys
				770					775					780
Asp	Ser	Val	Thr	Ala	Val	Val	Phe	Val	Ala	Phe	Gly	Thr	Ser	Val

785	790	795
Pro Asp Thr Phe	Ala Ser Lys Ala Ala	Ala Leu Gln Asp Val Tyr
800	805	810
Ala Asp Ala Ser	Ile Gly Asn Val Thr	Gly Ser Asn Ala Val Asn
815	820	825
Val Phe Leu Gly	Ile Gly Leu Ala Trp	Ser Val Ala Ala Ile Tyr
830	835	840
Trp Ala Leu Gln	Gly Gln Glu Phe His	Val Ser Ala Gly Thr Leu
845	850	855
Ala Phe Ser Val	Thr Leu Phe Thr Ile	Phe Ala Phe Val Cys Ile
860	865	870
Ser Val Leu Leu	Tyr Arg Arg Arg Pro	His Leu Gly Gly Glu Leu
875	880	885
Gly Gly Pro Arg	Gly Cys Lys Leu Ala	Thr Thr Trp Leu Phe Val
890	895	900
Ser Leu Trp Leu	Leu Tyr Ile Leu Phe	Ala Thr Leu Glu Ala Tyr
905	910	915
Cys Tyr Ile Lys	Gly Phe	
920		

<210> 10

<211> 1466

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6046484CD1

<400> 10

Met Tyr Ile Arg Val	Ser Tyr Asp Thr Lys	Pro Asp Ser Leu Leu
1	5	10
His Leu Met Val Lys	Asp Trp Gln Leu Glu	Leu Pro Lys Leu Leu
20	25	30
Ile Ser Val His Gly	Gly Leu Gln Asn Phe	Glu Met Gln Pro Lys
35	40	45
Leu Lys Gln Val Phe	Gly Lys Gly Leu Ile	Lys Ala Ala Met Thr
50	55	60
Thr Gly Ala Trp Ile	Phe Thr Gly Gly Val	Ser Thr Gly Val Ile
65	70	75
Ser His Val Gly Asp	Ala Leu Lys Asp His	Ser Ser Lys Ser Arg
80	85	90
Gly Arg Val Cys Ala	Ile Gly Ile Ala Pro	Trp Gly Ile Val Glu
95	100	105
Asn Lys Glu Asp Leu	Val Gly Lys Asp Val	Thr Arg Val Tyr Gln
110	115	120
Thr Met Ser Asn Pro	Leu Ser Lys Leu Ser	Val Leu Asn Asn Ser
125	130	135
His Thr His Phe Ile	Leu Ala Asp Asn Gly	Thr Leu Gly Lys Tyr
140	145	150
Gly Ala Glu Val Lys	Leu Arg Arg Gln Leu	Glu Lys His Ile Ser
155	160	165
Leu Gln Lys Ile Asn	Thr Arg Ile Gly Gln	Gly Val Pro Val Val
170	175	180
Ala Leu Ile Val Glu	Gly Gly Pro Asn Val	Ile Ser Ile Val Leu
185	190	195
Glu Tyr Leu Arg Asp	Thr Pro Pro Val Pro	Val Val Val Cys Asp
200	205	210
Gly Ser Gly Arg Ala	Ser Asp Ile Leu Ala	Phe Gly His Lys Tyr
215	220	225
Ser Glu Glu Gly Gly	Leu Ile Asn Glu Ser	Leu Arg Asp Gln Leu
230	235	240
Leu Val Thr Ile Gln	Lys Thr Phe Thr Tyr	Thr Arg Thr Gln Ala

	245		250		255
Gln His Leu Phe	Ile Ile Leu Met Glu	Cys Met Lys Lys Lys	Glu		
	260		265		270
Leu Ile Thr Val	Phe Arg Met Gly Ser	Glu Gly His Gln Asp	Ile		
	275		280		285
Asp Leu Ala Ile	Leu Thr Ala Leu Leu	Lys Gly Ala Asn Ala	Ser		
	290		295		300
Ala Pro Asp Gln	Leu Ser Leu Ala Leu	Ala Trp Asn Arg Val	Asp		
	305		310		315
Ile Ala Arg Ser	Gln Ile Phe Ile Tyr	Gly Gln Gln Trp Pro	Val		
	320		325		330
Gly Ser Leu Glu	Gln Ala Met Leu Asp	Ala Leu Val Leu Asp	Arg		
	335		340		345
Val Asp Phe Val	Lys Leu Leu Ile Glu	Asn Gly Val Ser Met	His		
	350		355		360
Arg Phe Leu Thr	Ile Ser Arg Leu Glu	Glu Leu Tyr Asn Thr	Arg		
	365		370		375
His Gly Pro Ser	Asn Thr Leu Tyr His	Leu Val Arg Asp Val	Lys		
	380		385		390
Lys Gly Asn Leu	Pro Pro Asp Tyr Arg	Ile Ser Leu Ile Asp	Ile		
	395		400		405
Gly Leu Val Ile	Glu Tyr Leu Met Gly	Gly Ala Tyr Arg Cys	Asn		
	410		415		420
Tyr Thr Arg Lys	Arg Phe Arg Thr Leu	Tyr His Asn Leu Phe	Gly		
	425		430		435
Pro Lys Arg Asp	Asp Ile Pro Leu Arg	Arg Gly Arg Lys Thr	Thr		
	440		445		450
Lys Lys Arg Glu	Glu Glu Val Asp Ile	Asp Leu Asp Asp Pro	Glu		
	455		460		465
Ile Asn His Phe	Pro Phe Pro Phe His	Glu Leu Met Val Trp	Ala		
	470		475		480
Val Leu Met Lys	Arg Gln Lys Met Ala	Leu Phe Phe Trp Gln	His		
	485		490		495
Gly Glu Glu Ala	Met Ala Lys Ala Leu	Val Ala Cys Lys Leu	Cys		
	500		505		510
Lys Ala Met Ala	His Glu Ala Ser Glu	Asn Asp Met Val Asp	Asp		
	515		520		525
Ile Ser Gln Glu	Leu Asn His Asn Ser	Arg Asp Phe Gly Gln	Leu		
	530		535		540
Ala Val Glu Leu	Leu Asp Gln Ser Tyr	Lys Gln Asp Glu Gln	Leu		
	545		550		555
Ala Met Lys Leu	Leu Thr Tyr Glu Leu	Lys Asn Trp Ser Asn	Ala		
	560		565		570
Thr Cys Leu Gln	Leu Ala Val Ala Ala	Lys His Arg Asp Phe	Ile		
	575		580		585
Ala His Thr Cys	Ser Gln Met Leu Leu	Thr Asp Met Trp Met	Gly		
	590		595		600
Arg Leu Arg Met	Arg Lys Asn Ser Gly	Leu Lys Val Ile Leu	Gly		
	605		610		615
Ile Leu Leu Pro	Pro Thr Ile Leu Phe	Leu Glu Phe Arg Thr	Tyr		
	620		625		630
Asp Asp Phe Ser	Tyr Gln Thr Ser Lys	Glu Asn Glu Asp Gly	Lys		
	635		640		645
Glu Lys Glu Glu	Glu Asn Thr Asp Ala	Asn Ala Asp Ala Gly	Ser		
	650		655		660
Arg Lys Gly Asp	Glu Glu Asn Glu His	Lys Lys Gln Arg Ser	Ile		
	665		670		675
Pro Ile Gly Thr	Lys Ile Cys Glu Phe	Tyr Asn Ala Pro Ile	Val		
	680		685		690
Lys Phe Trp Phe	Phe Gln Ile Ser Tyr	Leu Gly Tyr Leu Leu	Leu		
	695		700		705
Phe Asn Tyr Val	Ile Leu Val Arg Met	Asp Gly Trp Pro Ser	Leu		
	710		715		720

Gln	Glu	Trp	Ile	Val	Ile	Ser	Tyr	Ile	Val	Ser	Leu	Ala	Leu	Glu	
				725					730					735	
Lys	Ile	Arg	Glu	Val	Ala	Thr	Pro	Lys	Ala	Ser	Pro	Ser	Pro	Leu	
				740					745					750	
Ala	Arg	Lys	Ser	Lys	Phe	Gly	Phe	Gln	Glu	Tyr	Trp	Asn	Ile	Thr	
				755					760					765	
Asp	Leu	Val	Ala	Ile	Ser	Thr	Phe	Met	Ile	Gly	Ala	Ile	Leu	Arg	
				770					775					780	
Leu	Gln	Asn	Gln	Pro	Tyr	Met	Gly	Tyr	Gly	Arg	Val	Ile	Tyr	Cys	
				785					790					795	
Val	Asp	Ile	Ile	Phe	Trp	Tyr	Ile	Arg	Val	Leu	Asp	Ile	Phe	Gly	
				800					805					810	
Val	Asn	Lys	Tyr	Leu	Gly	Pro	Tyr	Val	Met	Met	Ile	Gly	Lys	Met	
				815					820					825	
Val	Ser	Ser	Gly	Ile	Leu	Trp	Val	Val	Ile	Met	Leu	Val	Val	Leu	
				830					835					840	
Met	Ser	Phe	Gly	Val	Ala	Arg	Gln	Ala	Ile	Leu	His	Pro	Glu	Glu	
				845					850					855	
Lys	Pro	Ser	Trp	Lys	Leu	Ala	Arg	Asn	Ile	Phe	Tyr	Met	Pro	Tyr	
				860					865					870	
Trp	Met	Ile	Tyr	Gly	Glu	Val	Phe	Ala	Asp	Gln	Ile	Asp	Arg	Lys	
				875					880					885	
Ser	Phe	Phe	Leu	Ser	Ala	Pro	Cys	Gly	Glu	Asn	Leu	Tyr	Asp	Glu	
				890					895					900	
Glu	Gly	Lys	Arg	Leu	Pro	Pro	Cys	Ile	Pro	Gly	Ala	Trp	Leu	Thr	
				905					910					915	
Pro	Ala	Leu	Met	Ala	Cys	Tyr	Leu	Leu	Val	Ala	Asn	Ile	Leu	Leu	
				920					925					930	
Val	Asn	Leu	Leu	Ile	Ala	Val	Phe	Ser	Asn	Thr	Phe	Phe	Glu	Val	
				935					940					945	
Lys	Ser	Ile	Ser	Asn	Gln	Val	Trp	Lys	Phe	Gln	Arg	Tyr	Gln	Leu	
				950					955					960	
Ile	Met	Thr	Phe	His	Asp	Arg	Pro	Val	Leu	Pro	Pro	Pro	Met	Ile	
				965					970					975	
Ile	Leu	Ser	His	Ile	Tyr	Ile	Ile	Ile	Met	Arg	Leu	Ser	Gly	Arg	
				980					985					990	
Cys	Arg	Lys	Lys	Arg	Glu	Gly	Asp	Gln	Glu	Glu	Arg	Asp	Arg	Gly	
				995					1000					1005	
Leu	Ser	Met	Phe	Leu	Ser	Asp	Glu	Glu	Leu	Lys	Arg	Leu	His	Glu	
				1010					1015					1020	
Phe	Glu	Glu	Gln	Cys	Val	Gln	Glu	His	Phe	Arg	Glu	Lys	Glu	Asp	
				1025					1030					1035	
Glu	Gln	Gln	Ser	Ser	Ser	Asp	Glu	Arg	Ile	Arg	Val	Thr	Ser	Glu	
				1040					1045					1050	
Arg	Val	Glu	Asn	Met	Ser	Met	Arg	Leu	Glu	Glu	Ile	Asn	Glu	Arg	
				1055					1060					1065	
Glu	Thr	Phe	Met	Lys	Thr	Ser	Leu	Gln	Thr	Val	Asp	Leu	Arg	Leu	
				1070					1075					1080	
Ala	Gln	Leu	Glu	Glu	Leu	Ser	Asn	Arg	Met	Val	Asn	Ala	Leu	Glu	
				1085					1090					1095	
Asn	Leu	Ala	Gly	Ile	Asp	Arg	Ser	Asp	Leu	Ile	Gln	Ala	Arg	Ser	
				1100					1105					1110	
Arg	Ala	Ser	Ser	Glu	Cys	Glu	Ala	Thr	Tyr	Leu	Leu	Arg	Gln	Ser	
				1115					1120					1125	
Ser	Ile	Asn	Ser	Ala	Asp	Gly	Tyr	Ser	Leu	Tyr	Arg	Tyr	His	Phe	
				1130					1135					1140	
Asn	Gly	Glu	Glu	Leu	Leu	Phe	Glu	Asp	Thr	Ser	Leu	Ser	Thr	Ser	
				1145					1150					1155	
Pro	Gly	Thr	Gly	Val	Arg	Lys	Lys	Thr	Cys	Ser	Phe	Arg	Ile	Lys	
				1160					1165					1170	
Glu	Glu	Lys	Asp	Val	Lys	Thr	His	Leu	Val	Pro	Glu	Cys	Gln	Asn	
				1175					1180					1185	
Ser	Leu	His	Leu	Ser	Leu	Gly	Thr	Ser	Thr	Ser	Ala	Thr	Pro	Asp	

1190	1195	1200
Gly Ser His Leu Ala Val Asp Asp Leu Lys Asn Ala Glu Glu Ser		
1205	1210	1215
Lys Leu Gly Pro Asp Ile Gly Ile Ser Lys Glu Asp Asp Glu Arg		
1220	1225	1230
Gln Thr Asp Ser Lys Lys Glu Glu Thr Ile Ser Pro Ser Leu Asn		
1235	1240	1245
Lys Thr Asp Val Ile His Gly Gln Asp Lys Ser Asp Val Gln Asn		
1250	1255	1260
Thr Gln Leu Thr Val Glu Thr Thr Asn Ile Glu Gly Thr Ile Ser		
1265	1270	1275
Tyr Pro Leu Glu Glu Thr Lys Ile Thr Arg Tyr Phe Pro Asp Glu		
1280	1285	1290
Thr Ile Asn Ala Cys Lys Thr Met Lys Ser Arg Ser Phe Val Tyr		
1295	1300	1305
Ser Arg Gly Arg Lys Leu Val Gly Gly Val Asn Gln Asp Val Glu		
1310	1315	1320
Tyr Ser Ser Ile Thr Asp Gln Gln Leu Thr Thr Glu Trp Gln Cys		
1325	1330	1335
Gln Val Gln Lys Ile Thr Arg Ser His Ser Thr Asp Ile Pro Tyr		
1340	1345	1350
Ile Val Ser Glu Ala Ala Val Gln Ala Glu His Lys Glu Gln Phe		
1355	1360	1365
Ala Asp Met Gln Asp Glu His His Val Ala Glu Ala Ile Pro Arg		
1370	1375	1380
Ile Pro Arg Leu Ser Leu Thr Ile Thr Asp Arg Asn Gly Met Glu		
1385	1390	1395
Asn Leu Leu Ser Val Lys Pro Asp Gln Thr Leu Gly Phe Pro Ser		
1400	1405	1410
Leu Arg Ser Lys Ser Leu His Gly His Pro Arg Asn Val Lys Ser		
1415	1420	1425
Ile Gln Gly Lys Leu Asp Arg Ser Gly His Ala Ser Ser Val Ser		
1430	1435	1440
Ser Leu Val Ile Val Ser Gly Met Thr Ala Glu Glu Lys Lys Val		
1445	1450	1455
Lys Lys Glu Lys Ala Ser Thr Glu Thr Glu Cys		
1460	1465	

<210> 11
 <211> 222
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7481427CD1

<400> 11
 Met Thr Glu Gln Ala Ile Ser Phe Ala Lys Asp Phe Leu Ala Gly
 1 5 10 15
 Gly Ile Thr Ala Ala Ile Ser Lys Thr Ala Val Ala Ser Ile Lys
 20 25 30
 Arg Val Gln Leu Leu Leu Gln Met Gln His Ala Ser Met Pro Met
 35 40 45
 Ala Ala Ala Lys Gln Cys Lys Gly Ile Val Asp Cys Ile Val Arg
 50 55 60
 Ile Pro Lys Asp Gln Gly Val Leu Ser Phe Trp Arg Gly Asn Leu
 65 70 75
 Ala Asn Val Ile Arg Tyr Ser Pro Thr Gln Ala Leu Asn Phe Ala
 80 85 90
 Phe Lys Asp Lys Tyr Lys Gln Ile Phe Leu Ala Gly Val Asp Lys
 95 100 105
 His Thr Gln Phe Cys Arg Tyr Phe Ala Gly Asn Leu Ala Ser Gly

Gly Thr Ala Val	110	Tyr Pro Leu Asp	115	Phe Thr Arg Thr Arg	120
Ala Ala Asp Val	125	Gly Lys Ser Gly Thr	130	Glu Arg Glu Phe Arg	135
Leu Gly Asp Cys	140	Leu Val Lys Ile Ser	145	Lys Ser Asp Gly Ile	150
Gly Leu Tyr Gln	155	Gly Phe Ser Val Ser	160	Val Gln Ala Ile Ile	165
Tyr Gln Ala Ala	170	Tyr Phe Arg Val Tyr	175	Asp Thr Ala Asn Gly	180
Phe Pro Asp Pro	185	Lys Asn Thr His Ile	190	Val Ser Trp Met	195
Ala Gln Thr Val	200	Thr Ala Val Ala Gly	205	Val Leu Ser	210
	215		220		

<210> 12
 <211> 461
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7483595CD1

<400> 12

Met Glu Thr Leu Leu	5	Phe Leu Glu Ser Ala	10	Ile Gly Ala Ile Ala	15
Gly Leu Lys Thr Phe	20	Tyr Pro Thr Leu Val	25	Phe Ser Ser Leu Gln	30
Leu Ile Met Gly Val	35	Leu Gly Leu Gly Phe	40	Ile Ala Thr Tyr Leu	45
Pro Glu Ser Ala Met	50	Ser Ala Tyr Leu Ala	55	Ala Val Ala Leu His	60
Ile Met Leu Ser Gln	65	Leu Thr Phe Ile Phe	70	Gly Ile Met Ile Ser	75
Phe His Ala Gly Pro	80	Ile Ser Phe Phe Tyr	85	Asp Ile Ile Asn Tyr	90
Cys Val Ala Leu Pro	95	Lys Ala Asn Ser Thr	100	Ser Ile Leu Val Phe	105
Leu Thr Val Val Val	110	Ala Leu Arg Ile Asn	115	Lys Cys Ile Arg Ile	120
Ser Phe Asn Gln Tyr	125	Pro Ile Glu Phe Pro	130	Met Glu Leu Phe Leu	135
Ile Ile Leu Gln Ala	140	Phe Ser Leu Ser Leu	145	Val Ser Ser Phe Leu	150
Leu Ile Phe Leu Gly	155	Lys Lys Ile Ala Ser	160	Leu His Asn Tyr Ser	165
Val Asn Ser Asn Gln	170	Asp Leu Ile Ala Ile	175	Gly Leu Cys Asn Val	180
Val Ser Ser Phe Phe	185	Arg Ser Cys Val Phe	190	Thr Gly Ala Ile Ala	195
Arg Thr Ile Ile Gln	200	Asp Lys Ser Gly Gly	205	Ser Thr Thr Val Cys	210
Ile Ser Gly Arg Arg	215	Arg Ala Lys Ile Leu	220	Leu Leu Gly Gln Ile	225
Pro Asn Thr Asn Ile	230	Tyr Arg Ser Ile Asn	235	Asp Tyr Arg Glu Ile	240
Ile Thr Ile Pro Gly	245	Val Lys Ile Phe Gln	250	Cys Cys Ser Ser Ile	255
Thr Phe Val Asn Val	260	Tyr Tyr Leu Lys His	265	Lys Leu Leu Lys Glu	270
Val Asp Met Val Lys		Val Pro Leu Lys Glu		Glu Glu Glu Ile Phe	Ser

275	280	285
Leu Phe Asn Ser Ser Asp Thr Asn Leu	Gln Gly Gly Lys Ile Cys	
290	295	300
Arg Cys Phe Cys Asn Cys Asp Asp Leu	Glu Pro Leu Pro Arg Ile	
305	310	315
Leu Tyr Thr Glu Arg Phe Glu Asn Lys	Leu Asp Pro Glu Ala Ser	
320	325	330
Ser Val Asn Leu Ile His Cys Ser His	Phe Glu Ser Met Asn Thr	
335	340	345
Ser Gln Thr Ala Ser Glu Asp Gln Val	Pro Tyr Thr Val Ser Ser	
350	355	360
Val Ser Gln Lys Asn Gln Gly Gln Gln	Tyr Glu Glu Val Glu Glu	
365	370	375
Val Trp Leu Pro Asn Asn Ser Ser Arg	Asn Ser Ser Pro Gly Leu	
380	385	390
Pro Asp Val Ala Glu Ser Gln Gly Arg	Arg Ser Leu Ile Pro Tyr	
395	400	405
Ser Asp Ala Ser Leu Leu Pro Ser Val	His Thr Ile Ile Leu Asp	
410	415	420
Phe Ser Met Val His Tyr Val Asp Ser	Arg Gly Leu Val Val Leu	
425	430	435
Arg Gln Val Ser Thr Glu Glu Ala Leu	Ala Gly Ala Leu Ile Pro	
440	445	450
Leu Leu Pro Ser Gln Pro His Pro Asp	Pro Asp	
455	460	

<210> 13
 <211> 502
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3788427CD1

<400> 13

Met Ser Ile Val Arg Leu Ser Val His Ala Lys Trp Ile Met Gly	
1 5 10	15
Lys Val Thr Gly Thr Lys Met Gln Lys Thr Ala Lys Val Arg Val	
20 25	30
Ile Arg Leu Val Leu Asp Pro His Leu Leu Lys Tyr Tyr Asn Lys	
35 40	45
Gln Lys Thr Tyr Phe Ala His Asn Ala Leu Gln Gln Cys Thr Ile	
50 55	60
Gly Asp Ile Val Leu Leu Lys Ala Leu Pro Val Pro Arg Thr Lys	
65 70	75
His Val Lys His Glu Leu Ala Glu Ile Val Phe Lys Val Gly Lys	
80 85	90
Leu Val Asp Pro Val Thr Gly Lys Pro Arg Ala Gly Thr Thr Tyr	
95 100	105
Leu Glu Ser Pro Leu Ser Ser Glu Thr Thr Gln Gly Val Asp Gly	
110 115	120
Ala Ser Arg Pro Ser Arg Gly Pro Ala Pro Cys Arg Ala Gly Pro	
125 130	135
Gly Ala Arg Arg Leu Arg Pro Trp Pro Glu Ser Pro Arg Pro Glu	
140 145	150
Pro Arg Gly Leu Pro Gly Pro Gly Arg Gly Ser Met Ala Thr Trp	
155 160	165
Arg Arg Asp Gly Arg Leu Thr Gly Gly Gln Arg Leu Leu Cys Ala	
170 175	180
Gly Leu Ala Gly Thr Leu Ser Leu Ser Leu Thr Ala Pro Leu Glu	
185 190	195
Leu Ala Thr Val Leu Ala Gln Val Gly Val Val Arg Gly His Ala	

Arg Gly Pro Trp	200	Ala Thr Gly His Arg	205	Val Trp Arg Ala Glu Gly	210
Leu Arg Ala Leu	215	Trp Lys Gly Asn Ala	220	Val Ala Cys Leu Arg Leu	225
Phe Pro Cys Ser	230	Ala Val Gln Leu Ala	235	Ala Tyr Arg Lys Phe Val	240
Val Leu Phe Thr	245	Asp Asp Leu Gly His	250	Ile Ser Gln Trp Ser Ser	255
Ile Met Ala Gly	260	Ser Leu Ala Gly Met	265	Val Ser Thr Ile Val Thr	270
Tyr Pro Thr Asp	275	Leu Ile Lys Thr Arg	280	Leu Ile Met Gln Asn Ile	285
Leu Glu Pro Ser	290	Tyr Arg Gly Leu Leu	295	His Ala Phe Ser Thr Ile	300
Tyr Gln Gln Glu	305	Gly Phe Leu Ala Leu	310	Tyr Arg Gly Val Ser Leu	315
Thr Val Val Gly	320	Ala Leu Pro Phe Ser	325	Ala Gly Ser Leu Leu Val	330
Tyr Met Asn Leu	335	Glu Lys Ile Trp Asn	340	Gly Pro Arg Asp Gln Phe	345
Ser Leu Pro Gln	350	Asn Phe Ala Asn Val	355	Cys Leu Ala Ala Ala Val	360
Thr Gln Thr Leu	365	Ser Phe Pro Phe Glu	370	Thr Val Lys Arg Lys Met	375
Gln Ala Gln Ser	380	Pro Tyr Leu Pro His	385	Ser Gly Gly Val Asp Val	390
His Phe Ser Gly	395	Ala Val Asp Cys Phe	400	Arg Gln Ile Val Lys Ala	405
Gln Gly Val Leu	410	Gly Leu Trp Asn Gly	415	Leu Thr Ala Asn Leu Leu	420
Lys Ile Val Pro	425	Tyr Phe Gly Ile Met	430	Phe Ser Thr Phe Glu Phe	435
Cys Lys Arg Ile	440	Cys Leu Tyr Gln Asn	445	Gly Tyr Ile Leu Ser Pro	450
Leu Ser Tyr Lys	455	Leu Thr Pro Gly Val	460	Asp Gln Ser Leu Gln Pro	465
Gln Glu Leu Arg	470	Glu Leu Lys Lys Phe	475	Phe Lys Thr Arg Lys Leu	480
Lys Pro Lys Lys	485	Pro Thr Leu	490		495
	500				

<210> 14
 <211> 261
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 6972455CD1

<400> 14
 Met Thr Lys Arg Tyr Ser Ala Leu Leu Thr Ala Leu Phe Ala Ser
 1 5 10 15
 Leu Met Leu Ser Gln Ala Pro Ala Gln Ala Ser Gly Leu Asp Asp
 20 25 30
 Ile Val Ala Arg Gly Thr Leu Lys Val Ala Val Pro Gln Asp Phe
 35 40 45
 Pro Pro Phe Gly Ser Val Gly Pro Asp Met Gln Pro Arg Gly Leu
 50 55 60
 Asp Ile Asp Thr Ala Lys Leu Leu Ala Asp Gln Leu Lys Val Lys
 65 70 75
 Leu Glu Leu Thr Pro Val Asn Ser Thr Asn Arg Ile Pro Phe Leu

				80					85					90
Thr	Thr	Gly	Lys	Val	Asp	Leu	Val	Ile	Ser	Ser	Leu	Gly	Lys	Asn
				95					100					105
Pro	Glu	Arg	Ala	Lys	Val	Ile	Asp	Phe	Ser	Asn	Ala	Tyr	Ala	Pro
				110					115					120
Phe	Tyr	Leu	Ala	Val	Phe	Gly	Pro	Pro	Asp	Ala	Ala	Ile	Ala	Ser
				125					130					135
Leu	Asp	Asp	Leu	Lys	Gly	Lys	Thr	Ile	Ser	Val	Thr	Arg	Gly	Ala
				140					145					150
Ile	Glu	Asp	Ile	Glu	Leu	Thr	Ala	Val	Ala	Pro	Lys	Glu	Ala	Thr
				155					160					165
Ile	Lys	Arg	Phe	Glu	Asp	Asn	Asn	Ser	Thr	Ile	Ala	Ala	Tyr	Leu
				170					175					180
Ala	Gly	Gln	Val	Asp	Leu	Ile	Ala	Ser	Gly	Asn	Val	Val	Met	Val
				185					190					195
Ala	Ile	Ser	Glu	Arg	Asn	Pro	Lys	Arg	Val	Pro	Ala	Leu	Lys	Val
				200					205					210
Lys	Leu	Lys	Asp	Ser	Pro	Val	Tyr	Val	Gly	Val	Asn	Lys	Asn	Glu
				215					220					225
Pro	Ala	Leu	Leu	Glu	Lys	Val	Asn	Gln	Ile	Leu	Val	Ala	Ala	Lys
				230					235					240
Ala	Asp	Gly	Ser	Leu	Gly	Lys	Asn	Ala	Met	Gln	Trp	Leu	Lys	Glu
				245					250					255
Pro	Leu	Pro	Ala	Asp	Leu									
				260										

<210> 15
 <211> 570
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 8077668CD1

<400> 15														
Met	Tyr	Asp	Pro	Pro	Lys	Val	Asn	Lys	Lys	Asn	Asp	Ser	Ala	Asp
1				5					10					15
His	Ser	Asp	Glu	Ser	Val	Glu	Ile	Gln	Ser	Ala	Leu	His	Ile	Cys
				20					25					30
Gly	Phe	Asp	Gln	Gly	Arg	Trp	Ile	Leu	Ser	Tyr	Arg	Arg	Ser	Pro
				35					40					45
Ala	Arg	Arg	His	Thr	Gly	Leu	Ala	Pro	Val	Leu	Gly	Val	Arg	Val
				50					55					60
Arg	Val	Cys	Val	Gly	Cys	Gln	Gly	Ala	Arg	Val	Pro	Ala	Trp	Pro
				65					70					75
Lys	Arg	Glu	Gly	Arg	Gly	Ser	Ala	Glu	Glu	Pro	Val	Glu	Arg	Lys
				80					85					90
Asp	Gly	Gln	Gln	Gly	Glu	Arg	Arg	Gly	Glu	Ala	Ser	Leu	Thr	Lys
				95					100					105
Asp	Ala	Val	Thr	Phe	Gln	Ser	Ser	Leu	Pro	Val	Gln	Ile	Thr	Arg
				110					115					120
Ile	Pro	Ala	Cys	Trp	Arg	Met	Thr	Gln	Met	Ser	Gln	Val	Gln	Glu
				125					130					135
Leu	Phe	His	Glu	Ala	Ala	Gln	Gln	Asp	Ala	Leu	Ala	Gln	Pro	Gln
				140					145					150
Pro	Trp	Trp	Lys	Thr	Gln	Leu	Phe	Met	Trp	Glu	Pro	Val	Leu	Phe
				155					160					165
Gly	Thr	Trp	Asp	Gly	Val	Phe	Thr	Ser	Cys	Met	Ile	Asn	Ile	Phe
				170					175					180
Gly	Val	Val	Leu	Phe	Leu	Arg	Thr	Gly	Trp	Leu	Val	Gly	Asn	Thr
				185					190					195
Gly	Val	Leu	Leu	Gly	Met	Phe	Leu	Val	Ser	Phe	Val	Ile	Leu	Val

Ala Leu Val Thr	200	Val Leu Ser Asp Ile	205	Gly Val Gly Glu Arg	210
Ser Ile Gly Ser	215	Gly Gly Val Tyr Ser	220	Met Ile Ser Ser Val	225
Gly Gly Gln Thr	230	Gly Gly Thr Ile Gly	235	Leu Leu Tyr Val Phe	240
Gln Met Tyr Ile	245	Thr Gly Phe Ala Glu	250	Ser Ile Ser Asp Leu	255
Gly Leu Gly Asn	260	Ile Trp Ala Val Arg	265	Gly Ile Ser Val Ala	270
Leu Leu Ala Leu	275	Leu Gly Ile Asn Leu	280	Ala Gly Val Lys Trp	285
Ile Arg Leu Gln	290	Leu Leu Leu Leu Phe	295	Leu Leu Ala Val Ser	300
Leu Asp Phe Val	305	Val Gly Ser Phe Thr	310	His Leu Asp Pro Glu	315
Gly Phe Ile Gly	320	Tyr Ser Pro Glu Leu	325	Gln Asn Asn Thr	330
Pro Asp Tyr Ser	335	Pro Gly Glu Ser Phe	340	Phe Thr Val Phe Gly	345
Phe Phe Pro Ala	350	Ala Thr Gly Val Met	355	Ala Gly Phe Asn Met	360
Gly Asp Leu Arg	365	Glu Pro Ala Ala Ser	370	Ile Pro Leu Gly Ser	375
Ala Ala Val Gly	380	Ile Ser Trp Phe Leu	385	Tyr Ile Gly Tyr Arg	390
His Gly Arg Leu	395	Gln His Gly Gly Arg	400	Pro Gln Gly Ala Cys	405
Gln His Ser Pro	410	Gly Leu Pro Gly Ser	415	Cys Trp His Leu Val	420
Ser Pro His Gly	425	Asn Gln Ser Glu Leu	430	Glu Ser Gly Arg Glu	435
Pro Arg Gln Lys	440	Arg Asp Cys Pro Phe	445	Cys Ser Glu Ser Ala	450
Thr Val Thr Asn	455	Leu Phe His Ile Pro	460	Ile Leu Leu Leu Thr	465
Gly Gly Leu Glu	470	Asn Ser Arg Leu Val	475	Gly Ser Asp Thr Ala	480
Ser Cys Ala Leu	485	Pro Gly Asn Ala Ala	490	Glu Glu Glu Cys Arg	495
Pro Asp His Arg	500	Ser Asn Pro Phe Phe	505	Pro Phe Leu Gly Leu	510
Pro Pro Ser Leu	515	Pro His Pro His Phe	520	Glu Leu Gly Asp Phe	525
Asn His Arg Val	530	Ser Arg Ile Thr Gly	535	Gly Ser Ile Lys Met	540
Ser Phe Ala Ile	545	Arg Arg Ile Gly Ala	550	Ala Ser Gln Leu Cys	555
	560		565		570

<210> 16

<211> 1033

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 55120485CD1

<400> 16

Met	Glu	Glu	Asn	Ser	Lys	Lys	Asp	His	Arg	Ala	Leu	Leu	Asn	Gln
1				5					10					15

Gly	Glu	Glu	Asp	Glu	Leu	Glu	Val	Phe	Gly	Tyr	Arg	Asp	His	Asn	
				20					25					30	
Val	Arg	Lys	Ala	Phe	Cys	Leu	Val	Ala	Ser	Val	Leu	Thr	Cys	Gly	
				35					40					45	
Gly	Leu	Leu	Leu	Val	Phe	Tyr	Trp	Arg	Pro	Gln	Trp	Arg	Val	Trp	
				50					55					60	
Ala	Asn	Cys	Ile	Pro	Cys	Pro	Leu	Gln	Glu	Ala	Asp	Thr	Val	Leu	
				65					70					75	
Leu	Arg	Thr	Thr	Asp	Glu	Phe	Gln	Arg	Tyr	Met	Arg	Lys	Lys	Val	
				80					85					90	
Phe	Cys	Leu	Tyr	Leu	Tyr	Thr	Leu	Lys	Phe	Pro	Val	Ser	Lys	Lys	
				95					100					105	
Trp	Glu	Glu	Ser	Leu	Val	Ala	Asp	Arg	His	Ser	Val	Ile	Asn	Gln	
				110					115					120	
Ala	Leu	Ile	Lys	Pro	Glu	Leu	Lys	Leu	Arg	Cys	Leu	Glu	Val	Gln	
				125					130					135	
Lys	Ile	Arg	Tyr	Val	Trp	Asn	Asp	Leu	Glu	Lys	Arg	Phe	Gln	Lys	
				140					145					150	
Val	Gly	Leu	Leu	Glu	Asp	Ser	Asn	Ser	Cys	Ser	Asp	Ile	His	Gln	
				155					160					165	
Thr	Phe	Gly	Leu	Gly	Leu	Thr	Ser	Glu	Glu	Gln	Glu	Val	Arg	Arg	
				170					175					180	
Leu	Val	Cys	Gly	Pro	Asn	Ala	Ile	Glu	Val	Glu	Ile	Gln	Pro	Ile	
				185					190					195	
Trp	Lys	Leu	Leu	Val	Lys	Gln	Val	Leu	Asn	Pro	Phe	Tyr	Val	Phe	
				200					205					210	
Gln	Ala	Phe	Thr	Leu	Thr	Leu	Trp	Leu	Ser	Gln	Gly	Tyr	Ile	Glu	
				215					220					225	
Tyr	Ser	Val	Ala	Ile	Ile	Ile	Leu	Thr	Val	Ile	Ser	Ile	Val	Leu	
				230					235					240	
Ser	Val	Tyr	Asp	Leu	Arg	Gln	Gln	Ser	Val	Lys	Leu	His	Asn	Leu	
				245					250					255	
Val	Glu	Asp	His	Asn	Lys	Val	Gln	Val	Thr	Ile	Ile	Val	Lys	Asp	
				260					265					270	
Lys	Gly	Leu	Glu	Glu	Leu	Glu	Ser	Arg	Leu	Leu	Val	Pro	Gly	Asp	
				275					280					285	
Ile	Leu	Ile	Leu	Pro	Gly	Lys	Phe	Ser	Leu	Pro	Cys	Asp	Ala	Val	
				290					295					300	
Leu	Ile	Asp	Gly	Ser	Cys	Val	Val	Asn	Glu	Gly	Met	Leu	Thr	Gly	
				305					310					315	
Glu	Ser	Ile	Pro	Val	Thr	Lys	Thr	Pro	Leu	Pro	Gln	Met	Glu	Asn	
				320					325					330	
Thr	Met	Pro	Trp	Lys	Cys	His	Ser	Leu	Glu	Asp	Tyr	Arg	Lys	His	
				335					340					345	
Val	Leu	Phe	Cys	Gly	Thr	Glu	Val	Ile	Gln	Val	Lys	Pro	Ser	Gly	
				350					355					360	
Gln	Gly	Pro	Val	Arg	Ala	Val	Val	Leu	Gln	Thr	Gly	Tyr	Asn	Thr	
				365					370					375	
Ala	Lys	Gly	Asp	Leu	Val	Arg	Ser	Ile	Leu	Tyr	Pro	Arg	Pro	Leu	
				380					385					390	
Asn	Phe	Lys	Leu	Tyr	Ser	Asp	Ala	Phe	Lys	Phe	Ile	Val	Phe	Leu	
				395					400					405	
Ala	Cys	Leu	Gly	Val	Met	Gly	Phe	Phe	Tyr	Ala	Leu	Gly	Val	Tyr	
				410					415					420	
Met	Tyr	His	Gly	Val	Pro	Pro	Lys	Asp	Thr	Val	Thr	Met	Ala	Leu	
				425					430					435	
Ile	Leu	Leu	Thr	Val	Thr	Val	Pro	Pro	Val	Leu	Pro	Ala	Ala	Leu	
				440					445					450	
Thr	Ile	Gly	Asn	Val	Tyr	Ala	Gln	Lys	Arg	Leu	Lys	Lys	Lys	Lys	
				455					460					465	
Ile	Phe	Cys	Ile	Ser	Pro	Gln	Arg	Ile	Asn	Met	Cys	Gly	Gln	Ile	
				470					475					480	
Asn	Leu	Val	Cys	Phe	Asp	Lys	Thr	Gly	Thr	Leu	Thr	Glu	Asp	Gly	

Leu Asp Leu Trp	485	Gly Thr Val Pro Thr	490	Ala Asp Asn Cys Phe	495
	500		505		510
Glu Ala His Ser	515	Phe Ala Ser Gly Gln	520	Ala Val Pro Trp Ser	525
Leu Cys Ala Ala	530	Met Ala Ser Cys His	535	Ser Leu Ile Leu Leu	540
Gly Thr Ile Gln	545	Gly Asp Pro Leu Asp	550	Leu Lys Met Phe Glu	555
Thr Ala Trp Lys	560	Met Glu Asp Cys Ile	565	Val Asp Ser Cys Lys	570
Gly Thr Ser Val	575	Ser Asn Ile Ile Lys	580	Pro Gly Pro Lys Ala	585
Lys Ser Pro Val	590	Glu Ala Ile Ile Thr	595	Leu Cys Gln Phe Pro	600
Ser Ser Ser Leu	605	Gln Arg Met Ser Val	610	Ile Ala Gln Leu Ala	615
Glu Asn His Phe	620	His Val Tyr Met Lys	625	Gly Ala Pro Glu Met	630
Ala Arg Phe Cys	635	Arg Ser Glu Thr Val	640	Pro Lys Asn Phe Pro	645
Glu Leu Arg Ser	650	Tyr Thr Val Gln Gly	655	Phe Arg Val Ile Ala	660
Ala His Lys Thr	665	Leu Lys Met Gly Asn	670	Leu Ser Glu Val Glu	675
Leu Ala Arg Glu	680	Lys Val Glu Ser Glu	685	Leu Thr Phe Leu Gly	690
Leu Ile Met Glu	695	Asn Arg Leu Lys Lys	700	Glu Thr Lys Leu Val	705
Lys Glu Leu Ser	710	Glu Ala Arg Ile Arg	715	Thr Val Met Ile Thr	720
Asp Asn Leu Gln	725	Thr Ala Ile Thr Val	730	Ala Lys Asn Ser Glu	735
Ile Pro Pro Gly	740	Ser Gln Val Ile Ile	745	Val Glu Ala Asp Glu	750
Glu Glu Phe Val	755	Pro Ala Ser Val Thr	760	Trp Gln Leu Val Glu	765
Gln Glu Thr Gly	770	Pro Gly Lys Lys Glu	775	Ile Tyr Met His Thr	780
Asn Ser Ser Thr	785	Pro Arg Gly Glu Gly	790	Gly Ser Cys Tyr His	795
Ala Met Ser Gly	800	Lys Ser Tyr Gln Val	805	Ile Phe Gln His Phe	810
Ser Leu Leu Pro	815	Lys Ile Leu Val Asn	820	Gly Thr Val Phe Ala	825
Met Ser Pro Gly	830	Gln Lys Ser Ser Leu	835	Ile Glu Glu Phe Gln	840
Leu Asn Ala Cys	845	Thr Val Gln Asn Glu	850	Ser Ile Ser Glu Leu	855
Met Ser Pro Thr	860	Ala Pro Glu Lys Met	865	Glu Ser Asn Ser Thr	870
Thr Ser Phe Glu	875	Asn Thr Thr Val Trp	880	Phe Leu Gly Thr Ile	885
Cys Ile Thr Val	890	Ala Leu Val Phe Ser	895	Lys Gly Lys Pro Phe	900
Gln Pro Thr Tyr	905	Thr Asn Tyr Ile Phe	910	Val Leu Val Leu Ile	915
Gln Leu Gly Val	920	Cys Leu Phe Ile Leu	925	Phe Ala Asp Ile Pro	930
Leu Tyr Arg Arg	935	Leu Asp Leu Leu Cys	940	Thr Pro Val Leu Trp	945
Ala Ser Ile Val	950	Ile Met Leu Ser Leu	955	Asn Phe Ile Val Ser	960

Val	Ala	Glu	Glu	Ala	Val	Ile	Glu	Asn	Arg	Ala	Leu	Trp	Met	Met	
				965					970					975	
Ile	Lys	Arg	Cys	Phe	Gly	Tyr	Gln	Ser	Lys	Ser	Gln	Tyr	Arg	Ile	
				980					985					990	
Trp	Gln	Arg	Asp	Leu	Ala	Asn	Asp	Pro	Ser	Trp	Pro	Pro	Leu	Asn	
				995					1000					1005	
Gln	Thr	Ser	His	Ser	Asp	Met	Pro	Glu	Cys	Gly	Arg	Gly	Val	Ser	
				1010					1015					1020	
Tyr	Ser	Asn	Pro	Val	Phe	Glu	Ser	Asn	Glu	Glu	Gln	Leu			
				1025					1030						

<210> 17
 <211> 496
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3112883CD1

<400> 17															
Met	Asp	Cys	Tyr	Arg	Thr	Ser	Leu	Ser	Ser	Ser	Trp	Ile	Tyr	Pro	
1				5					10					15	
Thr	Val	Ile	Leu	Cys	Leu	Phe	Gly	Phe	Phe	Ser	Met	Met	Arg	Pro	
				20					25					30	
Ser	Glu	Pro	Phe	Leu	Ile	Pro	Tyr	Leu	Ser	Gly	Pro	Asp	Lys	Asn	
				35					40					45	
Leu	Thr	Ser	Ala	Glu	Ile	Thr	Asn	Glu	Ile	Phe	Pro	Val	Trp	Thr	
				50					55					60	
Tyr	Ser	Tyr	Leu	Val	Leu	Leu	Leu	Pro	Val	Phe	Val	Leu	Thr	Asp	
				65					70					75	
Tyr	Val	Arg	Tyr	Lys	Pro	Val	Ile	Ile	Leu	Gln	Gly	Ile	Ser	Phe	
				80					85					90	
Ile	Ile	Thr	Trp	Leu	Leu	Leu	Phe	Gly	Gln	Gly	Val	Lys	Thr		
				95					100					105	
Met	Gln	Val	Val	Glu	Phe	Phe	Tyr	Gly	Met	Val	Thr	Ala	Ala	Glu	
				110					115					120	
Val	Ala	Tyr	Tyr	Ala	Tyr	Ile	Tyr	Ser	Val	Val	Ser	Pro	Glu	His	
				125					130					135	
Tyr	Gln	Arg	Val	Ser	Gly	Tyr	Cys	Arg	Ser	Val	Thr	Leu	Ala	Ala	
				140					145					150	
Tyr	Thr	Ala	Gly	Ser	Val	Leu	Ala	Gln	Leu	Leu	Val	Ser	Leu	Ala	
				155					160					165	
Asn	Met	Ser	Tyr	Phe	Tyr	Leu	Asn	Val	Ile	Ser	Leu	Ala	Ser	Val	
				170					175					180	
Ser	Val	Ala	Phe	Leu	Phe	Ser	Leu	Phe	Leu	Pro	Met	Pro	Lys	Lys	
				185					190					195	
Ser	Met	Phe	Phe	His	Ala	Lys	Pro	Ser	Arg	Glu	Ile	Lys	Lys	Ser	
				200					205					210	
Ser	Ser	Val	Asn	Pro	Val	Leu	Glu	Glu	Thr	His	Glu	Gly	Glu	Ala	
				215					220					225	
Pro	Gly	Cys	Glu	Glu	Gln	Lys	Pro	Thr	Ser	Glu	Ile	Leu	Ser	Thr	
				230					235					240	
Ser	Gly	Lys	Leu	Asn	Lys	Gly	Gln	Leu	Asn	Ser	Leu	Lys	Pro	Ser	
				245					250					255	
Asn	Val	Thr	Val	Asp	Val	Phe	Val	Gln	Trp	Phe	Gln	Asp	Leu	Lys	
				260					265					270	
Glu	Cys	Tyr	Ser	Ser	Lys	Arg	Leu	Phe	Tyr	Trp	Ser	Leu	Trp	Trp	
				275					280					285	
Ala	Phe	Ala	Thr	Ala	Gly	Phe	Asn	Gln	Val	Leu	Asn	Tyr	Val	Gln	
				290					295					300	
Ile	Leu	Trp	Asp	Tyr	Lys	Ala	Pro	Ser	Gln	Asp	Ser	Ser	Ile	Tyr	
				305					310					315	

Asn Gly Ala Val	Glu Ala Ile Ala Thr	Phe Gly Gly Ala Val	Ala
320	325	330	
Ala Phe Ala Val	Gly Tyr Val Lys Val	Asn Trp Asp Leu Leu	Gly
335	340	345	
Glu Leu Ala Leu	Val Val Phe Ser Val	Val Asn Ala Gly Ser	Leu
350	355	360	
Phe Leu Met His	Tyr Thr Ala Asn Ile	Trp Ala Cys Tyr Ala	Gly
365	370	375	
Tyr Leu Ile Phe	Lys Ser Ser Tyr Met	Leu Leu Ile Thr Ile	Ala
380	385	390	
Val Phe Gln Ile	Ala Val Asn Leu Asn	Val Glu Arg Tyr Ala	Leu
395	400	405	
Val Phe Gly Ile	Asn Thr Phe Ile Ala	Leu Val Ile Gln Thr	Ile
410	415	420	
Met Thr Val Ile	Val Val Asp Gln Arg	Gly Leu Asn Leu Pro	Val
425	430	435	
Ser Ile Gln Phe	Leu Val Tyr Gly Ser	Tyr Phe Ala Val Ile	Ala
440	445	450	
Gly Ile Phe Leu	Met Arg Ser Met Tyr	Ile Thr Tyr Ser Thr	Lys
455	460	465	
Ser Gln Lys Asp	Val Gln Ser Pro Ala	Pro Ser Glu Asn Pro	Asp
470	475	480	
Val Ser His Pro	Glu Glu Glu Ser Asn	Ile Ile Met Ser Thr	Lys
485	490	495	
Leu			

<210> 18
 <211> 573
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 4253888CD1

<400> 18	
Met Thr Asn Ser Lys	Gly Arg Ser Ile Thr Asp Lys Thr Ser Gly
1 5	10 15
Gly Pro Ser Ser Gly	Gly Gly Phe Val Asp Trp Thr Leu Arg Leu
20 25	30
Asn Thr Ile Gln Ser	Asp Lys Phe Leu Asn Leu Leu Leu Ser Met
35 40	45
Val Pro Val Ile Tyr	Gln Lys Asn Gln Glu Asp Arg His Lys Lys
50 55	60
Pro Asn Gly Ile Trp	Gln Asp Gly Leu Ser Thr Ala Val Gln Thr
65 70	75
Phe Ser Asn Arg Ser	Glu Gln His Met Glu Tyr His Ser Phe Ser
80 85	90
Glu Gln Ser Phe His	Ala Asn Asn Gly His Ala Ser Ser Ser Cys
95 100	105
Ser Gln Lys Tyr Asp	Asp Tyr Ala Asn Tyr Asn Tyr Cys Asp Gly
110 115	120
Arg Glu Thr Ser Glu	Thr Thr Ala Met Leu Gln Asp Glu Asp Ile
125 130	135
Ser Ser Asp Gly Asp	Glu Asp Ala Ile Val Glu Val Thr Pro Lys
140 145	150
Leu Pro Lys Glu Ser	Ser Gly Ile Met Ala Leu Gln Ile Leu Val
155 160	165
Pro Phe Leu Leu Ala	Gly Phe Gly Thr Val Ser Ala Gly Met Val
170 175	180
Leu Asp Ile Val Gln	His Trp Glu Val Phe Arg Lys Val Thr Glu
185 190	195

Val	Phe	Ile	Leu	Val	Pro	Ala	Leu	Leu	Gly	Leu	Lys	Gly	Asn	Leu
				200					205					210
Glu	Met	Thr	Leu	Ala	Ser	Arg	Leu	Ser	Thr	Ala	Val	Asn	Ile	Gly
				215					220					225
Lys	Met	Asp	Ser	Pro	Ile	Glu	Lys	Trp	Asn	Leu	Ile	Ile	Gly	Asn
				230					235					240
Leu	Ala	Leu	Lys	Gln	Val	Gln	Ala	Thr	Val	Val	Gly	Phe	Leu	Ala
				245					250					255
Ala	Val	Ala	Ala	Ile	Ile	Leu	Gly	Trp	Ile	Pro	Glu	Gly	Lys	Tyr
				260					265					270
Tyr	Leu	Asp	His	Ser	Ile	Leu	Leu	Cys	Ser	Ser	Ser	Val	Ala	Thr
				275					280					285
Ala	Phe	Ile	Ala	Ser	Leu	Leu	Gln	Gly	Ile	Ile	Met	Val	Gly	Val
				290					295					300
Ile	Val	Gly	Ser	Lys	Lys	Thr	Gly	Ile	Asn	Pro	Asp	Asn	Val	Ala
				305					310					315
Thr	Pro	Ile	Ala	Ala	Ser	Phe	Gly	Asp	Leu	Ile	Thr	Leu	Ala	Ile
				320					325					330
Leu	Ala	Trp	Ile	Ser	Gln	Gly	Leu	Tyr	Ser	Cys	Leu	Glu	Thr	Tyr
				335					340					345
Tyr	Tyr	Ile	Ser	Pro	Leu	Val	Gly	Val	Phe	Phe	Leu	Ala	Leu	Thr
				350					355					360
Pro	Ile	Trp	Ile	Ile	Ile	Ala	Ala	Lys	His	Pro	Ala	Thr	Arg	Thr
				365					370					375
Val	Leu	His	Ser	Gly	Trp	Glu	Pro	Val	Ile	Thr	Ala	Met	Val	Ile
				380					385					390
Ser	Ser	Ile	Gly	Gly	Leu	Ile	Leu	Asp	Thr	Thr	Val	Ser	Asp	Pro
				395					400					405
Asn	Leu	Val	Gly	Ile	Val	Val	Tyr	Thr	Pro	Val	Ile	Asn	Gly	Ile
				410					415					420
Gly	Gly	Asn	Leu	Val	Ala	Ile	Gln	Ala	Ser	Arg	Ile	Ser	Thr	Tyr
				425					430					435
Leu	His	Leu	His	Ser	Ile	Pro	Gly	Glu	Leu	Pro	Asp	Glu	Pro	Lys
				440					445					450
Gly	Cys	Tyr	Tyr	Pro	Phe	Arg	Thr	Phe	Phe	Gly	Pro	Gly	Val	Asn
				455					460					465
Asn	Lys	Ser	Ala	Gln	Val	Leu	Leu	Leu	Leu	Val	Ile	Pro	Gly	His
				470					475					480
Leu	Ile	Phe	Leu	Tyr	Thr	Ile	His	Leu	Met	Lys	Ser	Gly	His	Thr
				485					490					495
Ser	Leu	Thr	Ile	Ile	Phe	Ile	Val	Val	Tyr	Leu	Phe	Gly	Ala	Val
				500					505					510
Leu	Gln	Val	Phe	Thr	Leu	Leu	Trp	Ile	Ala	Asp	Trp	Met	Val	His
				515					520					525
His	Phe	Trp	Arg	Lys	Gly	Lys	Asp	Pro	Asp	Ser	Phe	Ser	Ile	Pro
				530					535					540
Tyr	Leu	Thr	Ala	Leu	Gly	Asp	Leu	Leu	Gly	Thr	Ala	Leu	Leu	Ala
				545					550					555
Leu	Ser	Phe	His	Phe	Leu	Trp	Leu	Ile	Gly	Asp	Arg	Asp	Gly	Asp
				560					565					570
Val	Gly	Asp												

<210> 19
 <211> 573
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7479974CD1

<400> 19

Met	Asp	Ala	Val	Lys	Tyr	Leu	Asn	Lys	Leu	Asn	Leu	Asp	Asn	Ile	
1				5					10					15	
Glu	Leu	Thr	Lys	Tyr	Leu	Phe	Phe	Thr	Gly	Lys	Gly	Gly	Val	Gly	
				20					25					30	
Lys	Thr	Thr	Ile	Ser	Ser	Phe	Ile	Ala	Leu	Asn	Leu	Ala	Glu	Asn	
				35					40					45	
Gly	Lys	Lys	Val	Ala	Leu	Val	Ser	Thr	Asp	Pro	Ala	Ser	Asn	Leu	
				50					55					60	
Gln	Asp	Val	Phe	Gln	Met	Glu	Leu	Ser	Asn	Lys	Leu	Thr	Lys	Tyr	
				65					70					75	
Gln	Pro	Ile	Pro	Asn	Leu	Ser	Ile	Ala	Asn	Phe	Asp	Pro	Ile	Val	
				80					85					90	
Ala	Ala	Asp	Asp	Tyr	Lys	Ala	Gln	Ser	Ile	Glu	Pro	Tyr	Glu	Gly	
				95					100					105	
Ile	Leu	Pro	Glu	Asp	Val	Leu	Ala	Glu	Met	Lys	Glu	Gln	Leu	Ser	
				110					115					120	
Gly	Ser	Cys	Thr	Val	Glu	Val	Ala	Ala	Phe	Asn	Glu	Phe	Thr	Asn	
				125					130					135	
Phe	Leu	Ser	Asp	Lys	Thr	Leu	Glu	Gln	Glu	Phe	Asp	Phe	Ile	Ile	
				140					145					150	
Phe	Asp	Thr	Ala	Pro	Thr	Gly	His	Thr	Leu	Arg	Met	Leu	Glu	Leu	
				155					160					165	
Pro	Ser	Ala	Trp	Thr	Asp	Tyr	Leu	Asn	Thr	Thr	Ser	Asn	Asp	Ala	
				170					175					180	
Ser	Cys	Leu	Gly	Gln	Leu	Ser	Gly	Leu	Asn	Glu	Asn	Arg	Val	Lys	
				185					190					195	
Tyr	Asn	Ser	Ala	Leu	Glu	Lys	Leu	Arg	Asn	Gln	Asp	Asp	Thr	Thr	
				200					205					210	
Met	Met	Leu	Val	Ala	Arg	Pro	Thr	His	Ser	Ser	Ile	Tyr	Glu	Ile	
				215					220					225	
Gln	Arg	Ala	Gln	Gln	Glu	Leu	Gln	Gln	Leu	Ser	Ile	Ser	Lys	Phe	
				230					235					240	
Lys	Val	Ile	Ile	Asn	Asn	Tyr	Ile	Glu	Glu	Ser	His	Gly	Leu	Ile	
				245					250					255	
Ser	Ser	Gln	Met	Lys	Ser	Glu	Gln	Asp	Lys	Asn	Ile	Asn	His	Phe	
				260					265					270	
Thr	Glu	Trp	Leu	Asn	Asn	Asn	His	Ala	Tyr	Tyr	Val	Pro	Tyr	Lys	
				275					280					285	
Lys	Gln	Lys	Glu	Glu	Gly	Ile	Glu	Asn	Leu	Thr	Asn	Leu	Leu	Asn	
				290					295					300	
Asp	Asp	Asn	Leu	Ile	Glu	Asn	Asp	Asp	Phe	Ile	Val	Glu	Asp	His	
				305					310					315	
Pro	Gln	Phe	Asn	Lys	Leu	Ile	Asp	Glu	Ile	Glu	Asn	Ser	Lys	Val	
				320					325					330	
Gln	Tyr	Leu	Phe	Thr	Met	Gly	Lys	Gly	Gly	Val	Gly	Lys	Thr	Thr	
				335					340					345	
Val	Ala	Thr	Gln	Leu	Ala	Thr	Ala	Leu	Ser	Asn	Lys	Gly	Tyr	Arg	
				350					355					360	
Val	Leu	Leu	Ala	Thr	Thr	Asp	Pro	Thr	Lys	Glu	Ile	Asn	Val	Glu	
				365					370					375	
Thr	Thr	Ser	Asn	Leu	Asn	Thr	Ala	Tyr	Ile	Asp	Glu	Glu	Gln	Ala	
				380					385					390	
Leu	Glu	Lys	Tyr	Lys	Lys	Glu	Val	Leu	Ala	Thr	Val	Asn	Asp	Asp	
				395					400					405	
Thr	Pro	Gln	Asp	Asp	Ile	Asp	Tyr	Ile	Met	Glu	Asp	Leu	Lys	Ser	
				410					415					420	
Pro	Cys	Thr	Glu	Glu	Ile	Ala	Phe	Phe	Lys	Ala	Phe	Ser	Asp	Ile	
				425					430					435	
Met	Glu	Asn	Gln	Asp	Asp	Met	Asp	Tyr	Val	Ile	Val	Asp	Thr	Ala	
				440					445					450	
Pro	Thr	Gly	His	Thr	Leu	Leu	Leu	Leu	Asp	Ser	Ser	Glu	Asn	His	
				455					460					465	
His	Arg	Glu	Leu	Lys	Lys	Lys	Ser	Thr	Gln	Thr	Thr	Ser	Asn	Val	

	470		475		480
Glu Thr Leu Leu	Pro Lys Ile Gln Asn	Lys Asn Leu Thr Gln Met			
	485		490		495
Ile Ile Val Thr	Leu Ala Glu Lys Thr	Pro Tyr Leu Glu Ser Lys			
	500		505		510
Arg Leu Val Glu	Asp Leu Asn Arg Ala	Asn Ile Gly His Asn Trp			
	515		520		525
Trp Val Val Asn	Gln Ser Leu Val Thr	Leu Asn Gln Arg Asp Asp			
	530		535		540
Leu Phe Ser Asn	Lys Lys Glu Asp Glu	Ser Phe Trp Ile Asn Lys			
	545		550		555
Ile Lys Asn Glu	Ser Phe Asp Asn Tyr	Phe Val Ile Pro Tyr Gly			
	560		565		570
Gly Leu Ser					

<210> 20
 <211> 248
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7483850CD1

<400> 20

Met Asn Ser Asn Leu Asn Leu Asp Gly Phe Leu Leu Pro Ile Ala	
1 5 10 15	
Val Met Asn Ala Ile Ser Ser Leu Pro Leu Leu Ile Leu Ala Pro	
20 25 30	
Phe Leu Glu Tyr Phe Ser Thr Cys Leu Phe Pro Ser Lys Arg Val	
35 40 45	
Gly Ser Phe Leu Ser Thr Cys Ile Ile Ala Gly Asn Leu Phe Ala	
50 55 60	
Ala Leu Ser Val Met Ile Ala Gly Phe Phe Glu Ile His Arg Lys	
65 70 75	
His Phe Pro Ala Val Glu Gln Pro Leu Ser Gly Lys Val Leu Thr	
80 85 90	
Val Ser Ser Met Pro Cys Phe Tyr Leu Ile Leu Gln Tyr Val Leu	
95 100 105	
Leu Gly Val Ala Glu Thr Leu Val Asn Pro Ala Leu Ser Val Ile	
110 115 120	
Ser Tyr Arg Phe Val Pro Ser Asn Val Arg Gly Thr Ser Met Asn	
125 130 135	
Phe Leu Thr Leu Phe Asn Gly Phe Gly Cys Phe Thr Gly Ala Leu	
140 145 150	
Leu Val Lys Leu Val Tyr Leu Ile Ser Glu Gly Lys Asn Arg Gln	
155 160 165	
Trp Phe Pro Asn Thr Leu Asn Lys Gly Asn Leu Glu Gly Phe Phe	
170 175 180	
Phe Phe Leu Ala Ser Leu Thr Leu Leu Asn Val Leu Gly Phe Cys	
185 190 195	
Ser Val Ser Gln Arg Tyr Cys Asn Leu Asn His Phe Asn Ala Gln	
200 205 210	
Asn Ile Arg Gly Ser Asn Leu Glu Glu Thr Leu Leu Leu His Glu	
215 220 225	
Lys Ser Leu Lys Phe Tyr Gly Ser Ile Gln Glu Phe Ser Ser Ser	
230 235 240	
Ile Asp Leu Trp Glu Thr Ala Leu	
245	

<210> 21
 <211> 761

<212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5508353CD1

<400> 21
 Met Lys Pro Ala Ser Pro Val Glu Glu Glu Val Ser Gln Val Cys
 1 5 10 15
 Glu Ser Pro Gln Cys Ser Ser Ser Ser Ala Cys Cys Thr Glu Thr
 20 25 30
 Glu Lys Gln His Gly Asp Ala Gly Leu Leu Asn Gly Lys Ala Glu
 35 40 45
 Ser Leu Pro Gly Gln Pro Leu Ala Cys Asn Leu Cys Tyr Glu Ala
 50 55 60
 Glu Ser Pro Asp Glu Ala Ala Leu Val Tyr Ala Ala Arg Ala Tyr
 65 70 75
 Gln Cys Thr Leu Arg Ser Arg Thr Pro Glu Gln Val Met Val Asp
 80 85 90
 Phe Ala Ala Leu Gly Pro Leu Thr Phe Gln Leu Leu His Ile Leu
 95 100 105
 Pro Phe Asp Ser Val Arg Lys Arg Met Ser Val Val Val Arg His
 110 115 120
 Pro Leu Ser Asn Gln Val Val Val Tyr Thr Lys Gly Ala Asp Ser
 125 130 135
 Val Ile Met Glu Leu Leu Ser Val Ala Ser Pro Asp Gly Ala Ser
 140 145 150
 Leu Glu Lys Gln Gln Met Ile Val Arg Glu Lys Thr Gln Lys His
 155 160 165
 Leu Asp Asp Tyr Ala Lys Gln Gly Leu Arg Thr Leu Cys Ile Ala
 170 175 180
 Lys Lys Val Met Ser Asp Thr Glu Tyr Ala Glu Trp Leu Arg Asn
 185 190 195
 His Phe Leu Ala Glu Thr Ser Ile Asp Asn Arg Glu Glu Leu Leu
 200 205 210
 Leu Glu Ser Ala Met Arg Leu Glu Asn Lys Leu Thr Leu Leu Gly
 215 220 225
 Ala Thr Gly Ile Glu Asp Arg Leu Gln Glu Gly Val Pro Glu Ser
 230 235 240
 Ile Glu Ala Leu His Lys Ala Gly Ile Lys Ile Trp Met Leu Thr
 245 250 255
 Gly Asp Lys Gln Glu Thr Ala Val Asn Ile Ala Tyr Ala Cys Lys
 260 265 270
 Leu Leu Glu Pro Asp Asp Lys Leu Phe Ile Leu Asn Thr Gln Ser
 275 280 285
 Lys Asp Ala Cys Gly Met Leu Met Ser Thr Ile Leu Lys Glu Leu
 290 295 300
 Gln Lys Lys Thr Gln Ala Leu Pro Glu Gln Val Ser Leu Ser Glu
 305 310 315
 Asp Leu Leu Gln Pro Pro Val Pro Arg Asp Ser Gly Leu Arg Ala
 320 325 330
 Gly Leu Ile Ile Thr Gly Lys Thr Leu Glu Phe Ala Leu Gln Glu
 335 340 345
 Ser Leu Gln Lys Gln Phe Leu Glu Leu Thr Ser Trp Gly Gln Ala
 350 355 360
 Val Val Cys Cys Arg Ala Thr Pro Leu Gln Lys Ser Glu Val Val
 365 370 375
 Lys Leu Val Arg Ser His Leu Gln Val Met Thr Leu Ala Ile Gly
 380 385 390
 Asp Gly Ala Asn Asp Val Ser Met Ile Gln Val Ala Asp Ile Gly
 395 400 405
 Ile Gly Val Ser Gly Gln Glu Gly Met Gln Ala Val Met Ala Ser

Asp Phe Ala Val	410	415	420
Ser Gln Phe Lys His	425	430	435
Val His Gly His	440	445	450
Tyr Phe Phe Tyr	455	460	465
Tyr Gln Phe Phe	470	475	480
Trp Val Leu Ile	485	490	495
Val Ile Tyr Gly	500	505	510
Met Gln Leu Pro	515	520	525
Tyr Leu Pro His	530	535	540
Gln Ser Leu Val	545	550	555
Ser Asp Thr Asp	560	565	570
Ala Leu Phe Ile	575	580	585
Leu Thr Trp Ile	590	595	600
Tyr Phe Leu Phe	605	610	615
Asn Pro Pro Ser	620	625	630
Asp Pro Val Phe	635	640	645
Leu Leu Pro Arg	650	655	660
Pro Ser Pro Ile	665	670	675
Glu Glu Arg Thr	680	685	690
Met Asn Gln Val	695	700	705
Ser Gly Arg Arg	710	715	720
Lys Ser Ala Ser	725	730	735
Cys Glu Thr Ala	740	745	750
Glu Met Ala Gly	755	760	

<210> 22
 <211> 219
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 8543628CD1

<400> 22
 Met Ala Ser Ser Gly Leu Glu Leu Leu Trp Val Ser Leu Pro Gln
 1 5 10 15
 Leu Gly Lys Gly Ala Ala Gln Thr Leu Ser Ile Ser Phe Leu Ser
 20 25 30
 Ile Gly Phe Ser Thr Val Gly Gly Val Leu Tyr Gly Val Leu Arg

	35		40		45
Thr Leu Asn Asn Lys Ala Ile Asn Gly Val Leu Arg Val Tyr Leu					
	50		55		60
Glu Leu Phe Arg Ala Ile Pro Val Leu Val Trp Leu Tyr Leu Leu					
	65		70		75
Phe Phe Gly Val Pro Ile Phe Phe Gly Leu Ser Ile Pro Ser Phe					
	80		85		90
Trp Cys Ala Val Leu Val Leu Ser Leu Trp Gly Ala Ser Glu Val					
	95		100		105
Gly Glu Val Val Arg Gly Ala Leu His Ser Leu Pro Arg Gly Gln					
	110		115		120
Arg Glu Ala Gly Leu Ser Ile Gly Leu Ser Asp Leu Gln Leu Tyr					
	125		130		135
Gly Tyr Val Leu Leu Pro Gln Ala Leu Arg Arg Met Thr Pro Pro					
	140		145		150
Thr Ile Asn Val Tyr Thr Arg Ile Ile Lys Thr Ser Ser Leu Ala					
	155		160		165
Val Leu Ile Gly Val Val Asp Val Ile Lys Val Gly Gln Gln Ile					
	170		175		180
Ile Glu Arg Thr Tyr Glu Ser Val Leu Ile Tyr Gly Ala Leu Phe					
	185		190		195
Leu Phe Phe Phe Phe Ile Cys Tyr Pro Leu Ser Ala Ala Ser Lys					
	200		205		210
Leu Leu Glu Arg Arg Trp Ala Gln Ala					
	215				

<210> 23

<211> 463

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7482754CD1

<400> 23

Met Glu Gly Gln Thr Pro Gly Ser Arg Gly Leu Pro Glu Lys Pro					
1	5		10		15
His Pro Ala Thr Ala Ala Ala Thr Leu Ser Ser Met Gly Ala Val					
	20		25		30
Phe Ile Leu Met Lys Ser Ala Leu Gly Ala Gly Leu Leu Asn Phe					
	35		40		45
Pro Trp Ala Phe Ser Lys Ala Gly Gly Val Val Pro Ala Phe Leu					
	50		55		60
Val Glu Leu Val Ser Leu Val Phe Leu Ile Ser Gly Leu Val Ile					
	65		70		75
Leu Gly Tyr Ala Ala Ala Val Ser Gly Gln Ala Thr Tyr Gln Gly					
	80		85		90
Val Val Arg Gly Leu Cys Gly Pro Ala Ile Gly Lys Leu Cys Glu					
	95		100		105
Ala Cys Phe Leu Leu Asn Leu Leu Met Ile Ser Val Ala Phe Leu					
	110		115		120
Arg Val Ile Gly Asp Gln Leu Glu Lys Leu Cys Asp Ser Leu Leu					
	125		130		135
Ser Gly Thr Pro Pro Ala Pro Gln Pro Trp Tyr Ala Asp Gln Arg					
	140		145		150
Phe Thr Leu Pro Leu Leu Ser Val Leu Val Ile Leu Pro Leu Ser					
	155		160		165
Ala Pro Arg Glu Ile Ala Phe Gln Lys Tyr Thr Ser Pro Ser His					
	170		175		180
Gly His Cys Val Ser Ile Leu Gly Thr Leu Ala Ala Cys Tyr Leu					
	185		190		195
Ala Leu Val Ile Thr Val Gln Tyr Tyr Leu Trp Pro Gln Gly Leu					

Val Arg Glu Ser	200	Pro Ser Leu Ser	205	Pro Ala Ser Trp Thr	210
Val Phe Ser Val	215	Phe Pro Thr Ile Cys	220	Phe Gly Phe Gln Cys	225
Glu Ala Ala Val	230	Ser Ile Tyr Cys Ser	235	Met Arg Lys Arg Ser	240
Ser His Trp Ala	245	Leu Val Ser Val Leu	250	Ser Leu Leu Ala Cys	255
Leu Ile Tyr Ser	260	Leu Thr Gly Val Tyr	265	Gly Phe Leu Thr Phe	270
Thr Glu Val Ser	275	Ala Asp Val Leu Met	280	Ser Tyr Pro Gly Asn	285
Met Val Ile Ile	290	Val Ala Arg Val Leu	295	Phe Ala Val Ser Ile	300
Thr Val Tyr Pro	305	Ile Val Leu Phe Leu	310	Gly Arg Ser Val Met	315
Asp Phe Trp Arg	320	Arg Ser Cys Leu Gly	325	Gly Trp Gly Pro Ser	330
Leu Ala Asp Pro	335	Ser Gly Leu Trp Val	340	Arg Met Pro Leu Thr	345
Leu Trp Val Thr	350	Val Thr Leu Ala Met	355	Ala Leu Phe Met Pro	360
Leu Ser Glu Ile	365	Val Ser Ile Ile Gly	370	Gly Ile Ser Ser Phe	375
Ile Phe Ile Phe	380	Pro Gly Pro Gly Gly	385	Lys His Arg Phe Cys	390
Gly Trp Phe Leu	395	Arg Lys Pro Ser Gln	400	Thr Ala Gln Ala Leu	405
Glu Lys Gly Lys	410	Pro Ala Arg Phe Val	415	Pro His Leu Cys Asn	420
Cys Arg Ala Tyr	425	Arg Thr Lys Ser Gln	430	Val Arg Asn Leu Arg	435
Thr Gly Arg Glu	440	Ser Leu Ser Thr Gln	445	Tyr Glu Gly Ile	450
	455		460		

<210> 24

<211> 1043

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3794818CD1

<400> 24

Met Glu Phe Val Arg	Ala Leu Trp Leu Gly	Leu Ala Leu Ala Leu
1	5	10
Gly Pro Gly Ser Ala	Gly Gly His Pro Gln	Pro Cys Gly Val Leu
20	25	30
Ala Arg Leu Gly Gly	Ser Val Arg Leu Gly	Ala Leu Leu Pro Arg
35	40	45
Ala Pro Leu Ala Arg	Ala Arg Ala Arg Ala	Ala Leu Ala Arg Ala
50	55	60
Ala Leu Ala Pro Arg	Leu Pro His Asn Leu	Ser Leu Glu Leu Val
65	70	75
Val Ala Ala Pro Pro	Ala Arg Asp Pro Ala	Ser Leu Thr Arg Gly
80	85	90
Leu Cys Gln Ala Leu	Val Pro Pro Gly Val	Ala Ala Leu Leu Ala
95	100	105
Phe Pro Glu Ala Arg	Pro Glu Leu Leu Gln	Leu His Phe Leu Ala
110	115	120
Ala Ala Thr Glu Thr	Pro Val Leu Ser Leu	Leu Arg Arg Glu Ala

Arg	Ala	Pro	Leu	125	Gly	Ala	Pro	Asn	Pro	130	Phe	His	Leu	Gln	Leu	His	135
Trp	Ala	Ser	Pro	140	Leu	Glu	Thr	Leu	Leu	145	Asp	Val	Leu	Val	Ala	Val	150
Leu	Gln	Ala	His	155	Ala	Trp	Glu	Asp	Val	160	Gly	Leu	Ala	Leu	Cys	Arg	165
Thr	Gln	Asp	Pro	170	Gly	Gly	Leu	Val	Ala	175	Leu	Trp	Thr	Ser	Arg	Ala	180
Gly	Arg	Pro	Pro	185	Gln	Leu	Val	Leu	Asp	190	Leu	Ser	Arg	Arg	Asp	Thr	195
Gly	Asp	Ala	Gly	200	Leu	Arg	Ala	Arg	Leu	205	Ala	Pro	Met	Ala	Ala	Pro	210
Val	Gly	Gly	Glu	215	Ala	Pro	Val	Pro	Ala	220	Ala	Val	Leu	Leu	Gly	Cys	225
Asp	Ile	Ala	Arg	230	Ala	Arg	Arg	Val	Leu	235	Glu	Ala	Val	Pro	Pro	Gly	240
Pro	His	Trp	Leu	245	Leu	Gly	Thr	Pro	Leu	250	Pro	Pro	Lys	Ala	Leu	Pro	255
Thr	Ala	Gly	Leu	260	Pro	Pro	Gly	Leu	Leu	265	Ala	Leu	Gly	Glu	Val	Ala	270
Arg	Pro	Pro	Leu	275	Glu	Ala	Ala	Ile	His	280	Asp	Ile	Val	Gln	Leu	Val	285
Ala	Arg	Ala	Leu	290	Gly	Ser	Ala	Ala	Gln	295	Val	Gln	Pro	Lys	Arg	Ala	300
Leu	Leu	Pro	Ala	305	Pro	Val	Asn	Cys	Gly	310	Asp	Leu	Gln	Pro	Ala	Gly	315
Pro	Glu	Ser	Pro	320	Gly	Arg	Phe	Leu	Ala	325	Arg	Phe	Leu	Ala	Asn	Thr	330
Ser	Phe	Gln	Gly	335	Arg	Thr	Gly	Pro	Val	340	Val	Thr	Gly	Ser	Ser	Ser	345
Gln	Val	His	Met	350	Ser	Arg	His	Phe	Lys	355	Val	Trp	Ser	Leu	Arg	Arg	360
Asp	Pro	Arg	Gly	365	Ala	Pro	Ala	Trp	Ala	370	Thr	Val	Gly	Ser	Trp	Arg	375
Asp	Gly	Gln	Leu	380	Asp	Leu	Glu	Pro	Gly	385	Gly	Ala	Ser	Ala	Arg	Pro	390
Pro	Pro	Pro	Gln	395	Gly	Ala	Gln	Val	Trp	400	Pro	Lys	Leu	Arg	Val	Val	405
Thr	Leu	Leu	Glu	410	His	Pro	Phe	Val	Phe	415	Ala	Arg	Asp	Pro	Asp	Glu	420
Asp	Gly	Gln	Cys	425	Pro	Ala	Gly	Gln	Leu	430	Cys	Leu	Asp	Pro	Gly	Thr	435
Asn	Asp	Ser	Ala	440	Thr	Leu	Asp	Ala	Leu	445	Phe	Ala	Ala	Leu	Ala	Asn	450
Gly	Ser	Ala	Pro	455	Arg	Ala	Leu	Arg	Lys	460	Cys	Cys	Tyr	Gly	Tyr	Cys	465
Ile	Asp	Leu	Leu	470	Glu	Arg	Leu	Ala	Glu	475	Asp	Thr	Pro	Phe	Asp	Phe	480
Glu	Leu	Tyr	Leu	485	Val	Gly	Asp	Gly	Lys	490	Tyr	Gly	Ala	Leu	Arg	Asp	495
Gly	Arg	Trp	Thr	500	Gly	Leu	Val	Gly	Asp	505	Leu	Leu	Ala	Gly	Arg	Ala	510
His	Met	Ala	Val	515	Thr	Ser	Phe	Ser	Ile	520	Asn	Ser	Ala	Arg	Ser	Gln	525
Val	Val	Asp	Phe	530	Thr	Ser	Pro	Phe	Phe	535	Ser	Thr	Ser	Leu	Gly	Ile	540
Met	Val	Arg	Ala	545	Arg	Asp	Thr	Ala	Ser	550	Pro	Ile	Gly	Ala	Phe	Met	555
Trp	Pro	Leu	His	560	Trp	Ser	Thr	Trp	Leu	565	Gly	Val	Phe	Ala	Ala	Leu	570
His	Leu	Thr	Ala	575	Leu	Phe	Leu	Thr	Val	580	Tyr	Glu	Trp	Arg	Ser	Pro	585
				590						595							600

Tyr	Gly	Leu	Thr	Pro	Arg	Gly	Arg	Asn	Arg	Ser	Thr	Val	Phe	Ser	605	610	615
Tyr	Ser	Ser	Ala	Leu	Asn	Leu	Cys	Tyr	Ala	Ile	Leu	Phe	Arg	Arg	620	625	630
Thr	Val	Ser	Ser	Lys	Thr	Pro	Lys	Cys	Pro	Thr	Gly	Arg	Leu	Leu	635	640	645
Met	Asn	Leu	Trp	Ala	Ile	Phe	Cys	Leu	Leu	Val	Leu	Ser	Ser	Tyr	650	655	660
Thr	Ala	Asn	Leu	Ala	Ala	Val	Met	Val	Gly	Asp	Lys	Thr	Phe	Glu	665	670	675
Glu	Leu	Ser	Gly	Ile	His	Asp	Pro	Lys	Leu	His	His	Pro	Ala	Gln	680	685	690
Gly	Phe	Arg	Phe	Gly	Thr	Val	Trp	Glu	Ser	Ser	Ala	Glu	Ala	Tyr	695	700	705
Ile	Lys	Lys	Ser	Phe	Pro	Asp	Met	His	Ala	His	Met	Arg	Arg	His	710	715	720
Ser	Ala	Pro	Thr	Thr	Pro	Arg	Gly	Val	Ala	Met	Leu	Thr	Ser	Asp	725	730	735
Pro	Pro	Lys	Leu	Asn	Ala	Phe	Ile	Met	Asp	Lys	Ser	Leu	Leu	Asp	740	745	750
Tyr	Glu	Val	Ser	Ile	Asp	Ala	Asp	Cys	Lys	Leu	Leu	Thr	Val	Gly	755	760	765
Lys	Pro	Phe	Ala	Ile	Glu	Gly	Tyr	Gly	Ile	Gly	Leu	Pro	Gln	Asn	770	775	780
Ser	Pro	Leu	Thr	Ser	Asn	Leu	Ser	Glu	Phe	Ile	Ser	Arg	Tyr	Lys	785	790	795
Ser	Ser	Gly	Phe	Ile	Asp	Leu	Leu	His	Asp	Lys	Trp	Tyr	Lys	Met	800	805	810
Val	Pro	Cys	Gly	Lys	Arg	Val	Phe	Ala	Val	Thr	Glu	Thr	Leu	Gln	815	820	825
Met	Ser	Ile	Tyr	His	Phe	Ala	Gly	Leu	Phe	Val	Leu	Leu	Cys	Leu	830	835	840
Gly	Leu	Gly	Ser	Ala	Leu	Leu	Ser	Ser	Leu	Gly	Glu	His	Ala	Phe	845	850	855
Phe	Arg	Leu	Ala	Leu	Pro	Arg	Ile	Arg	Lys	Gly	Ser	Arg	Leu	Gln	860	865	870
Tyr	Trp	Leu	His	Thr	Ser	Gln	Lys	Ile	His	Arg	Ala	Leu	Asn	Thr	875	880	885
Glu	Pro	Pro	Glu	Gly	Ser	Lys	Glu	Glu	Thr	Ala	Glu	Ala	Glu	Pro	890	895	900
Ser	Gly	Pro	Glu	Val	Glu	Gln	Gln	Gln	Gln	Gln	Gln	Asp	Gln	Pro	905	910	915
Thr	Ala	Pro	Glu	Gly	Trp	Lys	Arg	Ala	Arg	Arg	Ala	Val	Asp	Lys	920	925	930
Glu	Arg	Arg	Val	Arg	Phe	Leu	Leu	Glu	Pro	Ala	Val	Val	Val	Ala	935	940	945
Pro	Glu	Ala	Asp	Ala	Glu	Ala	Glu	Ala	Ala	Pro	Arg	Glu	Gly	Pro	950	955	960
Val	Trp	Leu	Cys	Ser	Tyr	Gly	Arg	Pro	Pro	Ala	Ala	Arg	Pro	Thr	965	970	975
Gly	Ala	Pro	Gln	Pro	Gly	Glu	Leu	Gln	Glu	Leu	Glu	Arg	Arg	Ile	980	985	990
Glu	Val	Ala	Arg	Glu	Arg	Leu	Arg	Gln	Ala	Leu	Val	Arg	Arg	Gly	995	1000	1005
Gln	Leu	Leu	Ala	Gln	Leu	Gly	Asp	Ser	Ala	Arg	His	Arg	Pro	Arg	1010	1015	1020
Arg	Leu	Leu	Gln	Ala	Arg	Ala	Ala	Pro	Ala	Glu	Ala	Pro	Pro	His	1025	1030	1035
Ser	Gly	Arg	Pro	Gly	Ser	Gln	Glu								1040		

<210> 25
<211> 480

<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4717525CD1

<400> 25
Met Arg Gly Ser Pro Gly Asp Ala Glu Arg Arg Gln Arg Trp Gly
1 5 10 15
Arg Leu Phe Glu Glu Leu Asp Ser Asn Lys Asp Gly Arg Val Asp
20 25 30
Val His Glu Leu Arg Gln Gly Leu Ala Arg Leu Gly Gly Gly Asn
35 40 45
Pro Asp Pro Gly Ala Gln Gln Gly Ile Ser Ser Glu Gly Asp Ala
50 55 60
Asp Pro Asp Gly Gly Leu Asp Leu Glu Glu Phe Ser Arg Tyr Leu
65 70 75
Gln Glu Arg Glu Gln Arg Leu Leu Leu Met Phe His Ser Leu Asp
80 85 90
Arg Asn Gln Asp Gly His Ile Asp Val Ser Glu Ile Gln Gln Ser
95 100 105
Phe Arg Ala Leu Gly Ile Ser Ile Ser Leu Glu Gln Ala Glu Lys
110 115 120
Ile Leu His Ser Met Asp Arg Asp Gly Thr Met Thr Ile Asp Trp
125 130 135
Gln Glu Trp Arg Asp His Phe Leu Leu His Ser Leu Glu Asn Val
140 145 150
Glu Asp Val Leu Tyr Phe Trp Lys His Ser Thr Val Leu Asp Ile
155 160 165
Gly Glu Cys Leu Thr Val Pro Asp Glu Phe Ser Lys Gln Glu Lys
170 175 180
Leu Thr Gly Met Trp Trp Lys Gln Leu Val Ala Gly Ala Val Ala
185 190 195
Gly Ala Val Ser Arg Thr Gly Thr Ala Pro Leu Asp Arg Leu Lys
200 205 210
Val Phe Met Gln Val His Ala Ser Lys Thr Asn Arg Leu Asn Ile
215 220 225
Leu Gly Gly Leu Arg Ser Met Val Leu Glu Gly Gly Ile Arg Ser
230 235 240
Leu Trp Arg Gly Asn Gly Ile Asn Val Leu Lys Ile Ala Pro Glu
245 250 255
Ser Ala Ile Lys Phe Met Ala Tyr Glu Gln Ile Lys Arg Ala Ile
260 265 270
Leu Gly Gln Gln Glu Thr Leu His Val Gln Glu Arg Phe Val Ala
275 280 285
Gly Ser Leu Ala Gly Ala Thr Ala Gln Thr Ile Ile Tyr Pro Met
290 295 300
Glu Thr Leu Lys Asn Trp Trp Leu Gln Gln Tyr Ser His Asp Ser
305 310 315
Ala Asp Pro Gly Ile Leu Val Leu Leu Ala Cys Gly Thr Ile Ser
320 325 330
Ser Thr Cys Gly Gln Ile Ala Ser Tyr Pro Leu Ala Leu Val Arg
335 340 345
Thr Arg Met Gln Ala Gln Ala Ser Ile Glu Gly Gly Pro Gln Leu
350 355 360
Ser Met Leu Gly Leu Leu Arg His Ile Leu Ser Gln Glu Gly Met
365 370 375
Arg Gly Leu Tyr Arg Gly Ile Ala Pro Asn Phe Met Lys Val Ile
380 385 390
Pro Ala Val Ser Ile Ser Tyr Val Val Tyr Glu Asn Met Lys Gln
395 400 405
Ala Leu Gly Val Thr Ser Arg Leu Glu Tyr Ser Gly Ser Ile Ser

Asp His Cys Asn	410	Cys Leu Pro Gly Ser Ser Asp Ser Pro	415	420
	425		430	435
Ser Ala Ser Arg Val	440	Ala Gly Ile Thr Gly Phe His His Val		450
Gln Ala His Leu Gly	455	Leu Val Gly Ser Arg Asn Ser Ala Ala		465
Ser Leu Pro Thr Cys	470	Trp Asp Tyr Arg Lys Pro Val Val Met		480

<210> 26
 <211> 518
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5091793CD1

<400> 26

Met Ala Gly Leu Arg	Asn Glu Ser Glu Gln	Glu Pro Leu Leu Gly
1	5	10 15
Asp Thr Pro Gly Ser	Arg Glu Trp Asp Ile	Leu Glu Thr Glu Glu
	20	25 30
His Tyr Lys Ser Arg	Trp Arg Ser Ile Arg	Ile Leu Tyr Leu Thr
	35	40 45
Met Phe Leu Ser Ser	Val Gly Phe Ser Val	Val Met Met Ser Ile
	50	55 60
Trp Pro Tyr Leu Gln	Lys Ile Asp Pro Thr	Ala Asp Thr Ser Phe
	65	70 75
Leu Gly Trp Val Ile	Ala Ser Tyr Ser Leu	Gly Gln Met Val Ala
	80	85 90
Ser Pro Ile Phe Gly	Leu Trp Ser Asn Tyr	Arg Pro Arg Lys Glu
	95	100 105
Pro Leu Ile Val Ser	Ile Leu Ile Ser Val	Ala Ala Asn Cys Leu
	110	115 120
Tyr Ala Tyr Leu His	Ile Pro Ala Ser His	Asn Lys Tyr Tyr Met
	125	130 135
Leu Val Ala Arg Gly	Leu Leu Gly Ile Gly	Ala Gly Asn Val Ala
	140	145 150
Val Val Arg Ser Tyr	Thr Ala Gly Ala Thr	Ser Leu Gln Glu Arg
	155	160 165
Thr Ser Ser Met Ala	Asn Ile Ser Met Cys	Gln Ala Leu Gly Phe
	170	175 180
Ile Leu Gly Pro Val	Phe Gln Thr Cys Phe	Thr Phe Leu Gly Glu
	185	190 195
Lys Gly Val Thr Trp	Asp Val Ile Lys Leu	Gln Ile Asn Met Tyr
	200	205 210
Thr Thr Pro Val Leu	Leu Ser Ala Phe Leu	Gly Ile Leu Asn Ile
	215	220 225
Ile Leu Ile Leu Ala	Ile Leu Arg Glu His	Arg Val Asp Asp Ser
	230	235 240
Gly Arg Gln Cys Lys	Ser Ile Asn Phe Glu	Glu Ala Ser Thr Asp
	245	250 255
Glu Ala Gln Val Pro	Gln Gly Asn Ile Asp	Gln Val Ala Val Val
	260	265 270
Ala Ile Asn Val Leu	Phe Phe Val Thr Leu	Phe Ile Phe Ala Leu
	275	280 285
Phe Glu Thr Ile Ile	Thr Pro Leu Thr Met	Asp Met Tyr Ala Trp
	290	295 300
Thr Gln Glu Gln Ala	Val Leu Tyr Asn Gly	Ile Ile Leu Ala Ala
	305	310 315

Leu Gly Val Glu	Ala Val Val Ile Phe	Leu Gly Val Lys Leu Leu	
320		325	330
Ser Lys Lys Ile	Gly Glu Arg Ala Ile	Leu Leu Gly Gly Leu Ile	
335		340	345
Val Val Trp Val	Gly Phe Phe Ile Leu	Leu Pro Trp Gly Asn Gln	
350		355	360
Phe Pro Lys Ile	Gln Trp Glu Asp Leu	His Asn Asn Ser Ile Pro	
365		370	375
Asn Thr Thr Phe	Gly Glu Ile Ile Ile	Gly Leu Trp Lys Ser Pro	
380		385	390
Met Glu Asp Asp	Asn Glu Arg Pro Thr	Gly Cys Ser Ile Glu Gln	
395		400	405
Ala Trp Cys Leu	Tyr Thr Pro Val Ile	His Leu Ala Gln Phe Leu	
410		415	420
Thr Ser Ala Val	Leu Ile Gly Leu Gly	Tyr Pro Val Cys Asn Leu	
425		430	435
Met Ser Tyr Thr	Leu Tyr Ser Lys Ile	Leu Gly Pro Lys Pro Gln	
440		445	450
Gly Val Tyr Met	Gly Trp Leu Thr Ala	Ser Gly Ser Gly Ala Arg	
455		460	465
Ile Leu Gly Pro	Met Phe Ile Ser Gln	Val Tyr Ala His Trp Gly	
470		475	480
Pro Arg Trp Ala	Phe Ser Leu Val Cys	Gly Ile Ile Val Leu Thr	
485		490	495
Ile Thr Leu Leu	Gly Val Val Tyr Lys	Arg Leu Ile Ala Leu Ser	
500		505	510
Val Arg Tyr Gly	Arg Ile Gln Glu		
515			

<210> 27
 <211> 501
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5945527CD1

<400> 27	
Met Arg Ser Ser Leu Ala Pro Gly Val Trp Phe Phe Arg Ala Phe	
1 5 10 15	
Ser Arg Asp Ser Trp Phe Arg Gly Leu Ile Leu Leu Leu Thr Phe	
20 25 30	
Leu Ile Tyr Ala Cys Tyr His Met Ser Arg Lys Pro Ile Ser Ile	
35 40 45	
Val Lys Ser Arg Leu His Gln Asn Cys Ser Glu Gln Ile Lys Pro	
50 55 60	
Ile Asn Asp Thr His Ser Leu Asn Asp Thr Met Trp Cys Ser Trp	
65 70 75	
Ala Pro Phe Asp Lys Asp Asn Tyr Lys Glu Leu Leu Gly Gly Val	
80 85 90	
Asp Asn Ala Phe Leu Ile Ala Tyr Ala Ile Gly Met Phe Ile Ser	
95 100 105	
Gly Val Phe Gly Glu Arg Leu Pro Leu Arg Tyr Tyr Leu Ser Ala	
110 115 120	
Gly Met Leu Leu Ser Gly Leu Phe Thr Ser Leu Phe Gly Leu Gly	
125 130 135	
Tyr Phe Trp Asn Ile His Glu Leu Trp Tyr Phe Val Val Ile Gln	
140 145 150	
Val Cys Asn Gly Leu Val Gln Thr Thr Gly Trp Pro Ser Val Val	
155 160 165	
Thr Cys Val Gly Asn Trp Phe Gly Lys Gly Lys Arg Gly Phe Ile	
170 175 180	

Met Gly Ile Trp	Asn Ser His Thr Ser	Val Gly Asn Ile Leu Gly	
185		190	195
Ser Leu Ile Ala	Gly Ile Trp Val Asn Gly	Gln Trp Gly Leu Ser	
200		205	210
Phe Ile Val Pro	Gly Ile Ile Thr Ala Val	Met Gly Val Ile Thr	
215		220	225
Phe Leu Phe Leu	Ile Glu His Pro Glu Asp	Val Asp Cys Ala Pro	
230		235	240
Pro Gln His His	Gly Glu Pro Ala Glu Asn	Gln Asp Asn Pro Glu	
245		250	255
Asp Pro Gly Asn	Ser Pro Cys Ser Ile Arg	Glu Ser Gly Leu Glu	
260		265	270
Thr Val Ala Lys	Cys Ser Lys Gly Pro Cys	Glu Glu Pro Ala Ala	
275		280	285
Ile Ser Phe Phe	Gly Ala Leu Arg Ile Pro	Gly Val Val Glu Phe	
290		295	300
Ser Leu Cys Leu	Leu Phe Ala Lys Leu Val	Ser Tyr Thr Phe Leu	
305		310	315
Tyr Trp Leu Pro	Leu Tyr Ile Ala Asn Val	Ala His Phe Ser Ala	
320		325	330
Lys Glu Ala Gly	Asp Leu Ser Thr Leu Phe	Asp Val Gly Gly Ile	
335		340	345
Ile Gly Gly Ile	Val Ala Gly Leu Val Ser	Asp Tyr Thr Asn Gly	
350		355	360
Arg Ala Thr Thr	Cys Cys Val Met Leu Ile	Leu Ala Ala Pro Met	
365		370	375
Met Phe Leu Tyr	Asn Tyr Ile Gly Gln Asp	Gly Ile Ala Ser Ser	
380		385	390
Ile Val Met Leu	Ile Ile Cys Gly Gly Leu	Val Asn Gly Pro Tyr	
395		400	405
Ala Leu Ile Thr	Thr Ala Val Ser Ala Asp	Leu Gly Thr His Lys	
410		415	420
Ser Leu Lys Gly	Asn Ala Lys Ala Leu Ser	Thr Val Thr Ala Ile	
425		430	435
Ile Asp Gly Thr	Gly Ser Ile Gly Ala Ala	Leu Gly Pro Leu Leu	
440		445	450
Ala Gly Leu Ile	Ser Pro Thr Gly Trp Asn	Asn Val Phe Tyr Met	
455		460	465
Leu Ile Ser Ala	Asp Val Leu Ala Cys Leu	Leu Leu Cys Arg Leu	
470		475	480
Val Tyr Lys Glu	Ile Leu Ala Trp Lys Val	Ser Leu Ser Arg Gly	
485		490	495
Ser Gly Tyr Lys	Glu Ile		
500			

<210> 28

<211> 801

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6941124CD1

<400> 28

Met Gln Ala His	Asn Thr Glu Asn Glu Ala	Thr Ser Gly Gly Cys	
1	5	10	15
Val Leu Leu His	Thr Ser Arg Lys Tyr Leu	Lys Leu Lys Asn Phe	
20		25	30
Lys Glu Glu Ile	Arg Ala His Arg Asp Leu	Asp Gly Phe Leu Ala	
35		40	45
Gln Ala Ser Ile	Val Leu Asn Glu Thr Ala	Thr Ser Leu Asp Asn	
50		55	60

Val	Leu	Arg	Thr	Met	Leu	Arg	Arg	Phe	Ala	Arg	Asp	Pro	Asp	Asn
				65					70					75
Asn	Glu	Pro	Asn	Cys	Asn	Leu	Asp	Leu	Leu	Met	Ala	Met	Leu	Phe
				80					85					90
Thr	Asp	Ala	Gly	Ala	Pro	Met	Arg	Gly	Lys	Val	His	Leu	Leu	Ser
				95					100					105
Asp	Thr	Ile	Gln	Gly	Val	Thr	Ala	Thr	Val	Thr	Gly	Val	Arg	Tyr
				110					115					120
Gln	Gln	Ser	Trp	Leu	Cys	Ile	Ile	Cys	Thr	Met	Lys	Ala	Leu	Gln
				125					130					135
Lys	Arg	His	Val	Cys	Ile	Ser	Arg	Leu	Val	Arg	Pro	Gln	Asn	Trp
				140					145					150
Gly	Glu	Asn	Ser	Cys	Glu	Val	Arg	Phe	Val	Ile	Leu	Val	Leu	Ala
				155					160					165
Pro	Pro	Lys	Met	Lys	Ser	Thr	Lys	Thr	Ala	Met	Glu	Val	Ala	Arg
				170					175					180
Thr	Phe	Ala	Thr	Met	Phe	Ser	Asp	Ile	Ala	Phe	Arg	Gln	Lys	Leu
				185					190					195
Leu	Glu	Thr	Arg	Thr	Glu	Glu	Glu	Phe	Lys	Glu	Ala	Leu	Val	His
				200					205					210
Gln	Arg	Gln	Leu	Leu	Thr	Met	Val	Ser	His	Gly	Pro	Val	Ala	Pro
				215					220					225
Arg	Thr	Lys	Glu	Arg	Ser	Thr	Val	Ser	Leu	Pro	Ala	His	Arg	His
				230					235					240
Pro	Glu	Pro	Pro	Lys	Cys	Lys	Asp	Phe	Val	Pro	Phe	Gly	Lys	Gly
				245					250					255
Ile	Arg	Glu	Asp	Ile	Ala	Arg	Arg	Phe	Pro	Leu	Tyr	Pro	Leu	Asp
				260					265					270
Phe	Thr	Asp	Gly	Ile	Ile	Gly	Lys	Asn	Lys	Ala	Val	Gly	Lys	Tyr
				275					280					285
Ile	Thr	Thr	Thr	Leu	Phe	Leu	Tyr	Phe	Ala	Cys	Leu	Leu	Pro	Thr
				290					295					300
Ile	Ala	Phe	Gly	Ser	Leu	Asn	Asp	Glu	Asn	Thr	Asp	Gly	Ala	Ile
				305					310					315
Asp	Val	Gln	Lys	Thr	Ile	Ala	Gly	Gln	Ser	Ile	Gly	Gly	Leu	Leu
				320					325					330
Tyr	Ala	Leu	Phe	Ser	Gly	Gln	Pro	Leu	Val	Ile	Leu	Leu	Thr	Thr
				335					340					345
Ala	Pro	Leu	Ala	Leu	Tyr	Ile	Gln	Val	Ile	Arg	Val	Ile	Cys	Asp
				350					355					360
Asp	Tyr	Asp	Leu	Asp	Phe	Asn	Ser	Phe	Tyr	Ala	Trp	Thr	Gly	Leu
				365					370					375
Trp	Asn	Ser	Phe	Phe	Leu	Ala	Leu	Tyr	Ala	Phe	Phe	Asn	Leu	Ser
				380					385					390
Leu	Val	Met	Ser	Leu	Phe	Lys	Arg	Ser	Thr	Glu	Glu	Ile	Ile	Ala
				395					400					405
Leu	Phe	Ile	Ser	Ile	Thr	Phe	Val	Leu	Asp	Ala	Val	Lys	Gly	Thr
				410					415					420
Val	Lys	Ile	Phe	Trp	Lys	Tyr	Tyr	Tyr	Gly	His	Tyr	Leu	Asp	Asp
				425					430					435
Tyr	His	Thr	Lys	Arg	Thr	Ser	Ser	Leu	Val	Ser	Leu	Ser	Gly	Leu
				440					445					450
Gly	Ala	Ser	Leu	Asn	Ala	Ser	Leu	His	Thr	Ala	Leu	Asn	Ala	Ser
				455					460					465
Phe	Leu	Ala	Ser	Pro	Thr	Glu	Leu	Pro	Ser	Ala	Thr	His	Ser	Gly
				470					475					480
Gln	Ala	Thr	Ala	Val	Leu	Ser	Leu	Leu	Ile	Met	Leu	Gly	Thr	Leu
				485					490					495
Trp	Leu	Gly	Tyr	Thr	Leu	Tyr	Gln	Phe	Lys	Lys	Ser	Pro	Tyr	Leu
				500					505					510
His	Pro	Cys	Val	Arg	Glu	Ile	Leu	Ser	Asp	Cys	Ala	Leu	Pro	Ile
				515					520					525
Ala	Val	Leu	Ala	Phe	Ser	Leu	Ile	Ser	Ser	His	Gly	Phe	Arg	Glu

Ile Glu Met Ser	530	Lys Phe Arg Tyr Asn	535	Pro Ser Glu Ser Pro	540
Ala Met Ala Gln	545	Ile Gln Ser Leu Ser	550	Leu Arg Ala Val Ser	555
Ala Met Gly Leu	560	Gly Phe Leu Leu Ser	565	Met Leu Phe Phe Ile	570
Gln Asn Leu Val	575	Ala Ala Leu Val Asn	580	Ala Pro Glu Asn Arg	585
Val Lys Gly Thr	590	Ala Tyr His Trp Asp	595	Leu Leu Leu Leu Ala	600
Ile Asn Thr Gly	605	Leu Ser Leu Phe Gly	610	Leu Pro Trp Ile His	615
Ala Tyr Pro His	620	Ser Pro Leu His Val	625	Arg Ala Leu Ala Leu	630
Glu Glu Arg Val	635	Glu Asn Gly His Ile	640	Tyr Asp Thr Ile Val	645
Val Lys Glu Thr	650	Arg Leu Thr Ser Leu	655	Gly Ala Ser Val Leu	660
Gly Leu Ser Leu	665	Leu Leu Leu Pro Val	670	Pro Leu Gln Trp Ile	675
Lys Pro Val Leu	680	Tyr Gly Leu Phe Leu	685	Tyr Ile Ala Leu Thr	690
Leu Asp Gly Asn	695	Gln Leu Val Gln Arg	700	Val Ala Leu Leu Leu	705
Glu Gln Thr Ala	710	Tyr Pro Pro Thr His	715	Tyr Ile Arg Arg Val	720
Gln Arg Lys Ile	725	His Tyr Phe Thr Gly	730	Leu Gln Val Leu Gln	735
Leu Leu Leu Cys	740	Ala Phe Gly Met Ser	745	Ser Leu Pro Tyr Met	750
Met Ile Phe Pro	755	Leu Ile Met Ile Ala	760	Met Ile Pro Ile Arg	765
Ile Leu Leu Pro	770	Arg Ile Ile Glu Ala	775	Met Ile Pro Ile Arg	780
Asp Ala Glu His	785	Arg Pro	790	Lys Tyr Leu Asp Val	795
	800				

<210> 29

<211> 344

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6972530CD1

<400> 29

Met Ser Ile Phe	Leu Leu Leu Arg	Met Tyr Ala Ser Ser Leu Phe
1	5	10 15
His Arg Phe Gly	Trp Ala Gly Leu Ile Val Ala Leu Gly Val His	
	20	25 30
Leu Ser Thr Ala	Tyr Leu Gly Leu Val Leu Leu Gly Glu Gln His	
	35	40 45
Leu Thr Ala Ala	Ala Thr Phe Ile Tyr Phe Tyr Leu Thr Thr Thr	
	50	55 60
Leu Thr Val Gly	Tyr Gly Asp Leu Ala Pro Gln Thr Ser Ala Gly	
	65	70 75
Arg Ile Phe Val	Ala Ala Trp Val Met Leu Gly Gly Ile Ala Leu	
	80	85 90
Leu Thr Ala Ala	Ile Gly Lys Thr Thr Ser Ser Val Ile Asp Ala	
	95	100 105
Trp Arg Lys Gly	Met Lys Gly Lys Gly Asp Phe Thr Gly Lys Val	

	110		115		120
Gly His Thr Val	Leu Ile Gly Trp Glu	Gly Ala Ser Ser Glu	Arg		
	125		130		135
Val Ile Glu Leu	Leu Leu Gln Asp Glu	Thr Ser Asn Asp Asn	Leu		
	140		145		150
Ile Val Ile Cys	Asp Cys Ser Leu Glu	Glu Asn Pro Met Pro	Gly		
	155		160		165
Lys Ala Ala Phe	Ile Arg Gly Glu Ser	Leu Ser Ser Thr Ala	Leu		
	170		175		180
Leu Leu Arg Ala	Gly Val Pro Gly Ala	Glu Arg Val Leu Val	Arg		
	185		190		195
Thr Pro Ser Asp	Asp Leu Thr Leu Ala	Thr Val Leu Ala Val	Asn		
	200		205		210
Gln Leu Ser Pro	Val Gly His Val Val	Ala His Phe Asn Glu	Ser		
	215		220		225
Glu Ile Ala Ala	Leu Ala Ser Ser Tyr	Ala Pro Arg Leu Glu	Cys		
	230		235		240
Thr Ser Ser Met	Ala Ile Glu Met Leu	Val Arg Ala Ser Gln	Asp		
	245		250		255
Pro Gly Ser Ser	Val Val Ile Asn Glu	Leu Leu Cys Val Gly	Gln		
	260		265		270
Gly Ala Thr Gln	Tyr Leu Met Lys Leu	Pro Glu Ala Phe Glu	Ala		
	275		280		285
Thr Phe Gly Glu	Leu Tyr Thr Gln Met	Lys Glu Arg His Asn	Ala		
	290		295		300
Thr Leu Ile Gly	Tyr Arg Ala Lys Gly	Val Gln Gln Pro Ser	Ile		
	305		310		315
Asn Pro Pro Ser	Ala Thr Glu Val Lys	Gly Gly Glu Leu Phe	Tyr		
	320		325		330
Ile Ala Ser Thr	Arg Leu Lys Glu Ile	Ser His Gly Met Ala			
	335		340		

<210> 30

<211> 2701

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6991750CD1

<400> 30

Met His Leu Leu Ile	Ile Tyr Ile Gln Phe	Gln Ile Ala Glu Glu	
1	5	10	15
Gly Ser Thr Ile Ser	Cys Val Val Glu Arg	Thr Arg Gly Ala Leu	
	20	25	30
Asp Tyr Val His Val	Phe Tyr Thr Ile Ser	Gln Ile Glu Thr Asp	
	35	40	45
Gly Ile Asn Tyr Leu	Val Asp Asp Phe Ala	Asn Ala Ser Gly Thr	
	50	55	60
Ile Thr Phe Leu Pro	Trp Gln Arg Ser Glu	Val Leu Asn Ile Tyr	
	65	70	75
Val Leu Asp Asp Asp	Ile Pro Glu Leu Asn	Glu Tyr Phe Arg Val	
	80	85	90
Thr Leu Val Ser Ala	Ile Pro Gly Asp Gly	Lys Leu Gly Ser Thr	
	95	100	105
Pro Thr Ser Gly Ala	Ser Ile Asp Pro Glu	Lys Glu Thr Thr Asp	
	110	115	120
Ile Thr Ile Lys Ala	Ser Asp His Pro Tyr	Gly Leu Leu Gln Phe	
	125	130	135
Ser Thr Gly Leu Pro	Pro Gln Pro Lys Asp	Ala Met Thr Leu Pro	
	140	145	150
Ala Ser Ser Val Pro	His Ile Thr Val Glu	Glu Glu Asp Gly Glu	

Ile Arg Leu Leu	155	Ile Arg Ala Gln	160	Leu Leu Gly Arg	165
Thr Ala Glu Phe	170	Thr Val Ser Leu	175	Thr Ala Phe Ser Pro	180
Asp Tyr Gln Asn	185	Val Ala Gly Thr Leu	190	Glu Phe Gln Pro Gly	195
Arg Tyr Lys Tyr	200	Ile Phe Ile Asn Ile	205	Thr Asp Asn Ser Ile	210
Glu Leu Glu Lys	215	Ser Phe Lys Val Glu	220	Leu Leu Asn Leu Glu	225
Gly Ala Ser Leu	230	Gly Val Ala Ser Gln	235	Ile Leu Val Thr Ile	240
Ala Ser Asp His	245	Ala His Gly Val Phe	250	Glu Phe Ser Pro Glu	255
Leu Phe Val Ser	260	Gly Thr Glu Pro Glu	265	Asp Gly Tyr Ser Thr	270
Thr Leu Asn Val	275	Ile Arg His His Gly	280	Thr Leu Ser Pro Val	285
Leu His Trp Asn	290	Ile Asp Ser Asp Pro	295	Asp Gly Asp Leu Ala	300
Thr Ser Gly Asn	305	Ile Thr Phe Glu Ile	310	Gly Gln Thr Ser Ala	315
Ile Thr Val Glu	320	Ile Leu Pro Asp Glu	325	Asp Pro Glu Leu Asp	330
Ala Phe Ser Val	335	Ser Val Leu Ser Val	340	Ser Ser Gly Ser Leu	345
Ala His Ile Asn	350	Ala Thr Leu Thr Val	355	Leu Ala Ser Asp Asp	360
Tyr Gly Ile Phe	365	Ile Phe Ser Glu Lys	370	Asn Arg Pro Val Lys	375
Glu Glu Ala Thr	380	Gln Asn Ile Thr Leu	385	Ser Ile Ile Arg Leu	390
Gly Leu Met Gly	395	Lys Val Leu Val Ser	400	Tyr Ala Thr Leu Asp	405
Met Glu Lys Pro	410	Pro Tyr Phe Pro Pro	415	Asn Leu Ala Arg Ala	420
Gln Gly Arg Asp	425	Tyr Ile Pro Ala Ser	430	Gly Phe Ala Leu Phe	435
Ala Asn Gln Ser	440	Glu Ala Thr Ile Ala	445	Ile Ser Ile Leu Asp	450
Asp Glu Pro Glu	455	Arg Ser Glu Ser Val	460	Phe Ile Glu Leu Leu	465
Ser Thr Leu Val	470	Ala Lys Val Gln Ser	475	Arg Ser Ile Pro Asn	480
Pro Arg Leu Gly	485	Pro Lys Val Glu Thr	490	Ile Ala Gln Leu Ile	495
Ile Ala Asn Asp	500	Asp Ala Phe Gly Thr	505	Leu Gln Leu Ser Ala	510
Ile Val Arg Val	515	Ala Glu Asn His Val	520	Gly Pro Ile Ile Asn	525
Thr Arg Thr Gly	530	Gly Ala Phe Ala Asp	535	Val Ser Val Lys Phe	540
Ala Val Pro Ile	545	Thr Ala Ile Ala Gly	550	Glu Asp Tyr Ser Ile	555
Ser Ser Asp Val	560	Val Leu Leu Glu Gly	565	Glu Thr Ser Lys Ala	570
Pro Ile Tyr Val	575	Ile Asn Asp Ile Tyr	580	Pro Glu Leu Glu Glu	585
Phe Leu Val Gln	590	Leu Met Asn Glu Thr	595	Thr Gly Gly Ala Arg	600
Gly Ala Leu Thr	605	Glu Ala Val Ile Ile	610	Ile Glu Ala Ser Asp	615
	620		625		630

Pro	Tyr	Gly	Leu	Phe	Gly	Phe	Gln	Ile	Thr	Lys	Leu	Ile	Val	Glu	
				635					640					645	
Glu	Pro	Glu	Phe	Asn	Ser	Val	Lys	Val	Asn	Leu	Pro	Ile	Ile	Arg	
				650					655					660	
Asn	Ser	Gly	Thr	Leu	Gly	Asn	Val	Thr	Val	Gln	Trp	Val	Ala	Thr	
				665					670					675	
Ile	Asn	Gly	Gln	Leu	Ala	Thr	Gly	Asp	Leu	Arg	Val	Val	Ser	Gly	
				680					685					690	
Asn	Val	Thr	Phe	Ala	Pro	Gly	Glu	Thr	Ile	Gln	Thr	Leu	Leu	Leu	
				695					700					705	
Glu	Val	Leu	Ala	Asp	Asp	Val	Pro	Glu	Ile	Glu	Glu	Val	Ile	Gln	
				710					715					720	
Val	Gln	Leu	Thr	Asp	Ala	Ser	Gly	Gly	Gly	Thr	Ile	Gly	Leu	Asp	
				725					730					735	
Arg	Ile	Ala	Asn	Ile	Ile	Ile	Pro	Ala	Asn	Asp	Asp	Pro	Tyr	Gly	
				740					745					750	
Thr	Val	Ala	Phe	Ala	Gln	Met	Val	Tyr	Arg	Val	Gln	Glu	Pro	Leu	
				755					760					765	
Glu	Arg	Ser	Ser	Cys	Ala	Asn	Ile	Thr	Val	Arg	Arg	Ser	Gly	Gly	
				770					775					780	
His	Phe	Gly	Arg	Leu	Leu	Leu	Phe	Tyr	Ser	Thr	Ser	Asp	Ile	Asp	
				785					790					795	
Val	Val	Ala	Leu	Ala	Met	Glu	Glu	Gly	Gln	Asp	Leu	Leu	Ser	Tyr	
				800					805					810	
Tyr	Glu	Ser	Pro	Ile	Gln	Gly	Val	Pro	Asp	Pro	Leu	Trp	Arg	Thr	
				815					820					825	
Trp	Met	Asn	Val	Ser	Ala	Val	Gly	Glu	Pro	Leu	Tyr	Thr	Cys	Ala	
				830					835					840	
Thr	Leu	Cys	Leu	Lys	Glu	Gln	Ala	Cys	Ser	Ala	Phe	Ser	Phe	Phe	
				845					850					855	
Ser	Ala	Ser	Glu	Gly	Pro	Gln	Cys	Phe	Trp	Met	Thr	Ser	Trp	Ile	
				860					865					870	
Ser	Pro	Ala	Val	Asn	Asn	Ser	Asp	Phe	Trp	Thr	Tyr	Arg	Lys	Asn	
				875					880					885	
Met	Thr	Arg	Val	Ala	Ser	Leu	Phe	Ser	Gly	Gln	Ala	Val	Ala	Gly	
				890					895					900	
Ser	Asp	Tyr	Glu	Pro	Val	Thr	Arg	Gln	Trp	Ala	Ile	Met	Gln	Glu	
				905					910					915	
Gly	Asp	Glu	Phe	Ala	Asn	Leu	Thr	Val	Ser	Ile	Leu	Pro	Asp	Asp	
				920					925					930	
Phe	Pro	Glu	Met	Asp	Glu	Ser	Phe	Leu	Ile	Ser	Leu	Leu	Glu	Val	
				935					940					945	
His	Leu	Met	Asn	Ile	Ser	Ala	Ser	Leu	Lys	Asn	Gln	Pro	Thr	Ile	
				950					955					960	
Gly	Gln	Pro	Asn	Ile	Ser	Thr	Val	Val	Ile	Ala	Leu	Asn	Gly	Asp	
				965					970					975	
Ala	Phe	Gly	Val	Phe	Val	Ile	Tyr	Asn	Ile	Ser	Pro	Asn	Thr	Ser	
				980					985					990	
Glu	Asp	Gly	Leu	Phe	Val	Glu	Val	Gln	Glu	Gln	Pro	Gln	Thr	Leu	
				995					1000					1005	
Val	Glu	Leu	Met	Ile	His	Arg	Thr	Gly	Gly	Ser	Leu	Gly	Gln	Val	
				1010					1015					1020	
Ala	Val	Glu	Trp	Arg	Val	Val	Gly	Gly	Thr	Ala	Thr	Glu	Gly	Leu	
				1025					1030					1035	
Asp	Phe	Ile	Gly	Ala	Gly	Glu	Ile	Leu	Thr	Phe	Ala	Glu	Gly	Glu	
				1040					1045					1050	
Thr	Lys	Lys	Thr	Val	Ile	Leu	Thr	Ile	Leu	Asp	Asp	Ser	Glu	Pro	
				1055					1060					1065	
Glu	Asp	Asp	Glu	Ser	Ile	Ile	Val	Ser	Leu	Val	Tyr	Thr	Glu	Gly	
				1070					1075					1080	
Gly	Ser	Arg	Ile	Leu	Pro	Ser	Ser	Asp	Thr	Val	Arg	Val	Asn	Ile	
				1085					1090					1095	
Leu	Ala	Asn	Asp	Asn	Val	Ala	Gly	Ile	Val	Ser	Phe	Gln	Thr	Ala	

	1100		1105		1110
Ser Arg Ser Val Ile	Gly His Glu Gly Glu	Ile Leu Gln Phe His			
	1115		1120		1125
Val Ile Arg Thr Phe	Pro Gly Arg Gly Asn Val Thr Val Asn Trp				
	1130		1135		1140
Lys Ile Ile Gly Gln Asn Gln Glu Leu Asn Phe Ala Asn Phe Ser					
	1145		1150		1155
Gly Gln Leu Phe Phe	Pro Glu Gly Ser Leu Asn Thr Thr Leu Phe				
	1160		1165		1170
Val His Leu Leu Asp	Asp Asn Ile Pro Glu Glu Lys Glu Val Tyr				
	1175		1180		1185
Gln Val Ile Leu Tyr Asp Val Arg Thr Gln Gly Val Pro Pro Ala					
	1190		1195		1200
Gly Ile Ala Leu Leu Asp Ala Gln Gly Tyr Ala Ala Val Leu Thr					
	1205		1210		1215
Val Glu Ala Ser Asp	Glu Pro His Gly Val Leu Asn Phe Ala Leu				
	1220		1225		1230
Ser Ser Arg Phe Val	Leu Leu Gln Glu Ala Asn Ile Thr Ile Gln				
	1235		1240		1245
Leu Phe Ile Asn Arg	Glu Phe Gly Ser Leu Gly Ala Ile Asn Val				
	1250		1255		1260
Thr Tyr Thr Thr Val	Pro Gly Met Leu Ser Leu Lys Asn Gln Thr				
	1265		1270		1275
Val Gly Asn Leu Ala	Glu Pro Glu Val Asp Phe Val Pro Ile Ile				
	1280		1285		1290
Gly Phe Leu Ile Leu	Glu Glu Gly Glu Thr Ala Ala Ala Ile Asn				
	1295		1300		1305
Ile Thr Ile Leu Glu	Asp Asp Val Pro Glu Leu Glu Glu Tyr Phe				
	1310		1315		1320
Leu Val Asn Leu Thr Tyr Val Gly Leu Thr Met Ala Ala Ser Thr					
	1325		1330		1335
Ser Phe Pro Pro Arg	Leu Asp Ser Glu Gly Leu Thr Ala Gln Val				
	1340		1345		1350
Ile Ile Asp Ala Asn	Asp Gly Ala Arg Gly Val Ile Glu Trp Gln				
	1355		1360		1365
Gln Ser Arg Phe Glu	Val Asn Glu Thr His Gly Ser Leu Thr Leu				
	1370		1375		1380
Val Ala Gln Arg Ser Arg Glu Pro Leu Gly His Val Ser Leu Phe					
	1385		1390		1395
Val Tyr Ala Gln Asn	Leu Glu Ala Gln Val Gly Leu Asp Tyr Ile				
	1400		1405		1410
Phe Thr Pro Met Ile	Leu His Phe Ala Asp Gly Glu Arg Tyr Lys				
	1415		1420		1425
Asn Val Asn Ile Met	Ile Leu Asp Asp Ile Pro Glu Gly Asp				
	1430		1435		1440
Glu Lys Phe Gln Leu Ile Leu Thr Asn Pro Ser Pro Gly Leu Glu					
	1445		1450		1455
Leu Gly Lys Asn Thr Ile Ala Leu Ile Val Leu Ala Asn Asp					
	1460		1465		1470
Asp Gly Pro Gly Val	Leu Ser Phe Asn Asn Ser Glu His Phe Phe				
	1475		1480		1485
Leu Arg Glu Pro Thr	Ala Leu Tyr Val Gln Glu Ser Val Ala Val				
	1490		1495		1500
Leu Tyr Ile Val Arg Glu Pro Ala Gln Gly Leu Phe Gly Thr Val					
	1505		1510		1515
Thr Val Gln Phe Ile Val Thr Glu Val Asn Ser Ser Asn Glu Ser					
	1520		1525		1530
Lys Asp Leu Thr Pro	Ser Lys Gly Tyr Ile Val Leu Glu Glu Gly				
	1535		1540		1545
Val Arg Phe Lys Ala	Leu Gln Ile Ser Ala Ile Leu Asp Thr Glu				
	1550		1555		1560
Pro Glu Met Asp Glu Tyr Phe Val Cys Thr Leu Phe Asn Pro Thr					
	1565		1570		1575

Gly Gly Ala Arg Leu Gly Val His Val Gln Thr Leu Ile Thr Val	1580	1585	1590
Leu Gln Asn Gln Ala Pro Leu Gly Leu Phe Ser Ile Ser Ala Val	1595	1600	1605
Glu Asn Arg Ala Thr Ser Ile Asp Ile Glu Glu Ala Asn Arg Thr	1610	1615	1620
Val Tyr Leu Asn Val Ser Arg Thr Asn Gly Ile Asp Leu Ala Asp	1625	1630	1635
Leu Asn Ile Glu Asn Pro Lys Thr Cys Glu Ala Phe Asn Ile Gly	1640	1645	1650
Phe Ser Pro Tyr Phe Val Ile Thr His Glu Glu Arg Asn Glu Glu	1655	1660	1665
Lys Pro Ser Leu Asn Ser Val Phe Thr Phe Thr Ser Gly Phe Lys	1670	1675	1680
Leu Phe Leu Val Gln Thr Ile Ile Ile Leu Glu Ser Ser Gln Val	1685	1690	1695
Arg Tyr Phe Thr Ser Asp Ser Gln Asp Tyr Leu Ile Ile Ala Ser	1700	1705	1710
Gln Arg Asp Asp Ser Glu Leu Thr Gln Val Phe Arg Trp Asn Gly	1715	1720	1725
Gly Ser Phe Val Leu His Gln Lys Leu Pro Val Arg Gly Val Leu	1730	1735	1740
Thr Val Ala Leu Phe Asn Lys Gly Gly Ser Val Phe Leu Ala Ile	1745	1750	1755
Ser Gln Ala Asn Ala Arg Leu Asn Ser Leu Leu Phe Arg Trp Ser	1760	1765	1770
Gly Ser Gly Phe Ile Asn Phe Gln Glu Val Pro Val Ser Gly Thr	1775	1780	1785
Thr Glu Val Glu Ala Leu Ser Ser Ala Asn Asp Ile Tyr Leu Ile	1790	1795	1800
Phe Ala Lys Asn Val Phe Leu Gly Asp Gln Asn Ser Ile Asp Ile	1805	1810	1815
Phe Ile Trp Glu Met Gly Gln Ser Ser Phe Arg Tyr Phe Gln Ser	1820	1825	1830
Val Asp Phe Ala Ala Val Asn Arg Ile His Ser Phe Thr Pro Ala	1835	1840	1845
Ser Gly Ile Ala His Ile Leu Leu Ile Gly Gln Asp Met Ser Ala	1850	1855	1860
Leu Tyr Cys Trp Asn Ser Glu Arg Asn Gln Phe Ser Phe Val Leu	1865	1870	1875
Glu Val Pro Ser Ala Tyr Asp Val Ala Ser Val Thr Val Lys Ser	1880	1885	1890
Leu Asn Ser Ser Lys Asn Leu Ile Ala Leu Val Gly Ala His Ser	1895	1900	1905
His Ile Tyr Glu Leu Ala Tyr Ile Ser Ser His Ser Asp Phe Ile	1910	1915	1920
Pro Ser Ser Gly Glu Leu Ile Phe Glu Pro Gly Glu Arg Glu Ala	1925	1930	1935
Thr Ile Ala Val Asn Ile Leu Asp Asp Thr Val Pro Glu Lys Glu	1940	1945	1950
Glu Ser Phe Lys Val Gln Leu Lys Asn Pro Lys Gly Gly Ala Glu	1955	1960	1965
Ile Gly Ile Asn Asp Ser Val Thr Ile Thr Ile Leu Ser Asn Asp	1970	1975	1980
Asp Ala Tyr Gly Ile Val Ala Phe Ala Gln Asn Ser Leu Tyr Lys	1985	1990	1995
Gln Val Glu Glu Met Glu Gln Asp Ser Leu Val Thr Leu Asn Val	2000	2005	2010
Glu Arg Leu Lys Gly Thr Tyr Gly Arg Ile Thr Ile Ala Trp Glu	2015	2020	2025
Ala Asp Gly Ser Ile Ser Asp Ile Phe Pro Thr Ser Gly Val Val	2030	2035	2040
Glu Lys Arg Met Ser Ala Lys Ile Leu Phe Thr Glu Gly Gln Val			

2045	2050	2055
Leu Ser Thr Ile Thr	Leu Thr Ile Leu Ala Asp Asn Ile Pro Glu	
2060	2065	2070
Leu Ser Glu Val Val	Ile Val Thr Leu Thr Arg Ile Thr Thr Glu	
2075	2080	2085
Gly Val Glu Asp Ser	Tyr Lys Gly Ala Thr Ile Asp Gln Asp Arg	
2090	2095	2100
Ser Lys Ser Val Ile	Thr Thr Leu Pro Asn Asp Ser Pro Phe Gly	
2105	2110	2115
Leu Val Gly Trp Arg	Ala Ala Ser Val Phe Ile Arg Val Ala Glu	
2120	2125	2130
Pro Lys Glu Asn Thr	Thr Thr Leu Gln Leu Gln Ile Ala Arg Asp	
2135	2140	2145
Lys Gly Leu Leu Gly	Asp Ile Ala Ile His Leu Arg Ala Gln Pro	
2150	2155	2160
Asn Phe Leu Leu His	Val Asp Asn Gln Ala Thr Glu Asn Glu Asp	
2165	2170	2175
Tyr Val Leu Gln Glu	Thr Ile Ile Ile Met Lys Glu Asn Ile Lys	
2180	2185	2190
Glu Ala His Ala Glu	Val Ser Ile Leu Pro Asp Asp Leu Pro Glu	
2195	2200	2205
Leu Glu Glu Gly Phe	Ile Val Thr Ile Thr Glu Val Asn Leu Val	
2210	2215	2220
Asn Ser Asp Phe Ser	Thr Gly Gln Pro Ser Val Arg Arg Pro Gly	
2225	2230	2235
Met Glu Ile Ala Glu	Ile Met Ile Glu Glu Asn Asp Asp Pro Arg	
2240	2245	2250
Gly Ile Phe Met Phe	His Val Thr Arg Gly Ala Gly Glu Val Ile	
2255	2260	2265
Thr Ala Tyr Glu Val	Pro Pro Pro Leu Asn Val Leu Gln Val Pro	
2270	2275	2280
Val Val Arg Leu Ala	Gly Ser Phe Gly Ala Val Asn Val Tyr Trp	
2285	2290	2295
Lys Ala Ser Pro Asp	Ser Ala Gly Leu Glu Asp Phe Lys Pro Ser	
2300	2305	2310
His Gly Ile Leu Glu	Phe Ala Asp Lys Gln Val Thr Ala Met Ile	
2315	2320	2325
Glu Ile Thr Ile Ile	Asp Asp Ala Glu Phe Glu Leu Thr Glu Thr	
2330	2335	2340
Phe Asn Ile Ser Leu	Ile Ser Val Ala Gly Gly Gly Arg Leu Gly	
2345	2350	2355
Asp Asp Val Val Val	Thr Val Val Ile Pro Gln Asn Asp Ser Pro	
2360	2365	2370
Phe Gly Val Phe Gly	Phe Glu Glu Lys Thr Val Met Ile Asp Glu	
2375	2380	2385
Ser Leu Ser Ser Asp	Asp Pro Asp Ser Tyr Val Thr Leu Thr Val	
2390	2395	2400
Val Arg Ser Pro Gly	Gly Lys Gly Thr Val Arg Leu Glu Trp Thr	
2405	2410	2415
Ile Asp Glu Lys Ala	Lys His Asn Leu Ser Pro Leu Asn Gly Thr	
2420	2425	2430
Leu His Phe Asp Glu	Thr Glu Ser Gln Lys Thr Ile Val Leu His	
2435	2440	2445
Thr Leu Gln Asp Thr	Val Leu Glu Glu Asp Arg Arg Phe Thr Ile	
2450	2455	2460
Gln Leu Ile Ser Ile	Asp Glu Val Glu Ile Ser Pro Val Lys Gly	
2465	2470	2475
Ser Ala Ser Ile Ile	Ile Arg Gly Asp Lys Arg Ala Ser Gly Glu	
2480	2485	2490
Val Gly Ile Ala Pro	Ser Ser Arg His Ile Leu Ile Gly Glu Pro	
2495	2500	2505
Ser Ala Lys Tyr Asn	Gly Thr Ala Ile Ile Ser Leu Val Arg Gly	
2510	2515	2520

Pro Gly Ile Leu Gly Glu Val Thr Val Phe Trp Arg Ile Phe Pro	2525	2530	2535
Pro Ser Val Gly Glu Phe Ala Glu Thr Ser Gly Lys Leu Thr Met	2540	2545	2550
Arg Asp Glu Gln Ser Ala Val Ile Val Val Ile Gln Ala Leu Asn	2555	2560	2565
Asp Asp Ile Pro Glu Glu Lys Ser Phe Tyr Glu Phe Gln Leu Thr	2570	2575	2580
Ala Val Ser Glu Gly Gly Val Leu Ser Glu Ser Ser Ser Thr Ala	2585	2590	2595
Asn Ile Thr Val Val Ala Ser Asp Ser Pro Tyr Gly Arg Phe Ala	2600	2605	2610
Phe Ser His Glu Gln Leu Arg Val Ser Glu Ala Gln Arg Val Asn	2615	2620	2625
Ile Thr Ile Ile Arg Ser Ser Gly Asp Phe Gly His Val Arg Leu	2630	2635	2640
Trp Tyr Lys Thr Met Ser Gly Thr Ala Glu Ala Gly Leu Asp Phe	2645	2650	2655
Val Pro Ala Ala Gly Glu Leu Leu Phe Glu Ala Gly Glu Met Arg	2660	2665	2670
Lys Ser Leu His Val Glu Ile Leu Asp Asp Asp Tyr Pro Glu Gly	2675	2680	2685
Pro Glu Glu Phe Ser Leu Thr Ile Thr Lys Val Glu Leu Gln Gly	2690	2695	2700

Arg

<210> 31
 <211> 610
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 71726948CD1

<400> 31

Met Asp Thr Pro Arg Gly Ile Gly Thr Phe Val Val Trp Asp Tyr	1	5	10	15
Val Val Phe Ala Gly Met Leu Val Ile Ser Ala Ala Ile Gly Ile	20	25	30	
Tyr Tyr Ala Phe Ala Gly Gly Gly Gln Gln Thr Ser Lys Asp Phe	35	40	45	
Leu Met Gly Gly Arg Arg Met Thr Ala Val Pro Val Ala Leu Ser	50	55	60	
Leu Thr Ala Ser Phe Met Ser Ala Val Thr Val Leu Gly Thr Pro	65	70	75	
Ser Glu Val Tyr Arg Phe Gly Ala Ile Phe Ser Ile Phe Ala Phe	80	85	90	
Thr Tyr Phe Phe Val Val Val Ile Ser Ala Glu Val Phe Leu Pro	95	100	105	
Val Phe Tyr Lys Leu Gly Ile Thr Ser Thr Tyr Glu Tyr Leu Glu	110	115	120	
Leu Arg Phe Asn Lys Cys Val Arg Leu Cys Gly Thr Val Leu Phe	125	130	135	
Ile Val Gln Thr Ile Leu Tyr Thr Gly Ile Val Ile Tyr Ala Pro	140	145	150	
Ala Leu Ala Leu Asn Gln Val Thr Gly Phe Asp Leu Trp Gly Ala	155	160	165	
Val Val Ala Thr Gly Val Val Cys Thr Phe Tyr Cys Thr Leu Gly	170	175	180	
Gly Leu Lys Ala Val Ile Trp Thr Asp Val Phe Gln Val Gly Ile	185	190	195	

Met Val Ala Gly	Phe Ala Ser Val Ile	Ile Gln Ala Val Val	Met
200	205	210	
Gln Gly Gly Ile	Ser Thr Ile Leu Asn Asp	Ala Tyr Asp Gly	Gly
215	220	225	
Arg Leu Asn Phe	Trp Asn Phe Asn Pro Asn	Pro Leu Gln Arg	His
230	235	240	
Thr Phe Trp Thr	Ile Ile Ile Gly Gly	Thr Phe Thr Trp Thr	Ser
245	250	255	
Ile Tyr Gly Val	Asn Gln Ser Gln Val	Gln Arg Tyr Ile Ser	Cys
260	265	270	
Lys Ser Arg Phe	Gln Ala Lys Leu Ser	Leu Tyr Ile Asn Leu	Val
275	280	285	
Gly Leu Trp Ala	Ile Leu Thr Cys Ser	Val Phe Cys Gly Leu	Ala
290	295	300	
Leu Tyr Ser Arg	Tyr His Asp Cys Asp	Pro Trp Thr Ala Lys	Lys
305	310	315	
Val Ser Ala Pro	Asp Gln Leu Met Pro	Tyr Leu Val Leu Asp	Ile
320	325	330	
Leu Gln Asp Tyr	Pro Gly Leu Pro Gly	Leu Phe Val Ala Cys	Ala
335	340	345	
Tyr Ser Gly Thr	Leu Ser Thr Val Ser	Ser Ser Ile Asn Ala	Leu
350	355	360	
Ala Ala Val Thr	Val Glu Asp Leu Ile	Lys Pro Tyr Phe Arg	Ser
365	370	375	
Leu Ser Glu Arg	Ser Leu Ser Trp Ile	Ser Gln Gly Met Ser	Val
380	385	390	
Val Tyr Gly Ala	Leu Cys Ile Gly Met	Ala Ala Leu Ala Ser	Leu
395	400	405	
Met Gly Ala Leu	Leu Gln Ala Ala Leu	Ser Val Phe Gly Met	Val
410	415	420	
Gly Gly Pro Leu	Met Gly Leu Phe Ala	Leu Gly Ile Leu Val	Pro
425	430	435	
Phe Ala Asn Ser	Ile Gly Ala Leu Val	Gly Leu Met Ala Gly	Phe
440	445	450	
Ala Ile Ser Leu	Trp Val Gly Ile Gly	Ala Gln Ile Tyr Pro	Pro
455	460	465	
Leu Pro Glu Arg	Thr Leu Pro Leu His	Leu Asp Ile Gln Gly	Cys
470	475	480	
Asn Ser Thr Tyr	Asn Glu Thr Asn Leu	Met Thr Thr Thr Glu	Met
485	490	495	
Pro Phe Thr Thr	Ser Val Phe Gln Ile	Tyr Asn Val Gln Arg	Thr
500	505	510	
Pro Leu Met Asp	Asn Trp Tyr Ser Leu	Ser Tyr Leu Tyr Phe	Ser
515	520	525	
Thr Val Gly Thr	Leu Val Thr Leu Leu	Val Gly Ile Leu Val	Ser
530	535	540	
Leu Ser Thr Gly	Gly Arg Lys Gln Asn	Leu Asp Pro Arg Tyr	Ile
545	550	555	
Leu Thr Lys Glu	Asp Phe Leu Ser Asn	Phe Asp Ile Phe Lys	Lys
560	565	570	
Lys Lys His Val	Leu Ser Tyr Lys Ser	His Pro Val Glu Asp	Gly
575	580	585	
Gly Thr Asp Asn	Pro Ala Phe Asn His	Ile Glu Leu Asn Ser	Asp
590	595	600	
Gln Ser Gly Lys	Ser Asn Gly Thr Arg	Leu	
605	610		

<210> 32
 <211> 552
 <212> PRT
 <213> Homo sapiens

 <220>

<221> misc_feature
<223> Incyte ID No: 7487393CD1

<400> 32

Met	Gly	Phe	Asp	Val	Leu	Leu	Asp	Gln	Val	Gly	Gly	Met	Gly	Arg
1				5					10					15
Phe	Gln	Ile	Cys	Leu	Ile	Ala	Phe	Phe	Cys	Ile	Thr	Asn	Ile	Leu
				20					25					30
Leu	Phe	Pro	Asn	Ile	Val	Leu	Glu	Asn	Phe	Thr	Ala	Phe	Thr	Pro
				35					40					45
Ser	His	Arg	Cys	Trp	Val	Pro	Leu	Leu	Asp	Asn	Asp	Thr	Val	Ser
				50					55					60
Asp	Asn	Asp	Thr	Gly	Thr	Leu	Ser	Lys	Asp	Asp	Leu	Leu	Arg	Ile
				65					70					75
Ser	Ile	Pro	Leu	Asp	Ser	Asn	Leu	Arg	Pro	Gln	Lys	Cys	Gln	Arg
				80					85					90
Phe	Ile	His	Pro	Gln	Trp	Gln	Leu	Leu	His	Leu	Asn	Gly	Thr	Phe
				95					100					105
Pro	Asn	Thr	Asn	Glu	Pro	Asp	Thr	Glu	Pro	Cys	Val	Asp	Gly	Trp
				110					115					120
Val	Tyr	Asp	Arg	Ser	Ser	Phe	Leu	Ser	Thr	Ile	Val	Thr	Glu	Trp
				125					130					135
Asp	Leu	Val	Cys	Glu	Ser	Gln	Ser	Leu	Lys	Ser	Met	Val	Gln	Ser
				140					145					150
Leu	Phe	Met	Ala	Gly	Ser	Leu	Leu	Gly	Gly	Leu	Ile	Tyr	Gly	His
				155					160					165
Leu	Ser	Asp	Arg	Val	Gly	Arg	Lys	Ile	Ile	Cys	Lys	Leu	Cys	Phe
				170					175					180
Leu	Gln	Leu	Ala	Ile	Ser	Asn	Thr	Cys	Ala	Ala	Phe	Ala	Pro	Thr
				185					190					195
Phe	Leu	Val	Tyr	Cys	Ile	Leu	Arg	Phe	Leu	Ala	Gly	Phe	Ser	Thr
				200					205					210
Met	Thr	Ile	Leu	Gly	Asn	Thr	Phe	Ile	Leu	Ser	Leu	Glu	Trp	Thr
				215					220					225
Leu	Pro	Arg	Ser	Arg	Ser	Met	Thr	Ile	Met	Val	Leu	Leu	Cys	Ser
				230					235					240
Tyr	Ser	Val	Gly	Gln	Met	Leu	Leu	Gly	Gly	Leu	Ala	Phe	Ala	Ile
				245					250					255
Gln	Asp	Trp	His	Ile	Leu	Gln	Leu	Thr	Val	Ser	Thr	Pro	Ile	Ile
				260					265					270
Val	Leu	Phe	Leu	Ser	Ser	Trp	Lys	Met	Val	Glu	Ser	Ala	Arg	Trp
				275					280					285
Leu	Ile	Ile	Asn	Asn	Gln	Leu	Asp	Glu	Gly	Leu	Lys	Glu	Leu	Arg
				290					295					300
Arg	Val	Ala	His	Ile	Asn	Gly	Lys	Lys	Asn	Thr	Glu	Glu	Thr	Leu
				305					310					315
Thr	Thr	Glu	Leu	Val	Arg	Ser	Thr	Met	Lys	Lys	Glu	Leu	Asp	Ala
				320					325					330
Val	Arg	Ile	Lys	Thr	Ser	Ile	Phe	Ser	Leu	Phe	Arg	Ala	Pro	Lys
				335					340					345
Leu	Arg	Met	Arg	Val	Phe	Gly	Leu	Cys	Phe	Val	Arg	Phe	Ala	Ile
				350					355					360
Thr	Val	Pro	Phe	Tyr	Gly	Leu	Ile	Leu	Asn	Leu	Gln	His	Leu	Gly
				365					370					375
Ser	Asn	Val	Ser	Leu	Phe	Gln	Ile	Leu	Cys	Gly	Ala	Val	Thr	Phe
				380					385					390
Thr	Ala	Arg	Cys	Val	Ser	Leu	Leu	Thr	Leu	Asn	His	Met	Gly	Arg
				395					400					405
Arg	Ile	Ser	Gln	Ile	Leu	Phe	Thr	Phe	Pro	Val	Gly	Leu	Phe	Ile
				410					415					420
Leu	Val	Asn	Thr	Phe	Leu	Pro	Gln	Glu	Met	Gln	Ile	Leu	Arg	Val
				425					430					435
Val	Leu	Ala	Thr	Leu	Gly	Ile	Gly	Ser	Val	Ser	Ala	Ala	Ser	Asn

	440		445		450
Ser Ala Ser Val	His His Asn Glu Leu	Val Pro Thr Ile Leu	Arg		
	455		460		465
Ser Thr Val Ala	Gly Ile Asn Ala Val	Ser Gly Arg Thr Gly	Ala		
	470		475		480
Ala Leu Ala Pro	Leu Leu Met Thr Leu	Met Ala Tyr Ser Pro	His		
	485		490		495
Leu Pro Trp Ile	Ser Tyr Gly Val Phe	Pro Ile Leu Ala Val	Pro		
	500		505		510
Val Ile Leu Leu	Leu Pro Glu Thr Arg	Asp Leu Pro Leu Pro	Asn		
	515		520		525
Thr Ile Gln Asp	Val Glu Asn Asp Arg	Lys Asp Ser Arg Asn	Ile		
	530		535		540
Lys Gln Glu Asp	Thr Cys Met Lys Val	Thr Gln Phe			
	545		550		

<210> 33
 <211> 2365
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7484831CB1

<400> 33

```

atggagcctg gtgacgcggc gcgccttggc tcgggtcggg ctaccggggc gccgccgcgc 60
cggtcgtcgc tgctgccgct gctgctgggt tgggggctgc gagtcgcggc cgcgccctcg 120
gcctcctcct ctggggcgcc ggccgaggac agcagcgcca tggaggagct cgctactgag 180
aaggaggcgg aggagagcca ccggcaagac agcgtgagcc tgctcacctt catcctgctg 240
ctcacgctca ccacctcac catctggctc ttcaagcacc gccgggtgcg ctttctgcac 300
gagaccgggc tggccatgat ctatgggctc atcggtgggg tgatcctgag gtatggtacc 360
cctgctacca gtggccgtga caaatcactc agctgcactc aggaagacag gcccttcagt 420
accttattag tgaatgtcag cggaaagtgc ttccaataca ctctgaaagg agaaatcagt 480
cctggcaaga tcaacagcgt agagcagaat gatatgctac ggaaggtaac attcgatcca 540
gaagtatttt tcaacattct tctgcctcca attatttttc atgctggata cagcttaaag 600
aagagacact ttttcagaaa tcttggtatc atactggcct atgccttctt ggggactgct 660
gtttcatgct tcattattgg aaatctcatg tatggtgtgg tgaagctcat gaagattatg 720
ggacagctct cagataaatt ttactacaca gattgtctct tttttggagc aatcatctct 780
gccactgacc cagtgactgt gctggcgata tttaatgaat tgcatgcaga cgtggatctt 840
tacgcacttc tttttggaga gagcgtccta aatgatgctg ttgccattgt actgtcctcg 900
tctattgttg cctaccagcc agcgggactg aacactcacg cctttgatgc tgctgccttt 960
tttaagtcat ttggcatttt tctaggtata tttagtggct cttttaccat gggagctgtg 1020
actggtgttg tgactgctct agtgactaag ttaccaaac tgcaactgctt cccctgctg 1080
gagacggcgc tgttcttctc catgtcctgg agcacgtttc tcttggcaga agcctgcgga 1140
tttacagggtg ttgtagctgt ccttttctgt ggaatcacac aagctcatta cacctacaac 1200
aatctgtcgg tggaaatcaag aagtcgaacc aagcagctct ttgaggtgtt acatttctctg 1260
gcagagaact tcactctctc ctacatgggc ctggcactgt ttaccttcca gaagcacgtt 1320
ttcagcccca ttttcatcat cggagctttt gttgccatct tectgggcag agccgcgcac 1380
atctaccgcg tctccttctt cctcaacttg ggcagaaggc ataagattgg ctggaatttt 1440
caacacatga tgatgttttc aggcctcagg ggagcaatgg catttgcgtt ggccatccgt 1500
gacacggcat cctatgctcg ccagatgatg ttcacgacca cccttctcat tgtgttcttc 1560
actgtctgga tcattggagg aggcacgaca cccatgttgt catggcttaa catcagagtt 1620
ggcgtcgagg agccctccga agaggaccag aatgaacacc actggcagta cttcagagtt 1680
ggtgttgacc ccgatcaaga cccaccaccc aacaacgaca gctttcaagt cttacaaggg 1740
gacggcccag attctgccag aggaaaccgg acaaaacagg agagcacatg gatattcagg 1800
ctgtgtgtaca gctttgatca caattatctg aagcccatcc tcacacacag tgggtcccca 1860
ctaaccacca cgctccccgc ctggtgtggc ttactagctc gatgtctgac cagtccccag 1920
gtgtacgata accaagagcc actgagagag gaagactctg atttcactct gaccgaaggg 1980
gacctgacat tgacctacgg ggacagcaca gtgactgcaa atggctctc aagttcgcac 2040
accgctcca cgagtctgga gggcagccgg agaacgaaga gcagctcgga ggaagtgtg 2100
gagcgagacc tgggaatggg agaccagaag gtttcgagcc ggggcacccg cctagtgttt 2160
cccctggaag ataatgcttg actttcccc caagccctgg cgcatggga ctgaagattg 2220

```

aaaatacatc	cacgaacatt	tcaacatgga	acgaagaatt	atagttcctt	ctctggctat	2280
atccataaag	aagtagttat	gaaatgttta	aaaccaaaag	caaatagtgt	tatactctta	2340
tttttgatta	atctgaggaa	aggag				2365

<210> 34

<211> 3400

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2477266CB1

<400> 34

agcggcggct	cagttgctgc	catggagtc	gccgggctag	agcagctcct	acgggagctg	60
ctgctaccgg	acaccgagcg	catccgtcgg	gccacggaac	agctccagat	cgttcttcgg	120
gccccgcggc	ctttgcgggc	tctctgcgac	ctgctagcct	cgggcgccga	ccccagatc	180
cgccagtttg	cggccgtgct	gacccgcaga	cgactgaaca	cccgtggcg	acggctggcg	240
gcggagcaac	gggagagcct	caagtccctg	atcctgacgg	ccctgcagag	agaaacagag	300
cactgtgtga	gcctcagcct	ggcccagctc	tcagccacca	tttttcgaaa	ggaaggcttg	360
gaggcctggc	cacagctttt	gcagctgctt	cagcacagta	cccacagccc	ccacagccca	420
gagagagaga	tggggctttt	gctgctaagt	gtggtggtga	cctcccggcc	cgaggccttc	480
caacccccacc	accgggagct	tcttcggctt	ctgaatgaga	ctcttggtga	ggtgggctct	540
cctgggctgc	tcttctactc	cctgcgcact	ctgaccacca	tggctcccta	cctcagcact	600
gaagatgtgc	ctctcgctcg	gatgttggtg	cccaagctga	tcattggccat	gcagactctg	660
atccccatag	atgaggcaaaa	ggcctgtgag	gcccttgagg	ctttggatga	actgttgagg	720
tcagaggtgc	cggtcatcac	cccctacctc	tctgaagtcc	tcacattctg	cctggaggta	780
gctagaaatg	tggccctggg	caatgcgata	cgcatagcta	ttctctgctg	cctcactttc	840
ttggtcaaaag	tcaagagcaa	ggccttactg	aagaatcgtc	tcctgccacc	cttgctgcac	900
acccttttcc	ccattgtggc	tgctgagccc	ccaccaggcc	agttggatcc	cgaggaccag	960
gattcagaag	aggaagagtt	ggagattgag	ctgatggggg	agactcccaa	gcatttcgct	1020
gtacaagttg	tggacatgct	ggcactacac	ctgccccccg	agaagctctg	tccccagctg	1080
atgcccattg	tggaagaggc	tttgccggagc	gagagcccat	accagcgcaa	agctggactc	1140
ctggtgctgg	ccgtgctgtc	tgacggagct	ggcgaccaca	tcaggcagag	actgctgccc	1200
ccactgctgc	agattgtgtg	caagggcctg	gaggaccctc	cgcaagtgtg	acgcaatgct	1260
gcgctgtttg	ccctggggcca	gttctcagaa	aacctacagc	cccatatcag	cagctattca	1320
agggaggtaa	tgccactgct	cctcgccctc	ttgaagtcgg	tgcctcttgg	acacacacac	1380
cacctagcca	aggcctgcta	tgccctggag	aattttgtgg	agaacctagg	gccccagggtg	1440
cagccctacc	ttccggagct	tatggaatgc	atgctgcagc	ttctgaggaa	ccccagcagt	1500
ccccggggcca	aggagctggc	tgtgagcgcc	ctgggagcca	ttgctacggc	tgcccaggcc	1560
tcgctgctgc	cctacttccc	tgccatcatg	gagcacctgc	gggaattcct	gttaacaggc	1620
cgtgaggacc	ttcagcctgt	gcagatccag	agcctggaga	cactgggggt	gctggcacga	1680
gcagtggggg	agccccatgag	gccgtgggct	gaggaatgct	gccagctggg	tctgggcctc	1740
tgcgaccagg	tagacgacgc	tgacttgcg	cgctgcacgt	acagcctatt	tgcacgctta	1800
tcgggtctga	tgggtgaggg	cctggcgccc	cacttggaac	agatcaccac	gctcatgctg	1860
ctgtcactgc	gttccaccga	gggcattgtg	cctcagtatg	acgggagcag	ctccttcctt	1920
ctgtttgacg	atgagagtga	tggggaagaa	gaggaggagc	tcattggatga	ggatgtggaa	1980
gaagaggatg	actcagagat	ctcagggtac	agcgtggaga	atgccttctt	cgatgagaag	2040
gaagacacct	gtgctgccgt	gggggagatc	tctgtgaaca	ccagtgtggc	cttccttcca	2100
tacatggaaa	gtgtctttga	agaagtattt	aaactgtctg	agtgcctca	cctgaatgtg	2160
cggaaggcag	cccatgaggc	tctgggtcag	ttttgtgtg	cactgcacaa	ggcctgtcaa	2220
agctgcccct	cggaacccaa	cactgctgct	ttgcaggctg	ccctggccc	agtcgtgcca	2280
tcctacatgc	aggcagtgaa	cagggagcgg	gaacgccagg	tggtgatggc	cgtgctggag	2340
gccctgacag	gggtgctccg	cagctgtggg	accctcacac	tgaagcccc	tgggcgccctc	2400
gctgagctct	gtggcgtgct	caaggctgtg	ctgcagagga	agacagcctg	tcaggatact	2460
gacgaggagg	aggaagagga	agatgatgat	caggctgaat	acgacgccat	gttgctggag	2520
cacgctggag	aggccatccc	tgccctggca	gccgcggctg	ggggagactc	ctttgcccc	2580
ttctttgccc	gtttcctgcc	attattgggtg	tgcaagacaa	aacagggtcg	cacagtggca	2640
gagaagtcct	ttgcagtggg	gaccttggca	gagactattc	agggcctggg	tgctgcctca	2700
gcccagtttg	tgtctcggtc	gctccctgtg	ctggtgagca	ccgcccaaga	ggcagacccc	2760
gaggtagcga	gcaatgccat	cttcgggatg	ggcgtgctgg	cagagcatgg	gggccaccct	2820
gcccaggaac	acttccccaa	gctggtgggg	ctccttttcc	ccctcctggc	gcgggagcga	2880
catgatcgtg	tccgtgacaa	catctgtggg	gcacttgccc	gcctgttgat	ggccagttccc	2940

accaggaaac	cagagcccca	ggtgctggct	gccctactgc	atgccctgcc	actgaaggag	3000
gacttgagg	agtgggtcac	cattggggcg	ctcttcagct	tcctgtacca	gagcagccct	3060
gaccagggtta	tagatgtggc	tcccagagctt	ctgcgtatct	gcagcctcat	tctggctgac	3120
aacaagatcc	caccagacac	caaggccgca	ctgttgctgc	tcctgacgtt	cctggccaaa	3180
cagcacaccg	acagctttca	agcagctctg	ggctcactgc	ctgttgacaa	ggctcaggag	3240
ctccaggctg	tactgggcct	ctcctagact	gcaggctgca	gccagtccag	agagaataga	3300
gcctgcccag	gccttaagac	cacctctcag	cccagttcag	ttctgcctta	ccaaagattc	3360
tgagactcat	acccatttgg	agccagcccc	acttgctgcc			3400

<210> 35

<211> 4458

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3552033CB1

<400> 35

gttgttgcta	gtatgatata	gatcatgtgt	acgtctatgt	tagtgctatg	tacgttgcta	60
tagtgtcttg	cttggtgtat	ctatatgtgt	attgtttcgt	tttgtgtgtg	tatatattat	120
tatgcttttg	cccgtttaat	taccctccat	ggggcccccga	gttttatttt	cccccttg	180
tgggatgcgt	cttcaatcac	cgcttttata	ccttgatatt	cggttcaagg	gactttctcc	240
gggggctctt	tggcaccac	cgcaagaacc	ggtctcagct	caaatcccg	aatgaaggcc	300
tttaaaaaga	agatgtgccc	aacagtga	ccccgcccc	aggcccata	ggtttccttg	360
ggcttctgat	aggcccagca	ttggccctca	ccccagtat	ctccggttc	agaattgaga	420
aaaatgaaag	tcgcctctcc	cgaaaggaca	tccagtctga	aaagtgggtcc	atcagcaaac	480
acactcaact	cagccctacg	gatgcttttg	ggaccattga	gttccaagga	gggtggccatt	540
ccaacaaagc	catgtatgtg	cgagtatctt	ttgatacaaa	acctgatctc	ctcttacacc	600
tgatgacca	ggaatggcag	ttggagcttc	ccaagcttct	catctctgtc	catgggggcc	660
tgcagaactt	tgaactccag	ccaaaactca	agcaagtctt	tgggaaaggg	ctcatcaaag	720
cagctatgac	aactggagcg	tggatattca	ctggaggggt	taacacaggt	gttattcgtc	780
atgttggcga	tgccttgaag	gatcatgcct	ctaagtctcg	aggaaagata	tgcaccatag	840
gtattgcccc	ctggggaatt	gtggaaaacc	aggaggacct	cattggaaga	gatgttgtcc	900
ggccatacca	gaccatgtcc	aatcccata	gcaagctcac	tgttctcaac	agcatgcatt	960
cccacttcat	tctggctgac	aacgggacca	ctggaaaata	tggagcagag	gtgaaacttc	1020
gaagacaact	ggaaaagcat	atttcaactc	agaagataaa	cacaagaatc	ggtcaagggtg	1080
ttcctgttgt	ggcactcata	gtggaaggag	gacccaatgt	gatctcgatt	gttttgaggt	1140
accttcgaga	cacccctccc	gtgccagtgg	ttgtctgtga	tgggagtggg	cgggcatcgg	1200
acatcctggc	ctttgggcat	aaatactcag	aagaaggcgg	actgataaat	gaatctttga	1260
gggaccagct	gttggtgact	atacagaaga	ctttcacata	cactcgaacc	caagctcagc	1320
atctgttcat	catcctcatg	gagtgcata	agaagaagga	attgattacg	gtatttcgga	1380
tgggatcaga	aggacaccag	gacattgatt	tggttatcct	gacagcttta	ctcaaaggag	1440
ccaatgcctc	ggccccagac	caactgagct	tagctttagc	ctggaaacaga	gtcgacatcg	1500
ctcgagcca	gatctttatt	tacgggcaac	agtggccggt	gggatctctg	gagcaagcca	1560
tggttgatgc	cttagttctg	gacagagtgg	attttgtgaa	attactcata	gagaatggag	1620
taagcatgca	ccgttttctc	accatctcca	gactagagga	attgtacaat	acgagacatg	1680
ggccctcaaa	tacattgtac	cacttggtca	gggatgtcaa	aaaggggaac	ctgccccag	1740
actacagaat	cagcctgatt	gacatcgcc	tggtgatcga	gtacctgatg	ggcggggctt	1800
atcgctgcaa	ctacacgcgc	aagcgcttcc	ggacctcta	ccacaacctc	ttcgggcccca	1860
agaggcccaa	agccttgaaa	ctgctgggaa	tggaggatga	tattcccttg	aggcgaggaa	1920
gaaagacaac	caagaaacgt	gaagaagagg	tggacattga	cttggatgat	cctgagatca	1980
accacttccc	cttccctttc	catgagctca	tgggtgtggc	tgttctcatg	aagcggcaga	2040
agatggccct	gttcttctgg	cagcacggtg	aggagccat	ggccaaggcc	ctgggtggcct	2100
gcaagctctg	caaagccatg	gctcatgagg	cctctgagaa	cgacatgggt	gacgacattt	2160
cccaggagct	gaatcacaat	tccagagact	ttggccagct	ggctgtggag	ctcctggacc	2220
agtcctacaa	gcaggacgaa	cagctggcca	tgaaactgct	gacgtatgag	ctgaagaact	2280
ggagcaacgc	cacgtgcctg	cagcttgccg	tggtgccaa	acaccgcgac	ttcatcgccg	2340
acacgtgcag	ccagatgctg	ctcaccgaca	tgtggatggg	ccggctccgc	atgcgcaaga	2400
actcaggcct	caggtaattt	ctgggaattc	tacttctctc	ttcaattctc	agcttgaggt	2460
tcaagaacaa	agacgacatg	ccctatatgt	ctcaggccca	ggaaatccac	ctccaagaga	2520
aggaggcaga	agaaccagag	aagcccacaa	aggaaaaaga	ggaaggaggac	atggagctca	2580
tagcaatggt	gggacgaaac	aacggggagt	cctccaggaa	gaaggatgaa	gaggaagttc	2640

agagcgagca	ccggttaatc	cccccgcca	gaaaaatcta	tgaattctac	aatgcaccca	2700
tcgtgaagtt	ctggttctac	acactggcgt	atateggata	cctgatgctc	ttcaactata	2760
tcgtgttagt	gaagatggaa	cgctggccgc	ccaccagga	atggatcgta	atctcctata	2820
ttttcaccc	gggaatagaa	aagatgagag	agattctgat	gtcagagcca	gggaagttgc	2880
tacagaaagt	gaaggtatgg	ctgcaggagc	actggaatgt	cacggacctc	atcgccatcc	2940
ttctgttttc	tgtcgggaatg	atccttcgtc	tccaagacca	gcccttcagg	agtgcaggga	3000
gggtcatcta	ctgcgtgaac	atcatttact	ggatatccg	tctcctagac	atcttcggcg	3060
tgaacaagta	tttgggcccc	tatgtaatga	tgattggaaa	aatgatgata	gacatgatgt	3120
actttgtcat	cattatgctg	gtggttctga	tgagctttgg	ggtcgccagg	caagccatcc	3180
tttttcccaa	tgaggagcca	tcatggaaac	tggccaagaa	catcttctac	atgccctatt	3240
ggatgattta	tggggaagtg	tttgcggacc	agatagaccc	tccctgtgga	cagaatgaga	3300
cccagagga	tggtaaaata	atccagctgc	ctccctgcaa	gacaggagct	tggatcgctg	3360
cggccatcat	ggcctgctac	ctcttagtgg	caaacatctt	gctgggtcaac	ctcctcattg	3420
ctgtctttaa	caatacattt	tttgaagtaa	aatcgatata	caaccaagtc	tggaagtttc	3480
agaggtatca	gtcatcatg	actttccatg	aaaggccagt	tctgccccca	ccactgatca	3540
tcttcagcca	catgaccatg	atattccagc	acctgtgctg	ccgatggagg	aaacacgaga	3600
gcgacccgga	tgaaggggac	tacggcctga	aactcttcat	aaccgatgat	gagctcaaga	3660
aagtacatga	ctttgaagag	caatgcatag	aagaatactt	cagagaaaag	gatgatcggt	3720
tcaactcatc	taatgatgag	aggatacggg	tgacttcaga	aagggtggag	aacatgtcta	3780
tgcggtctga	ggaagtcaac	gagagagagc	actccatgaa	ggcttcactc	cagaccgtgg	3840
acatccggct	ggcgcagctg	gaagacctta	tggggcgcat	ggccacggcc	ctggagcgcc	3900
tgacaggtct	ggagcggggc	gagtcacaaca	aaatccgctc	gaggacctcg	tcagactgca	3960
cggacgccgc	ctacattgtc	cgtcagagca	gcttcaacag	ccaggaaggg	aacaccttca	4020
agctccaaga	gagtatagac	cctgcagagc	atcctcttta	ttcagtataa	gccggcagca	4080
agcagttcta	cctaacgtcc	cacatccttc	tcatgccaac	acttctgtaa	ttgatcatta	4140
taaagaaaaa	acaaggtaac	agtcatagtt	cacctgtctc	ttatctattc	acttctgggtg	4200
ccacaactgt	ttatcctttt	ttgaagaaaa	taagggaaca	gaaatgcctt	tttgtattgc	4260
aatcgaaatg	aaagaagagt	tgatgttaaa	aaaacaaaag	tcaagtgatt	tattatatac	4320
agtgggcgtt	caagtctagt	cgagcaagct	caggagaatg	taattaaata	attttatatt	4380
ttttaattta	ttttgtatct	cacctgtcat	ggatgaattc	attcactgaa	tatgtaatat	4440
tgaaccttaa	aaaaaaaa					4458

<210> 36

<211> 2722

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4778139CB1

<220>

<221> unsure

<222> 2609

<223> a, t, c, g, or other

<400> 36

atggagatcg	ctggagagaa	gaaataccag	tattatagca	tgccctcttc	tttgctgagg	60
agcctggctg	gaggccggca	tcccccaaga	gtgcagaggg	gggcacttct	tgagattaca	120
aacagtaaaa	gagaggctac	aaatgtaaga	aatgaccagg	aaaggcaaga	aacacaaaagt	180
agtatagtgg	tttctggggg	gtctcctaac	aggcaagcac	actcaaagta	tggccagttt	240
cttctgggtcc	cctctaattct	aaagcgagtt	cctttttcag	cagaaaactgt	cttgccctctg	300
tccagaccct	ctgtgccaga	tgtgctggca	actgaacagg	acatccagac	tgaggttctt	360
gttcatctga	ctgggcagac	cccagttgtc	tctgactggg	catcagtgga	tgaacccaag	420
gaaaagcacg	agcctattgc	tcacttactg	gatggacaag	acaaggcaga	gcaagtgcta	480
cccactttga	gttgacacacc	tgaacccatg	acaatgagct	ccccctcttc	ccaagccaag	540
atcatgcaaa	ctggaggtgg	atatgtaaac	tgggcatttt	cagaaggtga	tgaaactggt	600
gtgttttagca	tcaagaaaaa	gtggcaaac	tgcttgccct	ccacttgatga	cagtgattcc	660
tctcggagtg	aacagcacca	gaagcaggcc	caggacagct	ccctatctga	taactcaaca	720
agatcggccc	agagtagtga	atgctcagag	gtgggaccat	ggcttcagcc	aaacacatcc	780
ttttggatca	atcctctccg	cagatacagg	cccttcgcta	ggagtcatag	ttttagattc	840
cataaggagg	agaaattgat	gaagatctgt	aagattaaaa	atctttcagg	ctcttcagaa	900
atagggcagg	gagcatgggt	caaagcgaaa	atgctaacca	aagacaggag	actgtcaaag	960

aaaaagaaga	atactcaagg	actccaggtg	ccaatcataa	cagtcaatgc	ctgctctcag	1020
agtgaccagt	tgaatccaga	gccaggagaa	aacagcatct	ctgaagagga	gtacagcaag	1080
aactggttca	cagtgtccaa	athtagtcac	acaggtgtag	aaccttacat	acatcagaaa	1140
atgaaaacta	aagaaattgg	acaatgtgct	atacaaatca	gtgattacct	aaagcagctc	1200
caagagtctg	ctcaggatct	cagcaaaaac	tctttgtgga	attccaggag	caccaacctc	1260
aataggaact	ccctgtcctc	tctaatttca	gagatctcag	cctccttaaa	aagccctcaa	1320
gagctcacc	atcattatcc	accttcactt	ctctttgcag	caggagaaga	aataactgtc	1380
tacaggttgg	aggagagttc	ccctttaaac	cttgataaaa	gcatgtcctc	ttggtctcag	1440
cgtgggagag	cggcaatgat	ccaggtattg	tcccagagag	agatggatgg	gggcctccgt	1500
aaagctatga	gagtcgtcag	cacttgggtc	gaggatgaca	ttctcaagcc	gggacaagtt	1560
ttcattgtca	agtcctttct	tcttgagggt	gtgcggaat	ggcataaaat	cttccaggag	1620
agcactgtgc	ttcatctttg	cctcagggaa	attcaacaac	aaagagctgc	tcaaaaattg	1680
atctatacct	tcaaccaagt	gaaaccacaa	accataccct	acacaccaag	gttcttgga	1740
gttttcttaa	tctactgcca	ttcagccaac	cagtgggtga	ccattgagaa	gtatatgaca	1800
ggggagttcc	ggaagtataa	caacaacaat	ggtgatgaaa	tcacccccac	caacaccctg	1860
gaggagctga	tgttggtctt	ctctcactgg	acctatgagt	acactcgggg	agagctgctg	1920
gttttagatt	tgcaagggtg	tggagaaaat	ttgacagatc	catctgttat	aaaacctgaa	1980
gtcaacaact	caagaggaat	ggtgtttgga	ccggccaatt	tgggggaaga	tgcaattaga	2040
aacttcattg	caaaacatca	ttggaactcc	tgctgccgga	agctcaaact	cccgatttta	2100
aaaagaatg	actattcccc	tgaaaggata	aattccacct	ttggacttga	gataaaaaata	2160
gaatcagctg	aggagcctcc	agcaagggag	acgggtagaa	attccccaga	agatgatattg	2220
caactataaa	aaggaggag	caagaagatc	ccagtgtctg	ccctgcctgc	caggaaactct	2280
gtgataacat	agattgatca	acgtgatgtt	gattacatca	gcgtctcctt	gggacacgcc	2340
ttctgagcct	cacatctcct	tctgttcaaa	ggcctcattg	gtatatgatc	aatgggttct	2400
cctagacact	gacctctgtc	cagggcactt	tgcagctcca	tctcaagtt	ccacacgaag	2460
atgcttggat	gagtcagctg	ggaatattgt	tcttgtgtac	ctcattgctt	tagctggtca	2520
cttggaaactt	tggagcagaa	tcttgcacat	taaaggatgg	ggttgggggg	gatacattta	2580
ttttattttc	tcactatgta	tgcagactng	acccctact	actatttgtc	acctcaccca	2640
cagattgtat	ttatgtctat	atatatgttt	cataaaaagc	ttaccaaacc	caaaaaaaaaa	2700
aaaaaaaaaa	aaaaaaaaaa	aa				2722

<210> 37

<211> 1924

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4787433CB1

<400> 37

cggcgcccg	tgacggccg	caccatgggg	tcccgccact	tcgaggggat	ttatgaccac	60
gtggggcact	tcggcagatt	ccagagagtc	ctctatttca	tatgtgcctt	ccagaacatc	120
tcttgtggta	ttcactactt	gccttctgtg	ttcatgggag	tcacccctca	tcatgtctcg	180
aggccccag	gcaatgtgag	tcaggttggt	ttccataatc	actctaattg	gagtttgag	240
gacaccgggg	ccctgtttgc	ttcaggccag	aaagattatg	ttacggtgca	gttgacgaat	300
ggtgagatct	gggagctctc	aaggtgtagc	aggaataaga	gggagaacac	atcgagtttg	360
ggctatgaat	acactggcag	taagaaagag	tttcttctgt	tggatggcta	catatatgac	420
cagaacacat	ggaaaagcac	tgcggtgacc	cagtggaacc	tggtctgtga	ccgaaaatgg	480
cttgcaatgc	tgatccagcc	cctattttatg	tttgaggtcc	tactgggatc	ggtgactttt	540
ggctactttt	ctgacaggct	aggacgcggg	gtggtcttgt	gggccacaag	cagtagcatg	600
tttttgtttg	gaatagcagc	ggcgtttgca	gttgattatt	acaccttcac	ggctgctcgc	660
ttttttcttg	ccatggttgc	aagtggctat	cttgtgggtg	ggtttgtcta	tgtgatggaa	720
ttcaattggca	tgaagtctcg	gacatgggcy	tctgtccatt	tgcatctcct	ttttgcagtt	780
ggaaacctgc	tgggtggctt	gacaggatac	ttggtcagga	cctgggtggc	ttaccagatg	840
atcctctcca	cagtgtactgt	ccccctttatc	ctgtgtctgt	gggtgtctcc	agagacacct	900
ttttggcttc	tctcagaggg	acgatatgaa	gaagcacaaa	aaatagttga	catcatggcc	960
aagtggaaaca	gggcaagctc	ctgtaaaactg	tcagaacttt	tatcactgga	cctacaaggt	1020
cctgttagta	atagccccac	tgaagttcag	aagcacaacc	tatcatatct	gttttataac	1080
tggagcatta	cgaaaaggac	acttacgggt	ttgctaactc	ggttccactg	aagtttggga	1140
ttctactcgt	tttcttggaa	ttctgttaac	ttaggaggca	atgaatactt	aaacctcttc	1200
ctcctgggtg	tagtggaat	tcccgccctac	accttcgtgt	gcatcgccat	ggacaaggtc	1260
gggaggagaa	cagtcctggc	ctactctctt	ttctgcagtg	cactggcctg	tgggtgcgtt	1320

atggtgatcc	cccagaaaca	ttatatattt	ggtgtggtga	cagctatggt	tggaataatt	1380
gccatcgggg	cagcatttgg	cctcatttat	ctttatacag	ctgagctgta	tccaaccatt	1440
gtaagatcgc	tggctgtggg	aagcggcagc	atggtgtgtc	gcctggccag	catcctggcg	1500
ccgttctctg	tggacctcag	cagcatttgg	atcttcatac	cacagtgtgt	tgttgggact	1560
atggccctcc	tgagtggagt	gttaacacta	aagcttccag	aaacccttgg	gaaacgggcta	1620
gcaactactt	gggaggaggc	tgcaaaactg	gagtcagaga	atgaaagcaa	gtcaagcaaa	1680
ttactttctc	caactaataa	tagtgggctg	gaaaaaacgg	aagcgattac	ccccagggat	1740
tctggtcttg	gtgaataaat	gtgccatgcc	tgctgtctag	cacctgaaat	attattttacc	1800
ctaattgcctt	tgtattagag	gaatcttatt	ctcatctccc	atatgttgtt	tgtatgtctt	1860
tttaataaat	tttgtaagaa	aatttttaag	caaatatgtt	ataaaaagaa	taaaaactaa	1920
gatg						1924

<210> 38
 <211> 1797
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7483598CB1

<400> 38						
agcatccccg	tcccgggagga	aaaaacattt	gtctggcgaa	ctccgggtgg	aaagcgcccc	60
aggctgccac	agcctagaga	tcttggggct	tcagcccctc	gcggcctgcc	gagggagcag	120
ggggcgcccc	tggaactggc	tccctgcagc	tctgcggcta	cacgcggacc	tcggctgtgt	180
gcgaggtggc	ggaggaggct	ggccgggtgc	gaatccgtac	ccagccccag	catcttccac	240
ctgctgagga	ccaccgctca	gccatgggct	accagaggca	ggagcctgtc	atccccgccg	300
agagagattt	agatgacaga	gaaacccttg	tttctgaaca	tgagtataaa	gagaaaaacct	360
gtcagtctgc	tgctcttttt	aatgttgtca	actcgattat	aggatctggt	ataataggat	420
tgccttattc	aatgaagcaa	gctgggtttc	ctttgggaat	attgctttta	ttctgggttt	480
catatgtttac	agactttttc	cttgttttat	tgataaaaag	aggggcccctc	tctggaacag	540
atacctacca	gtctttgggtc	aataaaaactt	tcggctttcc	agggtatctg	ctcctctctg	600
ttcttcagtt	tttgtatcct	tttatagcaa	tgataagtta	caatataata	gctggagata	660
ctttgagcaa	agttttttcaa	agaatcccag	gagttgatcc	tgaaaacgtg	tttattgggtc	720
gccacttcat	tattggactt	tccacagtta	cctttactct	gccttttatcc	ttgtaccgaa	780
atatagcaaa	gcttggaag	gtctccctca	tctctacagg	tttaacaact	ctgattcttg	840
gaattgtaat	ggcaagggca	atttcactgg	gtccacacat	acaaaaaaca	gaagacgctt	900
gggtatttgc	aaagcccaat	gccattcaag	cggtcgggggt	tatgtctttt	gcattttattt	960
gccaccataa	ctccttctta	gtttacagtt	ctctagaaga	accacagta	gctaagtgggt	1020
ccgccttat	ccatatgtcc	atcgtgattt	ctgtatttat	ctgtatatcc	tttgctacat	1080
gtggatactt	gacattttact	ggcttcaccc	aaggggactt	atttgaaaat	tactgcagaa	1140
atgatgaact	ggtaacattt	ggaagatttt	gttatgggtg	cactgtcatt	ttgacatacc	1200
catcggaatg	ctttgtgaca	agagaggtaa	ttggcaatgt	gttttttggt	gggaatcttt	1260
ctatcggttt	ccacattggt	gtaacagtga	tggtcatcac	tgtagccacg	cttgtgtcat	1320
tgctgattga	ttgcctcggg	atagttctag	aactcaatgg	tgtgctctgt	gcaactcccc	1380
tcatttttat	cattccatca	gcctgttatc	tgaaactgtc	tgaagaacca	aggacacact	1440
ccgataagat	tatgtcttgt	gtcatgcttc	ccattgggtg	tgtggtgatg	gtttttggat	1500
tcgtcatggc	tattacaaat	actcaagact	gcacccatgg	gcaggaaatg	ttctactgct	1560
ttcctgacaa	tttctctctc	acaaatacct	cagagtctca	tgttcagcag	acaacacaac	1620
tttctacttt	aaatattagt	atcttttcaat	gagttgactg	ctttaaaaat	atgtatgttt	1680
tcatagactt	taaaacacat	aacattttacg	cttgcttttag	tctgtattta	tgttatataa	1740
aattattatt	ttggcttttta	tcaagacttg	gctttttatga	gtagtgcaat	ataaaaaa	1797

<210> 39
 <211> 3277
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7484823CB1

<400> 39

atggggggaag	gagatagtg	gttgaggagc	ccaagaggcc	cacaggaagg	tgggaaatgc	60
agtagggaaa	aacagaagcg	caatatggag	gaactgaaga	aggaagtgg	catggatgat	120
cacaaattaa	ccttggaaga	gctgagcacc	aagtactccg	tggacctgac	aaagggccat	180
agccacccaaa	gggcaaagga	aatcctgact	cgaggtggac	ccaatactgt	tacccacccc	240
cccaccactc	cagaatgggt	caaattctgt	aagcaactgt	tcggaggctt	ctccctccta	300
ctatggactg	gggccattct	ctgctttgtg	gcctacagca	tccagatata	tttcaatgag	360
gagcctacca	aagacaacct	ctacctgagc	atcgctactg	ccgtcgtgg	catcgtcact	420
ggctgcttct	cctattatca	ggaggccaag	agctccaaga	tcatggagtc	ttttaagaac	480
atggtgcctc	agcaagctct	ggtaatcga	ggaggagaga	agatgcaaat	taatgtacaa	540
gaggtgggtg	tgggagacct	ggtggaaatc	aaggggtgg	accgagtc	tgctgacctc	600
cggcttatct	ctgcacaagg	atgtaagggt	gacaactcat	ccttgactgg	ggagtcagaa	660
cccagagacc	gctcccctga	cttcacccat	gagaaccctc	tggagacc	aaacatctgc	720
ttcttttcca	ccaactgtgt	ggaaggaacc	gcccggggt	ttgtgattgc	tacgggagac	780
tccacagtga	tgggcagaat	tgctccctg	acgtcaggcc	tggcggttgg	ccagacacct	840
atcgctgctg	agatcgaaca	cttcatccat	ctgatcactg	tgggtggcgt	cttccttgg	900
gtcacttttt	ttgcgctctc	acttctcttg	ggctatgggt	ggctggaggc	tatcattttt	960
ctcattggca	tcattgtggc	caatgtgcct	gaggggctgt	tggccacagt	actgtgtgtc	1020
ctgacctca	cagccaagcg	catggcgcg	aagaactgcc	tgggaagaa	cctggaggcg	1080
gtggagacgc	tgggctccac	gtccaccatc	tgctcagaca	agacgggcac	cctcaccacg	1140
aaccgcatga	ccgtcgccca	catgtggttt	gatatgaccg	tgtatgaggc	cgacaccact	1200
gaagaacaga	ctggaaaaac	atttaccag	agctctgata	cctgggtttat	gctggcccca	1260
atcgctggcc	tctgcaaccg	ggctgacttt	aaggctaate	aggagatcct	gcccattgtc	1320
aagagggcca	caacaggtga	tgcttccgag	tcagccctcc	tcaagttcat	cgagcagctc	1380
tacagctctg	tggcggagat	gagagagaaa	aaccccaagg	tggcagaggt	tccctttaat	1440
tctaccaaca	agtaccagat	gtccatccac	cttcgggagg	acagctccca	gacccacgta	1500
ctgatgatga	aggggtgctc	ggagaggatc	ttggagtttt	gttctacctt	tcttctgaat	1560
gggcaggagt	actcaatgaa	cgatgaaatg	aaggaagcct	tccaaaatgc	ctatttagaa	1620
ctgggaggct	tgggggaacg	tggtctaggc	ttctgcttct	tgaatctgcc	tagcagcttc	1680
tccaagggat	tcccatttaa	tacagatgaa	ataaatttcc	ccatggacaa	cctttgtttt	1740
gtgggectca	tatccatgat	tgacctccc	cgagctgcag	tgctgatgc	tgtgagcaag	1800
tgtcgcagtg	caggaattaa	ggtgatcatg	gtaacaggag	atcatcccat	tacagctaag	1860
gccattgcc	aggggtgtgg	catcatctca	gaaggcactg	agacggcaga	ggaagtgcgt	1920
gcccggctta	agatccctat	cagcaaggtc	gtgccagt	ctgccaaagc	cattgtggtg	1980
catggtgcag	aactgaagga	catacagtc	aagcagcttg	atcagatcct	ccagaaccac	2040
cctgagatcg	tgtttgctcg	gacctcccct	cagcagaagc	tcattcattgt	cgagggatgt	2100
cagaggctgg	gagccgttgt	ggcgtgaca	ggtgacggg	tgaacgactc	ccctgcgctg	2160
aagaaggctg	acattggcat	tgccatgggc	atctctggct	ctgacgtctc	taagcaggca	2220
gccgacatga	tcctgtctga	tgacaacttt	gcctccatcg	tcacgggggt	ggaggagggc	2280
cgctgatct	ttgacaacct	gaagaaatcc	atcatgtaca	ccctgaccag	caacatcccc	2340
gagatcacgc	ccttctctgat	gttcatcatc	ctcggtat	ccctgcctct	gggaaccata	2400
accatctct	gcattgatct	cggcactgac	atggtccctg	ccatctcctt	ggcttatgag	2460
tcagctgaaa	gagacatcat	gaagaggctt	ccaaggaacc	caaagacgga	taatctggtg	2520
aaccaccgtc	tcattggcat	ggcctatgga	cagattggga	tgatccaggc	tctggctgga	2580
ttctttacct	actttgtaat	cctggctgag	aatggtttta	ggcctgttga	tctgctgggc	2640
atccgcctcc	actgggaaga	taaatacttg	aatgacctgg	aggacagcta	cggacagcag	2700
tggacctatg	agcaacgaaa	agttgtggag	ttcacatgcc	aaacggcctt	ttttgtcacc	2760
atcggtgtg	tgcagtgggc	ggatctcatc	atctccaaga	ctcgccgcaa	ctcacttttc	2820
cagcagggca	tgagaaacaa	agtcttaata	tttgggatcc	tggaggagac	actcttggct	2880
gcattttctgt	cctacactcc	aggcatggac	gtggccctgc	gaatgtaccc	actcaagata	2940
acctggtggc	tctgtgccat	tccctacagt	attctcatct	tcgtctatga	tgaaatcaga	3000
aaactctca	tccgtcagca	cccggatggc	tgggtggaaa	gggagacgta	ctactaaact	3060
cagcagatga	agagcttcat	gtgacacagg	ggtgttgtga	gagctgggat	ggggccagag	3120
attataagtt	tgacacaaca	tctgagacac	taggatgaat	tatcttggat	gagaaagatg	3180
ggcaatcctg	ggctggcttg	agggaaatcat	gggcagagga	tgaggtgggc	tgaaggggaag	3240
cccagcctgc	atctagctgg	agccccgcag	ggagggg			3277

<210> 40

<211> 2773

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 143935CB1

<400> 40

```
atggaagaga tgtcaggaga aagtgtggtg agctcagcgg tgccagcggc tgctacccgc 60
accacttctt tcaagggcac gagccccagc tccaaatacg tgaagctgaa tgtgggtgga 120
gccctctact ataccacccat gcagacgctg accaagcagg acaccatgct gaaggccatg 180
ttcagcgggc gcatggaagt gctcacggac agtgaaggct ggatcctcat tgaccgctgt 240
gggaagcact ttggtacgat actcaactac ctctgagacg gggcggtgcc tttacccgag 300
agccgccggg agatcgagga gctgctagca gaagccaagt actacctagt ccaaggcctg 360
gtggaagagt gccaggcggc cctacaaaac aaagatactt atgagccttt ctgcaaggctc 420
cctgtgatca cctcatccaa ggaagaacaa aaacttatag cgacttcaaa taagccagcc 480
gtgaagttgc tctacaacag aagtaacaac aaatactcat ataccagcaa ttctgacgac 540
aatatgttga aaaacattga actgtttgat aagctgtctc tgcgctttaa cggaagggtc 600
ctgttcataa aggatgttat tggggatgaa atctgctgct ggtcctttta tggtcagggc 660
cggaagattg ctgaagtctg ttgtacctcc atcgtctatg ccactgagaa gaaacagacc 720
aagggtggagt ttcccgaagc ccggttttat gaggagaccc tgaacatttt gctgtatgag 780
gcccaggatg gccggggacc tgacaatgcg ctccctggagg ccacaggcgg ggcggcggg 840
cgctcccacc acctggacga ggacgaggag cgggagcggg tgcagcgcgt gcgaggatc 900
cacatcaagc gccctgatga ccgggccac ccccaccagt gagcaggcaa gagaccgagc 960
cgccctcttc tcaccgcccc cactccctgc cgtgctacac ccagatcctg tgcaggctgc 1020
cgggcccctt ctgcttccct tggagcctgg agatactttt gtaacaagcc agatgattat 1080
tttggtattg cttgacaagg caaattgatt gtcttgaccc aggcgtatga cccctgtcgt 1140
tgaacaagct gtgtctaaga tctctacttt tcatgagaat ctgagactct ttggagccag 1200
gctttctcgg tctcagagg aaaagtatga atgagtgtga agtgtatgtg agaacttttg 1260
tttgcaatat ttatttttgt ggggtgcgac ttcctatgtg ggcttttttg gtgacactcc 1320
cttaagggtt cagtttgaca attctgagag ttgtcctgca gttggaggcc accagaggta 1380
tctgagctcc ctgcttccta ttccataatc ctccagcccc agcagggtcca ctccctgggtc 1440
ctgtgtgttt ggcccgggca caatccccac tgctttgcta gacgtgcttt ctgccatgtg 1500
gctttggggc tagagcttgt tgataattgc agcttgtggc agtggaaata tggctgaatg 1560
agcgtctaaa tcgttgagac cagtgaact ttgggtgcaa ggctttgttt agggatcaag 1620
accttttgcca ccttgggctg gtctttggcc tgggtctcac tgggaccca tatgtctgcg 1680
taggagcaga actttccatg gcagtaagtg tccagctctg tttctgggtc tttccccaac 1740
tccagccccg tccagttgtt ctctgattg acccgactcc actccaggaa ggccatctga 1800
ccctgtgaca ggcatagtct ataaactacc cctccctggg atcccgtcc tcttcagcct 1860
cctcccccac gaagctgggc taactttcta agtcattttg cttagaaatt cagtgtggcc 1920
catacccttt gtcctcccag cctggcatcc aggcagggac accctcacac caccagcccc 1980
agggagcttc cctgtataaa acacagacct ccttgtcttt gcctctgatt tttacacagt 2040
gtagagtggc cagcagtga caggttgagg atgtgcgggt agatagataa ctttgggtct 2100
ggtttgtgtc tgtgttcctg tttgtttaag ggatatgtgt gactgtgggt ggggacgtgt 2160
gcttgtgggg cacagggtgc ggccctgct ggagcccggc tgggcgcagc gcctatgtag 2220
gacgggtgtt ctcagtgacc tacctcccag gctcctctgc acctgcaaag gaacaggagt 2280
gagtcgtgac tgacaggggt ggttgagact agactaggtg gagtagttac caggagatgt 2340
gaatgtgcgt caggtgatgg atgggtttgt caagggaatc gttaccgttt tataccaaag 2400
gtattaacat gggcagcctt tgacacatgt attccaaaaa cgagtttata ttttcaaacg 2460
gtttttacag cttagacttt gtacttactg ccctgcctgt gacagttgta tgccttcatt 2520
ttgtatccaa cagcaaagtc tacaataaaa ctttaaaaca atcatgactg aatgtcaaaa 2580
tcgtgtattg ggcagatgct ttttaaactg tcgtgtgaga aacttttata ttaggccatt 2640
tggattttat taagtgctaa ggaaagaggg cttacaaaat gtttcgtaaa tattttatac 2700
tgtttaagtg ttaaaccacca accctgtctt tcttttgggt tgagcttttt tagaaagtcg 2760
aagtgaatgt tgg 2773
```

<210> 41

<211> 2966

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5923789CB1

<400> 41

```
tttttccaag tgagagactg ccccatatgt tagtgcaata tgtcactgga ggtgaagcat 60
cagttgtatt ggtgggaacc tgccgtttgc tgtccctttt ttcctcatgc ctttctctgc 120
```

ctctctgac	ttttctaggt	ctctggccta	tcaggaggac	aactgggtgct	gcaatagaag	180
ccagtggcta	agtcctcggt	atggcgtggt	taagggtgca	gcctctcacc	tctgccttcc	240
tccatttttg	gctggttacc	tttgtgctct	tcctgaatgg	tcttcgagca	gaggctgggt	300
gctcagggga	cgtgccaaag	acagggcaga	acaatgagtc	ctgttcaggg	tcctcggact	360
gcaaggaggg	tgtcatcctg	ccaatctggt	acccggagaa	cccttcctct	ggggacaaga	420
ttgccagggt	cattgtctat	tttgtggccc	tgatatacat	gttccttggg	gtgtccatca	480
ttgtgaccg	cttcatggca	tctattgaag	tcacacctc	tcaagagagg	gagggtgaca	540
ttaagaaacc	caatgggagaa	accagcacaa	ccactattcg	ggctctggaat	gaaactgtct	600
ccaacctgac	ccttatggcc	ctgggttcct	ctgctcctga	gatactcctc	tctttaattg	660
aggtgtgtgg	tcatgggttc	attgctggtg	atctgggacc	ttctaccatt	gtagggagtg	720
cagccttcaa	catgttcac	atcattggca	tctgtgtcta	cgtgatccca	gacggagaga	780
ctcgcaagat	caagcatcta	cgagctctct	tcacaccgc	tgcttggagt	atctttgcct	840
acatctggct	ctatatgatt	ctggcagctc	tctcccctgg	tgtgggtccag	gtttgggaa	900
gcctcctcac	tctcttcttc	tttccagtgt	gtgtccttct	ggcctgggtg	gcagataaac	960
gactgtctct	ctacaaatac	atgcacaaaa	agtaccgcac	agacaaacac	cgaggaatta	1020
tcatagagac	agagggtgac	caccctaagg	gcattgagat	ggatgggaaa	atgatgaatt	1080
cccattttct	agatgggaac	ctggtgcccc	tggaaggga	ggaagtggat	gagtcccga	1140
gagagatgat	cggattctc	aaggatctga	agcaaaaaa	cccagagaag	gacttagatc	1200
agctggtgga	gatggccaat	tactatgctc	tttcccacca	acagaagagc	cgtgccttct	1260
accgtatcca	agccactcgt	atgatgactg	gtgcaggcaa	tatcctgaag	aaacatgcag	1320
cagaacaagc	caagaaggcc	tccagcatga	gcgaggtgca	caccgatgag	cctgaggact	1380
ttattttcaa	ggtcttcttt	gacccatgtt	cttaccagtg	cctggagaac	tgtggggctg	1440
tactcctgac	agtgtgagg	aaagggggag	acatgtcaaa	gaccatgtat	gtggactaca	1500
aaacagagga	tggttctgcc	aatgcagggg	ctgactatga	gttcacagag	ggcacggtgg	1560
ttctgaagcc	aggagagacc	cagaaggagt	tctccgtggg	cataattgat	gacgacattt	1620
ttgaggagga	tgaacacttc	tttctaaggt	tgagcaatgt	ccgcatagag	gaggagcagc	1680
cagaggaggg	gatgcctcca	gcaatattca	acagtcttcc	cttgccctcg	gctgtcctag	1740
cctccccttg	tgtggccaca	gttaccatct	tggaatgatga	ccatgcaggc	atcttcactt	1800
ttgaatgtga	tactattcat	gtcagtgaga	gtattggtgt	tatggaggtc	aaggttctgc	1860
ggacatcagg	tgcccgggg	acagtcacgt	tcccctttag	gacagtagaa	gggacagcca	1920
aggggtggcg	tgaggacttt	gaagacacat	atggggagtt	ggaattcaag	aatgatgaaa	1980
ctgtgaaaac	cataagggtt	aaaatagtag	atgaggagga	atacgaaagg	caagagaatt	2040
tcttcattgc	ccttggtgaa	ccgaaatgga	tggaacgtgg	aatatcagat	gtgacagaca	2100
ggaagctgac	tatggaagaa	gaggaggcca	agaggatagc	agagatggga	aagccagtat	2160
tgggtgaaca	ccccaaacta	gaagtcacat	ttgaagagtc	ctatgagttc	aagactacgg	2220
tggacaaact	gatcaagaag	acaaacctgg	ccttggttgt	ggggacccat	tcctggaggg	2280
accagttcat	ggaggccatc	accgtcagtg	cagcagggga	tgaggatgag	gatgaatccg	2340
gggaggagag	gctgccctcc	tgctttgact	acgtcatgca	cttctgact	gtcttctgga	2400
aggtgctgtt	tgctgtgtg	ccccccacag	agtactgcca	cggctgggcc	tgcttcggcc	2460
tctccatcct	catcattggc	atgtcacccg	ccatcattgg	ggacctggcc	tcgcacttcg	2520
gctgcaccat	tggctcctaa	gattcagtca	cagctgttgt	tttcgtggca	tttggcacct	2580
ctgtcccaga	tacgtttggc	agcaaagctg	ctgccctcca	ggatgtatat	gcagacgcct	2640
ccattggcaa	cgtgacgggc	agcaacgcgc	tcaatgtctt	cctgggcatc	ggcctggcct	2700
ggtccgtggc	cgccatctac	tgggtctctc	agggacagga	gttccacgtg	tcggcggcca	2760
cactggccct	ctccgtcacc	ctcttcacca	ttttgcatt	tgtctgcac	agcgtgctct	2820
tgtaccgaag	gcggccgcac	ctgggagggg	agcttgggtg	cccccgctgc	tgcaagctcg	2880
ccacaacatg	gctctttgtg	agcctgtggc	tcctctacat	actctttgcc	acactagagg	2940
cctattgcta	catcaagggg	ttctaa				2966

<210> 42

<211> 4404

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6046484CB1

<400> 42

atgtatatcc	gtgtatccta	tgacaccaag	ccagactcac	tgctccatct	catggtgaaa	60
gattggcagc	tggaaactcc	caagctctta	atatctgtgc	atggaggcct	ccagaacttt	120
gagatgcagc	ccaagctgaa	acaagtcttt	gggaaaggcc	tgatcaaggc	tgctatgacc	180
accggggcct	ggatcttcac	cgggggtgtc	agcacagggt	ttatcagcca	cgtaggggat	240

gccttgaaag	accactcctc	caagtcacaga	ggccgggttt	gtgctatag	aattgctcca	300
tggggcatcg	tggagaataa	ggaagacctg	gttggaagg	atgtaacaag	agtgtaccag	360
accatgtcca	accctctaag	taagctctct	gtgctcaaca	actcccacac	ccacttcac	420
ctggctgaca	atggcaccct	gggcaagtat	ggcgccgagg	tgaaacttcg	aagacaactg	480
gaaaagcata	tttactcca	gaagataaac	acaagaatcg	gtcaagggtg	tcctgtgggtg	540
gcactcatag	tggaggagg	acccaatgtg	atctcgattg	ttttggagta	ccttcgagac	600
accctcccg	tgccagtgg	tgtctgtgat	gggagtggac	gggcatcgga	catcctggcc	660
tttgggcata	aatactcaga	agaaggcgga	ctgataaatg	aatctttgag	ggaccagctg	720
ttggtgacta	tacagaagac	tttcacatac	actcgaaccc	aagctcagca	tctgttcac	780
atcctcatgg	agtgcataag	gaagaaggaa	ttgattacgg	tatttcggat	gggatcagaa	840
ggacaccagg	acattgattt	ggctatcctg	acagctttac	tcaaaggagc	caatgcctcg	900
gccccagacc	aactgagctt	agcttttagcc	tggaaacagag	tcgacatcgc	tcgcagccag	960
atctttat	acgggcaaca	gtggccgggtg	ggatctctgg	agcaagccat	gttggatgcc	1020
ttagttctgg	acagagtggg	ttttgtgaaa	ttactcatag	agaatggagt	aagcatgcac	1080
cgttttctca	ccatctccag	actagaggaa	ttgtacaata	cgagacatgg	gccctcaaat	1140
acattgtacc	acttggtcag	ggatgtcaaa	aaggggaacc	tgcccccaga	ctacagaatc	1200
agcctgattg	acatcggcct	ggtgatcgag	tacctgatgg	gcggggctta	tcgctgcaac	1260
tacacgcgca	agcgcttcgg	gacctctac	cacaacctct	tcggccccaa	gagggatgat	1320
attccttga	ggcgaggaag	aaagacaacc	aagaagaggt	aagaagaggt	ggacattgac	1380
ttggatgac	ctgagatcaa	ccacttcccc	ttccctttcc	atgagctcat	ggtgtgggct	1440
gttctcatga	agcggcagaa	gatggccctg	ttcttctggc	agcacgggtg	ggaggccatg	1500
gccaaggccc	tgggtggcctg	caagctctgc	aaagccatgg	ctcatgaggc	ctctgagaac	1560
gacatgggtg	acgacatttc	ccaggagctg	aatcacaatt	ccagagactt	tggccagctg	1620
gctgtggagc	tcctggacca	gtcctacaag	caggacgaac	agctggccat	gaaactgctg	1680
acgtatgagc	tgaagaactg	gagcaacgcg	acgtgcctgc	agcttgccgt	ggctgccaaa	1740
caccgcgact	tcacgcgcga	cacgtgcagc	cagatgctgc	tcaccgacat	gtggatgggc	1800
cggctccgca	tgcgcaagaa	ctcaggcctc	aaggtaattc	tgggaattct	tctaccccc	1860
accatcttgt	ttttggaatt	tcgcacatat	gatgatttct	cgatcaaac	atccaaggaa	1920
aatgaggatg	gcaaagaaaa	agaagaggaa	aatacggatg	caaatgcaga	tgctggctca	1980
agaaaagggg	atgaggagaa	cgagcacaaa	aaacagagaa	gtattcccat	cggaacaaag	2040
atctgtgaat	tctataacgc	gccattgtc	aaagtctggg	tctttcagat	atcatacttg	2100
ggctacctgc	tgctgtttaa	ctacgtcatc	ctggtgcgga	tggatggctg	gccgtccctc	2160
caggagtggg	tcgtcatctc	ctacatcgctg	agcctggcgt	tagagaagat	acgagagggtg	2220
gctactccaa	aggcctcccc	cagcccacta	gccagaaaat	caaagtttgg	cttcaggag	2280
tactggaaca	tcacagatct	cgtggccatt	tccacattca	tgattggagc	aattcttcgc	2340
ctacagaacc	agccctacat	gggctatggc	cgggtgatct	actgtgtgga	tatcatcttc	2400
tggtacatcc	gtgtcctgga	catctttgtg	ctcaacaagt	atctggggcc	atacgtgatg	2460
atgattggaa	agatgggttag	tagtggcatc	ctgtgggtag	tcacatgct	ggtcgtgctc	2520
atgagtttcg	gagtagcccg	tcaagccatt	ctgcatccag	aggagaagcc	ctcttgga	2580
ctggcccgaa	acatcttcta	catgccctac	tggatgatct	atggagagg	gtttgcagac	2640
cagatagacc	gtaagagttt	ttttctttca	gctccttggtg	gtgagaacct	atatgatgag	2700
gagggcaagc	ggcttcctcc	ctgtatcccc	ggcgccctggc	tcactccagc	actcatggcg	2760
tgctatctac	tggtcgccaa	catcctgctg	gtgaacctgc	tgattgctgt	gttcagcaat	2820
accttctttg	aagtaaaatc	aatatccaac	caggttggtg	agttccagcg	atatcagctg	2880
attatgacat	ttcatgacag	gccagtcctg	ccccaccga	tgatcatttt	aagccacatc	2940
tacatcatca	ttatgcgtct	cagcggccgc	tgcaggaaaa	agagagaagg	ggaccaagag	3000
gaacgggac	gtggattgag	tatgttcctt	agcgacgagg	agctaaagag	gctgcattgag	3060
ttcgaggagc	agtgcgtgca	ggagcacttc	cgggagaagg	aggatgagca	gcagtcgtcc	3120
agcgacgagc	gcacccgggt	cacttctgaa	agggttgaaa	atatgtcaat	gaggttgga	3180
gaaatcaatg	aaagagaaac	ttttatgaaa	acttcctgc	agactgttga	ccttcgactt	3240
gctcagctag	aagaattatc	taacagaatg	gtgaatgctc	ttgaaaatct	tcggggaatc	3300
gacagggtctg	acctgatcca	ggcacgggtcc	cgggcttctt	ctgaatgtga	ggcaacgtat	3360
cttctccggc	aaagcagcat	caatagcgct	gatggctaca	gcttgatcgc	atatcatttt	3420
aacggagaag	agttattatt	tgaggatata	tctctctcca	cgtcaccagg	gacaggagtc	3480
aggaaaaaaa	cctgttcctt	ccgtataaag	gaagagaagg	acgtgaaaac	gcacctagtc	3540
ccagaatgtc	agaacagctc	tcacctttca	ctgggcacaa	gcacatcagc	aacctcagat	3600
ggcagtcacc	ttgcagtaga	tgacttaaag	aacgctgaag	agtcaaaatt	agggtccagat	3660
attgggattt	caaaggaaga	tgatgaaaga	cagacagact	ctaaaaaaga	agaaactatt	3720
tccccaagtt	taaataaaac	agatgtgata	catggacagg	acaaatcaga	tgttcaaaac	3780
actcagctaa	cagtggaaac	gacaaatata	gaaggcacta	tttctatcc	cctgggaagaa	3840
acaaaaatta	cacgctattt	ccccgatgaa	acgatcaatg	cttgtaaaac	aatgaagtcc	3900
agaagcttcg	tctattcccc	gggaagaaag	ctggtcgggtg	gggttaacca	ggatgtagag	3960
tacagttcaa	tcacggacca	gcaattgacg	acggaatggc	aatgccaagt	tcaaaagatc	4020


```

acgcgctctc atagcacaga tattccttac atttgtgtcgg aagctgcagt gcaagctgag 4080
cataaagagc agttttgcaga tatgcaagat gaacacccatg tcgctgaagc aattcctcga 4140
atccctcgct tgtccctaac cattactgac agaaatggga tggaaaactt actgtctgtg 4200
aagccagatc aaacttttggg attcccatct ctccaggtcaa aaagtttaca tggacatcct 4260
aggaatgtga aatccattca gggaaaagtta gacagatctg gacatgccag tagtgtaagc 4320
agcttagtaa ttgtgtctgg aatgacagca gaagaaaaaa aggttaagaa agagaaagct 4380
tccacagaaa ctgaatgcta gtct 4404

```

```

<210> 43
<211> 669
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 7481427CB1

```

```

<400> 43
atgacggaac aagccatctc cttcgccaag gacttcttag ctggaggcat caccgccgct 60
atctccaaga cagccgtggc atcgatcaag cgggtccagc tgctgctgca gatgcagcac 120
gccagcatgc cgatggccgc cgccaagcag tgcaagggca tcgtgggactg catcgctccg 180
atccccaaag atcagggcgt gctgtccttc tggaggggca acctggccaa tgtcatccgc 240
tactccccca cgcaagccct caatttcgcc ttcaaggata agtacaagca gatcttccctg 300
gcgggcggtg acaagcacac gcagtctctg aggtactttg cgggcaacct ggccctctggc 360
ggcacggccg tcgtglatcc cctggatttc accagaacct gcctggcagc cgacgtggga 420
aagtcaggca cggagcgcga gttccgagggc ctgggagact gcctagtga gatcagcaag 480
tccgacggca tccggggcct ttaccagggc ttcagcgtct ccgtgcaggc catcatcatc 540
taccaggcag cctacttcag ggtgtacgat acggccaatg gcatgttccc cgaccccaag 600
aacacacaca tcctggtgag ctggatgacc gcgcagaccg tgacggccgt ggctggcgctg 660
ctctcctaa 669

```

```

<210> 44
<211> 1823
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 7483595CB1

```

```

<400> 44
aaaaaaaaac aaataaaaaa tgcccagtgat gagcatctgt agtcccagct atttgggaag 60
ttgaagcaga gaatcccttg tgcccaggag tttgagggtta cagtgaagta tgattgcacc 120
actgcactcc ggccctgggca acagagttag atcctgtctc ataaataaat aaataggcaa 180
aggcttggtc tgatcacctt gtccctgttt tccccaaagc aacctagaga gcagtagatt 240
ctagggcaag aacttaagtg agctgactgc tcacaaagaa ggaaaggagt agtgtgagct 300
agcacttggt gggagcctct gatcaacaat acaaggacct gtgttatcaa cttctgttca 360
ttagggaag agagttacaa gagttacaa aggggcctat cttaactttt ctatggaaac 420
ccttcttttc ctggagagt ccattggtgc cattgctgga ttgaagacat tctacccac 480
tctggttttc tcttctctgc agctaataat gggcggtatt gggttgggct tcattgccac 540
ttaccttccg gactctgcaa tgagtgtt cctggctgct gtggcacttc atatcatgct 600
gtcccagctg actttcatct ttgggattat gattagtttc catgccggtc ccatctcctt 660
cttctatgac ataattaatt actgtgtagc tctcccaaaa gcgaattcca ccagcattct 720
agtatttcta actgtgttg ttgctctgcy aatcaacaaa tgtatcagaa tttcttcaa 780
tcagtatccc attggtttc ccatggaatt atttctgata attttacaag ccttctcctt 840
atctttggtg agctccttgc tgctcatatt tctgggcaag aagattgcca gtcttcacaa 900
ttacagtgtc aattccaacc aggatatta agccatcggc ctttgcaatg tcgtcagttc 960
atttttcaga tcttgtgtgt ttactggtgc tattgctagg actattatcc aggataaatc 1020
tggaggaagc acaacagttt gcatctctgg taggcgcaga gctaagattc ttctcctggg 1080
tcaaatccct aacaccaaca tttatagaag catcaatgat tatcgggaga tcatcaccat 1140
tcttgggggtg aaaatcttcc agtgctgcag ctcaattaca tttgtaaatg tttactacct 1200
aaagcataag ctgttaaaag aggttgatat ggtaaagggt cctcttaaag aagaagaaat 1260
tttcagcttg ttttaattcaa gtgacaccaa tctacaagga ggaaagattt gcagggtgtt 1320

```

ctgcaactgt	gatgatctgg	agccgctgcc	caggattctt	tacacagagc	gatttgaaaa	1380
taaactggat	cccgaagcat	cctccggttaa	cctgattcac	tgctcacatt	ttgagagcat	1440
gaacacaagc	caaactgcat	ccgaagacca	agtgccatac	acagtatcgt	ccgtgtctca	1500
gaaaaatcaa	gggcaacagt	atgaggagggt	ggaggaagtt	tggcttccta	ataactcatc	1560
aagaaacagc	tcaccaggac	tgcttgatgt	ggcggaagc	caggggagga	gatcactcat	1620
cccttactca	gatgcgtctc	tactgcccag	tgtccacacc	atcatcctgg	atttctccat	1680
ggtacactac	gtggattcac	gggggttagt	cgtattaaga	caggtaagta	ctgaggaggc	1740
cttggcagga	gctctgatcc	ccctcctacc	atcccaaccc	caccctgac	ctgattgaat	1800
tctgttagtc	actgatcagc	tgc				1823

<210> 45

<211> 2931

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3788427CB1

<400> 45

atgtccatag	ttcgtttatc	cgtccatgcc	aaatggatta	tggggaaggt	gactgggaca	60
aaaatgcaaa	agactgctaa	agtgaagagt	atcaggcttg	ttctggatcc	ccatttatta	120
aagtattata	ataagcaaaa	aacgtacttt	gtccacaatg	cccttcagca	gtgcacaatt	180
ggggatattcg	tgcttctcaa	agctttacct	gttccacgaa	caaagcatgt	gaaacatgaa	240
ctggctgaga	ttgttttcaa	agttggaaaa	ctcgtagatc	ctgtgacagg	aaaacctcgt	300
gcaggaaacta	cctatctgga	gagtccattg	agttcggaaa	ccacccaggg	cgtagacggg	360
gcttcccgtc	cctcacgcgg	gcccgcacca	tgccggggcg	ggcctggggc	ccgccgcctc	420
cgcccgtggc	cggagagccc	caggcccag	ccacgcggtc	ttccggggcc	gggtcggggc	480
tcaatggcta	cgtggaggcg	ggacggccga	ctgacaggcg	gccaaaggct	gctgtgcgct	540
gggctggcgg	ggacgctcag	cctcagcctc	accgcgcccc	tggagctcgc	caccgtgctg	600
gcccaggttg	gcgtcgtgcg	aggccacgcc	cggggaccgt	gggccacagg	gcaccgggtg	660
tggcgggcag	aggggctccg	ggccctgtgg	aaggggaacg	cggtggcgctg	cctgcgcctc	720
ttcccctgca	gcgccgtgca	gctcgccgcc	taccgcaa	ttgttgtgct	gttcacagat	780
gacctggggc	acatttccca	gtggagctcc	atcatggctg	ggagtctcgc	aggcatgggt	840
tccaccattg	taacatatcc	tacagacctc	atcaaaaccc	ggttgatcat	gcagaacata	900
ctggaacct	cgtacagggg	gctcctccat	gctttttcta	ctatttacca	acaggaaggg	960
ttccttgccc	tttatcgagg	ggtttccttc	actgttgtag	gtgctctccc	gttctctgct	1020
ggctcccttc	ttgtttacat	gaacctggag	aaaatctgga	acggaccccg	agatcagttc	1080
tctctcccac	agaactttgc	taatgtctgt	ctggctgctg	cagtgaacca	gacctctctc	1140
tttccctttg	agaccgtgaa	gagaaagatg	caggctcaga	gccctacct	cccacacagt	1200
ggaggagtag	atgtccattt	ctcaggagca	gtggactgct	tccggcagat	agtgaaggcc	1260
cagggggctc	tggggctctg	gaatggattg	acagccaatt	tactgaagat	agttccatat	1320
tttggaatta	tgtttagcac	ctttgagttc	tgcaagagaa	tctgtcttta	tcaaaatggt	1380
tacattctgt	ctccactgag	ctataaattg	acccaggag	tcgatcagag	tttgcagccc	1440
caggaattac	gagaattaaa	gaagtctctc	aaaacgagaa	aactgaagcc	taaaaaacca	1500
actctataaa	atggaatgga	actagaagtg	cactgactga	cagcatgttg	caatcacaga	1560
taaatgtagc	ctcataactg	tgcacctgag	gagggatgag	aagctactgc	tatctgctgc	1620
tctgggaaat	gagatggttt	ggccatgcac	cacctcagat	ctccaaactg	atgtccctgt	1680
gaacacctgc	actatgagaa	ggtttcccaa	caagagtgtg	tcatgatggc	attccacgag	1740
attttataac	cagagtctag	cagtgataaa	atgtacaatt	tacgctctga	atagaaacat	1800
ggcaccaaag	aaagggcatt	gccatgacat	ctcaaagcaa	caggtaattg	aagtggctga	1860
gtggatacca	cgttgtgagg	tcagccactg	ggtcacttgt	agtcaatgca	aagcttgcac	1920
aaaccaacgt	cagcctagtt	tactcagtt	tgacctgaga	ctttccaata	caatctgttg	1980
ttttgtttg	tttttagaga	cagggtcttg	ctctgtcacc	cagactggag	tacaatgaca	2040
caatcattag	tcactgcagc	ctttaactac	tgggctcaag	acatcctcct	gcttcagcct	2100
ccagagagtt	gggaccatag	gtgcacacca	ccacacctag	ctaatttttg	ggggagggtct	2160
tgctatgttg	cccaggctgg	tcttgaactc	ctgggctcat	gcaatcctcc	tgcttggcc	2220
tcccaaagcg	ctaggattag	aggtgtgagc	cgctgcaccc	tgccccagta	caatcttttt	2280
tgaactcaaa	tttttgctga	catctgagtg	cacacaccac	agtgtaaatt	atgccttata	2340
agaatctaaa	tgaaaatagc	gaacatttaa	aagctatcac	cattgtagta	gaatcatcct	2400
tcttttttga	aatttgaagc	atcccaggct	taaaattctg	tgtttcagaa	agacagttta	2460
taccatgact	gcttaattat	cccccaaacg	accttctgat	tgaagtcag	tacagttcag	2520
tggcctaaat	tctctgcctt	tttaacttgc	tttgcaagcc	tactctgaaa	ataagttatt	2580

```

tagtcaagtt attctcaaag atgtcccagt tgcctagaaa ggatcaaagt gaacatttga 2640
cacacatact caaaaaaatg taactgacta taaacacttt aacctaataca tctgtatcaa 2700
acttttctaaa aatcaaactct caggattgtt ccacttttaga gattctatgt aaagtttata 2760
taactatact tgtcaaatac cacctatcta tgcattttaa aatgcattaa tatctaacat 2820
aaaattgtta atttatacac acacatacac ttatacatag agagagattt tcggtatggt 2880
gcaagtatatt tttccgatta aatttatatt ccaaagaaaa aaaaaaaaaa a 2931

```

```

<210> 46
<211> 1492
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 6972455CB1

```

```

<400> 46
cttgctcctt gatcagtttg cggatggcct gcaaggccgc ttccggtacg gcttggggcaa 60
tggaattcat aaaaagctca gggttcccga tagcgtgtgt gaccggtgtg aaaactattc 120
atagctggct gcaagccacg ccccaaaggc gtcgcgggct ttttgcaaac gctcgaaaag 180
gggtgcgggaa acctgaccac tggtcagacc agtaagacca ctgcacctca acaaacatca 240
gccttgacga cgatccgaac ggtgctggca tgggctgtgc actgggcaaa ctgagaaaat 300
tccttcgcct ttttcggaga gctgccatga ccaagcgcta cagegccctg ctcaactgcc 360
tgtttgccag cctgatgtcg agccaggcac ccgcccaggc gagtgggtctg gatgacatcg 420
tcgcccgtgg caccctgaag gttgccgtcc ccaaggactt cccgccgttt ggttcggtcg 480
gccctgacat gcaaccccgg ggccctggaca tcgacaccgc caagctgctg gccgaccaac 540
tcaaggtcaa gctggaactg acgccgggtca acagcaccaa ccgcataccg ttcttcacca 600
ctggcaaaagt cgacctggtt atttccagcc tgggcaagaa ccccagcgcg gcaaaggtca 660
tcgacttttc caacgcctac gcgcggttct accttgccgt gtttgggccc cctgatgccg 720
ccatcgccag cctcgacgac ctcaagggca agaccatcag cgtgaccggt ggcgccatcg 780
aagacatcga gctgaccgcg gtagcgccca aggaagccac gatcaagcgt tttgaagaca 840
acaactccac catcgccgcc tacctggccg gccaggtcga cctgatcgcc agtggcaacg 900
tggtcatggt ggccatcagc gaacgcaacc ccaagcgcgt accggcactg aaggtgaaac 960
tcaaggattc gccggtgtac gtaggcgtga acaagaacga gccggcgtg ctggaaaagg 1020
tcaaccagat cctggtggca gccaaggctg acggcagcct tgggaaaaac gcgatgcagt 1080
ggctcaaaga accgctgcct gccgacctct cctgctcctg cgtggcgcgc tgttcacct 1200
tgagctgacg gccattggcg ccactctcgg cgtggccctg ggcactgtcg gcgcgtggt 1260
acgggctggt aagatccaac cgtttgcgtg ggtctttggt gtgtatgtcg agttgatccg 1320
caacacgccc ttctgtgtc aactgttctt catcttcttc ggctgccat ccctcgggtt 1380
gaaaattacc gagtggcaag ccgccgtgct ggcgatggtg atcaacctgg gggcctactc 1440
caccgagatc atccgtgccg gcatccaggc catcccacgg gggcaactgg ag 1492

```

```

<210> 47
<211> 2406
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 8077668CB1

```

```

<400> 47
atgtatgacc caccaaaagt gaataagaaa aatgactctg ctgatcattc tgatgaatct 60
gtggaaatac agtcagccct tcatactgtt ggatttgacc aaggcagggt gatcctctcc 120
taccgcccgt caccgcgcg ccggcacacg ggcctggccc cagtacttgg ggtgcgggtc 180
cgcgctctcg tggggtgcca agggggcccg gtcccagcgt ggcccaaacg tgagggtagg 240
ggctccgcgg aggagccagt agagagaaaag gatggacaac aaggggagag gagaggagaa 300
gccagcctga ccaaggatgc tgttaccttc cagagcagtc tccctgtcca gatcaccagg 360
atccctgctt gctggagaat gaccagatg tcccagggtg aggaagctct ccatgaggca 420
gccagcagg atgccctggc ccagccccag ccctgggtgga agaccagct gttcatgtgg 480
gagcctgtgc tgtttgggac ctgggatggt gtgttccat cctgcatgat caacatcttt 540
ggggttgtgc tcttctcgag gactggctgg ctggtgggaa acacaggagt gctcctgggc 600

```

atgttcctgg	tgtccttcgt	catcctgggtg	gccctcgtca	cggtgctgtc	tgacattggc	660
gtcgggggagc	gcagcagcat	cggcagcggt	ggcgtctact	ccatgatctc	ctcggtcctg	720
ggtggggcaga	cgggaggcac	catcgggctg	ctctatgtgt	ttggacagat	gtatatcacc	780
ggcttttgctg	aatccatctc	ggatttgctg	ggcctcggga	atatctgggc	tgtagcgagga	840
atttcagttg	cggtgcttct	ggccttgctg	ggcattaacc	tcgcagggtg	caaatggata	900
atccgcctcc	agctgctgtt	gctgttcctg	ctggccgtgt	ccacactgga	ctttgtggtg	960
ggttctttca	cccacctgga	cccagaacat	gttttcattg	gatattcacc	cgaactgcta	1020
cagaacaaca	cgctgccgga	ttacagcccc	ggggaatctt	ttttcactgt	ctttgggggt	1080
ttcttcccag	cggtacaggg	agtcattggc	ggcttcaaca	tggggggcga	cctcagggag	1140
cctgccgcca	gcattcccc	gggctccctg	gcagctgttg	gcattctctg	gtttctgtac	1200
atcggtaca	ggagtcatgg	ccggcttcaa	catggggggc	gacctcaggg	agcctgccgc	1260
cagcattccc	ctgggctccc	tggcagctgt	tggcatctcg	taagttcccc	tcatggcaat	1320
cagtctgagc	tagagagtgg	gagagaaaac	cccaggcaga	agagggattg	ccccctttgt	1380
tctgagagtg	ccccgactgt	gaccaatcta	tttcatattc	cgatccttct	tttaacactc	1440
ggtgggctgg	aaaattcacg	tctggtgggt	tcagacactg	ccctttcatg	cgccctgcct	1500
gggaatgctg	ccgaggagga	gtgtcgggac	ccagatcaca	gatcgaatcc	tttctttcct	1560
ttcctcggcc	tcccgcctcc	gtccctcccc	cacccccatt	ttgaacttgg	ggattttttt	1620
aaccaccgag	tttccaggat	cactggaggg	agcataaaga	tgaagagttt	tgcaatcaga	1680
cgaattgggg	ctgcacttca	gctctgccgc	tgattggctg	catgactctg	gacaatttac	1740
tgagttctct	gagcctccat	ttcctttctt	gtgaaatggg	gataatgaca	ctgtatgtgc	1800
ttcctagatt	gcggcgggga	gagaaggcac	acagtggaag	ctcagcacc	agctcttctt	1860
cttccccccag	tgagcctccc	ctccagctcc	cccaggccgt	caggcctctg	gggttttagt	1920
tcacactgtg	ccacccacac	aagcaggctg	ggtaaccttg	ggtctatttc	tgacctttta	1980
gaatattggt	tctctctgta	ccacagggaag	aagcttctct	gcccttcatt	gggtagggtg	2040
gaagaggcaa	agagatcaga	gaccagaaa	aatgacttga	gaagttaaaa	gggcctgtgt	2100
tattctaacc	acagtattta	gaaaatatta	atgtatctgt	ttcacaacaa	ctgaatttgt	2160
tcttagctta	ctgcagtga	accattgcta	tcagcctggc	gtacagcatc	aggggtatttt	2220
gtgcaataac	attgggaaga	aaatgaagac	aacagagata	gagttgagtg	ttgggaagga	2280
aataaaaagaa	agaggcttct	gaatgaggac	cctgtcttgt	ttctggcccc	agctggggag	2340
ttccaggagg	aacccttggc	ccatcctctg	attaccaga	tgggaatgag	gagaccacag	2400
gaacct						2406

<210> 48

<211> 3686

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 55120485CB1

<400> 48

atggaagaga	acagtaagaa	ggaccatcgg	gctttgctca	accagggaga	ggaggatgaa	60
ctggagggtg	ttgggtaccg	ggaccacaat	gtacggaaag	ccttctgcct	tgtagcatcc	120
gtgctgacct	gtgggggcct	tctgctgggt	ttctactgga	gacccacagt	gagagtgtgg	180
gccaactgca	tcccatgccc	cttgcaagaa	gcagacactg	ttttgctgag	gacaacagac	240
gaatttcaaa	gatatatgag	gaagaaggta	ttctgcctct	acttatacac	actgaagttt	300
cctgtaagca	agaagtggga	agaatccctg	tggtgtgacc	gccactctgt	cataaaccac	360
gccttaataa	agccagaatt	aaaactgcgg	tgcctggaag	tgcaaaaaat	caggatgtgt	420
tggaaacgacc	tggagaagcg	gtttcagaaa	gttgggttgc	tagaagacag	caattcctgc	480
tctgacatcc	atcagacatt	tggattgggt	ctgaccagt	aagagcaaga	ggtcagaaga	540
ttagtgtgtg	ggcccaacgc	cattgagggt	gaaatccaac	ccatatggaa	gctgcttgtt	600
aaacagggtt	taaatccatt	ctatgtgttc	caagccttca	ccctaacttt	gtggctgtct	660
caagggttaca	tagaatactc	tgtggccatc	atcattttga	ctgttatctc	cattgtctta	720
agtgtgtatg	atttgcgaca	gcaatcagtt	aagctgcata	acctcgtgga	ggaccacaac	780
aaagtccagg	ttacaatcat	tgtaaaagac	aaagggttgg	aggagctgga	atcccgtctc	840
ttgggtcccg	gagacattct	tattcttcca	ggaaaatttt	cattgccatg	tgatgctgtt	900
ttgattgatg	gaagctgcgt	ggtgaatgaa	ggcatgctta	caggagaaag	tatacctgtt	960
acaaagacac	cattgcccc	gatggagaac	actatgcctt	ggaaatgtca	cagtttggag	1020
gattatagga	aacacgtcct	tttctgtgga	acagaagtta	tccagggtcaa	gccctctggg	1080
caggggcctg	tacgagcagt	cgttttgcaa	acaggttaca	atacagccaa	aggggaccta	1140
gtgagatcca	tcctgtacct	ccggcctctg	aacttcaaac	tatacagcga	tgccctcaag	1200
ttcatcgtgt	tcctggcctg	ccttgggtgc	atgggttttt	tctatgccct	aggggtatat	1260

atgtaccatg	gagttcctcc	aaaagatact	gtgaccatgg	ccctgatcct	cctcaccgtg	1320
actgtccctc	cagtgtgcc	agctgccctg	accataggca	acgtgtatgc	tcagaagaga	1380
ctgaagaaaa	agaaaatctt	ctgtatctcc	ccacagagaa	tcaacatgtg	tgggcaata	1440
aacctcgtgt	gctttgacaa	aactggcact	ctcactgaag	atgggctgga	cctctggggg	1500
actgtcccta	ctgctgacaa	ctgcttccag	gaagcccaca	gctttgcctc	aggccaggct	1560
gtgccatgga	gcccactgtg	tggggccatg	gccagctgcc	actctctgat	ccttctcaat	1620
gggaccatcc	agggagaccc	tctggacctc	aaaatgtttg	agggcactgc	ctggaaaatg	1680
gaagattgca	ttgtagactc	ctgcaaatctt	gggacgtcag	tttcaaacat	cataaaaacca	1740
ggacaaaaag	ccagtaagag	tccagtggaa	gccatcatca	ccttgtgcca	gtttccattt	1800
tcctcgagcc	tgcagaggat	gtccgtgatc	gctcagctag	ctggggagaa	tcatttccat	1860
gtctacatga	aagggtgcccc	agaaatgggtg	gccaggttct	gcagatctga	aacagtgcc	1920
aagaatttcc	cacaggaact	gaggagttag	acgggtgcaag	gcttccgtgt	cattgtctct	1980
gcccacaaaa	ccttaaagat	ggggaatctt	tcagaagtgc	agcacttagc	cagagaaaaa	2040
gtggagtcag	agttaacatt	tctgggactt	ctcatcatgg	agaatcgctt	gaaaaagaa	2100
accaaactgg	tcttgaagga	actgagttag	gcccgtatca	ggactgtgat	gattacaggt	2160
gataaccttc	aaacggccat	tactgttgca	aagaattctg	aatgatccc	tccaggcagc	2220
caagtgatca	ttgttgaggc	cgatgaacca	gaagaatttg	ttcctgcctc	tgtgacctgg	2280
cagctgggtg	agaaccaaga	gactggacct	gggaagaaag	aatctacat	gcatactgga	2340
aacagttcaa	cccctcgtgg	ggaaggagga	agctgttacc	attttgcaat	gagtgggaaa	2400
tcataccaag	tgatatttca	gcatttcaac	agcttgcttc	caaaaattct	ggtgaatgga	2460
acagtttttg	caagaatgtc	tcttgggcag	aatcaagcc	ttattgaaga	atttcagaaa	2520
ttaatgcct	gcacagtaca	aatgaaagc	atctcagagt	taaccatgtc	tccaactgct	2580
ccagaaaaaa	tggaaagtaa	tagcaccttc	acaagttttg	agaacactac	agtctgggtc	2640
ttgggaacaa	tcaactgtat	cactgtggct	cttgtgttct	ctaaaggaaa	accatttaga	2700
cagccaactt	atacaacta	tatatttgct	cttgtgtgta	taatacagct	tgggtgatgt	2760
ctattcattc	tatttgctga	tataccagaa	ttatatagac	gtttggatct	gctctgcact	2820
cccgtcctgt	ggagggcctc	cattgtcatc	atgctcagct	tgaatttcat	tgtgtccctt	2880
gtggccgagg	aggctgttat	tgaaaatcga	gccctgtgga	tgatgattaa	aagatgtttc	2940
ggctatcagt	caaaaagcca	gtatcggata	tggcagaggg	acttggcaaa	tgaccctagt	3000
tggccccgc	taaaccaaac	ctcccactct	gacatgccgg	agtgtggcag	aggagtgtct	3060
tacagcaatc	cagtatttga	gagcaatgaa	gaacaactct	gaaggacatg	tgatatccaa	3120
gttgatatta	cagagaaaca	atgacaaaag	ggaccagttt	cattgatttt	aagaaatgag	3180
actcttgtaa	catcagctgg	agttttgggg	ctacctatca	aatcatgggtg	acaaactaaa	3240
gtctgtttga	taaaatactg	tctacagaga	agaacattga	cccagaagag	tgctttcctc	3300
ttggcttctg	aaggatttag	aggcattcag	tgaaggcaag	aatgggcca	gaatttctat	3360
gggccaagag	acaagcaggc	taaaggggaa	aaatatgtga	tctttcctct	taggacagga	3420
caatactttc	ctttttataa	aaatgagttg	aggggaagta	gtactgtgta	tactcacgga	3480
gttgtaattt	ttgaattttt	acttcacgga	tggaaaaact	aatgcgtggg	aaacattaca	3540
ccaatcttta	ctgtctgggt	tctttttctc	tgtagtactt	ttcagatttg	aggtcttttc	3600
ttctgtttct	ggccttacc	aacatattgt	taaggataag	cttagcctat	gctgcaataa	3660
aaaacaactc	tcaaaaaaaaa	aaaaaa				3686

<210> 49

<211> 2807

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3112883CB1

<400> 49

aagaattcgg	cacgaggcca	cagccgcggg	tgcgtggctg	tgcggcaagt	gagcgatttg	60
gtgaacagac	actcccttct	gtagccatgg	attgttacag	aacttcacta	agcagttcct	120
ggattttacc	cactgtgatc	ctctgcttat	ttggtttttt	ctccatgatg	agaccttcag	180
aaccattcct	tatcccatat	ttatctggac	cagataaaaa	cctgaccagt	gcagagataa	240
caaatgagat	cttccccgtt	tggacatact	cctacctggt	gctgctgctg	cctgtgtttg	300
tcctcaccga	ttatgtccgc	tacaagccag	tcatcatctt	gcaagggtatc	agtttcatca	360
ttacctggct	gctgctgttg	tttggccaag	gagtgaagac	catgcagggt	gtagagttct	420
tctatgggat	ggtcaccgcc	gccgaggtgg	cctactacgc	ctacatatac	agcgtggtag	480
gccccgagca	ctaccagaga	gtgagcggct	actgcaggag	cgtcacgctg	gccgcctaca	540
cagcaggggc	ggtgctggct	caactcttgg	tatccctggc	gaacatgtcg	tacttttacc	600
tcaacgtcat	atccttggcc	tctgtctccg	tggctttcct	tttctcactt	ttcctaccaa	660

tgcccaagaa	aagcatgttt	tttcatgcaa	aaccagcag	agaaataaag	aagtcacaa	720
gcgtgaatcc	agtattagag	gaaactcacg	aagggtgaagc	accaggctgt	gaagagcaga	780
aaccacatc	agaaatactc	agcacttcag	ggaagctgaa	taagggccag	ctgaacagcc	840
tgaaaccaag	caatgtgact	gtggacgttt	ttgtgcagtg	gttccaagat	ttgaaggagt	900
gctactcctc	aaaacgtctt	ttctactggg	ctctatgggtg	ggctttcgcc	acagcagggt	960
ttaaccagg	tttgaactat	gttcaaactcc	tgtgggatta	caagggcgcca	tcccaagatt	1020
cttccatcta	taatggggcc	gtagaagcta	ttgcaacctt	tggaggggct	gtggctgcct	1080
ttgcagtg	ttatgtgaaa	gtcaactggg	accttctggg	agagctggct	ctgggtggct	1140
tctcagttgt	caatgccggt	tctttatttc	tcatgcatta	cacagccaat	atctgggcgt	1200
gctatgctgg	ctatttgata	ttcaagtcca	gctatatgct	tcttataacc	atagcagtat	1260
ttcagattgc	agttaatctg	aatgtggaac	gctatgcctt	ggtatttgga	atcaacacct	1320
ttattgcctt	ggtgattcag	accatcatga	ctgtgattgt	agtagatcag	agaggggtca	1380
acttgcaggt	cagcattcag	tttttagttt	atgggagcta	ttttgcagta	attgctggaa	1440
ttttccta	gagaagcatg	tattattac	actcaacc	atcccagaag	gatgtacaga	1500
gacctgtcc	aagtggaga	ccagatgtgt	ctcacc	ggaagagagt	aatatcatca	1560
tgcaacaaa	actcta	catcgcaaca	aacgcaacag	tggctttcaa	agttatgcaa	1620
taataaggaa	agattttgag	atgggtggca	tatgttttgc	cataacttga	catgctttgc	1680
aaatctggat	tccaatggac	ctttcaaaac	cacaacaaaa	cctcagtttt	agatgagttc	1740
tctatgtgac	caattttact	ggatgcaatt	gacaggaccc	gtcatcataa	ttaaacaacc	1800
catattgggg	acccctgtg	actagtagca	gctggaaaat	tctgggtttt	atcacttgta	1860
aagacatgca	gatggcggtg	aaccaaacca	tgagaaaact	ccagccatcc	tggagttgat	1920
attcaccatt	tgtgaggaga	aatactaact	ggactgaccc	tattgctagg	cttaataact	1980
tattttgatct	taccaaagaa	gtcaacacat	gggacctttg	tgtcacatga	accattttct	2040
ttcctcttct	attaagtgt	tttctgttta	agttacagtt	ctctaagaga	attacaatgt	2100
ttgtcccat	tctaagggt	tctcttcaac	tctaataaca	gcattattca	cgttatgatt	2160
tgatagtatt	attatttatt	ttttttatga	ttattttcca	ttttgtgctc	tgagttttgc	2220
tgttgaaagt	ctccctcaag	aatagcttca	gacccctctg	tgtatttgca	gaatacacia	2280
ggtcatttcc	cagtggcctg	ggagaggcag	tgagccttct	ctccaccacc	atagacaggt	2340
gttaatgcat	ctatgggcca	ggtgcagtg	ctcactcctg	taatccgagc	aatttgggag	2400
gccaagggtg	gagttttgct	tgaggctgg	ctcaaactcc	tgacttcagg	tgatctgtct	2460
gcctcggcct	cccaagagc	tgagattaca	ggcgtgagcc	accatgcctg	gccaaaacac	2520
ctgatttttta	aatggtagca	attgtgtctaa	ataacatgtg	tcaacaattt	tcaaagagtt	2580
gttaacattt	tttgatgaat	tctgctgaaa	attatctgaa	catacctgtt	tttcgaaact	2640
tcaagaaact	ttcaataagg	gatgcattga	gccgtctgac	agtgagaata	acgatgctga	2700
gtcagatttt	attaggctgg	acttgtgggt	acaactttat	cccgcatttt	gggaagctaa	2760
gtgagaggta	attgaggttg	gggttttaaac	ccttggcatt	ttaacct		2807

<210> 50

<211> 2170

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4253888CB1

<400> 50

gtgaatgccc	cttccatccc	ccgcccctgg	tgtctcggtc	tggtctgagg	agacggggac	60
ccttctcaca	ccggccgctg	ccgccgcgc	gctccggaac	agatccagtc	cttctgtgga	120
acttctgaac	atcttttatt	agtggaaata	ttttctacac	aatgaagtca	acaactta	180
ttaaaccagt	gtttgtgcgg	ttctgattca	tctgctgtgg	ttcccgaagc	ttgagatcta	240
aggagtacag	ggtcttttgt	gatgacaata	tgactaatag	taaaggaaga	tctattaccg	300
ataaaaacaag	tggtgggtcca	agtatgggag	gaggttttgt	agattggact	ttacgtttta	360
acacaattca	atccgacaag	tttttaaat	tactcttgag	tatgggtcca	gtgatttacc	420
agaaaaacca	agaagacagg	cacaaaaaac	caaacggcat	ttggcaagat	ggattatcaa	480
ctgcagtaca	gacttttagt	aatagattctg	agcaacacat	ggagtatcac	agtttctcag	540
agcagtcttt	tcatgccaat	aatgggcacg	catcatcaag	ctgcagccaa	aagtatgatg	600
actatgccaa	ttataattac	tgtgatggaa	gggagacttc	agaaaccact	gccatgttac	660
aagatgaaga	tatatctagt	gatgggtgatg	aagatgctat	tgtagaagtg	accccaaat	720
taccaaagga	atccagtggc	atcatggcat	tgcaataact	tgtgcccttt	ttgctagctg	780
gttttggaa	agtttcagct	ggcatggatc	tgatattagt	acagcactgg	gaggtgttca	840
gaaaagttac	agaagtttct	attttagtcc	ctgcacttct	tggtctcaaa	gggaacttgg	900
aaatgacatt	ggcatccaga	ttatccactg	cagtaaata	tggaagatg	gattcacc	960

```

ttgaaaagtg gaaccttaata attggcaact tggcttttaa gcaggttcag gcaacagtag 1020
tgggttttct agcagctgtg gcagcaatta tattgggctg gattccagaa ggaaaatatt 1080
accttgatca ttccatactt ctgtgctcta gcagtgtggc aactgccttc attgcatctc 1140
ttctgcaggg aataataatg gttgggggta tcgttgggtc aaagaagact ggtataaatc 1200
ctgataatgt tgctacaccc attgctgcta gttttggcga cttataact cttgccatat 1260
tggcttggtt aagtcagggc ttatactcct gtcttgagac ctattactac atttctccat 1320
tagttgggtg atttttcttg gctctaacc cttattggat tataatagct gccaaacatc 1380
cagccacaag aacagttctc cactcaggct gggagcctgt cataacagct atggttataa 1440
gtagcattgg gggccttatt ctggacacaa ctgtatcaga cccaaacttg gttgggattg 1500
ttgtttacac gccagttatt aatgggtatt gtggttaatt ggtggccatt caggctagca 1560
ggatttctac ctacctccat ttacatagca ttccaggaga attgcctgat gaacccaaag 1620
gttggttacta cccattttaga actttctttg gtccaggagt aaataataag tctgctcaag 1680
ttctactgct ttactgtatt cctggacatt taattttcct ctacactatt catttgatga 1740
aaagtgggtc tatttcttta actataatct tcatagtagt gtatttattt ggcgctgtgt 1800
tacagggtatt taccttgctg tggattgctg actggatggt ccatcacttc tggaggaaag 1860
gaaaggaccc ggatagtttc tccatccctt acctaacagc attgggtgat ctgctcggga 1920
cagctctgtt agccttaagt ttctattttc tttggcctat tggagatcga gatggagatg 1980
ttggagacta ataaattcta caaactgctc tcaagttacc aaggaagaaa atacacgaca 2040
accacttatg gctctttttc aaaactctta aatcagtagt ttgacttttg ccagggtaat 2100
cttcagttgg ccctgattca attaaatggc cttaattttt ttttaaggaa tttgtgtcaa 2160
aaaaaaaaa 2170

```

<210> 51
<211> 1722
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7479974CB1

```

<400> 51
atggatgctg ttaataactt aaataaattg aatttagata acattgagtt aacaaaaatat 60
ttgtttttta ctggttaaagg tggcgtaggc aaaacaacga tatcaagttt tattgcttta 120
aacttagcag agaattggaaa gaaagtagct ttagtaagta ctgatccagc tagtaattta 180
caagatgtat ttcaaatgga attatctaata aaattaacta aatatcaacc tatacctaata 240
ctctctatag ccaatttcga cccgattgtt gctgcagacg attataaagc acaatctata 300
gaaccttatg agggatttct accagaagat gtgcttgctg aaatgaaaga acagttaagt 360
ggttcatgta cagttgaagt agcagcattt aatgaattta caaatttttt atccgataaa 420
actttagaac aagaatttga tttcattata tttgatacag ctcccacagg tcacactttg 480
agaatgcttg aattaccttc tgcattggaca gattatttta atacaacgag taatgacgct 540
tcttgcttag gtcaattatc aggttttaata gaaaatagag ttaaataataa ttcagcactt 600
gaaaaaactac gtaaccaaga tgatacgacc atgatgttag ttgagagacc tactcactct 660
tctatatatg aaattcaaag agcgcaacaa gaattacaac aactgtcaat tttctaaattc 720
aaagtaaatca ttaacaacta tatagaagaa agtcacggtt taatttcgag tcagatgaaa 780
tcggaacaag ataaaaacat taatcatttt actgaatggt taaataacaa tcatgcttat 840
tacgtttccat ataaaaagca gaaagaagaa ggtatagaaa atttaactaa tctattaaat 900
gatgataact taattgaaaa tgatgacttt attgttgaag atcatccgca attcaataaa 960
ttaatcgatg aaattgaaaa tagtaaagtt caatattttt ttacaatggg aaaagggtgc 1020
gttggtaaaa cgacagtagc aacgcaatta gctacagcat tatctaataa aggatattcg 1080
gttcttttag caactactga ccctactaaa gaaattaatg ttgaaactac aagtaattta 1140
aatactgctt atattgatga agaacaagca ttagaaaagt ataaaaaaga agtactagcc 1200
acagtgaatg atgatacacc acaagacgat attgattata ttatggaaga tttaaaatca 1260
ccttgtagag aagaaatagc atttttcaaa gccttttagt acattatgga gaatcaagac 1320
gacatggatt acgtcattgt agacacagct cctacaggcc ataccttgct gttacttgat 1380
tctagtgaat atcatcatag agaattaaaag ctcaaactac cagtaattgt 1440
gaaacattat tacctaaaat tcaaaaataa aatttaacac agatgataat cgtaacacta 1500
gcagaaaaaa caccttattt agaattctaa cgtttagtag aagattttaa tagagctaata 1560
ataggccata attgggtggg tggttaatcaa tcgttagtta cgctaaatca acgtgatgac 1620
cttttttagta acaaaaaaga agatgaatca ttttgataaa acaagattaa aaatgaaagt 1680
tttgacaatt attttgtcat accttatggg ggggtatcat aa 1722

```

<210> 52

<211> 1424
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7483850CB1

<400> 52
ctgatgtcta ttttaggaaga aacaaactgg tgtatatattg cttgttttcta catttttctag 60
gcactgcttt gttatctgtg gtggcttttc ccttggaaga tttctatctg ggcacttacc 120
atgcagtttaa caacatacca aaaacagagc agcacaggct gttttatgta gcactgctga 180
ccatttgcct tggcattgga ggcgtaagag ccacgtctg tccactgggt gcttttggcc 240
ttcaggagta tggatcacaa aaaacgatgt ctttttttaa ctgattcctt caggatatta 300
tctgcaaact atgaattcca acctgaattt ggatggattt cttctgccga ttgcagtaat 360
gaatgccatc agcagcctac cattactaat tctggctcct tttctggagt atttcagcac 420
ctgcctgttt ccctctaaga gagttggatc atttctgtca acatgcatca ttgctggaaa 480
tcttttctgt gcattgtctg tgatgatagc tggcttcttt gaaatacacc gaaaacattt 540
cccttgcagt gagcagcccc tttcaggaaa agttctcact gtttctcca tgccctgttt 600
ctacctgatt cttcagtatg ttttacttgg agtggcggaa acactggtaa acccagccct 660
ctctgtaata tcatacagat ttgttccaag caatgtcaga ggaacctcca tgaattttct 720
gacactgttc aatggatttg gctgtttcac aggggcactg ctggtgaagt tggatatatct 780
catctcagaa ggtaaaaaata ggcaatgggt tccaaacaca ttaaacaag gcaatttaga 840
aggcttcttc ttcttctctg catcattaac attgttgaa gtcctgggat tctgcagtgt 900
ttcacaaaaga tattgtaatc taaatcattt taatgccag aacatccgtg gaagtaattct 960
tgaagaaaca cttctcctcc acgaaaaatc tctgaaattt tatggcagta tacaggaatt 1020
ttcttcaagt attgatcttt gggagacagc cctatgaaac tgtgtttgag tctacctgtc 1080
ttatgagaac agtattcatt gtttcttctc tcagttgagc attttatgtg ttttagtgta 1140
aaagccaata tatacagagg tgattttaca aatatcatct gtatacttta tttacaaaga 1200
ctaattatga attttctagt aaactgtcat gcttttgcac taacatgtta tagcattaga 1260
atttaataaaa ataatttcaa agtctcagtg attactctat gacaaaaaaa aaaggggggc 1320
gccgattagt gagcttcgtc gaccgggaaa taattccgga cggacctgca ggcgtaggcg 1380
atcctgagat tccatcaatg ggggcgtcga gcattgttaa aggc 1424

<210> 53
<211> 3598
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5508353CB1

<400> 53
caatttgcaa cacagtagtg gtttctgtct ctaaccaacc ccgacaaaag atcagacacc 60
cttcactggg ggggttgccc attaatgtct tggagagat taaaagtctt ttccagagat 120
ggctctgtccg aagatcaagt tctccatcgc ttaacagtgg gaaagagcca tcttctggag 180
ttccaaacgc ctttgtgagc agactccctc tcttttagtcg aatgaaacca gcttcacctg 240
tggaggaaga ggtctcccag gtgtgtgaga gcccacagt ctccagtagc tcagcttgct 300
gcacagaaac agagaaacaa cacggtgatg caggcctcct gaatggcaag gcagagtccc 360
tccttggaac gccattggcc tgcaacctgt gttatgaggg cgagagccca gacgaagcgg 420
ccttagtgta tgccgccagg gcttaccat gcactttacg gtctcggaca ccagagcagg 480
tcattggtgga ctttgtctgt ttgggacct taacatttca actcctacac atcctgccct 540
ttgactcagt aagaaaaaga atgtctgttg tggctccgaca cctcttttcc aatcaagttg 600
tgggtgtata gaaaggcgct gattctgtga tactggagtt actgtcgggtg gcttccccag 660
atggagcaag tctggagaaa caacagatga tagtaaggga gaaaaccag aagcacttgg 720
atgactatgc caaacaaggc cttcgtactt tatgtatagc aaagaagggtc atgagtgaac 780
ctgaatatgc agagtggctg aggaatcatt ttttagctga aaccagcatt gacaacaggg 840
aagaattact acttgaatct gccatgaggt tggagaacaa acttacatta cttggtgcta 900
ctggcattga agaccgtctg caggagggag tccctgaatc tatagaagct cttcacaag 960
cgggcatcaa gatctggatg ctgacaggga acaagcagga gacagctgtc aacatagctt 1020
atgcatgcaa actactggag ccagatgaca agctttttat cctcaatacc caagtaaaag 1080
atgcctgtgg gatgctgatg agcacaattt tgaaagaact tcagaagaaa actcaagccc 1140

tgccagagca	agtgtcatta	agtgaagatt	tacttcagcc	tctctgtccc	cggggaactcag	1200
ggttacgagc	tggactcatt	atcactggga	agaccctgga	gtttgccctg	caagaaagtc	1260
tgcaaaagca	gttcctggaa	ctgacatcct	ggggtcaagc	tggtggtctgc	tgccgagcca	1320
caccgctgca	gaaaagtgaa	gtggtgaaat	tggtccgcag	ccatctccag	gtgatgaccc	1380
ttgctattgg	tgatgggtgcc	aatgatgtta	gcatgatata	agtggcagac	attgggtag	1440
gggtctcagg	tcaagaaggc	atgcaggctg	tgatggccag	tgactttgcc	gtttctcagt	1500
tcaaacatct	cagcaagctc	cttcttgtcc	atggacactg	gtgttatata	cggtcttcca	1560
acatgattct	ctattttttc	tataagaatg	tggcctatgt	gaacctcctt	ttctggtacc	1620
agttcttttg	tggattttca	ggaacatcca	tgactgatta	ctgggttttg	atcttcttca	1680
acctcctctt	cacatctgcc	cctcctgtca	tttatgggtg	tttgagaaaa	gatgtgtctg	1740
cagagaccct	catgcaactg	cctgaacttt	acaaaagtgg	tcagaaatca	gaggcatact	1800
taccccatca	cttctggatc	accttattgg	atgcttttta	tcaaagcctg	gtctgcttct	1860
ttgtgcctta	ttttacctac	cagggtcag	atactgacat	ctttgcattt	ggaaaccccc	1920
tgaacacagc	cgctctgttc	atcggtctcc	tccatctggt	cattgaaagc	aagagtttga	1980
cttggattca	cttgcctggc	atcattggta	gcatcttgct	ttatttttta	tttgccatag	2040
tttttgaggc	catgtgtgta	acttgcaacc	caccatccaa	cccttactgg	attatgcagg	2100
agcacatgct	ggatccagta	ttctacttag	tttgtatcct	cacgacgtcc	attgctcttc	2160
tgcccagggt	tgtatacaga	gttcttcagg	gatccctgtt	tccatctcca	attctgagag	2220
ctaaagcactt	tgacagacta	actccagagg	agaggactaa	agctctcaag	aagtggagag	2280
gggctggaaa	gatgaatcaa	gtgacatcaa	agtatgctaa	ccaatcagct	ggcaagtcag	2340
gaagaagacc	catgcctggc	ccttctgctg	tatttgcaat	gaagtcagca	agttcctgtg	2400
ctattgagca	aggaaaactta	tctctgtgtg	aaactgcttt	agatcaaggc	tactctgaaa	2460
ctaaggcctt	tgagatggct	ggaccctcca	aaggtaaaag	aagctagata	ccctccttgg	2520
agttgcaagt	attcttttcaa	gggtggaaga	gggattttga	agaggtatct	ctccaagcaa	2580
gaatgacttg	tttttccata	agggacatga	gcattttact	aggcttggaa	gagctgacat	2640
gatgagcatt	attgtatggt	tgtatataca	tttgtgatag	agggctagag	tttgacctag	2700
agagagttta	aggaagtga	atattttaatt	cagaaccaa	tgcttttcta	aaactttttg	2760
gattttgtaa	aagcattttc	attctcttag	aaattcaagt	attttcaagg	ggagtcattt	2820
gagatatatt	tatttttacta	ggagatctta	tattctaggg	aaatgcttta	aatggtcagg	2880
ctccagtcgg	aatttttttta	agaaaaaagt	agtttttaat	acattggtta	ggactcagag	2940
gaaatacggg	aaaaacattg	tagatgggta	atttacagat	aaaatcccaa	gagcctttta	3000
aacaacaagg	tacctaaaat	aggggtataat	tatactgctt	aaaatacagt	tagtgcctat	3060
taatagcttt	ttatttctcta	tggggagatg	cttttgggtct	tctggctgaa	gatgtaggca	3120
tacctctcac	tcattttcaat	gttttccctga	ggtggagcct	tcattggaaa	ggggaaaagag	3180
ggattctagg	gtttcatcag	ggaccaggaa	tgcattcctc	tgtcagggtc	caatcaagag	3240
aagacctttt	atgagatctg	cctctgtata	gatgtcgtca	gttaggaaac	tgaagccata	3300
ggtcaggaga	catcagctca	gcctgtggcc	atgggtgatt	tcctgtattt	taaaactgac	3360
agtagcctga	tccaacgtga	tatcaatcat	tttcaacacc	atccttcaga	ggacaatgtg	3420
aggtcattaa	gttttacaat	tacctggaga	ttttcaggtg	gtggggcctc	taaaatttga	3480
ttaacacgga	actatacagt	ggtcgggagg	tcaaggggtc	tcgaaaattt	ggtagatctc	3540
tcggcggggag	tcacacagtc	cctcggactt	gtgcgggtgg	cacacattta	caggggca	3598

<210> 54

<211> 1485

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 8543628CB1

<400> 54

gctattggat	tctccctata	tgagtcgtat	taatttctac	tacgaaatgc	tcgccgtgct	60
gacgctgatt	tgctgtctgt	tggtcttgcc	gttgctcgctg	ttgctcagcc	gcctggaaag	120
gaggctccag	catggccagt	tcgggtcctg	agttgctctg	ggtgctcggtg	ccgcaactgg	180
gcaaggcgcg	tcgcgcaaacc	ctgtcaattt	cgtttttgag	catcggtctc	agtagcggtg	240
gcggcgtgct	ctacggcgtg	ctgcgcactt	tgaataacaa	ggcgatcaac	ggcgtggttc	300
gggtctacct	ggaactgttc	cgcgccattc	cggtgctggt	gtggttgtag	ctgctgtttt	360
ttggcgtgcc	gatcttcttc	ggcctgagca	tcccaggttt	ctgggtgcgcg	gtgctggtgc	420
tctcggttg	gggcgcagc	gaggtggg	aagtgggtgc	tggcgcgctg	cattcgctgc	480
ccgtggcca	acgcgaagca	ggcttgctga	ttggcctgtc	cgacctacag	ttgtacggct	540
acgtactgct	gccccaggcc	ctcaggcgca	tgacgcgcgc	gaccatcaac	gtgtacacgc	600
gcatcatcaa	gaccagctcc	ctggcgggtc	tgatcggcgt	ggtggatgtg	atcaaggtcg	660

```

gccagcaaat catcgagcgc acctacgagt cggatttgat ctacgggtgcg ctgttcctgt 720
ttttcttctt tatctgctac ccgttgctcg cgcctccaa gctgctggaa cggcgctggg 780
cccaagcatg agcgcattga tcgagttcca gggtttcaac aaattcttcg gcgaggcgca 840
ggtgctcaag ggcatcgacc tgagcgtgca gcgcggcgaa gtggtggtga tcttaggccc 900
cagcggctgt ggcaaaagca ccttggtgcg ctgcctcaat gggctggaag tcgcgcacag 960
cggcagcctg cgctttgccg gcaaagagct gctggataaa accaccgact ggcgccaggt 1020
acgccaggac attggcatgg tattccagag ctaccacctg tcccgcacat gagcgtgcct 1080
cgaaacatcc tgctcgcccg ctgaaagtgg aaaagcgcga ccgcgtgggt gcctgtgagc 1140
aggcggaata atgctgggag cgccgtggcc ttgccgaaag cgcgacgcct tcccacgcc 1200
agctttccgg tggccagcaa caacgcctcg catcgtccgt cgttggtgcat gaaccctcag 1260
tcatgctgtt gacgaagttc accggggcct cgccgaaatg gcaggaatgt tggagtgtcc 1320
agaattgccg gaggggtacc ctgtgtttcc cagaatggtt gccggcgggc cgacaggggt 1380
atgagggggc tctcaaaaac ccggttttta ccgcacgcgc gactggagct tttcccccac 1440
gaggtaatta cgctgcctcg gggagaacaa cggagacaca cgcg 1485

```

```

<210> 55
<211> 1470
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 7482754CB1

```

```

<400> 55
gcctgttctg cagaggagga ggctgggctc agggcacttt tcacgcccc tccgttgggc 60
tggggacctt ggtaagccat ggaggagacag accccaggaa gcaggggcct tccagaaaag 120
cctcaccctg ccacggctgc tgccactctg tcctcgatgg gcgctgtctt catcctcatg 180
aagtccgcgc tgggagctgg cctgctcaac ttcccctggg ccttctccaa agcgggcgga 240
gtggtccctg ccttctgtgt ggagctggtc tcgttggtct tcctgatcag cgggctggtc 300
atcctgggct atgctgctgc tgtcagtggc caggccacct accagggtgt ggtcaggggg 360
ctgtgtggcc ctgccattgg gaagctgtgt gaggcctgct tcctcctcaa cctgctcatg 420
atctccgtgg ccttctctcag ggtgatcggg gaccagctgg agaagctgtg tgactccctc 480
ctgtctggca cccgcgccgc cccgcagccg tggtagcgag accagcgctt caccctgccc 540
ctgctctccg tgctggctcat cctgcccctg tctgcccgcg gggagatcgc cttccagaaa 600
tacacaagcc cctcacacgg tcaactgtgt agcatcctag gcaactctgg tcgctgttac 660
ctggccctgg tcatcacctg gcagtaactc ctctggcccc agggcctcgt gcgtgagtc 720
catccttcac tgagccctgc ctctggacc tctgtgttca gtgtcttccc caccatctgc 780
ttcgggtttc agtgtcacga agctgccgtc tccatctact gcagcatgcg caaacggagc 840
ctctccactt gggccctggt gtctgtgctg tccttgetgg cctgctgcct catctattca 900
ctgacggggg tttatggctt cctgactttt gggacagaag tttctgctga cgtcttgatg 960
tcctaccagc gcaatgatat ggtcatcatt gtggcccggg tcctttttgc tgtctccatc 1020
gtaactgtct accccatcgt gctcttctct gggaggtcag tgatgcagga cttctggagg 1080
aggagctgct tgggggagtg gggggccagc gccctggccg acccctcagg gctgtgggtc 1140
cggatgccgc tgaccatcct gtgggtcacc gtgacgctcg ccatggcgct gtttatgct 1200
gacctcagcg agatcgctcag catcatcgga ggcacagtt ccttcttcat cttcatcttc 1260
ccaggccctg gaggcaaaca ccgtttctgc gaaggatggt ttcttaggaa accttcccaa 1320
acagcccaag cattatctga gaaggggaag ccagcaaggt ttgtgcctca tctgtgcaat 1380
gggtgtcgag cctataggac caagagtcaa gtgagaaacc tgcgagccac aggaagagag 1440
tctctgtcta cccagtatga gggcatctga 1470

```

```

<210> 56
<211> 3132
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 3794818CB1

```

```

<400> 56
atggagtttg tgcgggctgt gtggctgggc ctggcgctgg cgctggggcc ggggtccgcg 60
gggggccacc ctcagccgtg cggcgctcct gcgcgcctcg ggggctccgt gcgcctgggc 120

```

```

gcccctcctgc cccgcgcgcgc tctcgcgcgc gcccgcgcgc gcgcgcgcct ggcccggggcc 180
gcccctggcgc cgcggctgcc gcacaacctg agcttgagc tgggtggtcgc cgcgcgcgc 240
gcccgcgacc ccgcctcgtc gaccgcgggc ctgtgccagg cgtgtgtgcc tccgggctgt 300
gcgggccctgc tcgcctttcc cgaggctcgg cccgagctgc tgcagctgca cttcctggcg 360
gcgggccaccg agacccccgt gctcagcctg ctgcggcggg aggcgcgcgc gcccctcgga 420
gccccgaacc cattccacct gcagctgcac tgggccagcc ccctggagac gctgtgtgat 480
gtgctgggtgg cgggtgctgca ggcgacgcgc tgggaagacg tcggcctggc cctgtgcgcg 540
actcaggacc ccggcggcct ggtggccctc tggacaagcc gggctggccg gccccacag 600
ctggtcctgg acctaaagcc gcgggacacg ggagatgcag gactgcgggc acgcctggcc 660
ccgatggcgg cgcagtgagg ggggtgaagca ccggtaccgc cggcggtcct cctcggtgtg 720
gacatcgccc gtgcccgtcg ggtgctggag gccgtacctc ccggccccca ctggctgttg 780
gggacaccac tgcgcgccc aa ggcctgccc acccgggggc tgccaccagg gctgtggcg 840
ctggggcagg tggcacgacc cccgctggag gccgccatcc atgacattgt gcaactgggtg 900
gccccgggcgc tgggcagtg gcgccaggtg cagccgaagc gagccctcct ccccgccccg 960
gtcaactgcg gggacctgca gccggccggg cccgagtcgc cggggcgctt cttggcacgg 1020
ttcctggcca acacgtcctt ccagggccgc acgggccccg tgtgggtgac aggcagctcc 1080
caggtacaca tgtctcggca ctttaaggtg tggagccttc gccgggaccc acggggcgcc 1140
ccggcctggg ccacgggtgg cagctggcgg gacggccagc tggacttggg accgggaggt 1200
gcctctgcac ggcccccgcc cccacagggg gccaggtct ggcccaagct gcgtgtggtg 1260
acgctgttgg aacacccatt tgtgtttgcc cgtgatccag acgaagacgg gcagtgcaca 1320
gcggggcagc tgtgcctgga ccctggcacc aacgactcgg ccaccctgga cgcactgttc 1380
gccgcgtgg ccaacggctc agcgcgccgt gccctgcgca agtgcgtgta cggctactgc 1440
attgacctgc tggagcggct ggcgaggac acgcccctcg acttcgagct gtacctcgtg 1500
ggtgacggca agtacggcgc cctgcgggac ggccgtgga ccggcctggt cggggacctg 1560
ctggccggcc gggcccacat ggcggtcacc agcttcagta tcaactccgc ccgctcacag 1620
gtggtggact tcaccagccc cttcttctcc accagcctgg gcatcatggt gcgggcacgg 1680
gacacggcct caccatcgg tgcccttatg tggccctgc actggtccac gtggctgggc 1740
gtctttgcgg ccctgcacct caccgcgtc ttcctcaccg tgtacgagtg gcgtagcccc 1800
tacggcctca cggcacgtgg ccgcaaccgc agcaccgtct tctcctactc ctcagccctc 1860
aacctgtgct acgccatcct cttcagacgc accgtgtcca gcaagacgcc caagtgcacc 1920
acgggcccgc tgetcatgaa cctctgggcc atctctgcgc tgctggtgct gtccagctac 1980
acggccaacc tggctgccgt catggtcggg gacaagacct tcgaggagct gtcggggatc 2040
cacgacccca agctgcacca cccggcgag ggcttcgct tcggcaccgt gtgggagagc 2100
agcgcctagg cgtacatcaa gaagagcttc cccgacatgc acgcacacat gcggcgccac 2160
agcgcgccca ccacgccccg cggcgctcgc atgctcagca gcgaccccc caagctcaac 2220
gccttcatca tggacaagtc gctcctggac tacgaggtct ccatcgacgc cgactgcaaa 2280
ctgctgaccg tgggaaagcc cttcgccatt gagggtatg ggatcggaact gcccagaaac 2340
tcgccgctca cctccaacct gtccgagttc atcagccgct acaagtcctc cggcttcac 2400
gacctgctcc acgacaagtg gtgccttgcg gcaagcgggt ctttgcggtt 2460
acagagaccc tgcagatgag catctaccac ttcgcgggcc tcttcgtgtt gctgtgcctg 2520
ggcctgggca gcgctctgct cagctcgtcg ggcgagcacg cttcttccg cctggcgctg 2580
ccgcgcaccc gcaaggggag caggctgcag tactggctgc acaccagcca gaaaatccac 2640
cgcgccctca acacggagcc accagagggg tcgaaggagg agacggcaga ggcgggagcc 2700
agcgccccc aggtggagca gcagcagcag cagcaggacc agccaacggc tccggagggc 2760
tggaaacggg cgcgcgggc cgtggacaag gagcgccgc tgcgcttct gctggagccc 2820
gccgtggttg tggcacccga agcggacgcg gagcgggagg ctgcgccgc agagggccc 2880
gtctggtgt gctcctacgg ccgcccgcgc gccgcaaggc ccacgggggc ccccagccc 2940
ggggagctgc aggagctgga gcgcgcgcatc gaagtcgcgc gtgagcggt ccgccaggcc 3000
ctggtgcggc gcggccagct cctggcacag ctcggggaca gcgcacgtca ccggcctcg 3060
cgcttgcttc aggcagagc ggcccccgcg gagggccac cacactctgg ccgaccgggg 3120
agccaggaat ga 3132

```

<210> 57

<211> 1832

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4717525CB1

<400> 57

ggagctgacc ctgcgggggc ccgggggggg agggggagcc gcgaagcccc cactgagtg 60

cgccgctgcc	gggggggggag	ggggagccgc	gaagccccc	ctgaggccgc	cgctgccggg	120
cctccccctc	cccccgggcg	ggcgccatgc	gggggagccc	ggcgacgcgc	gagcgccggc	180
agcgctgggg	tcgcctgttc	gaggagctgg	acagtaacaa	ggatggccgc	gtggacgtgc	240
acgagttgcg	ccaggggctg	gccaggctgg	gcgggggcaa	cccagacccc	ggcgcccaac	300
agggtatctc	ctctgagggg	gatgctgacc	cagatggcgg	gctcgacctg	gaggaatatt	360
cccgtatctc	gcaggagcgg	gaacagcgtc	tgctgctcat	gtttcacagt	cttgaccgga	420
accaggatgg	tcacattgat	gtctctgaga	tccaacagag	tttccgagct	ctgggcattt	480
ccatctcgct	ggagcaggct	gagaaaattt	tgcacagcat	ggaccgagac	ggcacaatga	540
ccattgactg	gcaagaatgg	cgcgaccact	tcctgttgca	ttcgctggaa	aatgtggagg	600
acgtgctgta	tttctggaag	cattccacgg	tcctggacat	tggcgagtgc	ctgacagtgc	660
cggacgagtt	ctcaaagcaa	gagaagctga	cgggcatgtg	gtggaagcag	ctggtggccg	720
gcgcagtggt	agggtgccgtg	tcacggacag	gcacggcccc	tctggaccgc	ctcaaggctc	780
tcatgcaggt	ccatgcctca	aagaccaacc	ggctgaacat	ccttgggggg	cttcgaagca	840
tggtccttga	gggaggcatc	cgctccctgt	ggcgcgccaa	tggtattaat	gtactcaaga	900
ttgcccccg	gtcagctatc	aagtccatgg	cctatgaaca	gatcaagagg	gccatcctgg	960
ggcagcagga	gacactgcat	gtgcaggagc	gcttcgtggc	tgggtccctg	gctggtgcca	1020
cagcccaaac	catcatttac	cctatggaga	ctctgaagaa	ctggtggctt	cagcagtaca	1080
gccacgactc	ggcagaccca	ggcatcctcg	tgctcctggc	ctgcggtacc	atatccagca	1140
cctgcggcca	gatagccagt	taccgctgg	ccctgggtccg	gaccgcgatg	caggcacaag	1200
cctccatcga	gggtggcccc	cagctgtcca	tgctgggtct	gctacgtcac	atcctgtccc	1260
aggagggcat	gcggggcctc	taccggggga	tcgcccccaa	cttcatgaag	gttattccag	1320
ctgtgagcat	ctcctatgtg	gtctacgaga	acatgaagca	ggccttaggg	gtcacgtcca	1380
ggctcgagta	cagtggctcg	atttcagatc	actgcaacct	ctgccttcca	ggttcaagcg	1440
attctcctgc	ctcagcctcc	agagtagctg	gtattacagg	atttcatcat	gttgcccagg	1500
ctcatctcgg	actcgtgggt	tcaaggaatt	cggcagcctt	cagccttcca	acgtgctggg	1560
attacaggaa	gccggctcgtc	atgccatgag	cagccttatg	gagtggacca	tgtggtaagg	1620
aactcagcca	atagccatgt	aactgagctt	tgaagaggat	cttgctgtcc	tggccaacat	1680
ctcactgcga	ttctatcagt	tgaatttcct	ggatagtcca	agctttgttg	gatccctgca	1740
ccggtacagc	tgggttccag	taactgaatc	ctgagtctta	tgatgtttta	cttcaagcat	1800
gggtcagggg	acagcggggt	atgggttctt	tg			1832

<210> 58

<211> 1902

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5091793CB1

<400> 58

cccaccttca	gtcctggctc	tgacaagccc	tccagcttca	cgccaccggg	gatgggagaa	60
agcaggtgtc	gcgagagttg	ggcgcaagac	gccttgtagg	gagtgttaact	atggccggcc	120
tgcggaacga	aagtgaacag	gagccgctct	taggcgacac	acctggaagc	agagaatggg	180
acatttttaga	gactgaagag	cattataaga	gccgatggag	atctattagg	attttatatc	240
ttactatgtt	tctcagcagt	gtaggggttt	ctgtagtgat	gatgtccata	tggccatata	300
tccaaaagat	tgatccgaca	gctgatacaa	gttttttggg	ctgggttatt	gcttcatata	360
gtcttgccca	aatggtagct	tcacctatat	ttggtttatg	gtctaattat	agaccaagaa	420
aagagcctct	tattgtctcc	atcttgattt	ccgtggcagc	caactgcctc	tatgcataac	480
tccacatccc	agcttctcat	aataaatact	acatgctggg	tgctcgtgga	ttgttgggaa	540
ttggagcagg	aaatgtagca	gttggttagat	catatactgc	tggtgctact	tccttccagg	600
aaagaacaag	ttccatggca	aacataagca	tgtgtcaagc	attaggtttt	attctagggtc	660
cagtttttca	gacttgtttt	acattccttg	gagaaaaagg	tgtgacatgg	gatgtgatta	720
aactgcagat	aaacatgtat	acaacaccag	ttttacttag	cgcttctctg	ggaatttttaa	780
atattattct	ataccttgcc	atactaagag	aacatcgtgt	ggatgactca	ggaagacagt	840
gtaaaagtat	taatttttgaa	gaagcaagta	cagatgaagc	tcagggtccc	caaggaaata	900
ttgaccaggt	tgctgtttgtg	gccatcaatg	ttctgttttt	tgtgactcta	tttatctttg	960
ccctttttga	aaccatcatt	actccattaa	caatggatat	gtatgcctgg	actcaagaac	1020
aagctgtgtt	atataatggc	ataatacttg	ctgctcttgg	ggttgaagcc	gttggtattt	1080
tcttaggagt	taagttgctt	tccaaaaaga	ttggcgagcg	tgctattcta	ctgggaggac	1140
tcacgttggt	atgggttggc	ttctttatct	tgttaccttg	gggaaatcaa	tttcccaaaa	1200
tacagtggga	agatttgcac	aataattcaa	tccttaatac	cacatttggg	gaaattatta	1260
ttgggtctttg	gaagtctcca	atggaagatg	acaatgaaag	accaaactgg	tgctcgattg	1320

aacaagcctg	gtgcctctac	accccggtga	ttcatctggc	ccagttcctt	acatcagctg	1380
tgctaatagg	attaggctat	ccagtcctga	atcttatgtc	ctatactcta	tattcaaaaa	1440
ttctaggacc	aaaacctcag	ggtgtatata	tggtctggtt	aacagcatct	ggaagtggag	1500
cccggattct	tgggcctatg	ttcatcagcc	aagtgtatgc	tcactgggga	ccacgatggg	1560
cattcagcct	ggtgtgtgga	ataatagtgc	tcaccatcac	cctcctggga	gtgggtttaca	1620
aaagactcat	tgctctttct	gtaagatatg	ggaggattca	ggaataaact	agctaagact	1680
gtgatggaaa	ctacttgctg	tgtggcactt	cctggtctaa	agctctgcta	gacaattgcg	1740
gttgggtgca	gtgtctcatg	cctgtaatcc	cagcactttg	gaaggccaag	gcaggaggat	1800
tgcttgaggc	caggaattca	agaccagcct	gggaaacaaa	gtgagaccct	gtctttacaa	1860
aaaataaaaa	caaaaattta	aaactgtaaa	aaaaaaaaaa	aa		1902

<210> 59

<211> 2820

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5945527CB1

<400> 59

gcgcccagct	ctgtagcctc	ctccgtcgac	tcagccttag	gtaccgggtca	ggcaaaatgc	60
ggctcctcct	ggctccggga	gtctggttct	tccgggcctt	ctccaggggac	agctgggttc	120
gaggcctcat	cctgtctgtg	accttcttaa	tttacgcctg	ctatcacatg	tccaggaagc	180
ctatcagtat	cgtcaagagc	cgtctgcacc	agaactgctc	ggagcagatc	aaacccatca	240
atgataactca	cagtctcaat	gacaccatgt	ggtgcagctg	ggccccattt	gacaaggaca	300
actataagga	gttactaggg	ggcgtggaca	acgccttcc	catgccttat	gccatcggca	360
tgttcatcag	tgggggtttt	ggggagcggc	ttccgctccg	ttactacctc	tcagctggaa	420
tgctgctcag	tggccttttc	acctcgctct	ttggcctggg	atatttcttg	aacatccacg	480
agctctggta	ctttgtggtc	atccagggtc	gtaatggact	cgtccagacc	acaggctggc	540
cctctgtggt	gacctgtgtt	ggcaactggt	tcgggaaggg	gaagcggggg	ttcatcatgg	600
gcactctggaa	ttcccacaca	tctgtgggca	acatcctggg	ctccctgatc	gccggcatct	660
gggtgaacgg	gcagtggggc	ctgtcgttca	tcgtgcctgg	catcattact	gccgtcatgg	720
gcgtcatcac	cttccctctc	ctcatcgaac	accagaaga	tgtggactgc	gcccctcctc	780
agcaccacgg	tgagccagct	gagaaccagg	acaaccctga	ggaccctggg	aacagtccct	840
gctctatcag	ggagagcggc	cttgagactg	tggccaaatg	ctccaagggg	ccatgcgaag	900
agcctgctgc	catcagcttc	tttggggcgc	tcgggattccc	aggcgtggtc	gagttctctc	960
tgtgtctgct	gtttgccaag	ctggctagtt	acaccttcc	ctactggctg	cccccttaca	1020
tcgccaatgt	ggctcacttt	agtgccaaag	aggctgggga	cctgtctaca	ctcttcgatg	1080
ttggtggcat	cataggcggc	atcgtggcag	ggctcgtctc	tgactacacc	aatggcaggg	1140
ccaccacttg	ctgtgtcatg	ctcatcttgg	ctgcccccat	gatgttcttg	tacaactaca	1200
ttggccagga	cgggattggc	agctccatag	tgatgctgat	catctgtggg	ggcctgggtca	1260
atggcccata	cgcgtcatc	accactgctg	tctctgctga	tctggggact	cacaagagcc	1320
tgaagggcaa	gcccaaagcc	ctgtccacgg	tcacggccat	cattgacggc	accggctcca	1380
taggtgcggc	tctggggcct	ctgctggctg	ggctcatctc	ccccacgggc	tggaaacaatg	1440
tcttctacat	gctcatctct	gccgacgtcc	tagcctgctt	gctcctttgc	cggttagtag	1500
acaaagagat	cttggcctgg	aaggtgtccc	tgagcagagg	cagcgggtat	aaagaaatat	1560
gaggcccaa	ttggaacagc	agcatggagg	gtcccagttg	ggtccccaac	gtgctcccca	1620
tgggcaagac	aatggaaact	tccacaagca	ggggaggcaa	accctcttta	ttgaacatta	1680
gccagcccag	cccagacccc	agggctgcct	aaggacacag	agattctcca	tgggaagggg	1740
actgccaagc	atgaggaaat	agaagattca	ggggcctgag	ctctggaagc	tgcaagcaaa	1800
agggatggga	ctagggtctga	gttgtgtctc	cattttgata	aggaaaggat	atgctcacac	1860
tcttgcttgt	tcagattcca	agacagaagg	cttcacaagg	ccaacgcctg	gaaaatgggc	1920
atctctccct	ccatgttaa	gctttaacct	ctgtaactcg	cctgtatcta	taggtgggca	1980
tctactcca	tcaaaggagc	ccagcctctc	ttgtccctc	taccatgcaa	cagtcttctc	2040
tgtgcatttc	cccaagctgg	gcccctcttc	actctccatt	taggcctgtt	gataactcca	2100
ttaccacccc	atcactgctg	ttcctccagg	gccagcactc	gggcgaggca	ggggagctgc	2160
cttcgggtaca	taatttgaag	gggcactccc	tcttgggcac	atgccggccc	tgagtgcctc	2220
ccttgccctca	ctctgatccc	ggccccataa	tgtcctcagt	ggaaggtgac	tgggggcccgg	2280
tgctgtgggg	agctagaaaa	gaggggttgg	catgactaaa	aataccagta	tgtgtattaa	2340
gtatttttag	aatgaaatgc	caaggagtgc	ctactgtatg	ccagctctgc	tctaggaatg	2400
gagtagacag	tggacacaag	aaggacttac	gcctgagca	caggtgccaa	cggtgacaag	2460
actggcaaga	cgtgagggca	tgaatggttc	attcaggcag	ctgctgcagg	tgtggtcacc	2520

tggtgccatc	tgctgctccc	ttttccactt	ttctatgtcc	tccttccacc	ccaagtcccc	2580
gatcactcgc	tgttttctgg	ctagctcttg	gcattctccat	ctgagcctaa	agttgcccac	2640
tggcaccaat	agattctgtt	tgacctgctg	tgcccatgct	catctttgtc	ggggcttggc	2700
ttggcagcga	gtgaggctgg	catggggtgc	tgaagtgggg	tctcagttag	gggtgacagc	2760
gtgctggcag	tcctcacagc	cctcgctcgc	tctcggcgcc	tcctctgcct	gggtccccac	2820

<210> 60

<211> 3920

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6941124CB1

<400> 60

ccggccgtga	gtgcgcgagt	gtgccatggc	cgcgccacc	aggcgcggtg	tccatctgca	60
gccgtgcggg	gggtgcctga	acccgggggc	gcggcgggaa	ggccgcccgg	gtctccgcca	120
ccgtctcccc	tcggggagacc	cggggagaaac	gcggatgccg	tctgcctgcg	cgggccgggg	180
ccggtggggc	agagggctgc	gggattccca	gccgcgggga	ggagggcgcg	ggtgcgggag	240
gcccggggcg	ggcttcgcgg	ccaccgcgcg	cttggtttca	ttagggctct	gctgtcgccg	300
tcttgaattt	cttaccagggt	ttgaacagct	gatgcagcgg	gtcgagggcg	gggagctcga	360
aagtggggag	ggcggagctg	tggggctccc	agcgccccga	gcgcgcgagct	tttgggagcc	420
tggcggggcg	cgcctccgga	aggtctcatt	ttaccttccg	cccgggcatc	ttcccgtccg	480
gcgcgcgggt	gggagccccg	gaacccctgg	agttttggga	gtcccgggac	ccctgaccgt	540
gccctgcgcg	gccgcagcgg	tttctccctt	gctctgacac	gggagggcca	gccctgggtc	600
cccgcaggga	cccaggtttg	tacgaccctt	tacctgcacg	tgggcccggc	ggacggaagc	660
ggagtgtgca	ccggccccaac	cctcccagac	cctcgctcgc	cacggcctgg	gacgcgcccc	720
agcgccccct	agcagatggg	ctaagcaatt	gaattttctga	gattaaggct	ggcttcccct	780
gctatggggc	ccccccccga	gcactgtccc	ctgcttccct	ttctccctag	ggtggcggtg	840
gttgcatccc	tcggaagagc	gaaggaatga	gccaggtcgg	ggggcgggga	gacaggtgca	900
cacaggaggt	ccagggtctg	gtccatgggg	ctgggtgacct	ttctgcttcc	cttgagaaaa	960
actctcccac	catgtcgcag	aatggatact	tcgaggattc	aagctactac	aagtgtgaca	1020
cagatgacac	cttcgaagcc	cgagaggaga	tcctggggga	tgaggccttc	gacactgcca	1080
actcctccat	cgtgtctggc	gagagtatcc	gtttctttgtc	aatgtcaacc	ttgagatgca	1140
ggcccacaa	actgagaatg	aagcgacttc	cggtggctgt	gtgctcctgc	acacctcccg	1200
aaagtacctg	aagttaaaga	acttcaagga	agagatccgt	gcgcaccgcg	acctagatgg	1260
cttctctggc	caggccagca	tcgtcctgaa	cgagacggcc	acctccctgg	ataacgtgct	1320
gcggaccatg	cttcgcccgt	tcgcccggga	ccctgacaac	aatgagccca	actgcaacct	1380
ggacctgtct	atggccatgc	tcttcaccga	tgccggggca	cccatgcggg	gtaaagtcca	1440
cctgtctgtc	gataccatcc	aaggggtcac	cgccacagtg	acaggggtgc	ggtaccagca	1500
gtcgtggctc	tgcatcatct	gtaccatgaa	ggccctacag	aagcggcacg	tgtgcatcag	1560
cgccctgggt	cgcccacaga	actgggggga	gaattctctg	gaggttcggg	tcgtcatcct	1620
ggtgtctggc	ccacccaaga	tgaaaagcac	taagactgcg	atggaggtgg	cgcgcacgtt	1680
tgccaccatg	ttctcggata	tcgccttccg	ccagaagctc	ctggagaccc	gcacagagga	1740
ggaattcaag	gaggccttgg	tgcatcagag	acagctgtct	accatggtga	gccacggtcc	1800
agtggcgccg	agaacgaagg	aacgcagcac	agtctccctc	cctgcccaca	gacaccacga	1860
gcccccaaa	tgcaaggact	ttgtcccttt	tgggaagggc	atccgggagg	acatcgcacg	1920
caggttcccc	ttgtacccct	tggacttcac	tgatggcatt	attgggaaaa	acaaggctgt	1980
gggcaaatac	atcaccacca	ccctgttccct	ctacttcgcc	tgctcctgc	ccaccatcgc	2040
tttcgggtct	ctcaatgacg	agaacacaga	cggggccatc	gacgtgcaga	agaccatagc	2100
cgggcagagc	atcggggggc	tgctctacgc	gctcttctct	gggcagccat	tggtgattct	2160
gctgaccacc	gcgccccttg	cgctctacat	ccaggtgatt	cgtgtcatct	gtgatgacta	2220
tgacctggac	ttcaactcct	tctacgcagt	gacgggcctg	tggaaatagt	tcttctctgc	2280
gttttatgcc	tttttcaacc	tcagcctggg	catgagctct	ttcaagaggt	cgacggagga	2340
gatcatcgcc	ctcttcattt	ccatcacgtt	tgtgctggat	gccgtcaagg	gcacgggtta	2400
aatcttcttg	aagtactact	atgggcatta	cttggaacgac	tatcacacaa	aaaggacttc	2460
atcccttgtc	agcctgtcag	gcctcggcgc	cagcctcaac	gccagcctcc	acactgccct	2520
caatgccagc	ttcctcgcca	gccccacgga	gctgccctcg	gccacacact	caggccaggc	2580
gaccgcccgt	ctcagcctcc	tcacatcatg	gggcacgctc	tggctgggct	acacctctta	2640
ccaattccaag	aagagccctc	acctgcaccc	ctgcgtgcga	gagatccctg	ccgactgcgc	2700
cctgcccate	gcgggtgctcg	ccttctccct	catcagctcc	catggcttcc	gggaaatcga	2760
gatgagcaag	ttccgctaca	accccagcga	gagccccctt	gcgatggcgc	agatccagtc	2820

```

gctgtccctg agggccgtca ggggtgccat gggcctcggc ttcctgctgt ccatgctctt 2880
cttcatcgag cagaacttgg tggccgcctt ggtgaatgca ccggagaaca ggctggtgaa 2940
gggcactgcc taccactggg acctcctgct cctcgccatc atcaacacag ggctgtctct 3000
gtttgggctg ccttgatcc atgccgcta cccccaactcc ccgctgcacg tgcgagccct 3060
ggccttagtg gaggagcgtg tggagaacgg acacatctat gacacgattg tgaacgtgaa 3120
ggagacgcgg ctgacctcgc tgggcgccag cgtcctgggtg ggcctgtccc tgttgtgtgt 3180
gccggtcccc cttcagtggg tccccaagcc cgtgtcttat ggcctcttcc tctacatcgc 3240
gctcacctcc ctcgatggca accagctcgt ccagcgcgtg gccctgctgc tcaaggagca 3300
gactgcgtac ccccgacac actacatccg gaggggtgcc cagaggaaga tccactactt 3360
cacgggcctg caggtgcttc agctgctgct gctgtgtgcc ttcggcatga gctccctgcc 3420
ctacatgaag atgatctttc cctcatcat gatcgccatg atccccatcc gctatatact 3480
gctgccccga atcattgaag ccaagtactt ggatgtcatg gacgctgagc acaggccttg 3540
actggcagac cctgcccacg ccccatcgc cagccctcca cgtcctccca ggctggctgt 3600
ggagctgtga ggggaggtgt aggtgtgtgt gtgactgtc tgtgtgcgc cttctcatgg 3660
ctgactcagg cctggggcat ctgggcattg taggggtgca gtggtatgtg cccacccctc 3720
tcccattatc ctttagcttt aggccaaagag cgttgtctcag ggcagcttct gccagggtg 3780
ggtgggactg agcaggatgg attttctttt gataaaagag tcgatgcctg aaagagaaac 3840
catttccttg attgtgtaag gaacttgctg gacgcacatt agagaataaa gctcctgttt 3900
ctaggctcct aaaaaaaaaa

```

```

<210> 61
<211> 1333
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 6972530CB1

```

```

<400> 61
tggggcaacc tgctaacagc cgctgttgtg gctttgctgt atggcggact ggtcgtgggc 60
ttccttccgc ggcagggcgt ttccttcgaa gggcatctgt ttggtgcgct cgccgatttt 120
attgcagcca aggtacttct atccacgcgc cgcagcgggt ttaatgcccg gtgaacgcac 180
ttgagcatcc agacgccgag gcgatgctgt cgtcaggatt caagtaccca gggagccagg 240
ggctaaatgt cgattttcct actgctacgc atgtacgcct cgtccctctt tcatcgcttc 300
ggttgggcag gcctgatcgt tgccttgggt gtccacctga gcaccgctta cctgggcctg 360
gtgttgcctg gcgaacaaca cctcaccgct gccgccacgt ttatctactt ctatctcacc 420
accacactca ccgtcggcta tggcgacctc gcgcgcgaga cgtctgctgg gcgaattttc 480
gtggcggcct gggtcagtgt cgggggcatt gcgctgtcga cggcagccat cggcaaaacc 540
accagcagtg ttatcgatgc atggagaaaa ggcatagaagg gcaaagggtga tttcacccgc 600
aaggctcgcc ataccgtgtt gatcggctgg gagggcgcgt ccagcgagcg ggtgattgag 660
ttgttgcctg aagacgaaac ctggaacgac aacctgatcg tgatctgcga ttgcagcctt 720
gaagaaaatc cgatgccggg caaagcagcg ttcattccgc gcgaaagcct gtcttccacc 780
gcactgttgc tgcgtgccgg tgtgcccggg gccgagcgtg tgctggtgcg aaccccgctt 840
gatgacctga cgtggccac cgtgctggcg gtgaaccaac tgagtccgt cgggcatgtg 900
gtcgccact tcaacgaaag tgaaatcgcc gcactcgcca gctcctacgc cccgcgcctg 960
gagtgcacgt ccagcatggc aattgaaatg ctggtgcgcg cctctcagga tccgggctcg 1020
tcggtgtgca tcaatgaatt gctgtgcgtg ggcagggcg ccaccagta cctgatgaaa 1080
ttgccgaag cctttgaggc aacattcggc gagctgtaca cgcagatgaa ggagcgccac 1140
aacgccaccc tcattggcta tcgcgccaaa ggtgttcagc agccgtcgat caaccgccc 1200
agtgccacag aggtcaaaag cggcgaaatc ttctacatcg cttccactcg ccttaaggaa 1260
atctcccatg ggatggctta aacagttgat ggggcttgag gccccaaaag ccactaccga 1320
ctcgagccga acc
1333

```

```

<210> 62
<211> 8487
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 6991750CB1

```


<400> 62

atgcacctat	taataattta	cattcaattt	cagattgcag	aggagggatc	aaccattttct	60
tgtgtggttg	agagaaccag	aggggctctg	gattatgtgc	atgtttttta	caccattttca	120
cagattgaaa	ctgatggcat	taattacctt	gttgatgact	ttgctaattgc	cagtggaaact	180
attacattcc	ttccttggca	gagatcagag	gttctgaata	tatatgttct	tgatgatgat	240
attcctgaac	ttaatgagta	tttccgtgtg	acatttggtt	ctgcaattcc	tggagatggg	300
aagctaggct	caactcctac	cagtgggtgca	agcatagatc	ctgaaaagga	aacgactgat	360
atcaccatca	aagctagtga	tcattccatat	ggcttgctgc	agttctccac	agggctgcct	420
cctcagccta	aggacgcaat	gaccctgcct	gcaagcagcg	ttccacatat	cactgtggag	480
gaggaagatg	gagaaatcag	gttattgggtc	atccgtgcac	agggacttct	gggaaggggtg	540
actgcggaat	ttagaacagt	gtccttgaca	gcattcagtc	ctgaggatta	ccagaatgtt	600
gctggcacat	tagaatttca	accaggagaa	agataataat	acattttcat	aaacatcact	660
gataattcta	ttcctgaact	ggaaaaatct	tttaaagtgt	agttgttaaa	cttgggaagg	720
ggagccagtc	taggagtggc	ttcccaaatt	ctagtgcaca	ttgcagcctc	tgaccacgct	780
catggcgat	ttgaatttag	ccctgagtca	ctctttgtca	gtggaactga	accagaagat	840
gggtatagca	ctgttacatt	aaatgttata	agacatcatg	gaactctgtc	tccagtgact	900
ttgcattgga	acatagactc	tgatcctgat	gggtatctcg	ccttcacctc	tggcaacatc	960
acatttgaga	ttgggcagac	gagcgccaat	atcactgtgg	agatattgcc	tgacgaagac	1020
ccagaactgg	ataaggcatt	ctctgtgtca	gtcctcagtg	tttccagtgg	ttctttggga	1080
gctcatatta	atgccacgtt	aacagttttg	gctagtgatg	atccatatgg	gatattcatt	1140
ttttctgaga	aaaacagacc	tgtaaagttt	gaggaagcaa	cccagaacat	cacactatca	1200
ataataaggt	tgaaaggcct	catgggaaaa	gtccttgtct	catatgcaac	actagatgat	1260
atggaaaaac	caccttattt	ttccactaat	ttagcgagag	caactcaagg	aagagactat	1320
ataccagctt	ctggatttgc	ttcttttggg	gctaatacaga	gtgaggcaac	aatagctatt	1380
tcaatttttg	atgatattga	gccagaaaag	ttcgaattctg	ttctttatcga	actactcaac	1440
tctacttttag	tagcguaagt	acagagtcgt	tcaattccaa	attctccacg	tcttgggctt	1500
aaggtagaaa	ctattgcgca	actaattatc	attgccaatg	atgatgcatt	tgggaactctt	1560
cagctctcag	caccaattgt	ccgagtggca	gaaaatcatg	ttggacccat	tatcaatgtg	1620
actagaacag	gaggagcatt	tgagatgtc	tctgtgaagt	ttaaagctgt	gccaataact	1680
gcaatagctg	gtgaagatta	tagtatagct	tcatacagatg	tggtcttgct	agaaggggaa	1740
accagtaaa	ccgtggcaat	atatgtcatt	atagatatgt	atcctgaact	ggaagaactt	1800
tttcttgtgc	aaactgatga	tgaaacaaca	ggaggagcca	gactaggggc	tttaacagag	1860
gcagtcatta	ttattgaggc	ctctgatgac	ccctatggat	tattttgggtt	tcagattact	1920
aaacttattg	tagaggaacc	tgagttaaac	tcagtgaagg	taaacctgcc	aataattcga	1980
aattctggga	cactcggcaa	tgttactggt	cagtgggttg	ccaccattaa	tggacagctt	2040
gctactgggc	acctgcgagt	tgctcaggt	aatgtgacct	ttgcccctgg	ggaaaccatt	2100
caaaccttgt	tgtagaggt	cctggctgac	gacgttcagg	agattgaaga	ggttatccaa	2160
gtgcaactaa	ctgatgcctc	tggtggaggt	actattgggt	tagatcgaat	tgcaaatatt	2220
attattcctg	ccaatgatga	tccttatggt	acagtgcctt	ttgctcagat	ggtttatcgt	2280
gttcaagagc	ctctggaaa	aaagtccctgt	gctaataata	ctgtcaggcg	aagcggaggg	2340
cactttgggtc	ggctgttggt	gttctacagt	acttccgaca	ttgatgtagt	ggctctggca	2400
atggaggaag	gtcaagattt	actgtcctac	tatgaatctc	caattcaagg	ggtgcctgac	2460
ccactttgga	gaacttgga	gaatgtctct	gccgtggggg	agccccgtga	tacctgtgcc	2520
actttgtgcc	ttaaggaaaca	agcttgctca	gcgttttcat	ttttcagtgc	ttctgaggtt	2580
ccccagtgtt	tctggatgac	atcatggatc	agcccagctg	tcaacaattc	agacttctgg	2640
acctacagga	aaaacatgac	cagggtagca	tctcttttta	gtggtcaggc	tgtggctggg	2700
agtgactatg	agcctgtgac	aaggcaatgg	gccataatgc	aggaaggtga	tgaattcgca	2760
aatctcacag	tgtctattct	tcctgatgat	ttcccagaga	tggaatgagag	ttttctaat	2820
tctctccttg	aagttcacct	catgaacatt	tcagcaggtt	tgaaaaatca	gccaaccata	2880
ggacagccaa	atattttctac	agttgtcata	gcactaaaatg	gtgatgcctt	tggagtgttt	2940
gtgatctaca	atattagtcc	caatacttcc	gaagatggct	tattttgttga	agttcaggag	3000
cagccccaaa	ccttgggtgga	gctgatgata	cacaggacag	ggggcagctt	aggtcaagtg	3060
gcagtcgaat	ggcgtgttgt	tggtggaaca	gctactgaag	gtttagattt	tataggtgct	3120
ggagagattc	tgacctttgc	tgaaggtgaa	acaaaaaga	cagtcatttt	aaccatcttg	3180
gatgactctg	aaccagagga	tgacgaaagt	atcatagtta	gtttggtgta	cactgaaggt	3240
ggaagtagaa	ttttgccaa	ctccgacact	cttagagtga	acattttggc	caatgacaat	3300
gtggcaggaa	ttgttagctt	tcagacagct	tccagatctg	tcataaggtca	tgagggagaa	3360
attttacaat	tccatgtgat	aagaactttc	cctggctcgag	gaaatgttac	tgttaactgg	3420
aaaattattg	ggcaaaatca	agaactcaat	tttgctaact	ttagcggaca	acttttcttt	3480
cctgaggggt	cggtgaatac	aacattgttt	gtgcatttgt	tggatgacaa	cattcctgag	3540
gagaagaag	tataccaagt	cattctgtat	gatgtcagga	cacaaggagt	tccaccagcc	3600
ggaatcgccc	tgcttgatgc	tcaaggatat	gcagctgtcc	tcacagtaga	agccagtgat	3660
gaaccacatg	gagttttaaa	ttttgctctt	tcataagat	ttgtgttact	acaagaggct	3720

aacataacaa	ttcagctttt	catcaacaga	gaatttggat	ctctaggagc	tatcaatgtc	3780
acatatacca	cggttcctgg	aatgctgagt	ctgaagaacc	aaacagtagg	aaacctagca	3840
gagccagaag	ttgattttgt	ccctatcatt	ggctttctga	ttttagaaga	aggggaaaca	3900
gcagcagcca	tcaacattac	cattcttgag	gatgatgtac	cagagctaga	agaatatttc	3960
ctggtgaatt	taacttacgt	tggacttacc	atggctgctt	caacttcatt	tcctcccaga	4020
ctagattcag	aaggtttgac	tgacaaagt	attattgatg	ccaatgatgg	ggcccagagt	4080
gtaattgaat	ggcaacaaag	caggtttgaa	gtaaatgaaa	cccatggaag	tttaacattg	4140
gtagcccaga	ggagcagaga	acctcttggc	catgtttcct	tattttgtgt	tgctcagaat	4200
ttggaagcac	aagtggggct	ggattatata	ttcaccccaa	tgattcttca	ttttgctgat	4260
ggagaaaagg	ataaaaatgt	caatatcatg	attcttgatg	atgacattcc	agaaggagat	4320
gaaaaatttc	agctgatttt	aacaaatcct	tctcctggac	tagagctagg	gaaaaatata	4380
atagccttaa	ttattgtcct	tgctaataat	gacggccctg	gagttctatc	atttaacaac	4440
agtgcagact	ttttcctaag	agagccaaca	gctctctacg	tccaggagag	tggtgcagta	4500
ttgtacattg	ttcgggaacc	tgacaaagga	ttgtttggaa	cagtgcagct	tcagttcatt	4560
gtgacagaag	tgaattcctc	aaatgaatct	aaagatctga	ctccttccaa	aggctatatt	4620
gttttagaag	aagggtgttcg	attcaaggcc	ctacaaatat	ctgccatatt	agacacggaa	4680
ccagaaatgg	atgagtattt	tgtttgacc	ttgtttaatc	caactggagg	tgctagacta	4740
ggggtgcagt	ttcaaacctt	gataacagtt	ttgcaaaaacc	aggccccttt	ggggctattc	4800
agtatctctg	cagttgaaaa	tagagccacc	tccatagaca	tcgaagaagc	caataggacc	4860
gtgtatttaa	atgtatctcg	aactaatggc	attgatttgg	ctgatttaaa	tatagaaaat	4920
ccgaaaactt	gtgaggcctt	taatattggg	ttttctccct	actttgtgat	tactcatgaa	4980
gaaagaaatg	aagaaaaagcc	ttctcttaac	agtgtgttta	cattcacatc	tggtatttaa	5040
ttattctcgg	tacaaaacat	cattattctg	gaaagtcttc	aagtaagata	ttttacttca	5100
gacagccaag	attatttaat	cattgcaagt	caaagagatg	attccgaatt	aactcaggtc	5160
ttcaggtgga	atggaggaag	cttcgtgttg	catcaaaaac	tcctgtccg	agggtgtgctg	5220
accgtggcct	tgttcaacaa	gggaggctct	gtgttcttag	ccatttccca	ggctaattgc	5280
aggctaaact	cccttttatt	cagatgggtc	ggcagtggtg	ttattaactt	tcaagagggtg	5340
cctgtcagtg	ggacaacaga	agttgaggct	ttgtcttcag	ccaatgatat	ttaccttaata	5400
tttgccaaaa	atgtctttct	aggagatcag	aattcaattg	atattttcat	ctgggagatg	5460
ggacagctct	ccttcaggta	ttttcagttc	gtagattttg	ctgctgttaa	cagaatccac	5520
tccttcacac	cagcctcagg	aatagcccac	atacttctta	ttggccaaga	tatgtctgct	5580
ctttactgct	ggaattcggg	gcgtaataca	ttctcttttg	ttctggaagt	accttctgct	5640
tatgtgtggt	cttcgtttac	agtaaatgcc	cttaattcaa	gcaagaattt	aatagctcta	5700
gtgggagctg	attcacatat	atatgagcta	gcctacattt	ccagccattc	tgactttatt	5760
cctagtccag	gtgaactgat	atttgaacct	ggtgagagag	aagctacaat	agcagtaaat	5820
atccttgatg	atacagttcc	agaaaaagaa	gaatccttca	aagttcaact	taaaaatccc	5880
aaaggaggag	cagagattgg	cattaatgat	tctgtaacaa	taaccattct	gtctaattgat	5940
gatgcctatg	gaattgttgc	atttgcctag	aattcattat	ataagcaagt	ggaagaaatg	6000
gagcaagata	gcctagtaac	cttgaacggt	gaacgcttaa	aaggaaacata	tggccgtata	6060
accatagcat	gggaagctga	tggaagtatt	agtgatatat	ttcctacctc	aggagtgggtg	6120
gaaaaacgaa	tgctagcaaa	gattttattt	actgaaggcc	aggtagctgc	aacaatcact	6180
ctaactattc	ttgctgataa	tataccagag	ttatcagagg	ttgtgattgt	aaccctcacc	6240
cgtatcacca	cagaaggggt	tgaggactca	tacaaagggtg	ctactattga	tcaggacaga	6300
agcaagtctg	ttataacaac	tttgcccaat	gactcacctt	ttggcttggt	gggctggcgt	6360
gctgcgtctg	tcttcattag	agtagcagag	cctaaagaaa	acaccaccac	tcttcagtta	6420
caaatagctc	gagataaagg	actacttggg	gatattgcca	ttcacttgag	agctcaaccc	6480
aatttcttac	tgcatgtcga	taatcaagct	actgagaatg	aagattatgt	attgcaagaa	6540
acaataataa	taatgaaaga	aaacataaaa	gaagctcatg	ccgaagtttc	cattttgccc	6600
gatgaccttc	ctgaattgga	ggaaggattt	attgtcacta	tcactgaggt	gaacctgggt	6660
aactctgact	tctctacagg	acagccaagt	gtgcggaggc	ccggaatgga	aatagctgag	6720
ataatgatag	aagaaaatga	cgatcccaga	ggaattttta	tgtttcatgt	tactagaggc	6780
gctggggaag	ttattactgc	ctatgagggtg	cctccaccct	tgaacgttct	tcaagttcct	6840
gtagtccggc	tggttggaag	ctttggggca	gtaaatgttt	attggaaagc	atcaccagac	6900
agtgtctggc	tggaagactt	taaaccatct	catgggatcc	ttgaatttgc	agataaacag	6960
gttactgcaa	tgatagaaat	caccataatt	gatgatgctg	aatttgaaat	gacagagacg	7020
ttcaatattt	ccttgatcag	tggtgctgga	ggtggcagac	ttggtgatga	tggttggtga	7080
actgtgttta	ttccacaaaa	tgattctcca	tttgaggatg	ttggatttga	agaaaagact	7140
gtaatgattg	atgaatccct	ttcatccgat	gaccctgatt	catatgtgac	attgacgggt	7200
gtccggtccc	caggaggaaa	aggaaccgtc	cgacttgagt	ggaccataga	tgagaagggt	7260
aaacataaac	ttagtccttt	gaatgggacc	cttcattttg	atgagactga	gtcccagaag	7320
accattgtgt	tgacacact	tcaagacaca	gtgttgagg	aggacaggcg	tttcaccatt	7380
cagctgatat	caattgatga	ggtagaaata	tctccagtaa	aaggtagtgc	atcaataatt	7440
attcgggggtg	ataagcgagc	atcaggagaa	gttgggtag	ctccgtcatc	taggcacatc	7500

ctcattgggg	aaccctcagc	aaaatataat	ggtaccgcta	ttatcagcct	tgttcgaggc	7560
ccaggggattt	tgggggaggt	cacagtgttc	tggaggatat	tccctccttc	cgtgggggaa	7620
tttgctgaaa	catcaggaaa	actgacaatg	cgagacgaac	agtctgcagt	cattgtagta	7680
atacaggctt	tgaacgatga	cattccccgag	gaaaaaagct	tctatgagtt	tcagctcact	7740
gcagtcagtg	agggaggagt	tctgagtga	tccagcagca	ctgccaacat	cacgggtggtg	7800
gccagcgact	ctccctatgg	ccgatttggc	ttttcacatg	agcaacttcg	agtgtcagaa	7860
gcacagaggg	ttaacatcac	aatcatccgt	tccagtggag	atdddggcca	tgtgcgactc	7920
tggtacaaga	cgatgagcgg	gacagcggaa	gcaggcttgg	atdddgttcc	tgcagcaggg	7980
gagctcctct	ttgaagcagg	ggagatgagg	aaaagtctgc	atgttgaaat	ccttgatgat	8040
gactatcctg	aaggcccaga	ggaatdddct	ctaacaatta	caaaggtgga	actccagggg	8100
aggtaaagga	gaaaggcaat	taggaaaaag	aaagcaaaga	gcagagagaa	agagagaaaag	8160
ttctattgtg	tagagattaa	tactgagctc	taaagcagtt	ctttccctac	tctttctcag	8220
attdgtgtga	cattagaaca	ggacatacaa	gggaaattat	gacaatgact	gagtdttttt	8280
ttttaatddd	gttaaataata	acttccctct	gaaaattgaa	agtacgtgtt	tctattgtgt	8340
ggacacactc	tgggtagcca	ggaagttgaa	tatgataacg	gcttctaatt	ggtgaagaca	8400
cagcctaaca	gctctctaaa	tcagaggtca	gctggtgtgg	ctgaattdgc	ttcttdttgat	8460
ttccataactt	gtgaaaggtg	gaaggga				8487

<210> 63

<211> 3264

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 71726948CB1

<400> 63

cgctggaagc	agctggaggg	tccagttctc	atctgctcag	gtgtccccgg	cgccttggcg	60
aactcggcca	ctccagttcc	tcacgtgggt	agcactcagg	gcagcgggtc	gattttccga	120
ggtcccatat	ctgggtttga	ggggcgcgcg	tcgcagcgcc	gggtgcaggg	gcgactgcca	180
gccctcacc	cgcctcgggg	tgcgttcgga	ggccgacacc	tggaggacgc	ctccagttccc	240
cgcgggacgc	cacgcctgcg	cgccagggat	ccgggataag	aagtgcgcgc	cgggctccgg	300
ctgcgcgccc	cggggccacc	agtttgcgcg	cagggctcag	gcgaccgtgc	ggccatggac	360
acgccacggg	gcacgcggac	cttcgtgggt	tgggactacg	tgggtgttcg	gggcatgctg	420
gtcatctcgg	ccgcatcgg	catctactac	gccttcgctg	ggggcgggcca	gcagacctcc	480
aaggacttcc	tgatggggcg	ccgcagaatg	accgcagtcg	ccgtggcgct	gtccctcacc	540
gctagcttca	tgtcagccgt	cactgtcctg	ggcaccctcc	ccgaggtcta	ccgttttggg	600
gccattttta	gcacctttgc	cttcacctac	ttctttgtgg	tgggtcatcag	cgcggaggtc	660
ttcctcccgg	tgttctacaa	actgggaatt	accagcacct	acgagtattt	agaacttcga	720
tttaacaaat	gtgttcgtct	ctgtggaaca	gtcctcttca	ttgttcaaac	aattctgtat	780
actggaattg	ttatttatgc	ccctgccctg	gctttgaatc	aagtcacagg	attdgatctg	840
tggggcgcg	tagtgggaac	gggggtgggt	tgcacattct	actgcacact	gggtgggtct	900
aaagcagtta	tctggacaga	tgtttttcaa	gttgggatca	tgggtggctg	attdgcattc	960
gtgattatac	aggctgtggg	gatgcaaggt	ggaatcagca	ctatttttaa	tgatgcctat	1020
gatggtggaa	gattaaattt	ctggaatttt	aatcctaacc	ctttgcaaag	acacaccttc	1080
tggacaatta	ttataggagg	gaccttcaca	tggaccagca	tctacgggtg	caaccaatcc	1140
caggtgcaga	gatataattc	ttgtaaaagc	agattccagg	caaaaactgt	tctctacatc	1200
aatcttgtgg	gactctgggc	aatcctcaca	tgctcagttg	ttgttgggct	cgccttatat	1260
tccaggtacc	atgactgtga	tccttggaca	gccaagaaaag	tgtctgcacc	agaccagctc	1320
atgccttatt	tgggtactgga	cattctgcaa	gattatccag	gaattcctgg	actttttgtg	1380
gcctgtgctt	acagtgggac	attaagcaca	gtgtcctcca	gtattaatgc	cttagcagca	1440
gtaactgtgg	aagatctaag	caaaccttac	ttcagatcgc	tctcagaaaag	gtctctgtct	1500
tggatttccc	aaggaatgat	tgtggtgtat	ggagccctgt	gtatttggat	ggctgcgctg	1560
gcgtcactta	tgggagcttt	gttgaggcca	gcactcagcg	tatttgggtat	gggttgggtgga	1620
ccacttatgg	gcctgttcgc	tttgggcatt	ttggttccct	ttgccaactc	aattggagca	1680
cttgttgggt	tgatggctgg	attdgccatt	tctctatggg	ttggaattgg	agctcaataa	1740
tatcctccac	ttcctgagag	aacattgcca	ttgcaccttg	atatccaagg	ctgtaacagc	1800
acctacaatg	agacaaaatt	gatgacaacc	acagaaatgc	catttactac	tagtgttttt	1860
caaataatac	atgttcaaaag	gactccactg	atggataact	ggtattcttt	atcatatctg	1920
tacttcagca	ctgttgggaac	tttggtaacc	ttattagtgg	ggataactgt	cagtttatca	1980
acaggaggaa	gaaaacagaa	cttagacccc	agatatatac	taaccaaaaga	ggacttttta	2040
tccaattttg	atatttttta	gaaaaagaag	catgttttga	gctataaatc	acatccagtg	2100

gaagatgggtg	gaactgataa	tcttgctttc	aaccacattg	aattgaactc	agatcagagt	2160
ggcaagagca	atgggactcg	tttgtgaagc	tgctctgata	ctagatatcc	ttaaatgatg	2220
tttcaatttt	atatgttttc	taagataatt	ggatcagggt	ttctttgtgt	gtgtgtgtgt	2280
gttgatcat	gagtgtttgg	gggataagtt	tttgttaaaa	caaagtctgg	actatcttca	2340
tttactacat	cattaattga	tgttactctg	gagtttagaa	ttctggcatt	gacatttccc	2400
tctctttcct	ttatttcgat	gaagctataa	ttgtgaaaat	tgtaactaca	tagatgctga	2460
aaggctaata	cacacatatg	cacatgtatt	tgattgtcaa	aggtatatcc	ttaaatttgg	2520
gtattattga	aaatattttc	catgccttgg	tgctagcata	taagtttggg	agtttgccaa	2580
catcacaatt	catcttgaaa	agagcttttt	tccctcctac	cacatacacc	attcttaggg	2640
agcaatgagg	taacagggtct	gtgttgctca	gatctttgct	ttttatcccc	ctatcagtc	2700
agggcatata	ctaactcgca	aactgattct	gaatcaggaa	ggtggtaatc	aataagtatt	2760
ctggctggga	aagaccgtgg	gccccaatgat	caaagtcttc	ttggtgctgt	tcattaattc	2820
ttgtgccttt	tggttgcttt	tctagagttt	ctgggctttg	gctgctgata	ctgcctttct	2880
tagactgtaa	tttttatctg	catgcccagt	ttctgacctc	tcaacttggg	ttttattgtg	2940
cactctaact	gagcttgctc	tcataatttt	ctgtttattg	ccctgggctt	ggatattgtc	3000
caagacactc	atgtgaatca	tgccacccca	aatcctggct	tatcaagtcc	cagactataa	3060
attatgaact	cccattagct	tggtactaac	ataacttga	tgtaggtatt	tatggacttg	3120
atgatccaag	aattattatat	tcttcaaaaat	ggtttaagctc	catggagtta	gatgactaca	3180
cttaatgcta	ttaagttgaa	cttttgaatg	tcaactaatt	tgcaatcaat	taaagataca	3240
tatgcctaga	aaaaaaaaaa	aaaa				3264

<210> 64

<211> 1659

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7487393CB1

<400> 64

atgggctttg	atgtgctcct	ggatcaagtg	ggtggcatgg	ggagattcca	gatttgtctg	60
atagctttct	tttgcacac	caacatccta	ctgttcccta	atatgtgtgt	ggagaacttc	120
actgcattca	cccctagtca	tcgctgctgg	gtccccctcc	tggaacatga	cactgtgtct	180
gacaatgata	ccgggaccct	cagcaaggat	gacctcctga	gaatctccat	cccactggac	240
tcaaacctga	ggccacagaa	gtgtcagcgc	tttatccatc	cccagtggca	gctccttcac	300
ctgaacggga	ccttccccaa	cacaaatgag	ccagacacgg	agccctgtgt	ggatggctgg	360
gtgtacgaca	gaagctcttt	cctctccacc	atcgtgactg	agtgggacct	ggtatgtgaa	420
tctcagtcac	taaaatcaat	ggttcaatcc	ctatttatgg	ctgggtcact	gctgggaggt	480
ctaatatatg	gccatctttc	agacagggtt	ggacggaaga	tcatatgcaa	attgtgtttc	540
ctccagctgg	ccatctctaa	cacctgtgcg	gccttcgctc	ccaccttcc	tgtttactgc	600
atactgcgct	tcttggcagg	gttctccacc	atgactatatt	tgggaaacac	ttttattctc	660
agcttagagt	ggacattgcc	ccggtcacga	tctatgacaa	taatgggtgt	attatgttcc	720
tacagtgttg	ggcagatgct	cctaggaggg	ctggcttttg	ccattcagga	ctggcacata	780
ttgcaactga	ctgtgtctac	accataaatt	gtcctcttct	tgctctcttg	gaagatgggtg	840
gagtctgtct	ggtggctgat	tatcaacaat	cagctagatg	agggcttaaa	ggagcttaga	900
agagttgcac	acataaatgg	aaaaaagaat	actgaagaga	cactgaccac	tgagcttgtg	960
agatccacca	tgaagaagga	gttggatgca	gtccgaatta	aaacatccat	tttttccctg	1020
ttccgtgcac	ccaaattgcg	aatgagagtc	ttcggcctgt	gctttgtgag	attcgcaatc	1080
actgtaccct	tttatggcct	gataactcaac	ttgcagcaat	tagggagcaa	tgtctccctg	1140
ttccagattc	tctgtggagc	tgtcacattc	acagccagat	gtgtttccct	tttgacactg	1200
aatcatatgg	gtcgtcgaat	aagccagata	ttgttcacgt	tcccgtggg	acttttcatt	1260
ctgggtcaaca	cctttttgcc	ccaagaaatg	cagatcctgc	gtgtggtttt	agcaactttg	1320
ggaaattggtg	gtgtttctgc	tgctagcaac	agtgcctctg	tccaccacaa	cgagctcgct	1380
cccaccatat	tgaggtcaac	agttgcagga	atcaatgcag	tgtccggtag	gactggggca	1440
gcactggctc	ctctgttgat	gaccttaatg	gcgtattctc	cccacctacc	ctggatttcc	1500
tatggagtct	tccccatcct	tgctgtccct	gttatcctcc	tccttcacga	aaccagggat	1560
ctacctcttc	ctaaccacat	ccaggatgtg	gaaaatgaca	gaaaagattc	aagaaacata	1620
aagcaggaag	atacttgcac	gaaagtaaca	cagtttttaa			1659

THIS PAGE BLANK (USPTO)